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The research presented within this thesis concentrates on the signal transduction pathways 
downstream of the chemokine receptor CCR4, and those pathways that are critical for T 
cell migration. Chemokines are a family of small molecular weight (~ 8 -  11 kDa) proteins 
that have been divided into 4 groups based on their arrangement of 4 highly conserved 
amino-terminal cysteine residues. Chemokines are critical factors involved in the 
localisation of leukocytes (and other cell types) to various areas within the body for 
differentiation/maturation and immunity processes. However, chemokines have been 
implicated in the dysregulation of the immune process due to an over 
exuberant/unnecessary recruitment of cells to areas of antigen and this leads to a 
debilitating inflammatory/autoimmune response. Thus, a greater understanding o f the 
biochemical and functional pathways mediated by CCR4 may potentially provide novel 
therapeutic targets. Until now, CCR4 signalling events have been poorly characterised. 
Results presented within demonstrate the ability of MDC/TARC in a dose-dependent and 
pertussis toxin sensitive manner to flux calcium in a leukaemic T cell line (CEM) and 
polarised human Th2 cells. Pre-incubation o f these cells with the PLC inhibitor, U73122, 
resulted in the abrogation of CCR4-mediated calcium mobilisation. This MDC-induced 
calcium response was found to be wholly sensitive to the IP3 receptor antagonist 2-APB. 
MDC is able to induce the pertussis toxin sensitive migration of CEM and polarised human 
Th2 cells. Th2/CEM cell migration in response to MDC is sensitive to the PLC and PKC 
selective inhibitors U73122 and RO-32-0432. However, 2-APB has no effect, implicating a 
role for a novel PKC isoform (Ca1+-independent, DAG-dependent). This observation is 
supported by the ability of Rottlerin (PKC5 inhibitor) to abrogate this MDC-induced T cell 
chemotaxis. Surprisingly, this CCR4-mediated chemotaxis is insensitive to the PI3K 
inhibitors, LY294002 (to 30jiM) and wortmannin (to 300nM). Yet, PI3K is activated 
downstream of CCR4 as demonstrated by MDC-induced PIP3 accumulation, and activation 
of the PI3K isoforms, p i 108 and p llO y  (each being Wortmannin/LY294002 sensitive). 
Additionally, studies have demonstrated that this MDC-mediated CEM cell chemotaxis is 
sensitive to the ROCK inhibitor, Y27632, with MDC possessing the ability to 
phosphorylate the downstream ROCK effector MLC.
These results indicate that whilst CCR4 activates analogous pathways to other chemokine 
receptors, there are distinct dissimilarities in the cascades that are required for directed cell 
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PKB protein kinase B
PKC protein kinase C
PLC phospholipase C
PLP2A phospholipase 2A
PP2A phosphoprotein phosphatase 2A
PPARy peroxisome proliferator-activated receptor
PTB phosphotyrosine binding domain
PTEN phosphatase and tensin homologue deleted on chromosome ten
PYK2 proline-rich tyrosine kinase
RGS regulator of G protein signalling
ROCK rho-associated, coiled-coil-containing protein kinase
RSK ribosomal S6 kinase
RTK receptor tyrosine kinase
RR ryanodine receptors
S6 small subunit ribosomal protein S6
S6K S6 kinase
SAPK stress-activated protein kinase
SEK SAPK kinase
SH2 Src-homology 2 domain
SH3 Src-homology 3 domain
She SH2-containing collagen-related proteins (adaptors)
SHP SH2-containing phosphatase
Sos son of sevenless guanine nucleotide exchange factor
SRE serum response element
SRF serum response factor
STAT signal transducer and activator of transcription
Chemokine Acronyms
6Ckine chemokine with 6 cysteines
AMAC alternative macrophage activation-associated CC chemokine
ATAC activation-induced, chemokine-related molecule exclusively
expressed in CD8+ T lymphocytes.
BCA-1 B cell-activating chemokine-1
BLC B lymphocyte Chemoattractant
BRAK breast and kidney chemokine
XVII
CTACK cutaneous T cell-attracting chemokine
DARC Duffy antigen receptor for chemokines
DC-CK-1 dendritic cell chemokine 1
ELC Epstein-Barr virus-induced receptor ligand chemokine
ENA-78 epithelial cell-derived neutrophil-activating factor, 78 amino
acids
GCP granulocyte chemoattractant protein
Gro growth-related o n c o g e n e ...................................................................
HCC haemofiltrate CC chemokine
IL-8 interleukin-8
IP -10 interferon-y-inducible protein-10
ITAC interferon-inducible T cell a  chemoattractant
LARC liver- and activation-related chemokine
LEC liver-expressed chemokine
Lkn-1 leukotactin-1
MCP monocyte chemoattractant protein
MDC macrophage-derived chemokine
MEC mucosae-associated epithelial chemokine
MGSA melanoma growth-stimulatory activity
Mig monokine induced by y-interferon
MIP macrophage inflammatory protein
MPIF myeloid progenitor inhibitory factor
NAP neutrophil-activating protein
PARC pulmonary- and activation-regulated chemokine
PF-4 platelet factor-4
RANTES regulated on activation, normal T cell expressed and secreted
SDF-1 stromal cell-derived factor-1
SLC secondary lymphoid tissue chemokine
STCP-1 stimulated T cell chemoattractant protein-1
TARC thymus- and activation-related chemokine
TECK thymus-expressed chemokine
Inhibitors




AG9 tyrphostin A l;tyrphostin 1; a-cyano-(4-
methoxy)cinnamonitrile; (4-methoxybenzylidene)malonitrile 
2-APB 2-aminoethoxydiphenylborate
8-Br-cADPR 8-bromo-cyclic adenosine diphosphate ribose
Caffeine 1,3,7-trimethylxanthine
Dantrolene l-([5-(p-nitrophenyl)fiirfurylidene]amino)hydantoin





pyridinedicarboxylic acid dimethyl ester 
PD PD98059; 2-(2-amino-3-methoxyphenyl)-4H-l-benzopyran-4-
one
PKBi (PKB inhibitor) lL -6-Hydroxymethyl-chiro-inositol 2-(R)-2-0-m ethyl-3-0-
octadecylcarbonate 
PTX pertussis toxin, source Bordetella pertussis
RO RO-32-0432; Bisindoylmaleimide XI; 2-(8-
[ {dimethylamino} methyl]-6,7,8,9-tetrahydropyrido[ 1,2- 
a]indol-3-yl)-3-(l-methylindol-3-yl)maleimide 






TLCK Na-tosyl-lys chloromethyl ketone
TPCK Na-tosyl-phe chloromethyl ketone
U73122 1-(6-[ {[ 17p]-3-M ethoxyestra-1,3,5 [ 10]-trien-17-
y l} amino]hexyl)- lH-pyrrole-2,5-dione 
U73343 1 -(6-[- {[ 17p]-3-M ethoxyestra-1,3,5 [ 10]-trien-17-
y l} amino]hexyl)-1 H-pyrrolidinedione 
WHI-P154 4-[(3'-Bromo-4'-hydroxyphenyl)amino]-6,7-
dimethoxyquinazoline 
Wort. Wortmannin, source Penicillium funiculosum
Cell Types/Tissue
APC antigen presenting cell
B B cell
Ba basophil
CHO Chinese hamster ovary cell
CNS central nervous system
DC dendritic cell
iDC immature dendritic cell









NK natural killer T  cell
P platelet
RBC red blood cell/erythrocyte
XIX
SI small intestine
SMC smooth muscle cell
T T cell
Tc cytotoxic T cell
Th helper T cell
Thy thymocyte
Tn naive T cell








CNSi central nervous system inflammation
D dermatitis
GN glomerulonephritis
GVHD graft-versus-host disease (allograft rejection)
IBD inflammatory bowel disease
II intestinal inflammation
















EGTA ethylene glycol-bis(p-aminoethyl ether)-N, N, N ', N '-
tetraacetic acid
Em fluorescence emission maximum (in nanometres)
EtOH ethanol











PAGE polyacrylamide gel electrophoresis
PBMC peripheral blood mononuclear cell
PE phycoerythrin




SDS sodium dodecyl sulphate
SEB staphylococcal enterotoxin B
Sec second(s)
TBS tris-buffered saline
TBST tris-buffered saline with tween-20
TEMED N, N, N \ N'-Tetramethylethylenediamine









1. In t r o d u c t io n
1.1 The Immune System
The surrounding environment contains a multitude of pathogens -  viruses, bacteria, fungi, 
protozoa and multicellular parasites -  that can cause disease and kill the host if their 
existence is unchecked. Fortunately, for the human species (and indeed other species), a 
complex method has evolved over many millennia in which the body is able to distinguish 
self from what is nonself (i.e. host from foreign) -  the IMMUNE SYSTEM. Without the 
immune system all living matter would be driven into one colossal ball of protoplasm. 
Thus, organisms have developed this system of molecular recognition that involves cell 
surface molecules specifically identifying and adhering to molecules on other surfaces that 
are nonself and eject the offending pathogen from the organism. This immune response 
can be divided into 2 distinct, but complementary, systems -  INNATE and ADAPTIVE 
immunity (from the latin word immunis meaning ‘exempt’). The type of pathogen and the 
site of infection largely determine the type of immune response.
Innate (non-adaptive) immunity is conferred by all those components present from birth. 
This form of immunity is always present and available at short notice to prevent the entry 
of microorganisms or to eject them prior to occurrence of disease, in a non-specific manner. 
The mechanistic components of the immune system include skin, mucous membranes, 
coughing and vomiting. Chemical barriers include pH levels (e.g. the acidic environment 
of the stomach) and antibacterial substances in secretions. Various internal components 
contribute to the features of the innate immune system, including fever (temperature rise), 
interferons and some opsonins (e.g. complement) -  these affect pathogenic invaders 
directly or enhance the host’s effectiveness against them. Another component includes the 
phagocytic cells (monocytes, macrophages, neutrophils) that bind to microorganisms, 
internalise them and kill them. Phagocytes are able to bind a variety of microbial products 
making them part of the innate response. The innate response does not alter on repeated 
exposure to the same pathogen.
1
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Adaptive (acquired) immunity improves with each successive exposure to a given 
infectious agent and is more specialised than the innate response. Acquired immunity is 
present exclusively in invertebrates and, in evolutionary terms is a recent phenomenon, 
with each response specific for a particular immunogen/antigen. This response protects 
against future invasion by previously encountered pathogens and the primary ‘players’ in 
this response are the subset of leukocytes termed ‘lymphocytes’. These cells are able to 
specifically recognise individual pathogens through the expression of antigen-specific 
receptors (the T cell receptor (TCR) and B cell receptor (BCR) for T and B lymphocytes, 
respectively). These cells, upon contact with antigen, lead to the synthesis of antibody (B 
cells -  humoral immunity) or cytokines and other soluble factors (T cells -  cellular 
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Figure 1.1. Components of the immune system. Figure depicts the principal elements of 
the immune system, indicating the cells and the soluble mediators that they produce. In 
addition to the cells displayed, the dendritic cells have a major role in presenting antigen to 




These two arms of the immune response are not mutually exclusive and there is 
considerable interaction between the two. Some phagocytes, such as macrophages, and 
other cells (e.g. dendritic cells) are able to present antigen to T lymphocytes in a form they 
are able to recognise. These cells are known as antigen-presenting cells (APCs) and 
display two types of molecule that participate in this antigen presentation -  MHC (major 
histocompatibility complex) class I and MHC class II. The processed antigen is riori- 
covalently bound to either of these molecules and presents it to the TCR (MHC I = 
cytotoxic T cells, MHC II = helper T cells). B cells can act as APCs as well (MHC class 
II). Additionally, antibody released by B cells is used by phagocytes to more efficiently 
recognise pathogen, and the soluble proteins released by T cells can recruit more 
phagocytes to the area of infection.
The cells of the immune system are widely distributed throughout the body, but in the event 
of invasion by a pathogen it is necessary for the cells (generally leukocytes) of the immune 
system to be concentrated locally at the area of infection (a process that manifests itself as 
inflammation). The initial response will require the localisation of cells of the innate 
system, with APCs such as dendritic cells requiring to migrate from the infected peripheral 
areas to draining lymph nodes where they present their antigen to T cells. After T cell 
differentiation and proliferation into antigen-specific T cells, they need to migrate to the 
periphery. Additionally, if it is a previously encountered antigen then there is a 
requirement for the mobilisation of memory B and T cells to the area of infection. Besides 
this mobilisation, leukocytes are generated every day (as part of a general turnover process 
termed ‘haematopoiesis’) and this process requires the cells to be directed to various sites 
within the body as part of the differentiation/maturation process (incidentally, T cells are 
produced in the thymus and B cells in the bone marrow).
Therefore, this localisation of leukocytes (and other cell types) is of fundamental 
importance in the immune system, and a lack of cell mobility will result in an ineffectual 
immune sytem. There are a number of molecules that have been demonstrated to play a 
role in this localisation process, among them selectins, integrins, and the non-specific 
chemoattractants C5a, fMLP and prostaglandins (PGs). However, the most significant 
group of molecules implicated in this directed cell migration are those of the chemokine 
family, and this group will be the focus of this thesis.
3
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1.2 Chemokines & Their Receptors 
History
Up until the late 1980s (1987-‘88), the existence of chemokines was unknown and the 
phenomenon of specific leukocyte subtype migration during various disease processes was 
hard to explain. Prior to 1987, only molecules such as C5a and formyl peptide were known 
for their attraction of leukocytes, unspecifically. This all changed in 1987, firstly with the 
discovery of the cytokine Interleukin-8 (IL-8) (Walz et al., 1987; Yoshimura et al., 1987a; 
Yoshimura et al., 1987b) and, followed closely on its heels, with Macrophage 
Inflammatory P rotein-la (M IP-la) (Wolpe et al., 1988). Within a few years a large 
number of these molecules were discovered. As a consequence, the term chemokine was 
coined to describe these chemotactic cytokines at the 3rd International Symposium on 
Chemotactic Cytokines at Baden, Germany in 1992 (Lindley et al., 1992), where two 
groups of chemokines were identified -  alpha and beta (CXC and CC, respectively).
Today, a PubMed search for the word “chemokine” would result in more than 22000 hits, 
with a vast number coming in the last 5 years (table 1.1), reflecting the discovery of an 
ever-increasing role of chemokines in diseases. However, the last 2-3 years has seen the 
number of papers produced plateau, suggesting that the chemokine field has now 
effectively reached maturity.
Table 1.1. N um ber of papers published each year since 1991.
Year 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
No. of 
Papers
291 361 511 621 800 1076 1456 1721 2018 2239 2745 2798 2626
Papers publis led with the word “chemokine’’ in the title or abstract. PubM ed used as
search engine.
Nomenclature and Structural Characteristics of Chemokines
Chemokines share a limited sequence homology but possess similar secondary and tertiary 
structures. This similar structure is known as the ‘Greek-key’ motif -  three anti-parallel 
beta-pleated sheets overlaid by a C-terminal alpha helix (Chung et al., 1995; Clore et al., 
1989). Chemokines are in the range of 8-11 kDa in size and bind to one of four classes of
4
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chemokine receptor, normally achieving biological functions at nanomolar concentrations. 
These four classes are:
•  CC Receptors (CCR)
•  CXC Receptors (CXCR)
•  XC Receptor (XCR)..................................................................
•  CX3C Receptor (CX3CR)
Silent Receptors
In addition to these 4 classes of chemokine receptors, there are two 
chemokine-binding proteins called Duffy (DARC (Duffy Antigen Receptoi 
for Chemokines)) (Horuk et al., 1993) and D6 (Nibbs et al., 1997) that bind 
various chemokines but appear not to signal and, as a consequence, will nol 
be discussed in any detail (for a review see (Pogo and Chaudhuri, 2000)). 
However, their role may be to act as a sink for inflammatory chemokines. 
thereby modulating the inflammatory response (Fra et al., 2003; Kashiwazaki 
et al., 2003).
Though the chemokines are specific for a particular subclass o f receptor there are several 
chemokines that possess the ability to bind to more than one receptor subtype, for example, 
Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES) is able to 
bind CCR1, CCR3 and CCR5 (table 1.2). However, the chemokines Macrophage-Derived 
Chemokine (MDC) and Thymus- and Activation-Regulated Chemokine (TARC) only bind 
CCR4. To date there are over 40 recognised chemokines and many of these have more 
than one name, e.g. Pulmonary and Activation-Regulated Chemokine (PARC) had at least 
three other names (AMAC-1, MIP-4 and DC-CK1) (Murphy et al., 2000). These names 
arose due to various research groups independently identifying chemokines and naming 
them according to the protein’s function. Recently, to overcome the confusion that can 
arise with different groups calling the same chemokine different names, the international 
chemokine community has developed a new approved nomenclature where the chemokines 
are named according to the arrangement of their two highly conserved
5
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C C  C hem okine/R ecep to r ( f t  F am ily
CCL1 1309 17q 1 1 . 2 CCR8 4 cysteines Inducible
CCL2 MCP-1 17q 1 1 . 2 CCR2 4 cysteines Inducible
CCL3 M IP-la 17q 1 1 . 2 CCR1/CCR5 4 cysteines Inducible
CCL4 MIP-ip 17q 1 1 . 2 CCR5 4 cysteines Inducible
CCL5 RANTES 17ql 1.2 CCR1 /CCR3/CCR5 4 cysteines Inducible
CCL6 ? 7 7 4 cysteines 7
CCL7 MCP-3 17q 1 1 . 2 CCR 1 /CCR2/CCR3 6  cysteines Inducible
CCL8 MCP-2 17q 1 1 . 2 CCR2/CCR3 4 cysteines Inducible
CCL9 ? 7 7 6  cysteines 7
CCL10 7 7 7 4 cysteines 7
CCL11 Eotaxin 17ql 1.2 CCR3 4 cysteines Inducible
CCL12 7 7 7 4 cysteines 7
CCL13 MCP-4 17q 11 . 2 CCR2/CCR3 4 cysteines Inducible
CCL14 HCC-1 17ql 1.2 CCR1 4 cysteines Constitutive
CCL15 HCC-2/Lkn-1 17q 11.2 CCR1/CCR3 6  cysteines Constitutive
CCLI6 HCC-4/LEC H q^ 2 CCR1 4 cysteines Constitutive
CCL18 PARC/DC-CK1 /AM AC 17q 1 1 . 2 Unknown 4 cysteines Constitutive
CCL19 MIP-3p/ELC 9p 13 CCR7/CCR11 4 cysteines Constitutive
CCL20 MIP-3a/LARC 2q33 -  q37 CCR6 4 cysteines Both
CCL21 6 Ckine/SLC 9pl3 CCR7/CCR11 6  cysteines Constitutive
CCL23 MPIF-l/MIP-3 17q 1 1 . 2 CCR1 6  cysteines Inducible
CCL24 MPIF-2/Eotaxin-2 7q 11.23 CCR3 4 cysteines Inducible
CCL25 TECK 19p 13.2 CCR9/CCR11 4 cysteines Constitutive
CCL26 Eotaxin-3 7q 11.23 CCR3 4 cysteines Inducible
CCL27 CTACK/ILC/ESkine 9pl3 CCR 10 4 cysteines Constitutive
CCL28 MEC 5pl2 CCR3/CCR10 6  cysteines Constitutive
CA'C C hem okine/R ecep tor ( a) F am ily
CXCL1 Groa/MGSA-a 4q 12 — q 13 CXCR2 ELR + Inducible
CXCL2 Grog/MGSA-^ 4q 12 -  q 13 CXCR2 ELR + Inducible
CXCL3 Gro-/MGSA-Y 4q 12 — q 13 CXCR2 ELR + Inducible
CXCL4 PF-4 4q 12 -  q 13 Unknown E L R - ?
CXCL5 ENA-78 4q 12 — q 13 CXCR2 ELR + Inducible
CXCL6 GCP-2 4q 12 -  q 13 CXCR1/CXCR2 ELR + Inducible
CXCL7 NAP-2 4q 12 -  q 13 CXCR2 ELR + Inducible
CXCL8 IL- 8 4q 12 — q 13 CXCR1/CXCR2 ELR + Inducible
CXCL9 Mig 4q21.21 CXCR3 E L R - Inducible
CXCL10 IP-10 4q 21.21 CXCR3 E L R - Inducible
CXCL11 ITAC 4q21.21 CXCR3 E L R - Inducible
CXCL12 SDF-Iq/b lO q ll.l CXCR4 E L R - Constitutive
CXCL13 BLC/BCA-1 4q21 CXCR5 E L R - Constitutive
CXCL14 BRAK/Bolekine 5q31 Unknown E L R - Inducible? 1
CXCL15 Lungkine Unknown Unknown E L R - ?
CXCL16 SR-PSOX 17p 13 CXCR6 ELR TMD + Inducible?
C C hem okine/R ecep tor (}) F am ily
XCL1 Lymphotactin a/ATAC lq23 XCR1 2  cysteines Both
XCL2 Lymphotactin B lq23 XCR1 2  cysteines Both
CX3C C hem okine/R ecep tor ( d) F am ily
CX3CL1 | Fractalkine/neurotactin | 16ql3 | CX3CR1 | TMD + | Both
6
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Legend fo r T able 1.2. Abbreviations: ELR +/-, presence or absence (respectively) of the 
tripeptide motif glutamic acid-leucine-arginine in the NH2 -  terminal region of CXC 
chemokines; TMD, transmembrane domain; \  only a single paper published (Mitsui et al., 
2003). See “abbreviations” for chemokine acronyms.
amino-terminal cysteine residues. Four cysteines are present in total, except Lymphotactin 
that has only the first and third cysteines of the four-cysteine motif (a few members of the 
CC family possess an extra 2 cysteines (6 in total) that can further be used to subdivide the 
CC family (fig. 1.2, table 1.2)). Disulphide bonds form between the first and third 
cysteines and between the second and fourth, giving the chemokines their characteristic 
three-dimensional folding mentioned earlier. In the CXC family a single amino acid is 
interposed between the two amino-terminal cysteines, whilst in the CC family the cysteines 
are adjacent. As a result, PARC becomes CCL18, MDC becomes CCL22 and RANTES is 
now CCL5 (table 1.2). However, this thesis will use the acronyms MDC and TARC for the 
CCR4 ligands (instead of CCL22 and CCL17, respectively), due to their greater familiarity. 
There are currently 16 chemokines in the CXCL group, 28 in the CCL class and just two in 
the XCL (Lymphotactin 1 & 2) and one in the CX3CL (Fractalkine (three amino acids 
separate the two cysteines)) groups. Fractalkine is interesting in that it is tethered to the 
cells that produce it via a mucin-like stalk (Bazan et al., 1997), thereby promoting 
leukocyte adhesion (the newly identified CXCL 16 also has a membrane-anchored form 
(Matloubian et al., 2000)). The CXCL group can further be sub-categorised into two 
groups depending on the presence of the ELR (Glu-Leu-Arg) motif preceding the first 
cysteine. CXCR1 and CXCR2 binding chemokines (e.g. IL-8) are ELR-positive, while the 
other CXCR-binding chemokines (e.g. IP-10) lack this motif. (Strieter et al., 1995a). ELR + 
chemokines tend to, therefore, be specific for myeloid cells (mainly neutrophils), whilst 
E L R - attract a variety o f leukocytes. These four chemokine families tend to be clustered at 
four separate human chromosomal loci: 4ql2-21 for CXC (exceptions include SDF- 
1/CXCL12 at lO q ll and CXCL14 at 5q31); 17ql 1.2-21 for CC (notable exceptions are 
TARC/CCL17 and MDC/CCL22 both at 16ql3); lq23 for XCL; and 16ql3 for CX3CL1 
(Murphy et al., 2000) Chemokines that bind to the same receptors tend to have the same 
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Figure 1.2. General structure of chemokine superfamily members. Schematic 
representation of the cysteine signature motifs that divide the family in to 4 subfamilies. 
Further subdivisions can be made within the CXC and CC families according to the 
presence or absence of an ELR motif immediately preceding the CXC motif, or the 
presence of either four or six cysteines in the CC members. * most common arrangement 
of extra cysteines depicted (in some cases the second extra cysteine can appear after the 
fourth conserved cysteine). Abbreviations: TM, transmembrane; M-L S, mucin-like stalk.
Chemokines are synthesised with a prosequence of approximately 20 amino acids that is 
cleaved off before secretion (except for Fractalkine), and all posses a positive charge 
meaning that they bind to proteoglycans on cell surfaces or the extracellular matrix 
(Kuschert et al., 1999; Tanaka et al., 1993; Webb et al., 1993). This ensures that the 
chemokines remain concentrated locally, forming stable gradients and, in some cases, 
enhances potency (Schall and Bacon, 1994). In addition, chemokines are able to form 
dimers in concentrated solutions (much higher than required for biological activity and will 
dissociate when diluted), with the exception of a few, e.g. MCP-3 which is always 
monomeric. Monomeric forms possess full biological activity (Baggiolini et al., 1997; 
Horcher et al., 1998; Kim et al., 1996; Lowman et al., 1997). It has been suggested that, in
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vivo, chemokines can form tetrameric structures and that these may be promoted by the 
binding to glycosaminoglycans (Swaminathan et al., 2003).
Chemokine Receptor Structure
All chemokines bind to a branch of the rhodopsin family of seven transmembrane G- 
protein coupled receptors (Class A (6 GPCR classes in total (Qian et al., 2003))) -  which 
have a size of about 40 kDa (340 -  370 amino acids), and classified according to the type of 
chemokine they bind (table 1.3). The heptahelical chemokine receptors also share the highly 
conserved sequence motifs characteristic of the rhodopsin-like family of GPCRs, with the 
majority of these located in the transmembrane regions. This suggests the conservation of a 
common fold throughout the rhodopsin family (Strosberg, 1991). However, there is broad 
structural diversity among the extracellular regions. These features result in a 25-80% 
homology among all known chemokine receptors (fig. 1.3). Chemokine receptors possess 
an extracellular N-terminus, seven hydrophobic transmembrane regions, three extracellular 




















Figure 1.3. D endrogram  showing the 
am ount of protein sequence similarity 
among all known hum an chemokine 
receptors. The scale bar reflects the 
horizontal distance at which sequences 
diverge by 10% (90% identity). Amino 
acid identity (%) between a pair of 
chemokine receptors is given by 1 -  x, 
where x is the sum of the 2 horizontal 
distances to the right of the pair's vertical 
branch point. For example, the horizontal 
distances before the vertical branch point of 
CXCR1 and CXCR2 are 12.9 and 11.8%, 
respectively. Therefore, the amino acid 
identity between these chemokine receptors 
is 100-(12 .9+ 11 .8)%  or 75.3%. 
(Reproduced from (Olson and Ley, 2002)).
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Table 1.21. C haracteristics o f chemokine receptors.
Chemokine






CCR1 CCL3, 5 ,7 , 14, 15, 
16, 23
NK, Thl, Th2, iDC, M, 
MO, Ba, Eo, N
Thl response MS, RA, GVHD
CCR2 CCL2, 7, 8 , 13, 16 NK, Thl, Th2, M, Ba, iDC Inflammation MS, RA, A, GN, AS
CCR3 CCL5, 7, 8 , 11, 13, 15, Th2, Ba, Eo, P, DC Th2 response A, CD
CCR4 W 'T f m m m r Thy, NK, Th2, Tc2, Tm, Th2 response S, A, CD, AD
Ba, P, iDC
CCR5 CCL3, 4, 5, 8 , 14 M, MO, Thy, T h l,T c l,iD C Thl response MS, RA, II, GVHD, 
HIV
CCR6 CCL20 Tm, B, iDC, M, MO. DC function Ps
CCR7 CCL19. 21 Thy, Tn, B, mDC. DC/ LO migration 
to lymph nodes
C
CCR8 CCL1 Thy, Th2, M, N, B Th2 response AD, A
CCR9 CCL25 Thy, Tm, B LO trafficking in 
thymus & SI
II
CCR 10 CCL27, 28 Tm LO trafficking in 
skin & colon
UC, SKI
CCR 11 CCLI9, 21. 25 T, iDC Not known Not identified
CXC
CXCR1 CXCL6 , 8 N, T, M, MO, DC N. recruitment LRI, Gout, Ps, C
CXCR2 CXCL1, 2, 3, 5, 6 , 7 ,8 N, T, M, MO, DC, Eo N. recruitment & 
angiogenesis
LRI, Gout, Ps, C, 
AS
CXCR3 CXCL9, 10, 11 N, T hl, B, DC, Eo, P Th 1 response & 
angiostasis
MS, RA, GVHD, 
C, SD
CXCR4 CXCL 12 N, M, MO, T, B, DC, P Organogenesis HIV, C
CXCR5 CXCL 13 M, MO, T, B B cell migration Not identified
CXCR6 CXCL 16 T, DC Not known Not identified
XCRl CX3CLI T Not known Not identified
CX3C
CX3CR1 XCL1, 2 N, M, MO Cell adhesion to 
endothelia/neurons
GVHD, GN, CNSi
Ligands CCL6, CCL9/10, CCL18, CXCL4, CXCL14, CXCL 15 were omitted, as the 
corresponding receptor(s) have not been identified. Colour coding: blue =
inflammatory/inducible chemokines; -me uni nsmui iw chemokines: green
= both inflammatory and constitutive chemokines. Abbreviations fo r  cell types: B, B cell; 
Ba, basophil; DC, dendritic cell; iDC, immature dendritic cell; mDC, mature dendritic cell; 
Eo, eosinophil; LO, lymphocyte; M, monocyte; MO, macrophage; N, neutrophil; NK, 
natural killer cell; P, platelet; SI, small intestine; T, T-cell; Th, T-helper cell; Thy, 
thymocytes; Tc, cytotoxic T cells; Tm, memory T cells; Tn, naive T cells. Abbreviations 
for diseases: A, asthma; AD, atopic dermatitis; AS, atherosclerosis; C, cancer; CD, contact 
dermatitis; CNSi, central nervous system inflammation; GN, glomerulonephritis; GVHD, 
graft-versus-host disease; II, intestinal inflammation; LRI, lung reperfusion injury; MS, 
multiple sclerosis; Ps, psoriasis; RA, rheumatoid arthritis; S, sepsis; SD, sarcoidosis; SKI, 
skin inflammation; UC, ulcerative colitis.
The chemokine receptors share a high structural homology in certain areas, most notably 
with conserved sequences in the second and seventh transmembrane domains:
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TM2 = ADLLFxxTLPFW 
TM7 = HCCxNPxxY
In addition to these transmembrane domains, there is also a conserved sequence, 
DRYLAIVH, in the second intracellular loop (loop 3) domain that is adjacent to the third 
transmembrane region and is involved in G protein coupling (Power and Wells, 1996; 
Rollins, 1997); a significant number of acidic amino acid residues within the 30+ long 
amino acid extracellular N-terminus; and two extracellular disulphide bonds created from 
the 4 single cysteine residues in each of the extracellular domains (N-terminal -  second 
loop and first loop -  third loop). The extracellular domain consists of the N-terminus and 
three extracellular loops (loops 2, 4 and 6), whilst the remaining loops (loops 1, 3, 5) and 
the C-terminus are intracellular. Structure-activity studies with CXC and CC chemokines 
have revealed that they have two major sites of interaction with their receptors: an amino- 
terminal domain that acts as a triggering domain (also known as the ‘message’ in the ‘two- 
site hypothesis’ model), activating the receptor; and a domain in the exposed loop after the 
second cysteine that acts as a docking domain (or ‘address’), restricting chemokine mobility 
allowing for the correct orientation of the triggering domain and responsible for receptor 








Figure 1.4. Model of the interaction between a chemokine and its receptor. The
scheme indicates that chemokines interact first with their docking and then with their 
triggering site, example given is for SDF-1/CXCL12 docking with CXCR4 (reproduced 
from (Baggiolini, 2001) initially published by (Crump et al., 1997)). B) indicates 
interaction of CXCL 12 with the N-terminal segment of the receptor (blue), followed by 
C), binding of the N-terminal region of CXCL12 with the groove (pink) above the 
helices leading to activation of the receptor (depicted as a conformational change).
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A number of chemokine receptors demonstrate remarkable promiscuity for the chemokines 
they bind. Although the receptors will only bind chemokines of their own class (i.e. 
CXCRs only bind CXCs), receptors such as CCR3 can bind up to 9 different chemokines 
(table 1.3). This is discussed in the ‘Receptor Promiscuity’ section in more detail.
All known chemokine receptors are coupled to the Bordetella pertussis toxin sensitive Gai 
proteins (excluding the ‘Silent Receptors’). Activated G ai subunits of heterotrimeric G 
proteins inhibit adenylate cyclase. Gpy subunits make up the heterotrimeric complex (See 
the “Signal Transduction Pathways” section for more detail). Currently, there are 11 
CCRs, 6 CXCRs and a solitary CX3CR and XCR. Generally, very little research has been 
carried out on these individual receptors. The two exceptions to this are CCR5 and CXCR4 
that were found to be co-receptors for HIV in the middle of the 1990s (Bleul et al., 1996; 
Deng et al., 1996; Feng et al., 1996; Oberlin et al., 1996). As would be expected, this led to 
a substantial increase in the study of these two receptors (table 1.4).





1 2 3 D 5 6 7 8 9 10 11
XCR 10 - - - - - - - - - -
CXC R 192 316 362 1922 82 49 - - - - -
C X 3C R 108 - - - - - - - - -
540 487 537 2523 185 324 129 42 28 6
Number of papers published for each individual chemokine receptor that is mentioned in 
the title or abstract, up until 31st December 2003. PubMed used as search engine.
* Includes papers associated with CCR4-NOT complex research (estimated total of CCR4 
chemokine papers is 247 (search = CCR4 + chemokine).
1.3 Chemokine & Receptor Biology 
Features
Inflammatory vs. Constitutive Chemokines
Every year, chemokines are found to play a role in an ever increasing number of 
pathological conditions and, depending on their function in immunity and inflammation,
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can be classified into two groups: inflammatory chemokines and homeostatic chemokines 
(figure 1.5). Inflammatory (inducible) chemokines are produced by many different cells 
(by both resident (e.g. endothelial and epithelial cells) and immigrating cells (e.g. 
leukocytes)) in inflamed tissue, in response to pro-inflammatory cytokines and bacterial 
toxins, with mRNA levels able to increase over 300-fold within a few hours of activation 
(Gerard and Rollins, 2001). These chemokines function to recruit effector cells, such as 
monocytes, granulocytes, and effector T cells, for host defence in infection and immunity. 
Conversely, homeostatic (constitutive/housekeeping/lymphoid) chemokines are expressed 
constitutively in defined microenvironments within lymphoid tissue and in the skin and 
mucosa. These chemokines are responsible for maintaining homeostatic leukocyte traffic 
and cell compartmentalisation within secondary lymphoid tissues. As a consequence, they 
are involved in relocation and recirculation of lymphocytes in maturation, differentiation 
and activation, therefore playing a role in the innate immune system (Baggiolini, 2001; 
Moser and Loetscher, 2001; Youn et al., 2000). In general, homing chemokine receptors 
are selective for no more than two ligands and inflammatory chemokine receptors are able to 
bind multiple ligands, with the exception of CXCR1 (IL-8 & GCP-2).
Figure 1.5. The functional classification of chemokines into inflam m atory, 
homeostatic and those tha t belong to both subfamilies.









However, this division of the receptors/ligands should not be regarded as absolute. It is 
clear, subsequent to reading the many chemokine reviews, that this classification varies 
from paper-to-paper, especially with regard to a few chemokines and where they should be 
placed (these include CX3CL1, CCL19, CCL28, CCL17, XCL1, XCL2). It is perhaps 
more accurate to use the terms constitutive and inducible rather than homeostatic or 
inflammatory, respectively. For example, CCR7/CCL19/CCL21 participate in the 
presentation of antigen to T cells due to its expression on B cells and dendritic cells (DCs), 
and even then CCL19 production is induced in maturing DCs and CCL18 production is 
massively upregulated (both generally considered to be constitutive, although CCL18 is 
constitutively transcribed in DCs before an increase in the levels of induction) (Sallusto et 
al., 1999b).
The ELR Motif  -  A Further Sub-Classification o f CXC Chemokines
The CXC subfamily of chemokines can further be divided in to two groups depending upon 
the presence of the tripeptide motif glutamic acid-leucine-arginine (ELR) preceding the 
first amino-terminal cysteine (table 1.2; fig. 1.2). Although ELR+ chemokines (ELR-CXC) 
tend to be specific for myeloid cells and the E L R - chemokines attract a variety of 
leukocytes; it is more interesting to note the opposing effects the two groups have on 
angiogenesis. Angiogenesis is the biological process through which blood vessels are 
generated. The ELR-CXC chemokines have been demonstrated to be very potent 
angiogenic factors, whilst the ELR-deficient CXC chemokines are strong angiostatic 
factors that inhibit the endothelial cell migration induced by ELR-CXC chemokines (Koch 
et al., 2001; Strieter et al., 1995b). This discovery has led to the observation that the 
balance between angiogenic and angiostatic chemokines appears to be altered in several 
diseases that will be discussed in the “Chemokines & Pathology” section.
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Chemokine Receptors as Markers o f Leukocytes and Subsets
Chemokine receptors are expressed on a large number of different cells in a wide variety of 
tissues (table 1.3), as are the chemokines produced by a variety of cells. However, certain 
leukocytes express certain chemokine receptors and subsets of different leukocytes display 
varying receptor profiles. This allows cells to be characterised according to their 
chemokine receptor expression profile (fig. 1.6). For instance, T helper cell subsets can be 
distinguished by the presence or absence of CXCR3, CCR4, CCR8; immature DCs can be 
defined from mature DCs by the presence of CCR1, CCR5, and CCR6 (with mature DCs 
additionally inducing the expression of CCR7). This allows for an efficient immune 
system where type of cell and its maturity defines its localisation and role within the 
immune response (this is reviewed in depth in the imminent “Chemokines and Their 
Physiological Role” section).
CCR7
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Figure 1.6. Overview of chemokine receptor expression on leukocytes. Represents a 
simplified view of some of the more important chemokine receptors on each cell type and 
the differences observed within subsets (e.g. the T cell subset). Abbreviations: NK, natural 




As mentioned earlier, most chemokine receptors can bind more than one chemokine in its 
class, e.g. CCR3 binds with high affinity no less than 9 CCL chemokines. Receptor 
promiscuity correlates generally with whether the chemokine is considered to be 
inflammatory or homeostatic, with the homeostatic (constitutive) chemokines generally 
having a “monogamous” relationship with their receptor (to be more precise, one or two 
ligands per receptor) and the receptors such as CCR1-3, 5 and CX CRI-2 binding multiple 
inflammatory chemokines (table 1.3). This is likely to be a result of evolutionary pressures, 
with the proliferation of inflammatory chemokines due to the ongoing battle with 
pathogens and the need to generate a more robust chemokine response (a result of 
redundancy in the system and is highlighted by knockout studies that are mentioned later). 
This is supported by the fact that species-specific chemokines are found normally within 
the inflammatory chemokines, yet the homeostatic chemokines exhibit a very conserved 
phenotype between mouse and human. Additionally, the genes encoding inflammatory 
chemokines tend to be present in clusters (CC = chr. 17; CXC = chr. 4), with homeostatic 
chemokine genes found in isolated chromosomal locations. This indicates that the 
homeostatic chemokines are under pressure not to diverge due to a critical function for the 
organism. The inflammatory chemokines cluster their genes suggesting that these are 
newer developments in evolution and are likely to share similar functions (A. Zlotnik, 
lecture, Chemokines II conference, Paris, Oct. 23, 2003). Robustness in the chemokine 
system is discussed in more depth in a review of chemokines by Alberto Mantovani 
(Mantovani, 1999).
Chemokines & Their Physiological Role
Chemokines and their receptors are involved in a variety of physiological processes (fig. 
1.7). The ELR-CXC chemokines are involved in the formation of new blood vessels that, 
along with other processes, are essential for effective wound healing (Gillitzer and 
Goebeler, 2001). During maturation, B and T cells regulate several chemokine receptors 
allowing these cells to traffic from bone marrow to spleen and then to other lymphoid tissue
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microenvironments (Annunziato et al., 2001; Bleul et al., 1998; Bowman et al., 2000; 
Hernandez-Lopez et al., 2002; Uehara et al., 2002). This discriminating migration is 
helped by the selective expression of chemokines within the lymphoid organs (Rossi and 
Zlotnik, 2000). Chemokines are also integral for effective immunity by both the innate and 
adaptive systems, involved in immune surveillance and leukocyte differentiation (Campbell 
et al., 2003; Kunkel et al., 2003; Luster, 2002; Luther and Cyster, 2001). Some receptors 
are essential for life, e.g. CXCR4 is required for embryogenesis and organogenesis. This 
was demonstrated with CXCR4 knockout models displaying defects in cardiogenesis and 
subsequent foetal lethality (chemokine knockout models are discussed in the following 
“Chemokines & Pathology” section) (Ma et al., 1998; Tachibana et al., 1998; Zou et al.,
1998). Conversely, the requirement for some chemokine receptors, most notably CCR5, 
appear to be redundant as highlighted by the fact that this chemokine receptor is 
functionally missing in some individuals without any apparent consequences in the 
individuals health, but its loss can provide a degree of protection from HIV (Dean et al., 
1996; Huang et al., 1996; Liu et al., 1996; Martinson et al., 1997; Samson et al., 1996a). 
There are a number of papers reviewing the biological functions of chemokines in much 
more detail than reviewed here (Mackay, 2001; Rossi and Zlotnik, 2000).
Angiogenesis/Angiostasis
Lymphocyte Maturation Wound Healing
Innate
Immunity Chemokines/Receptors




Figure 1.7. Physiological functions of chemokines and chemokine receptors.
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Naive T cells (and other leukocytes) continuously recirculate from the blood to lymph 
nodes and other secondary lymphoid tissues during immune surveillance, returning to the 
blood via the lymphatics. Activated T cells, and other leukocytes, are additionally recruited 
from the blood to sites of inflammation and tissue damage. A key process in this pathway 
is the extravasation of the leukocyte in to the surrounding tissue from the blood vessels, 
with chemokines playing a pivotal role.
Leukocyte Extravasation
Intravascular leukocytes are exposed to extraordinarily high shear stresses within the 
mainstream of blood and, without adequate equipment, would be extremely difficult to exit 
the flow, much like an individual attempting to exit a raging river after falling in. 
Fortunately, leukocytes have a well-coordinated and efficient mechanism of extravasation 
from the blood vessel. Von Andrian and Mackay (Von Andrian and Mackay, 2000) made 
an enlightening comment about the extent of the physical conditions the leukocytes are 
under in the blood stream: “the jet d ’eau fountain in Lake Geneva spouts 500 litres of water 
per second with a mean velocity of 200 km per hour, reaching a height of 140 m. 
Assuming that a cross-section of the water column is circular, the wall shear stress at the 
nozzle equals approximately 41.5 dyn per square centimetre.” Compare this to a shear 
stress of up to 50 dyn per square centimetre for the flow of blood in a vessel.
In order to enable a better efficiency of extravasation, leukocytes usually attach to post­
capillary venules where the shear stress is the lowest (Alon et al., 1998). The initial step in 
leukocyte extravasation is the tethering/rolling of marginated leukocytes to the endothelium 
via transient interactions with selectins (at highest density on microvillous surface 
protrusions -  L- and P-selectins being most effective) that bind ligands modified with 
specific carbohydrate epitopes (fig. 1.8) (Vestweber and Blanks, 1999; Von Andrian et al.,
1995). L-selectin is expressed constitutively on leukocytes and recognises sulphated sialyl- 
Lewis (sLex)-like sugars (called peripheral-node addressin (PNAd)) in high endothelial 
venules; E- and P-selectin are upregulated by activated endothelium in response to 
inflammatory stimuli and bind P-selectin glycoprotein ligand 1 (PSGL-1) and free sLex - 
like glycans. PSGL-1 binding to P-selectin requires sLeMike sugars to be close to a tri­
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tyrosine sulphated motif in the N-terminal. The a4  integrins (activation-independent) are 
also able to support leukocyte rolling and tethering (Alon et al., 1995; Bargatze et al., 1995; 
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Figure 1.8. The process of leukocyte extravasation. The movement of leukocytes from 
the micro vasculature to the area of pathogen in the surrounding tissue involves: tethering; 
rolling; activation of integrins; arrest (firm adhesion); diapedesis; and chemotaxis. 
Abbreviations: sL e\ sialylated Lewis X -  like glycans; Y, tyrosine sulphated motif; LPS, 
lipopolysaccharide; PSGL-1, P-selectin glycoprotein ligand 1; PNAd, peripheral-node 
addressin; MAdCAM-1, mucosal addressin-cell adhesion molecule 1; VCAM-1, vascular­
cell adhesion molecule 1; ICAM, intercellular adhesion molecule.
In order for firm adhesion to occur, the integrins (in their low-affinity state for ligands) 
must become activated. Specific GPCRs on the leukocytes respond to chemoattractants, 
such as chemokines, PAF, LTB4, C5a and formyl peptides, displayed by endothelial cells 
where they cause the rapid activation of p2 and/or a4  integrins which then bind to members 
of the endothelial immunoglobulin superfamily. Although most chemokines are secreted 
(except CX3CL1 and CXCL16) it is unlikely that they would persist at the blood- 
endothelium interface due to the shear flow. Therefore, it is likely that the chemokines
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bind to GAGs leading to the immobilisation of chemokines on the endothelial cell surface 
(Amara et al., 1999; Tanaka et al., 1993; Webb et al., 1993).
Once the leukocyte has arrested it then transmigrates across the endothelium and in to the 
tissue, a process termed ‘diapedesis’. Diapedesis is a technique in which the leukocyte, via 
rapid disassembly o f  its cytoskeleton, crawls between tightly apposed endothelial cells by 
forming a pseudopod, and reassembles itself on the abluminal side of the endothelium. 
Unlike the processes mentioned so far, where all the interactions have been heterophillic, 
diapedesis relies on at least 2 major homophilic interactions involving platelet-endothelial- 
cell adhesion molecule-1 (PECAM-1/CD31) and CD99 (Schenkel et al., 2002). These 2 
molecules and along with another 4 (VE-cadherin, JAM-A, -B, -C) are thought to play 
major roles in diapedesis (JAM-A and -C  are also expressed on leukocytes and may take 
part in homophilic interactions) (Muller, 2003). Blocking homophilic PECAM interaction 
blocks diapedesis with no pseudopods entering the intercellular junction (Liao et al., 1995; 
Liao et al., 1997). Diapedesis also requires a transient increase in intracellular free calcium 
within the endothelial cells the leukocyte is adjacent to (Huang et al., 1993). The increase 
in intracellular calcium activates myosin light chain kinase leading to a conformational 
change in myosin II and subsequent contraction of actin-myosin bundles. This leads to the 
retraction of the endothelial cells facilitating leukocyte passage (Hixenbaugh et al., 1997; 
Saito et al., 1998). Once the cell has squeezed through the endothelium it then becomes 
susceptible to chemokine gradients, leading to chemotaxis of the cell to specific locations 
in the tissue.
Chemotaxis
Chemotaxis is the directional cell movement up a chemoattractant gradient. In order for a 
cell to chemotax it requires dynamic and spatially regulated changes to the cytoskeleton 
and cell adhesion. This results in a defined cell polarity in which the cytoskeletal 
components are differentially localised at two poles of the cell, determining the front and 
rear. Cell migration is a multi-step process that can be divided into four mechanistically 




2) New adhesion formation,
3) Cell body contraction,
4) Tail (uropod) detachment & retraction.
Lamellipodium extension requires actin polymerisation, with lamellipodia consisting of 
branching networks o f F-actin. Lamellipodium can vary in breadth from 1 - 5  jam 
depending on cell type and can exhibit variable numbers of radiating bundles 0.1 -  0.2 pm  
in diameter and many pm  long (microspikes or filopodia) (Small et al., 2002). This 
lamellipodia extension is then stabilised through the formation of new adhesions to the 
extracellular matrix. These small focal complex structures (involving integrins) are 
localised to the lamellipodia and it is important that focal complexes/adhesions turn over 
for cells to migrate. This is demonstrated with the inhibition of cell migration when there is 
a high-level of integrin-mediated adhesion (due to strength of attachment) (Cox et al.,
2001). Actomyosin contractility regulates cell body contraction (Mitchison and Cramer,
1996) and adhesion turnover regulates cell retraction.
Chemotaxis is an important phenomenon that plays a pivotal role in physiological 
processes, including embryogenesis/organogenesis, wound healing, leukocyte maturation, 
lymphoid trafficking and general immunity. The unique pattern of receptor expression and 
the distinct activity of chemokines allows for the precise control of the above-mentioned 
functions through tissue-specific leukocyte homing.
Immune Function & Tissue-Specific Leukocyte Homing
Leukocytes express several types of chemokine receptor that are required for extravasation 
and positioning within secondary lymphoid organs. Receptors are upregulated (CXCR5, 
CCR4 and CCR8) and downregulated (CCR7) following T cell activation to promote the 
cooperation with B cells (that secrete MDC (CCR4 ligand) among others) in primary 
immune responses and to direct these new subsets of cells to specific areas within the body 
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Figure 1.9. The role of chemokines in general allergic pulm onary inflammation. (1)
Immature DCs traffic from the bone marrow in to the respiratory epithelium. (2) Once DCs 
have picked up antigen in the tissue they become activated and downregulate specific 
chemokine receptors and upregulate CCR7. This results in the DCs migrating to the lymph 
node where they activate naive T cells generating Th2 cells. (3) These Th2 cells then leave 
the lymph node and travel back to the lung where they can be reactivated by exposure to 
inhaled antigen. Activated Th2 cells release Th2 cytokines (IL-4 and IL-13), which then 
induce the release of eotaxins (CCL11, CCL24, CCL26) and the CCR4 ligands MDC 
(CCL22) and TARC (CCL17) from the respiratory epithelium. (4) These ‘Th2 
chemokines’ then recruit more Th2 cells as well as other leukocytes (eosinophils, 
basophils, mast cells). SLC (CCL21), M IP-3a (CCL20), 1-309 (CCL1), ELC (CCL19), 
BLC (CXCL 13), MCP-4 (CCL13). Reproduced from (Luster, 2001).
Immature DCs are attracted to the tissue by inflammatory chemokines and, once in the 
vicinity of the inflammatory stimulus, pick up antigen causing the DCs to mature in to cells 
capable of activating lymphocytes. During this maturation DCs downregulate their 
expression of CXCRI, CCR1, 2, 5, 6 and upregulate CCR7 (and CXCR4/CCR4) 
expression (Dieu et al., 1998), making the cells less responsive to inflammatory 
chemokines but allowing them to respond to CCL21 and CCL19 (both CCR7). These 
guide the cell into the lymphatics and, ultimately, into the T cell rich regions of lymph 
nodes where they are able to interact with and stimulate T cells (Forster et al., 1999; 
Sallusto et al., 1999b; Sallusto and Lanzavecchia, 2000). Chemokines are also involved in 
bringing naive T and B cells from blood across high endothelial venules (HEV) into the
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lymph nodes and in to the T and B cell follicles. CCL19 and CCL21 are required for the T 
cell localisation, whereas CXCL13 is required for the B cells (Cyster, 1999; Gunn et al., 
1998a; Gunn et al., 1998b). This activation o f T cells leads to their polarization and the 
generation of distinctive sets of T cells. Thl cells express high levels of CCR5 and CXCR3 
and are directed towards sites where IFNy has induced the production of these receptors’ 
respective chemokines. Thl cells play a role in the defence against intracellular bacteria 
and many viruses. Th2 cells express CCR4, CCR8 and CCR3, and IL-4/IL-13-induced 
production of their respective chemokines recruits these cells to sites of allergic 
inflammation (and parasitic infections) (Moser and Loetscher, 2001). Follicular homing T 
(Tfh) cells upregulate expression of CXCR5 and are localised to within germinal centres of 
secondary lymphoid organs and may play a role in antibody responses (Mackay, 2000). All 
of these T cell subsets downregulate CCR7.
Where trafficking of CCR7+ T lymphocytes is generally restricted to T cell areas of 
lymphoid organs, effector memory T (T em) cells are found at low levels in every tissue 
within the body and are preferentially recruited to extra-lymphoid sites and display 
selective homing abilities for tissue type. Some of these cells must also mount secondary 
proliferative responses and therefore require CCR7 expression (and L-selectin -  binds E- 
selectin, MAdCAM and all sLex-like sugars) -  central memory T (T cm) cells . T em cells 
combat the spread of pathogen whereas T cm guard against subsequent infections. Naive T 
cells are distinguished from memory by the presence or absence of CD45RA, respectively 
(memory are CD45RO+), with CCR7 expression distinguishing the two types of memory T 
cells (T cm cells can differentiate in to T em cells) (Sallusto et al., 1999a). These T em cells 
can be further subdivided and these subsets display remarkable specificity for types of 
tissue. CLA+ (cutaneous lymphocyte antigen -  binds E-selectin) ot4pl+ (VLA-4 -  binds 
VCAM-1, fibronectin, oc4 integrin) CCR4+ CCR10+ T em cells migrate specifically to 
subcutaneous tissue (skin) (Campbell et al., 1999a; Homey et al., 2000); oc4P7+ (binds 
MAdCAM, fibronectin, VCAM-1 weakly) CCR9+ T em cells migrate specifically to gut 
mucosal tissue (fig. 1.10) (Zabel et al., 1999). The memory T cells lack L-selectin whereas 
all other leukocytes express it, and both memory populations possess increased levels of 
























Figure 1.10. The different m igration preferences for different types of memory cell.
See text for more detail (Mackay, 1999).
Chemokines & Pathology
The ease in which induction of chemokines can occur along with their high levels of 
expression can, and does, lead to inappropriate tissue damage. The initial chemokine- 
recruited leukocytes may induce even higher levels of new chemokine expression leading 
to more extensive tissue damage, a feed-forward mechanism. Therefore, the protective 
effects of leukocytes can lead to disease. There is widespread evidence of chemokine 
expression in diseases (table 1.5) and one of the human pathological conditions in which 
chemokines or their receptors have been unequivocally implicated in is HIV infection.
In the mid-1990s, chemokines got immense publicity when it emerged that CCR5 and 
CXCR4 were co-receptors for HIV and that their ligands were able to block HIV entry into 
CD4+ cells (macrophages (M-tropic -  CCR5) and T cells (T-tropic -  CXCR4)) (Choe et al., 
1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996). The importance of these 
receptors for HIV entry is highlighted by the fact that individuals who lack functional 
CCR5 are resistant to HIV-1 infection (Samson et al., 1996a). Over the last few years a 
large number of chemokine receptors have been shown to serve as co-receptors for the 
virus (Simmons et al., 2000).
24
QShtrociuctwn
Table 1.5. A selection of diseases that chemokines/receptors have been implicated in 
their pathology (either due to increased or decreased expression on cells or in tissue).
Diseases Chemokine Receptors Involved
Liver Disease
Ischeamia reperfusion CCR2, CCR9/10, CXCR2, CXCR3
Hepatitis CCR2, CCR9/10, CXCR3, CXCRI, CXCR2
Graft-Versus-Host Disease (GVHD) CCR1, CCR5, CCR9/10, CXCR3
Liver cancer CXCR3, CXCR4
Respiratory Disorders
Asthma/Allergic inflammation of the CCR1, CCR2, CCR3, CCR4, CCR8
airways CXCRI, CXCR2
Idiopathic pulmonary fibrosis CX CRI, CXCR2, CXCR3
Chronic bronchitis CX CRI, CXCR2, CCR2
Chronic obstructive pulmonary disease CX CRI, CXCR2, CCR2
Autoimmune Diseases
Multiple sclerosis/EAE CXCR3, CCR2, CCR5
Type-1 diabetes CXCR3
GVHD CXCR3, CCR1, CCR2, CCR5
Rheumatoid arthritis CCR2, CCR5, CXCR2, CXCR3
Neoplasia
Tumour growth CX CRI, CXCR2, CXCR3, XCR1,
Metastasis formation CXCR4, CCR7, CCR10
Infections






Wound Healing CX CRI, CXCR2
Psoriasis CXCR2, CCR4, CCR6, CCR 10
An interesting structural feature of the CXC chemokines with relation to diseases is the 
presence of the ELR motif preceding the first cysteine in the CXCRI and CXCR2 receptor 
ligands. These chemokines have been shown to be angiogenic whereas the ELR-negative 
CXC receptor ligands are angiostatic. Therefore, the angiogenic (promote new blood 
vessel formation) chemokines have been implicated in tumours, where a good blood supply 
is essential, and metastasis. Conversely, angiostatic chemokines inhibit tumour growth. 
Other diseases associated with angiogenesis include psoriasis, rheumatoid arthritis (pannus 
formation) and idiopathic pulmonary fibrosis. These references provide far more in depth
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information on the roles of chemokines and their receptors in disease (Baggiolini, 2001; 
Gerard and Rollins, 2001; Homey et al., 2002; Murphy et al., 2000; Owens et al., 2001; 
Rossi and Zlotnik, 2000).
Chemokines & Their Receptors as Therapeutic Targets
To date there are currently no chemokine receptor antagonists or agonists on the market to 
treat a pathological condition. However, the development of knockout and transgenic mice 
for almost all the chemokine receptors and many of the chemokines has demonstrated the 
importance of chemokines in disease (and physiology) and the potential benefit as 
therapeutic targets (table 1.6). In general, the deletion o f chemokines and receptors pivotal 
to basal trafficking and homing have noticeable phenotypes, whereas those that are 
inducible are viable and normal, with phenotypic differences only evident when the animals 
are exposed to specific inflammatory conditions (although there are differences in 
leukocyte compartmentalisation in the absence of stimuli). To date, only the CXCR4 
knockout has proven to be embryonically lethal. There is extensive research being carried 
out to look at the potential role of chemokine receptor agonists for diseases such as HIV 
and conditions like cancer, and the role of antagonists in chronic deleterious immune 
conditions (Cascieri and Springer, 2000). Three types of antagonist stand out: small 
molecule chemokine receptor inhibitors (e.g. TAK-779 a CCR5 antagonist (Baba et al., 
1999)); modified chemokines e.g. MetRANTES (arthritis/airway inflammation) and AOP- 
RANTES (HIV-1 infection) -  both N-terminal peptides (Plater-Zyberk et al., 1997); and 
monoclonal antibodies to chemokine receptors or ligands (e.g. anti-Mig (Koga et al.,
1999)). A recently found twist in the tail is the ability of CXCR3 agonists to acts as CCR3 
antagonists (Loetscher et al., 2001), and the CCR3 agonists, CCL11/CCL26, to inhibit 
CCR2 (Ogilvie et al., 2001; Ogilvie et al., 2003), suggesting a new mechanism of 
regulation of leukocyte recruitment during inflammatory and immune reactions. The next 
few years is likely to see a flurry of chemokine-related treatments for various diseases 
entering clinical trials and whether the treatments currently in Phase I clinical trials are able 
to make it to the market (Boehncke and Schon, 2003; Gao and Metz, 2003; Houshmand and 
Zlotnik, 2003; Onuffer and Horuk, 2002; Proudfoot et al., 2003; Schwarz and Wells, 2002).
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Table 1.6. Chemokine receptor knockouts and transgenic models.
C h e m o k in e  R e c e p t o r  K n o c k o u t s
CC Receptors
CCR2
Reduced atherosclerosis in ApoE ' mice, at least partly due to defects in macrophage 
recruitment; Imbalance in the production of Th2 cytokines, such as IFNy; Increased 
susceptibility to pulmonary Cryptococcus infection; Reduced Langerhans cell migration 
to draining lymph nodes; Increased severity of experimental glomerulonephritis; 
Inability to clear Listeria infections but less susceptible to L. donovani infection, 
cockroach allergen-induced bronchial hyperreactivity, and granuloma formation (beta 
glucan, Schistosome egg or PPD challenge), but were more susceptible to the injurious 
effects of Aspergillus fumigatus challenge in the lung; Reduced EAE susceptibility 
(MOG model); Partial protection in DSS-induced colitis; CCR2 is a negative regulator 
of hematopoiesis.
CCR3
No effect on the basal trafficking of eosinophils to the lung but does effect trafficking to 
the intestinal mucosa. However, eosinophil recruitment to the lung is severely curtailed 
following antigen challenge, but paradoxically, an increase in airway 
hyperresponsiveness to methacholine stimulation and increased mast cell accumulation 
to the airways. Additionally, knockout mice showed reduced infiltration of eosinophils 
to the skin in an atopic dermatitis model, with no effect on Th2 or mast cell recruitment.
CCR5
Increased mortality following Cryptococcus infection; Reduced clearance of Listeria 
infections; No protection in EAE; Resistance to DSS-induced colitis; Enhanced T cell- 
dependent immune responses (DTH reaction); Reduced macrophage recruitment and 
demyelination in a mouse model of hepatitis intracranial infection, but comparable T 
cell migration to wild-type mice; Protection against various M-tropic strains of HIV.
CCR8
Defective Th2 responses in models of Schistosoma mansonii-soluble egg antigen- 
induced granuloma formation and in ovalbumin and cockroach antigen-induced airways 
inflammation, with reduced eosinophilia; Normal Th2 development but aberrant Th2 
cytokine production; Another asthma model demonstrated no effect of CCR8  deletion




CXCR1 Reduced neutrophil recruitment.
CXCR2
Lymphadenopathy, splenomegaly and increased B cell numbers; Delayed wound 
healing; Defective acute neutrophil accumulation; Reduced macrophage recruitment in 
atherosclerosis; Required for protection against Toxoplasm a gondii infection and 
urinary tract infection; Protection against septic injury.
CXCR3 Resistance to GVHD (cardiac); Phenotypically normal.
1 CXCR6 No data available.
Others
Chemokines
MCP-1/CCL2 Reduced atherosclerosis in ApoE7 mice; Protection in EAE.
M IP-1 a/CCL3 Reduced inflammation of the airways; No protection in EAE.
Eotaxin/CCLl 1
No effect on eosinophil accumulation in lung inflammation; Eotaxin gene knockout and 
protein neutralization in animal models has suggested a role for CCR3 in eosinophil 
mobilisation and distribution (intestinal but not lung), and in allergic inflammation 
(skin); An alternative study demonstrated 10%  reduction in eosinophil recruitment to 
the airways in the ovalbumin model o f allergic inflammation of the airways.
IP-10/CXCL10 Prolonged survival of hearts in GVHD model; No effect on the trafficking of T cells to the CNS in an EAE model.
SDF-1/CXCL12 Similar phenotype to its receptor (CXCR4) knockout.
T r a n s g e n ic  E x p r e s s i o n  o f  L ig a n d s
MCP-1/CCL2 Exacerbation of ischemic brain injury, with recruitment of inflammatory cells; Transient and severe encephalopathy.
M IP-la/CCL3 Increased neutrophil and NK cell accumulation and stimulation of innate immunity in murine bacterial pneumonia.
TECK/CCL25 Localiastion of activated CD8a(3 lymphocytes to intestinal mucosa.
IP-10/CXCL10 Increased leukocyte infiltration in the CNS; Increased airway hyperreactivity and airway inflammation in mouse model of asthma
SDF-1/CXCL12
Enhanced myeloid progenitor cell survival/antiapoptosis and myelopoiesis (marrow and 
splenic); Recruitment of DCs, B cells and plasma cells (but not T cells) to pancreatic 
islets after ectopic expression of SDF-1/CXCL12.
BLC/CXCL13
In addition to attracting B cells, BLC/CXCL13 expression in pancreatic islets led to 
development of lymph node-like structures that contained B and T cell zones, high 
endothelial venules, stromal cells, and the chemokine SLC/CCL21 (lymphoid 
neogeneisis).
The chemokine receptors have been colour coded to denote homeostatic, 
homeostatic/inflammatory, or inflammatory (no colour) chemokine receptors. Please note 
that the chemokine knockout and transgenic section is by no means an exhaustive collection 
of the published data. The majority of the data is derived from the following references: 
(Lucas and Greaves, 2001; Power, 2003; Proudfoot, 2002; Proudfoot et al., 2003).
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1.4 CC Chemokine Receptor 4 (CCR4)
The research contained within this thesis is primarily concerned with the signal 
transduction pathways downstream of CCR4 upon ligation with its respective ligands, 
MDC/CCL22 and TARC/CCL17. For that reason, a brief review of CCR4/MDC/TARC 
biology follows.
Physiological Characteristics of CCR4, MDC & TARC 
CCR4
CCR4 is a 41.4 kDa seven-transmembrane G protein-coupled receptor with a high affinity 
for the ligands, Thymus- and Activation-Regulated Chemokine (TARC/CCL17) and 
Macrophage-Derived Chemokine (MDC/CCL22) (Imai et al., 1996; Imai et al., 1998). 
Previously known as K5-5, it has an open reading frame predicting a polypeptide 360 
amino acids long with the gene mapped to chromosome 3p24 (Samson et al., 1996b). The 
cDNA was originally cloned from a human basophilic leukaemia cell line in 1995, and 
RANTES/CCL5, MCP-1/CCL2 and MIP-lot/CCL3 have shown to be weak CCR4 agonists 
(Power et al., 1995b).
CCR4 is expressed on T helper cells type 2 (Th2s) (Bonecchi et al., 1998; DAmbrosio et 
al., 1998; Sallusto et al., 1998), CLA+ cutaneous memory T cells (Campbell et al., 1999a), 
natural killer (NK) cells (Godiska et al., 1997; Inngjerdingen et al., 2000), thymocytes 
(Andrew et al., 2001; Chantry et al., 1999; Taylor, Jr. et al., 2001), immature dendritic 
cells, basophils, monocytes and platelets (Abi-Younes et al., 2001; Clemetson et al., 2000; 
Power et al., 1995a; Power et al., 1995b). CCR4 functions currently include the migration 
of CLA+ cutaneous memory T cells to the skin (Campbell et al., 1999a; Campbell and 
Butcher, 2000); dendritic cell trafficking (Godiska et al., 1997); T cell maturation 
(Campbell et al., 1999b; Chantry et al., 1999); and Th2 cell recruitment to areas of antigen 




TARC is an 8 kDa (71 amino acids (94 amino acids (ORF) with first 23 forming a signal 
peptide)) secreted protein that binds with high affinity (Kd < 0.5 nM) to CCR4 (Imai et al., 
1996; Imai et al., 1997) and has also been linked to CCR8 (fig. 1.11) (Bernardini et al.,
1998). It is constitutively expressed by the thymus, monocytes and dendritic cells and can 
be induced in other cells, such as B cells, keratinocytes and airway epithelial cells, but not 





Figure 1.11. S tructure of TARC. Each monomer of TARC has the characteristic fold of 
CC chemokines consisting of a three-stranded anti-parallel p-sheet flanked by a C-terminal 
a-helix (top). In the majority of CC chemokines, dimerization is promoted by interactions 
between the N-termini of both monomers, while the C-terminal helices are the most distant 
regions of the molecules. Although both of these features are present in the case of TARC, 
the dimers found are more compact compared with other CC chemokines. Reproduced 




MDC, like TARC, is also an 8 kDa (69 amino acids (93 amino acids ORF)) secreted 
protein with high affinity (Kd ~ 0.2 nM) exclusively for CCR4 (Godiska et al., 1997). It is 
constitutively expressed by macrophages, mature dendritic cells, intestinal epithelial cells 
and B cells, and can also be upregulated in monocytes and T cells (Andrew et al., 1998; 
Berin et al., 2001a; Galli et al., 2000; Vulcano et al., 2001). Both MDC and TARC are 
classed as homeostatic and inflammatory chemokines (fig. 1.5) and share a 32% sequence 
similarity (Mantovani et al., 2000).
Pathological Roles of CCR4, MDC & TARC
Figure 1.12 shows the pathological conditions that CCR4 and/or its ligands have been 
implicated in. Until recently, there has been a lack of neutralising monoclonal antibodies, 
small molecule antagonists and knockout mice towards CCR4, which has made it hard to 
determine the role of the receptor in pathologies. Consequently, potential roles for CCR4 
in diseases have been largely inferred based on the analysis of TARC and MDC in animal 
models of diseases.
Allergic Inflammation of the Airways 
(Asthma)
Lymphomas





Fulminant Hepatic Failure Endotoxic Shock (Sepsis)
Juvenile Rheumatoid Arthritis
Figure 1.12. A few of the pathological conditions CCR4 and its ligands have been 




Owing to the initial belief that CCR4 was exclusively expressed on Th2 cells, early 
pathological roles for CCR4 concentrated on known Th2-mediated conditions. One of the 
most widespread Th2-mediated diseases in the general population, and consequently most 
profitable should a first-rate treatment be found, is allergic inflammation of the airways 
(e.g. asthma). As a result, the majority of research into the role of CCR4 in diseases has 
been in this area. A study by Lloyd et al. (Lloyd et al., 2000), showed that MDC/CCR4 
plays a critical role in the homing of antigen-specific Th2 cells in a T cell transfer model of 
allergen-induced lung injury in mice. This migration of Th2 cells gave rise to eosinophilia 
and bronchial hyperresponsiveness. The CCR3/CCL11 pathway is critical in the acute 
stages but CCR4/MDC dominates the chronic inflammatory response (after repeated 
allergen challenge), being primarily responsible for the long-term recruitment of antigen 
specific Th2 cells to the airways. It has been shown that the bronchial epithelial cells are a 
source of TARC, with more intense expression in asthmatics compared to normal subjects 
(Berin et al., 2001b; Panina-Bordignon et al., 2001; Sekiya et al., 2000). A recent study has 
demonstrated that bronchial epithelial cells are also a source of MDC, and that the BAL 
fluid of asthmatics has massively increased levels o f MDC compared to normals (Panina- 
Bordignon also showed MDC levels increased but Sekiya found MDC levels were 
unaltered in asthmatics compared to normal) (Bochner et al., 2003; Lezcano-Meza et al., 
2003). T N Fa + IL-4 and IFNy separately were able to induce the expression of TARC and, 
with all three, the enhancement was greatest, and showed that IL-4 on its own has no effect 
both in vitro and in vivo (Berin et al., 2001b). In addition, naive T cells have been observed 
to produce both TARC and MDC, contributing to the local migration of Th2 cells (Hirata et 
al., 2003). Interestingly, glucocorticoids were shown to almost completely inhibit TARC 
expression at both the mRNA and protein levels, suggesting that the beneficial effects of 
glucocorticoids in current treatments for asthma may be at least in part due to their 
inhibitory effects on TARC production by the bronchial epithelium. Steroidal treatment 
has also been demonstrated to shift the balance away from CCR4 Th2 cells to CXCR3 
expressing T cells (Kurashima et al., 2001). Recently, a group showed for the first time 
that TARC was pivotal in the development of Th2-mediated allergen-induced asthma, with 
eosinophilia and airway hyperresponsiveness, by attenuating this condition with an 
antibody against TARC. It was also the first time that there had been success in controlling
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Th2 cytokine production in vivo by targeting a chemokine (Kawasaki et al., 2001). Mouse 
polyclonal antibodies against MDC have also been shown to protect against eosinophilia 
and bronchial hyperresponsiveness despite MDC not appearing to play a role in 
inflammatory airway disease according to other groups (Gonzalo et al., 1999). In patients 
with chronic hypereosinophilia, high levels of TARC (but not MDC) induces the down- 
regulation of CGR4 on Th2 cells in vivo, and that the source of TARC is likely to be 
dendritic cells stimulated by Th2 cytokines. This receptor down-regulation can be inhibited 
with a mAb against TARC (but not MDC) (de Lavareille et al., 2001). Panina-Bordignon 
and co. (Panina-Bordignon et al., 2001) demonstrated there was a significantly higher 
number of infiltrating CCR4+ Th2 cells compared with controls, but Campbell et al. 
(Campbell et al., 2001) showed that there was no difference in the expression o f receptors 
on T cells in asthmatic subjects compared with normals. They did observe that the lung T 
cell expressed a profile of chemokine and adhesion receptors distinct from gut or skin 
homing T cells. Another study that quenches the role of CCR4 in asthma much more 
seriously used a knockout model. The deletion had no effect on Th2 differentiation in vitro 
or in a Th2-dependent model of airway inflammation, with no differences in eosinophilia or 
bronchial hyperresponsiveness (Chvatchko et al., 2000). In contrast, a second CCR4'7' 
model displayed attenuated airway hyperresponsiveness in an Aspergillus fumigatus mouse 
model of airway inflammation (there was no effect on airway remodelling) (Schuh et al.,
2002). Recently, a study using an anti-CCR4 Ab had no effect on a guinea-pig model of 
allergic inflammation of the airways (Conroy et al., 2003). These conflicting views on the 
role of CCR4 in asthma may be explained by the intrinsic differences in blocking with a 
ligand rather than a receptor; using genetically modified mice rather than a neutralising 
antibody; or the varying model system. Two other airway diseases, chronic obstructive 
pulmonary disease and pulmonary sarcoidosis, are characterised by infiltrating T cells that 
lack CCR4 (Panina-Bordignon et al., 2001).
Skin Disease
Another extensive area of CCR4-mediated disease research is that of atopic dermatitis. 
Four years ago it was observed that CCR4 is present on almost all cutaneous lymphocyte 
antigen (CLA) expressing memory T cells and other systemic memory T cells that are 
CLA* and a4(37‘ (gut homing T cells are oc4p7+) (Campbell et al., 1999a). Major subsets of
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these memory T cells have both T hl and Th2 potential expressing the receptor CCR4 as 
well as the Thl-associated receptor CXCR3 (Andrew et al., 2001). The CLA+ memory T 
cells are skin homing and have been found in areas of chronically inflamed skin, and 
TARC induces the integrin-dependent adhesion of these cells to ICAM-1 (Campbell et al., 
1999a). A paper published the same year showed that TARC is highly expressed in a 
mouse model of atopic dermatitis and not at all in controls, and that keratinocytes could be 
induced to produce TARC. MDC levels were also upregulated and the source identified as 
dermal dendritic cells (Vestergaard et al., 1999) ((Vestergaard et al., 2000) showed that the 
same features occurred in the human form of the disease as in mice). Additionally, TARC 
production by maturing Langerhans cells (immature DCs found in epidermis) has been 
observed in response to IL-4 (Xiao et al., 2003). Subsequently, a relatively large number of 
papers have confirmed the role of CCR4 and its ligands in atopic dermatitis (Biedermann et 
al., 2002; Okazaki et al., 2002; Uchida et al., 2002; Vestergaard et al., 2003; Zheng et al.,
2003). Another pathological condition concerning the skin, psoriasis vulgaris, has 
implicated CCR4 in the T lymphocyte homing to the psoriatic dermis along with CXCR3 
(Rottman et al., 2001). There appears to be a role for CCR4-expressing Tc2 cells (Inaoki et 
al., 2003) in this condition, but this is generally considered to be a T hl disease and other 
groups have demonstrated no role for CCR4-expressing skin-homing cells (Vestergaard et 
al., 2003).
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a Thl-mediated disease and, as mentioned above, 
CCR4 is not present on a4 p 7 + (gut homing) T cells (<10%). However, MDC and TARC 
levels are increased in animal models o f colitis along with CCR4 (Scheerens et al., 2001). 
A population of circulating T cells that are CD45RO+p7hl and are thought to preferentially 
migrate to the intestinal lamina propria and epithelium are CCR4+ (28%) (Agace et al.,
2000). Conversely, a recent study indicated that CCR4 expressing memory T cells had a 
role to play in Crohn’s disease but not ulcerative colitis (Jo et al., 2003). Furthermore, 
MDC has been shown to be constitutively expressed and upregulated on intestinal epithelial 




Other diseases CCR4 and/or MDC/TARC have been implicated in include endotoxic shock 
(Chvatchko et al., 2000); rheumatoid and juvenile rheumatoid arthritis (Katschke, Jr. et al., 
2001; Ruth et al., 2001; Thompson et al., 2001); anti-leukaemia T cells (Ghia et al., 2001); 
Fulminant hepatic failure (Yoneyama et al., 1998); Hodgkin’s lymphoma (van den et al.,
1999); and T cell non-Hodgkin lymphoma (Jones et al., 2000); Adult T cell lymphoma 
(Ishida et al., 2003; Yoshie et al., 2002). Recently, a study observed that CCR4-expressing 
regulatory T cells appeared responsible for the reversal of Type I diabetes upon treatment 
with an anti-CD3 mAb (Herold and Taylor, 2003; Kim et al., 2002). Finally, MDC exhibits 
antiviral activity against M- and T-tropic HIV-1 strains, however, this does not occur via 
CCR4 (Struyf et al., 1998). Moreover, MDC is able to induce human eosinophil 
chemotaxis despite the lack of CCR4 mRNA (Bochner et al., 1999; Borchers et al., 2002; 
Nagase et al., 2001). Therefore, there appears to be a second unidentified receptor for 
MDC and this may explain some of the conflicting results observed in other disease 
models.
1.5 Signal Transduction Pathways 
Overview
Thus far, the pathophysiology of chemokines and their receptors have been discussed. A 
chemokine exerts its effect on a cell by activating a plethora of signal transduction 
pathways via ligation of its specific receptor (e.g. CCR4). This leads to the induction of a 
cellular function, such as cell spreading, proliferation, cytokine secretion, and cell 
migration. The following section will review the principal players and the signalling 
pathways thought to be involved in chemokine-mediated directed cell migration.
As with all G-protein coupled 7-transmembrane receptors, the receptor acts as a ligand- 
dependent GDP exchange factor with receptor ligation leading to the exchange of GDP for 
GTP in the receptor-associated GDP-bound G protein. This leads to the Ga and Gpy subunits 
dissociating and activating various signalling cascades, with the receptor reverting to a low 
affinity state. Subsequently, following GTP hydrolysis, the Ga subunit (now in its GDP-
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bound inactive form) reassociates with the Gpy subunit and terminates the signalling 
response. To date, almost all chemokine receptor activated signalling pathways are 
Bordetella pertussis toxin (PTX) sensitive, indicating that the Gaj subunit is the principal 
G a protein utilised (PTX catalyses ADP-ribosylation of the G«i protein thus preventing it 
interacting with the receptor). However, some chemokine receptors also demonstrate the 
ability to couple to other G-proteins as well, such as Gaq, G«i6 and G«i 1 (Kuang et al., 1996; 
Soede et al., 2001). Nevertheless, only G«i coupled 7TMR display chemotactic activity.
Phospholipase C (PLC)




Cytosolic leaflet of 
lipid bilayer
(PLC product = DAG)
Cytosol
(PLC product = IP3)
Figure 1.13. Phosphatidylinositol structu re  (PI -  structure represented in black). PI is 
the basic building block for the intracellular inositol-containing lipids, which consist of a 
D-myo-inositol-1 -phosphate (Ins 1-P) linked via its phosphate group to diacylglycerol 
(DAG). Phospholipase C (PLC) hydrolyses PI(4,5)P2 (PIP2) to generate inositol (1,4,5)- 
trisphosphate and DAG (required substrate alterations to PI (i.e. structure of PIP2) 
highlighted in blue). The inositol head of PI has five free hydroxyl groups but only groups 
at positions 3, 4 and 5 can be phosphorylated in different combinations, with 
phosphatidylinositol 3-kinase acting at the 3 position (highlighted in red). Diagram 
modified from (Sotsios and Ward, 2000).
The phosphoinositide-specific phospholipase C (PLC) isozymes play a key role in signal 
transduction by hydrolysing the membrane phospholipid phosphatidylinositol 4, 5- 
bisphosphate (PI(4,5)P2), generating the two intracellular second messengers inositol 1, 4, 
5-trisphosphate (Ins(l,4 ,5)P3 or IP3) and diacylglycerol (DAG) (fig. 1.13) (Rebecchi and 
Pentyala, 2000). IP3 can then act on its receptor present on endoplasmic reticulum to 
release calcium that then has the potential to activate a number of downstream molecules 
(refer to “Calcium Signalling” section for more information). The other product generated
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from the hydrolysis reaction, DAG, activates members of the protein kinase C (PKC) 
superfamily among other target proteins. This hydrolysis by PLC is one of the earliest 
signalling events to occur after receptor ligation. Currently, there are five PLC families ((3 - 
4 isoforms; y - 2 isoforms; 8 - 4  isoforms; e and £). Although all the PLCs have multiple 
cellular regulators, only the PLCp and £ isoforms are regulated by heterotrimeric G proteins 
(Rhee and Bae, 1997; Wing et al., 2001). PLCy isoforms tend to be regulated by receptor 
and non-receptor tyrosine kinases, and PLCS by calcium (Allen et al., 1997). The 
chemokine receptor-associated Gpy subunits activate the PLCp2 and PLCP3 isoenzymes 
(Jiang et al., 1997; Li et al., 2000). The G«i subunit is unable to activate the PLCp 
isoforms directly (Wu et al., 1992). Interestingly, the PLCS isoform may serve to amplify 
the response of the PLCp isozymes (fig. 1.14). Calcium binding to the C2 domain of PLCS 
increases its enzymatic activity suggesting that calcium may regulate PLCS and that it is 
activated secondarily to an increase in intracellular calcium induced by PLCp or PLCy 
(Kim et al., 1999b). For more in depth reviews on all the PLC isoforms see (Philip et al., 
2002; Rebecchi and Pentyala, 2000).
Receptor Stimulus
Figure 1.14. H ierarchy of PLC subtypes in cell signalling. A range of receptor stimuli 
appears to engage the activities of various PLC isoforms with PLCy and PLCS additionally 
playing a possible role in amplifying the initial PLCp response. Diagram adapted from 




In London 120 years ago, Sidney Ringer (Ringer, S. (1883) J. Physiol. 4, 29-43) made a 
landmark observation. He was studying the contraction of isolated rat hearts and noticed 
that when he switched from suspending the organs in London tap water (which is hard) to 
distilled water, the beautiful contractions he. had observed previously became slower and, 
after about 20 minutes, the heart would stop beating all together. In order to maintain the 
contraction he discovered that it was necessary to supplement the suspension medium with 
calcium salts. Thus, Ringer had dispelled the myth that calcium was exclusively a 
structural element required for bone and teeth formation and serendipitously revealed that 
calcium formed part of the signal required for heart contraction (Carafoli, 2002). After a 
very slow start (calcium’s signalling role was not fully appreciated until the late 1950s), 
calcium has been shown to be involved in many intracellular signalling processes (e.g. gene 
transcription, proliferation, apoptosis, migration and muscle contraction) and its 
intracellular mobilisation/accumulation is initiated by a wide variety of receptors.
Resting cells have a cytoplasmic calcium concentration of 100 nM with levels rising to 
about 1000 nM when the cell mobilises calcium upon activation. The levels of calcium are 
determined by a balance between the ‘on’ (calcium into cytoplasm) and ‘o f f  (calcium 
removed) mechanisms. Cells generate their calcium signals by utilising both internal 
(release) and external (entry) sources o f calcium (Berridge et al., 2000).
The ‘ON* Signals
A  major intracellular source of calcium is found within the membrane systems of the 
endoplasmic reticulum (ER), or sarcoplasmic reticulum (SR) of muscle cells. There are 
two major mechanisms for the release of calcium from these stores and both are via 
multimeric ligand gated ion channels: IP3 receptor (IP3R) and the ryanodine receptor (RR) 
(fig. 1.15). The IP3R is operated by IP3, as its name suggests, whilst the RR receptor 
(named according to its ability to bind ryanodine) is gated by calcium itself (also known as 
calcium-induced calcium release (CICR)). The RR is, however, also operated by an 
endogenous ligand named cyclic ADP ribose (cADPR) (Galione and Churchill, 2000), and
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both channels are sensitive to physiological changes in calcium (Bootman et al., 2002). 
Thus, both channels can be considered to be ligand-gated, calcium modulated release 
mechanisms. There are currently three IP3Rs and three RRs (Berridge et al., 2003). A 
further internal store operated by nicotinic acid adenine dinucleotide phosphate (NAADP) 
has been recently identified. The NAADP-mediated release mechanism is insensitive to 
cytosolic changes in calcium levels and therefore does not support CICR (see reviews 
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Figure 1.15. An overview of the pathways involved in calcium mobilisation. Calcium 
mobilising signals are shown in blue. ON mechanisms are in green, with OFF pathways 
highlighted in red. Abbreviations: cADPR, cyclic adenosine diphosphate ribose; CAM, 
calmodulin; CAMK, calcium/calmodulin-dependent protein kinase; ER, endoplasmic 
reticulum; G, G-protein; InsP.^R, inositol (l,4,5)-trisphosphate receptor; MLCK, myosin 
light chain kinase; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine 
dinucleotide phosphate; NAADP, nicotinic acid adenine dinucleotide phosphate; NOS, 
nitric oxide synthase; PDE, phosphodiesterase; PKC, protein kinase C; PLC, phospholipase 
C; PMCA, plasma membrane calcium ATPase; PTP, permeability transition pore; PYK2, 
proline-rich tyrosine kinase 2; R, receptor; RTK, receptor tyrosine kinase; RYR, ryanodine 
receptor; SIP, sphingosine 1-phosphate; SCaMPER, sphingolipid calcium release- 
mediating protein of the ER; SERCA, sarco(endo)plasmic reticulum calcium ATPase; SR, 
sarcoplasmic reticulum; TnC, troponin C. Acquired from (Berridge et al., 2000).
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Additionally, calcium is able to enter the cell from an external source via various entry 
channels that vary greatly in their properties: voltage-operated channels (VOCs) are
plasma membrane ion channels that are activated by membrane depolarisation; receptor- 
operated channels (ROCs) open in response to the binding of an extracellular ligand; 
second-messenger-operated channels (SMOCs) open in response to the binding of 
intracellular second messengers such as DAG, cyclic nucleotides or arachiodoriic acid; arid 
store-operated channels (SOCs) open in response to the depletion of internal stores of 
calcium.
The ‘OFF* Signals
For a cell to be able to maintain viability, the calcium influx must be balanced by calcium 
efflux. Four different mechanisms are responsible -  plasma membrane calcium ATPase 
(PMCA), sodium/calcium exchanger (NCX), sarco(endo)plasmic reticulum calcium 
ATPase (SERCA), and the mitochondrial uniporter (fig. 1.16). PMCA and SERCA have 
high affinities but limited capacities meaning they can respond to modest increases in 
calcium levels and set basal calcium levels. The remaining two calcium transporters, NCX 
and the mitochondrial uniporter, have much higher capacities and can limit the calcium 
transient over a wider range (i.e. optimal mitochondrial calcium accumulation occurs when 
calcium is in the pM  range but do accumulate calcium even when presented with modest 
nM global calcium changes). The PMCA couples ATP hydrolysis to the transport of 
calcium from cytosolic to extracellular spaces. NCX (plasma membrane) exchanges three 
moles of sodium for one mole of calcium, either inward or outward, depending on the ionic 
gradients across the membrane. The mitochondrial uniporter transports calcium from the 
cytosol into the mitochondrial matrix and is located on the inner mitochondrial membrane. 
SERCA is located on SR and ER membranes and couples ATP hydrolysis to the transport 
of calcium from the cytosol to the lumenal space. Removal of calcium can also be 
achieved through the use of calcium buffer proteins such as parvalbumin, calretinin and 
calbindin D-28 (reviews (Berridge et al., 2000; Berridge et al., 2003; Bootman et al., 2001; 
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Figure 1.16. The ON and OFF 
mechanisms involved in calcium 
signalling. During the ON phase, 
stimuli induce both the entry of 
external calcium (red circles) and 
the formation of second
messengers that release internal 
calcium stored within the ER/SR. 
During the OFF phase, calcium 
leaves the effectors and buffers 
and is removed from the
cytoplasm by various exchangers 
and pumps. From (Berridge et 
al., 2003).
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Rises in cytosolic calcium levels are decoded by various intracellular calcium binding 
proteins coupling the calcium flux to a biochemical and cellular response. EF hand 
proteins (see appendix 9) are calcium-binding proteins of which there are more than 600, 
with calmodulin being the most abundant and well known of these calcium sensors. 
Calmodulin binding to calcium leads to its conformational change and activation of the 
serine-threonine phosphatase calcineurin, allowing this protein to then activate the 
transcription factor nuclear factor of activated T cells (NFAT) and subsequent transcription 
of various genes, such as IL-2. Proteins containing C2 domains are also able to decipher 
calcium signals and these proteins include the classical protein kinase C isoforms 
(discussed in next section) (Carafoli, 2002). All chemokine receptors have been 
demonstrated to elicit a calcium flux upon ligation.
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Protein Kinase C (PKC) Family
Figure 1.17. Schematic representation of PKC kinase 
family members and phylogenetic tree. Like many 
other signalling effectors, PKC is not a single entity but 
products of various mammalian PKC genes. The 
molecular weight (MW) is given as calculated MW and 
chromosomal location refers to human. The PKC family 
has traditionally been classified into 3 groups (classical, 
novel and atypical), however, it has recently become 
evident that PKCp, originally classified by some as a 
member of the novel family, is the first member of a new 
group of kinases termed the protein kinase D (PKD) 
family (sometimes classified as a subgroup of the PKCs, 
but shares little structural homology with the others, as 
demonstrated by the phylogenetic tree -  obtained from 
(Kofler et al., 2002)). Abbreviations: PS,













Protein kinase C (PKC) was first identified in 1977 in bovine cerebellum (Takai et al., 
1977) and since then its involvement in many biological processes has been demonstrated, 
including development, memory, cell differentiation, migration, proliferation, 
carcinogenesis, and apoptosis (reviews (Baier, 2003; Dempsey et al., 2000; Liu and 
Heckman, 1998; Mochly-Rosen and Kauvar, 2000). The PKCs are a large family of 
serine/threonine kinases consisting of at least 10 isoforms that can be split into three (or 
four) groups based upon their requirements of calcium and phorbol esters for activation 
(fig. 1.17). The classical PKC (cPKC) isoforms are calcium-dependent via their C2 
domains and are activated by DAG, phosphatidyl serine (PS) and phorbol esters (e.g. PMA) 
through their cysteine-rich C l domains; novel PKC (nPKC) isoforms are calcium- 
independent but still regulated by DAG, PS and PMA; atypical PKC (aPKC) isoforms are 
calcium-independent and also don’t require DAG for their activation (Mellor and Parker, 
1998; Moscat and Diaz-Meco, 2000; Newton, 1995a; Newton, 1995b; Ron and Kazanietz, 
1999; Way et al., 2000). The three classes of PKC mentioned above all possess a 
pseudosubstrate or auto-inhibitory domain that binds to the substrate-binding site in the 
catalytic (kinase) domain preventing its activation in the absence of activators (Orr and 
Newton, 1994). In recent years, distantly related PKC members have been discovered 
(PKCp (human homologue of mouse PKD) (Johannes et al., 1994; Valverde et al., 1994), 
PKCv (PKD3) (Hayashi et al., 1999) and PKD2 (Sturany et al., 2001)) and, like the nPKCs, 
are regulated by DAG (i.e. contain a C l domain that is homologous to the C l domains of 
the other PKC classes) and lack the C2 domain. However, similarities with the other 
classes end there: the catalytic domain is only 30-35% homologous to the catalytic domains 
of the other three classes of PKC isoforms; there is a PH domain in the regulatory region; 
the auto-inhibitory pseudosubstrate motif is absent; and the catalytic domain has distinctly 
different substrate specificties (for reviews of PKD see (Lint et al., 2002; Rykx et al., 2003; 
Van Lint et al., 2002)). This has recently led to the proposal by some researchers that this 
fourth group of PKCs is considered as a distinct group o f new protein kinases, termed the 
PKD family. Another group of distantly related PKC enzymes are the PKC-related kinases 
(PRKs), also known as the protein kinase N (PKN) family. This group currently comprises 
3 members (PKN a/PRK l, PKNp, PRK2/PKNy) and are activated by Rho (not DAG or 
calcium) binding to the HR1 (homology region 1) domain (Mukai, 2003).
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The activity of PKC is under the control of three distinct phosphorylation events (fig. 1.18). 
Upon ligand binding at the membrane, PKC becomes a substrate for kinases 
phosphorylating: 1). threonine (Thr497 for PKCa) in the activation loop (T-loop) by 3- 
phosphoinositide-dependent protein kinase 1 (PDK1) in many instances (Le Good et al., 
1998; Sonnenburg et al., 2001), rendering the kinase catalytically competent to 
autophosphorylation; 2). kinase-mediated/autophosphorylation of serine (S657 for PKCa) 
in the hydrophobic C-terminal site (Keranen et al., 1995); 3). autophosphorylation of 
threonine (Thr638 for PKCa) in the C-terminus (the ‘turn m otif) results in the kinase 
domain taking up a closed conformation state that confers stability and phosphatase 
resistance (Parekh et al., 2000). The aPKCs lack phosphorylation at the hydrophobic site 








Figure 1.18. Regulation of PKC activity. See text for details on the phosphorylation 
events. The molecular chaperone Hsp70 binds the dephosphorylated turn motif and 
stabilizes PKC, allowing it to become rephosphorylated and to re-enter the pool of 
signalling-competent PKC. In the absence of Hsp70 binding, or as a result of chronic 
activation, dephosphorylated PKC accumulates in a detergent-insoluble cell fraction, where 
it is eventually degraded (Newton, 2003).
Inactive PKC isoforms are able to bind a number of scaffolding proteins including A 
kinase-anchoring proteins (AKAPs) that may serve to localise PKC enzymes to specific 
sites within the cell and thus helping to regulate cellular activities (DellAcqua et al., 1998; 
Faux et al., 1999; Faux and Scott, 1997; Klauck et al., 1996). Activated PKC enzymes bind 
proteins and substrates including STICKs (Substrates That Interact with C-Kinase), RACKs
44
C^ ntrekiuctufn
(Receptors for Activated C-Kinase -  not a substrate), MARCKS (myristoylated alanine- 
rich C-kinase substrate), actin, PLD (phospholipase D), and calmodulin (Jaken and Parker,
2000). PKC-mediated signalling pathways, as well as cross-talking effects (i.e. not direct), 
include the MAPK (mitogen-activated protein kinase) pathways, PKB (protein kinase B), 
PKD, IKK (IKB-Kinase), and NFAT (Baier, 2003). Chemokine receptors have been 
implicated in eliciting the activation of various PKC isoforms upon ligation (Carnevale and 
Cathcart, 2003; Ni et al., 2003; Pollok-Kopp et al., 2003).
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Figure 1.19. DAG stim ulation of PK C -dependent and independent signalling 
pathways. The generation of DAG, through stimulation of membrane receptors, leads to 
the activation of various proteins that possess DAG- and phorbol ester-responsive C l 
domains (Yang and Kazanietz, 2003).
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T lymphocytes contain up to 8 of the PKC isozymes making it difficult to elucidate the 
function of specific PKC isoforms, especially with the lack of isoform selective inhibitors. 
In addition to the use of pharmacological inhibitors, functions have been attributed to PKC 
through the use of prolonged phorbol ester treatment. However, it has become clear that 
DAG activates a number of unrelated targets and more than just PKC, with this concept 
largely being ignored in the past. Figure 1.19 highlights some of these DAG targets (for 
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Figure 1.20. Metabolism and immune system functions of phosphoinositides.
Phosphorylation of the 4- and 5-position of the inositol ring is catalysed by distinct 
phosphoinositide kinases. Phosphoinositide 3-kinase (PI3K) products are shown in red. 
There are also several 3-, 4- and 5-phosphatases (Koyasu, 2003). Abbreviations (not 
defined in text): SHIP, 5’ phosphatase Src Homology 2 domain-containing inositol 
polyphosphate; PTEN, 3’ phosphatase and tensin homologue deleted on chromosome 10.
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Over the last few years the extent and variety o f the role the phosphoinositides (Pis) play in 
cellular signalling has emerged. Besides PI(4,5)P2, mentioned above, the precursor of the 
intracellular second messengers DAG and Ins(l,4,5)P3, there have been many other 
metabolic pathways identified that lead to the generation of seven different Pis (for a 
general review o f Pis in cell signalling see the review by (Payrastre et al., 2001)). A few of 
these appear to play major roles in key signalling pathways, with the D3 Pis playing, 
perhaps, the most prominent duties. The phosphatidylinositol 3-kinases (PI3Ks) are 
responsible for the generation of these D3 Pis (fig. 1.20). The multiple isoforms of PI3Ks 
(fig. 1.21) are able to phosphorylate the 3'-OH position of the myo-inositol ring of inositol 
phospholipids to produce phosphatidylinositol 3-phosphate (PI(3)P), phosphatidylinositol 
3,4-bisphosphate (PI(3,4)P2), and phosphatidylinositol 3,4,5-trsiphosphate (PI(3,4,5)Ps) 
(fig. 1.12, in ‘PLC’ section -  incidentally, the D3 Pis are not substrates for known PLC 
isoforms). These 3 ’-phosphoinositides have been demonstrated, through the use of 
pharmacological tools and gene targeting techniques, to govern many cellular events, 
including cell growth and survival, cytoskeletal remodelling, migration, differentiation, and 
adhesion (fig. 1.20) (Katso et al., 2001; Koyasu, 2003; Okkenhaug and Vanhaesebroeck, 
2003a; Vanhaesebroeck et al., 2001). Furthermore, the importance of PI3K is evident from 
the various knockout studies that have been performed into each of the class I PI3K 
isoforms. The p i 10a and p i 10p knockout mice display embryonic lethality and the class 
IA p85a adaptor knockout is perinatally lethal. The p i 108 and PI3Ky knockouts are not 
lethal but display defective immune functions consistent with their restricted expression in 
leukocytes (Okkenhaug and Vanhaesebroeck, 2003b; Sasaki et al., 2002).
The PI3K family can be subdivided into 3 classes based on structural similarities and 
substrate specificity -  class I, class II, and class III (fig. 1.21). All PI3K catalytic subunits 
share a homologous region that consists of the catalytic domain (homology region 1 (HR1) 
linked to a PIK (phosphatidylinositol kinase) domain (HR2) and a C2 domain (HR3). The 
PIK (helical) domain is found in lipid kinases but not protein kinases, and acts as the 
structural spine around which the other domains are anchored (Djordjevic and Driscoll, 
2002). The C2 domains of PI3K likely bind phospholipid in a calcium-independent manner 
(contrary to the C2 domains found in other kinases, such as cPKC isoforms). Although the 
C2 domains of class I PI3Ks are similar in structure to the C2 domains of PKC8, PLCS and
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cPLA2, they lack the necessary residues to coordinate calcium binding and therefore may 
be involved in calcium-independent events. The catalytic domain is divided structurally 
into two lobes. The N-terminal lobe contains the nucleotide-binding loop (P-loop) with a 
conserved lysine residue within the ATP binding pocket and is critical for the correct 
alignment of ATP with the active site. The active site is found in the activation loop of the 
second lobe (the C-terminal lobe). This region, in addition to contributing to ATP binding, 
contains the activation and catalytic loops. The activation loop determines substrate 
specificity and the catalytic loop is responsible for deprotonating the substrate, generating 
the nucleophile that attacks the y-phosphate of ATP (Vanhaesebroeck et al., 2001).
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Figure 1.21. The classification of PI3K family members and schematic structures.
The PI3K family consists of 3 classes of isoforms, with each class demonstrating varying 
substrate specificities. A catalytic and a regulatory isoform associate to generate a 
biologically active complex. Abbreviations: Ras-BD, Ras-binding domain; PIK, 
phosphatidylinositol kinase domain (also known as the ‘helical domain’); SH2, Src 
homology 2 domain; SH3, Src homology 3 domain; PX, Phox homology domain; P, 




Class I  PI3Ks
The class I PI3Ks are further divided into 2 groups based on structural and functional 
differences - class Ia and class Ib. The class Ia PI3Ks are heterodimers comprising a 
regulatory subunit (p85a, p55a, p50a (all 3 derived from a single gene by alternative 
splicing (Fruman et al., 1996)), p85(3 or p55y (each encoded by distinct genes)) and a 
catalytic subunit (pi 10a, p i  10(3, or p i 108). The p85a subunit is the most abundantly 
expressed of the regulatory adaptors. The p i 10a and p catalytic subunits are ubiquitously 
expressed whilst the p i 105 subunit is restricted to leukocytes. Each of the catalytic 
subunits can associate with all of the regulatory subunits and the catalytic subunits are 
constitutively associated with a regulatory subunit (maintains stability of p i 10). The class 
Ia regulatory subunits contain two SH2 domains that bind specific phosphorylated tyrosine 
residues in proteins located at the plasma membrane, thus bringing the catalytic subunit to 
within proximity of its substrate. This leads to the activation of the PI3K catalytic subunit, 
which is normally inhibited in the p 8 5 /p ll0  complex (Koyasu, 2003; Yu et al., 1998b). 
The class Ia PI3Ks are activated by tyrosine kinase receptors (cytokine, antigen, etc) and to 
a lesser extent GPCRs (G-protein coupled receptors).
The class Ib PI3K (PI3Ky) is only found in mammals and, like p i 108, expression is 
restricted to leukocytes. PI3Ky is similar in structure and function to the class Ia PI3K but 
there is only one catalytic subunit (pi lOy) and one regulatory subunit (plO l). PI3Ky is the 
only PI3K isoform that is specifically activated by the GPCR-associated small G proteins 
Gpy (Brock et al., 2003; Krugmann et al., 1999; Stephens et al., 1997).
The class I PI3Ks are able to utilise PI, PI(4)P and PI(4,5)P2 as substrates in vitro, however, 
PI(4,5)P2 is the main substrate in vivo (Katso et al., 2001).
Class II PI3Ks
This class currently contains three members: PI3K-C2a, PI3K-C2P, and PI3K-C2y. C 2a  
and C2p are ubiquitously expressed, whereas C2y expression is restricted to the liver 
(Koyasu, 2003). This class differ significantly from the class I PI3Ks in both their mode of
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regulation and substrate preference (PI and PI(4)P in vitro, but preferred in vivo substrate is 
unknown). These enzymes are much larger (~ 170 kDa) than class I PI3Ks and have two 
distinct domains in the C-terminal: a Phox (PX) domain and another C2 domain (fig. 1.21). 
The PX domain binds PI(3)P and PI(3,4)P2 whereas the C2 domain function is unclear. 
The class II PI3Ks have been demonstrated to be activated downstream of growth factor 
receptors, cytokine/chemokine receptors, receptor tyrosine kinases and integrin receptors 
(Arcaro et al., 2000; Brown et al., 1999; Turner et al., 1998; Urso et al., 1999). The class II 
PI3Ks have been relatively under-investigated compared to their class I PI3K counterparts 
and thus, moderately little is known about them.
Class III PI3Ks
Consisting of a single member, Vps34p (the homologue of the Saccharomyces cerevisiae 
yeast vesicular-protein-sorting protein), it exclusively generates PI(3)P from PI and is 
broadly expressed in complex with a Ser/Thr protein kinase termed p i 50 (V psl5p in yeast). 
Its thought that, along with class II PI3Ks, it plays a role in vesicular trafficking (Simonsen 
et al., 2001; Wurmser et al., 1999). However, very little is known about the activation of 
the class III PI3Ks in vivo.
Chemokine-Mediated PI3K Activation
Various chemokines have been demonstrated to elicit a PI3K response in different cell 
systems (Knall et al., 1997; Sotsios et al., 1999; Turner et al., 1998). PI3Ky is the only Gpy- 
dependent PI3K and it is believed that it has a central role to play in chemokine-mediated 
PI(3,4,5)P3 accumulation and migration (fig. 1.22) (Al Aoukaty et al., 1999; Hirsch et al., 
2000; Wu et al., 2000). The most widely studied lipid kinase is the p85/pl 10 PI3K, and its 
role in chemokine-stimulated PI(3,4,5)P3 accumulation is somewhat controversial. There is 
plenty of evidence to suggest that p85/pl 10 is activated (Kurosu et al., 1997; Turner et al., 
1998; Vicente-Manzanares et al., 1999) but there are doubts about how much it contributes 
to PI(3,4,5)P3 levels. An excellent example of this is the CCL2-stimulated PI(3,4,5)P3 
accumulation is inhibited by PTX (pertussis toxin) but yet activation of p 8 5 /p ll0  is PTX- 
independent (Turner et al., 1998). It is possible that the Gtti subunits bind and activate Src
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(and other tyrosine kinases) which can then lead to the activation of the p85/pl 10 
heterodimer and the subsequent activation of distinct signalling pathways. Indeed, in 
PD K y7 mice there was incomplete inhibition of cell migration in response to various 
chemokines (Sasaki et al., 2000). It is therefore likely that various PI3Ks are involved in 
cell motility. Finally, the class II PI3K, PI3K-C2ot, has been shown to lie downstream of 
the MCP-1/CCL2 chemokine receptor (CCR2) but the functional relevance of this class is 
unknown (Turner et al., 1998). For reviews see (Curnock et al., 2002; Rickert et al., 2000; 
Sotsios and Ward, 2000; Stephens et al., 2002).
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Figure 1.22. Activation of class Ib PI3Ky by G-protein-coupled receptors (GPCRs).
Binding of a ligand to GPCRs initiates the dissociation of heterotrimeric G proteins, which 
liberates py-subunits that interact with the N- and C-terminal regions of PI3Ky. This 
triggers translocation and allosteric activation of PI3Ky. PI3Ky is associated tightly with 
p i01 through interactions in the adaptor-binding domain and the C-terminal lobe of the 
catalytic domain. The presence of p i01 sensitizes PI3Ky to activation by py-subunits. 
Interaction with GTP-bound Ras is proposed to induce conformational changes and 
membrane reorientation of the lipid kinase in relation to its substrate, PI(4,5)P2, thus further 
increasing its activity. Although PI3Ky-Py-pl01-Ras interaction leads to massive 
production of PI(3,4 ,5 )P3 (e.g. in neutrophils), the sequence of actions and the quantitative 
contribution of PI3Ky-interacting proteins in physiological processes need further 
elucidation. The interaction of p-adrenoceptor kinase 1 (pARKl) with the PI3K helical 
domain (also called the PIK domain) of PI3Ky is instrumental for the localized production 
of PI(3,4 ,5)P3 that is required for the recruitment of the clathrin adaptor AP-2 (possibly via 
the p2 subunit of the AP2 complex) and endocytosis of p2-adrenoceptors. Interestingly, 
inhibition of the PI3Ky-pARKl interaction interferes with endocytosis of P2- 
adrenoceptors, but not with PI3Ky-mediated activation of protein kinase B (Naga Prasad et 




PI is the most abundant phosphoinositide in mammalian cells (10% of total 
glycerophospholipids) with phosphorylations at the D3, D4, and D5 positions by specific 
kinases leading to the generation of 7 different polyPI products. PI(4)P and PI(4,5)P2 each 
represent about 10% of total Pis (1% total glycerophospholipids) and, along with PI,.levels 
are kept at a steady state in cell membranes. The PI3K products, PI(3,4)P2 and PI(3,4,5)P3, 
are rapidly and transiently produced in response to agonist and their levels never exceed 
10% of PI(4,5)P2 levels (0.1% total glycerophospholipids). PI(3)P is constitutively present 
in small quantities and the levels are relatively stable in mammalian cells, unlike PI(5)P and 
PI(3,5)P2, that although present in relatively small amounts, their levels do alter upon cell 
activation (Pendaries et al., 2003). A plethora of proteins display an ability to interact with 
these phospholipids via various Pi-binding motifs. These interactions vary from high to 
low affinity and the different domains have a preference for specific Pis (table 1.7). Hence, 
the activity of PI3K is able to regulate cellular processes via their ability to generate a 
variety of D3-PIs that act as site-specific membrane signals for a range of effector proteins. 
Following is a brief description of some of the more relevant domains found to date.
Epsin NH^Terminal Homology (ENTH) Domain
First found in the endocytic protein epsin 1, it is a region of approximately 140 amino acids 
usually located in the N-terminus with binding selectivity for PI(4,5)P2. It is found 
predominantly in endocytic and cytoskeletal organisational proteins such as API 80 
(adaptor protein 180) and CALM (clathrin assembly lymphoid myeloid leukaemia protein). 
Compared with the other Pi-binding domains mentioned, very little detail is known about 
the role of this domain in cellular processes (Itoh and Takenawa, 2002; Xu et al., 2001).
Band 4.1, Ezrin, Radixin, Moesin (FERM) Domains
There are more than 40 FERM domain-containing proteins with the majority serving as 
regulated cross-linkers connecting actin filaments to membranes via the specific binding of 
PI(4,5)P2 lipids. Additionally, in many cases they also possess a spectrin/actin-binding 
domain (SABD) to facilitate this role. As a consequence, FERM proteins have been 
implicated in cytoskeletal processes, such as reorganisation (DiNitto et al., 2003).
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Fablp, YOTB,  VaclpandEEAl (FYVE) Domain
The FYVE domain is a compact double Zn2+ finger module and was first identified in the 
four proteins it derives its name from (see heading) and is a -6 0  -  80 amino acid domain 
that consists of 8 conserved cysteine residues that are characteristic of the zinc-finger. 
There is a cluster of basic residues that surround the third and fourth cysteines 
[R(R/K)HHCR)] and this positively charged sequence, along with Zn2+ (2 atoms), is 
essential for the folding of the zinc finger and the electrostatic interaction with the 
negatively charged head group of PI(3)P (its specific PI target). The FYVE domain is 
thought to play a significant role in membrane/vesicular trafficking due to the specific 
localisation of PI(3)P to the membranes of early endosomes and to the internal vesicles of 
multivesicular bodies (Gillooly et al., 2003; Itoh and Takenawa, 2002; Vanhaesebroeck et 
al., 2001; Xu et al.,2001).
Pleckstrin Homology (PH) Domains
PH domains have been found in a wide variety of proteins (> 250). It was first identified as 
a 100 -  200 amino acid sequence homology domain found originally in the PKC substrate 
pleckstrin (in platelets). However, there is limited sequence similarity between the PH 
domains of different molecules (typically 10 -  20%) and are defined instead by a conserved 
tertiary structure (Xu et al., 2001). The PH domains are able to bind most of the 
doubly/triply phosphorylated Pis (mostly PI(3,4)P2, PI(4,5)P2 and PI(3,4,5)P3) but do 
display, in general, greater selectivity for the D3 Pis (table 1.7). The PH domains are 
classified into 3 groups based on their selectivity for Pis (Group 1 = bind a specific PI; 
Group 2 = demonstrate a low specificity and/or affinity; Group 3 = bind non-specifically to 
Pis) (Cullen et al., 2001; Maffucci and Falasca, 2001).
Phox (PX) Domains
The PX domain averages 100 -  120 amino acids in size and was first identified in two of 
the cytosolic components of NADPH oxidase, p40phox and p47phox. It has since been 
identified in a number of proteins (~ 65) that are implicated in diverse biological processes. 
Interestingly, the PX domain contains a polyproline motif (PxxP) in the middle that is 
characteristic of SH3 domain-binding motifs, and there is evidence that PX may be an
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interacting partner of SH3 domains. The PX domain is generally considered to have 
binding selectivity for the D3 Pis (Ellson et al., 2002; Itoh and Takenawa, 2002; Wishart et 
al., 2001; Xu et al., 2001).
Table 1.7. Phosphoinositide-binding domains.




















P47phox PI(3,4)P2, PI(3)P. PI(3,5)P2, PI(3,4,5)P2
Vam 7p PI(3)P
Bern Ip PI(3)P, PI(5)P
PI3K-C2ot PI(4,5)P2
CISK PI(3,5)P2, PI(3,4,5)P3






This table is derived and modified from those published by (Itoh and
Takenawa, 2002; Maffucci and Falasca, 2001). PH domains highlighted in red 
are classified as Group 1 PH domains, blue are Group 2 PH domains, and 
green are Group 3 PH domains. The PX domains are divided into 3 groups 
based on the PX domain representing more than half of the polypeptide (red), 
have longer flanking sequences but contain no other motifs (blue), and proteins 
that contain other characterised domains such as SH3 and PH domains (green).
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Downstream Effectors of PI3K: PKB and company
The PI3K-mediated signalling pathways have been one of the most intensely studied areas 
of signal transduction over the last decade or so. Thus, vast arrays of studies have been 
carried out into multitude of cellular processes searching for roles of the PI3K isoforms. 
Consequently, PI3K has been found to play a central role in control of metabolism, cell 
growth, proliferation, survival, migration, and membrane transport and secretion. As 
would be expected from the variety of cellular processes PI3K has been implicated in, there 
have been discovered a vast number of proteins that lie downstream of the products of 
PI3K and, therefore, a variety of signalling cascades (fig. 1.23). Discussed below are a few 
of the key proteins involved in these signalling pathways and that will be mentioned during 
this thesis (for more in depth reviews read (Cantley, 2002; Cantrell, 2001; Seminario and 









Figure 1.23. A PI3K pathway dartboard. PI(3,4 ,5)P3 produced by class I PI3Ks recruits 
proteins that contain PH domains (among other D3 Pi-binding domains), including PKB, 
phosphoinositide-dependent kinase 1 (PDK1), guanine nucleotide exchange factors (GEFs), 
protein tyrosine kinases of the Tec family (e.g. Bruton's tyrosine kinase (Btk)), 
phospholipase Cy (PLCy). PI3K exerts control on most cellular processes and, although 
this control is central, the signalling pathways depicted intersect with parallel, non-PI3K- 
dependent mechanisms (not shown) (Wymann et al., 2003b). Abbreviations: 4E-BP1, 
eukaryotic initiation factor 4E binding protein 1; Glc, glucose; GLUT4, glucose transporter 
4; IkB, inhibitor of NFkB; NFkB, nuclear factor kB; TSC1, hamartin; TSC2, tuberin.
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3 ’-Phosphoinsitide-Dependent Kinase (PDK) 1 & 2
The AGC (named after its original constituent members, the protein kinases A, G, and C) 
superfamily of serine/threonine kinases was recognised as a group of enzymes that were a 
key mediator of the PD K  signal, but the majority of its members required phosphorylation 
for activation. This led to the search for a potential upstream kinase that was linked to the 
PDK  pathway and this search culminated in the discovery of 3’-phosphoinositide- 
dependent kinase-1 (PDK-1) in 1997, initially purified from rabbit skeletal muscle and rat 
brain and cloned later that year (Alessi et al., 1997a; Alessi et al., 1997b; Stokoe et al., 
1997).
PDK-1 is a 63 kDa serine/threonine kinase ubiquitously expressed in human tissues and is 
responsible for the phosphorylation of PKB on Thr 308. The ability of PDK-1 to carry out 
this activity relies on the presence of PI(3,4)P2 and PI(3,4,5)P3, resulting in the kinase 
obtaining its current name (Vanhaesebroeck and Alessi, 2000). PDK-1 posseses a N- 
terminal kinase domain that shares homology with the catalytic domains found in the 
cAMP-dependent protein kinase A (PKA) and PKC subfamilies, and a C-terminal PH 
domain that is responsible for binding to the PI(3,4)P2 and PI(3,4,5)P3 lipids (Brazil and 
Hemmings, 2001). The activity of PDK-1 to phosphorylate PKB relies upon the 
conformation of PKB. Specifically, the PH domain of PKB is required to bind PI(3,4)P2 or 
PI(3,4,5)P3 lipids in order to remove the autoinhibiton of the active site of PKB, allowing 
PDK-1 to access Thr 308 on the activation loop and phosphorylate the residue (fig. 1.24) 
(Toker and Newton, 2000b). However, PDK-1 is only able to phosphorylate Thr 308 on 
PKB and is unable to phosphorylate Ser 473 in the hydrophobic motif of PKB, which is 
additionally required for full PKB activity. PDK-1 appears to exist in an active, 
phosphorylated configuration predominantly localised in the cytosol under basal conditions 
and possibly tranlocates to the membrane in response to increased D3 PI production 
(Vanhaesebroeck and Alessi, 2000).
Over the years, the kinase responsible for this phosphorylation of Ser 473 has remained 
elusive, and it was widely accepted early on that a separate kinase was responsible for this 
phosphorylation and was tentatively termed PDK-2. This has led to at least three models 
for Ser 473 phosphorylation in this time: 1). PDK-2 is a modified form of PDK-1, with the 
interaction of PDK-1 with a fragment of the C-terminal of PRK2 (protein kinase C-related
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kinase 2 -  mentioned earlier), termed PDK-1- interacting fragement (PIF), converts PDK-1 
into an enzyme that is able to phosphorylate both Thr 308 and Ser 473 of PK B a in vitro 
(Balendran et al., 1999); 2). PKB autophosphorylation of Ser 473, similar to that observed 
with the regulation of the hydrophobic site in the cPKC isoforms -  phosphorylation of Thr 
308 by PDK-1 results in partial activation of PKB allowing it to autophosphorylate itself 
(Toker and Newton, 2000a); 3). PDK-2 is a distinct kinase -  cells lacking PDK-1 
demonstrate no phosphorylation of Thr 308 in PKB upon stimulation of cells with growth 
factor, but phosphorylation of Ser 473 still occurs (Williams et al., 2000). A a recent study 
has provided a strong argument for PDK-2 being a cytoskeleton-associated kinase distinct 
from PDK1 (Hresko et al., 2003).
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Figure 1.24. Role of PDK-1/2 in the activation of PKB. In unstimulated cells, PKB is 
not phosphorylated at either Thr 308 or Ser 473 and resides predominantly in the cytosol. 
Stimulation of PI3K leads to the accumulation of D3 Pis, thereby recruiting PKB to the 
membrane via its PH domain, where it is phosphorylated on Thr 308 by PDK-1 (which is 
constitutively recruited to the membrane via its PH domain) and on Ser 473 by an unknown 
mechanism, but may involve: (A) phosphorylation by a modified form of PDK-1; (B)
phosphorylation by a distinct kinase termed PDK-2; or (C) autophosphorylation of Ser 473 
by the kinase domain. Activated PKB translocates to various parts of the cell where it 
activates a number of downstream effector molecules.
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There is evidence that PDK-1 does not solely act as an activator of PKB, and that it may be 
involved in the activation of other AGC kinases such as PKC, p70S6K, SGK, PAK, RSK 
and PRK, with the activation of these molecules likely to be similar to that of PKB (Toker 
and Newton, 2000b; Vanhaesebroeck and Alessi, 2000). Indeed, PDK-1 is essential for T 
cell development and along with the evidence that it regulates multiple pathways has led to 
PDK-1 being increasingly referred to as a ‘master kinase’ (Hinton et al., 2004).
Protein Kinase B (PKB)
A significant breakthrough in understanding how membrane-bound lipids convey signals to 
the cytosol was made with the identification o f PH domains. Protein kinase B (PKB) 
contains a PH domain that specifically binds PD K  lipid products (preferentially PI(3,4)P2 
and PI(3,4,5)P3), and thereby establishing a firm link between PDK  and PKB signalling 
(James et al., 1996; Stephens et al., 1998). PKB is a family of 57 kDa serine/threonine 
kinases with a high homology to the protein kinase A and C families, and was first cloned 
in 1991 (Bellacosa et al., 1991; Coffer and Woodgett, 1991; Jones et al., 1991b; Jones et 
al., 1991a). There are three PKB isoforms, PK B a/A ktl, PKB(3/Akt2 and PKBy/AkD, with 
each consisting of an N-terminal PH domain, a kinase domain, and a C-terminal regulatory 
tail. PK B a needs to be phosphorylated at both Thr 308 (kinase domain or T-loop) and Ser 
473 (C-terminal regulatory/hydrophobic domain) for full activation (with PKB(3 at Thr 
309/Ser 474 and PKBy at Thr 305/Ser 472 (a splice variant of PKBy has been reported 
(PKByl) and lacks the Ser 472 site (as only 465 aa long) and may limit its potential) 
(Nicholson and Anderson, 2002)), and are ubiquitously expressed (PKBy is in particularly 
large amounts in the brain, lung and kidney). PKB isoforms are phosphorylated at the T- 
loop by PDK1, with a number of possible mechanisms regulating the phosphorylation of 
Ser 473 (see ‘PDK-1’ section and fig. 1.24). PKB activation is rapid and the site of action 
of the activated kinase differs between cell types, with activation solely dependent upon 
PDK  activity, as demonstrated by complete inhibition of PKB activity with PD K  inhibitors 
(Alessi et al., 1996). Epithelial cells display active PKB at the membrane, whereas in 
lymphocytes, PKB dissociates from the membrane to the cytosol and enters the nucleus 
(the mechanism for this is unknown) (Cantrell, 2002). During this time, PKB 
phosphorylates a plethora of proteins that include glycogen synthase kinase-3, BAD,
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FKHR, p70S6K, eNOS and Raf (for reviews see (Brazil and Hemmings, 2001; Lawlor and 
Alessi, 2001; Nicholson and Anderson, 2002; Scheid and Woodgett, 2001)). To date, all 
PKB substrates (fig. 1.23 & 1.24) contain the motif: Arg-Xaa-Arg-Yaa-Zaa-Ser/Thr-Hyd, 
where Xaa is any amino acid, Yaa and Zaa are preferably small residues other than glycine, 
and Hyd is a bulky hydrophobic residue (leucine or phenylalanine). PKB has been shown to 
have a central role to play in apoptosis, proliferation (cancer), insulin signalling (diabetes), 
and migration (fig. 1.23). A number of chemokines have been observed to activate PKB, 
including SDF-1/CXCL12, RANTES/CCL5, IL-8/CXCL8 and MIP-loc/CCL3 ((Lentzsch 
et al., 2003; Sotsios et al., 1999; Tilton et al., 1997)) and this is prevented in PBKy"7"- 
deficient neutrophils with regards to IL-8/CXCL8 (Hirsch et al., 2000).
Glycogen Synthase Kinase-3 (GSK-3)
A serine/threonine kinase, glycogen synthase kinase-3 (GSK-3) was first isolated and 
purified as an enzyme capable of phosphorylating and, in so doing, inhibiting the enzyme 
glycogen synthase. GSK-3 was first isolated in 1980 and in the mid-90s it was discovered 
that PKB was responsible for the phosphorylation and inhibiton of GSK-3 (Cross et al., 
1995; Embi et al., 1980). Currently, there are two mammalian GSK-3 isoforms identified, 
G SK -3a (phosphorylated at Ser 21/Tyr 279) and GSK-3p (phosphorylated at Ser 9/Tyr 
216), with molecular weights of 51 and 47 kDa, respectively, and are not functionally 
identical. The two GSK-3 isoforms have a unique glycine-rich N-terminal domain (where 
Ser 21/9 is found) and a conserved (98% homology) kinase domain (Tyr 279/216). GSK-3 
is normally active in cells and is unusual in that it is regulated through inhibiton. Although, 
originally found to play a pivotal role in glycogen metabolism, it has since been realised 
that GSK-3 has far more numerous signalling roles, including the Hedgehog pathway, 
Wnt/P-catenin pathway and NFAT inactivation (see reviews (Cohen and Frame, 2001; 
Doble and Woodgett, 2003; Dominguez and Green, 2001; Frame and Cohen, 2001; 
Harwood, 2001)).
Phospholipase D (PLD)
Phospholipase D (PLD) is activated in response to various chemokines (Bacon et al., 1998) 
and is involved in vesicular protein transport and may additionally play a part in actin
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polymerisation that is thought to be required for cell movement. Recent evidence suggests 
a link between PI3Ky and PLD (Toda et al., 1999). ARF-GEFs (ADP-ribosylation factor 
guanine-nucleotide-exchange factors) such as Arno, Grp-1 and cytohesin contain PH 
domains that bind D3 Pis on the plasma membrane and may then activate ARFs (ADP- 
ribosylation factors), in particular ARF6, which in turn leads to PLD activation and 
subsequent phosphatidic acid accumulation and actin reorganisation (fig. 1.25). See the 
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Figure 1.25. The potential interactions between PI3K, PLD and actin rearrangem ent 
upon chemokine receptor ligation. Reproduced from (Sotsios and Ward, 2000). 
Abbreviations: Arf6, ADP-ribosylation factor 6 ; ArfGEF, ADP-ribosylation factor guanine- 
nucleotide-exchange factor; PA, phosphatidic acid.
Regulation of PI3K-Dependent Signalling: SHIP and PTEN
Both positive and negative regulatory signalling cascades are vital for homeostasis during 
cell activation. The activity of PI3K is opposed by the inositol 3-lipid phosphatase PTEN 
(Phosphatase and tenisn homologue deleted on chromosome ten) and more indirectly by the 
inositol 5-phosphatase SHIP (SH2-containing inositol (poly)phosphate 5-phosphatase) (fig. 
1.20). PTEN is a human suppressor gene for which this status is supported by numerous 
lines of evidence. PTEN was first identified in 1997 at chromosome 10q23 and encodes the 
403 amino acid PTEN protein that is a member of the protein tyrosine phosphatase family
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(Leslie and Downes, 2002; Seminario and Wange, 2002). This chromosomal region has 
been found to be deleted in many tumour types and, after p53, has been found to be the 
most highly mutated gene in human cancers (Cairns et al., 1997; Li et al., 1997; Risinger et 
al., 1997; Steck et al., 1997; Tashiro et al., 1997). This additionally highlights the 
importance of PDK  in mammalian cells along with the data from PTEN'7' mice that die 
during embryonic development (Di Cristofano et al., 1998). PTEN (also known as 
MMAC1 and TEP1) is responsible for dephosphorylating several phosphoinositide 
signalling molecules in vitro, specifically removing the phosphate group from the D3 
position of the inositol ring. PI(3,4)P2 and PI(3,4,5)P3 are the most efficient substrates and 
this is further highlighted in cells lacking PTEN that display elevated levels of these lipids 
(Astoul et al., 2001; Cantrell, 2001).
The SHIP (110 -  145 kDa) family of proteins is responsible for dephosphorylating the D5 
position of the inositol ring and its major substrate is PI(3,4,5)P3. There are currently three 
SHIP1 isoforms (a,p,8) and one SHIP2 (160kDa). Loss of SHIP results in an unbalanced 
immune response and culminates in the development of autoimmunity (for more detail see 
(March and Ravichandran, 2002)).
Although PTEN and SHIP regulate the products of activated PDK, it is also necessary to 
terminate the action of the kinase itself. This requires the dephosphorylation of the tyrosine 
residues recognised by the SH2 domains of the regulatory p85 subunit of PD K  (class I). 
This process may require SHP-1 (SH2-containing phosphatase-1) as this phosphatase has 
been shown to bind PDK  and can also dephosphorylate Tyr 688 of p85 to further inactivate 
PDK (Cuevas et al., 2001).
The Extracellular Regulated Kinase-Mitogen Activated Protein Kinase 
Pathway (ERK-MAPK)
In additon to the PDK pathway, the mitogen-activated protein kinase pathways have been 
intensely studied over the years, and especially the extracellular-regulated kinase (ERK)- 
MAPK pathway. The activation of a MAPK involves a three kinase cascade consisting of a 
MAP kinase kinase (MAPKKK, MKKK or MEKK) which activates a MAP/ERK kinase
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(MAPKK, MKK or MEK), which then stimulates a phosphorylation-dependent increase in 
the activity of the MAPK (e.g. ERK), and the subsequent phosphorylation of a variety of 
intracellular targets, including transcription factors, transcriptional adaptor proteins, 
membrane and cytoplasmic substrates, and other kinases (fig. 1.26).
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Figure 1.26. The m ajor MAPK signalling modules. The MAPK module is composed of 
a MAPKKK, MAPKK, and a MAPK. Each pathway can be activated with a variety of 
stimuli, with the MAPKKs being activated by one or more MAPKKKs, but MAPKKs are 
relatively specific for their activation of target MAPKs (modified from (Garrington and 
Johnson, 1999; Rincon, 2001)).
The MAPK family consists of both stress-activated (SAPK) and mitogen-activated kinases 
and there are currently three major groups of MAPK modules: the p38 Map kinase family 
(4 isoforms - a , (3, 8, y), the classical ERK family (isoforms ERK 1/2, but 6 others 
identified, ERK3-8, and are involved in different pathways/modules), and the c-Jun NH2- 
terminal kinase (JNK) family (3 isoforms -  JNK1/2/3) (Platanias, 2003). Each MAPK is
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activated by dual phosphorylation on a Thr-Xaa-Tyr motif by upstream kinases (e.g. Thr 
202/Tyr 204 for ERK1 by MEK1/2 -  ERK1/2 is the only known substrate of MEK1/2). 
Despite the wide use of ERK1/2, p38 and JNK phospho-antibodies in cell signalling (and 
largely used as an indicator of receptor activation), very little detail is known about how 
they are regulated by the MAPKKKs. MAPKs phosphorylate their substrates on serine or 
threonine residues which preceed a proline but specificity in vivo is further enhanced by the 
presence of distinct docking sites. The MAPKs are ubiquitously expressed and activated 
by a wide variety of stimuli, including chemokines, growth factors, cytokines and, as their 
name suggests, mitogens and cellular stress (p38 and JNK) (Arndt et al., 2003; Bonello and 
Khachigian, 2003; Sodhi and Sethi, 2003; Uchida et al., 2003; Wuyts et al., 2003). The 
MAPK family phosphorylate MAPK-activated protein (MAPKAP) kinases, which can be 
subdivided into two groups: two kinase domains within a single polypeptide and the single 
kinase domain proteins. Two kinase domain enzymes are MAPKAP-K1 (more commonly 
known as p90RSK) -  involved in processes such as cell survival, gene transcription and 
meiosis, and mitogen and stress-activated protein kinase (MSK) -  possible role in gene 
transcription. The single kinase domain MAPKAPs are MAPKAP-K2, MAPKAP-K3, 
MAPKAP-K5 (also known as PRAK (p38-regulated/activated kinase)), and MAPK- 
integrating kinase (MNK) (Garrington and Johnson, 1999; Marinissen and Gutkind, 2001; 
Rincon, 2001; Rincon et al., 2001; Widmann et al., 1999).
Following chemokine-induced G protein heterotrimeric dissociation, the Got subunit is 
released in additon to the (3y subunits. The G a  subunit does not appear to be involved in 
cell migration events but does bind to and activate Src, and possibly other related, tyrosine 
kinases. This provides a possible means of activating the ERK-MAPK pathway via the 
Ras-Raf pathway (reviews see (Gutkind, 2000; Kerkhoff and Rapp, 2001)). Another 
possible route is dependent on the GPy subunit activating the PKC (and may involve the £ 
or 5 isoforms) pathway and then the Raf-MEK-ERK pathway (this maybe Ras independent 
(Faure et al., 1994) and coupled to a G aq  subunit) (Bonacchi et al., 2001; Smit et al., 2003; 
Tilton et al., 2000). The activation of ERK may also involve the PD K  pathway, and in 
particular PDKy’s intrinsic protein kinase activity, as some studies have shown that PDK 
inhibitors can block ERK phosphorylation in response to chemokine receptor ligation 
(Knall et al., 1996; Sotsios et al., 1999; Sullivan et al., 1999b) (fig. 1.27). The other two
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major MAPK pathways, p38 and JNK, have also been described to lie downstream of 
chemokine receptors (Merz et al., 2003; Mocsai et al., 2003; Sodhi and Biswas, 2002; 
Vlahakis et al., 2002).
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Figure 1.27. Possible pathways linking chemokine receptors to ERK-M APK 
activation. Biochemical routes initiated by py-subunits can stimulate Ras by the activation 
of receptor and non-receptor tyrosine kinases, which results in the recruitment of Sos to the 
membrane and the exchange of GDP for GTP bound to Ras. Activated Gaq can stimulate 
Rafl through protein kinase C (PKC) or by stimulating Ras by the Ca2+-dependent 
activation of RasGRF and tyrosine kinases acting on Sos. Gai, Gao and Gas can also use 
tissue-restricted pathways regulating Rap, which can stimulate B-Raf and lead to the 
activation of MAPK. Activated MAPK translocates to the nucleus and phosphorylates 
nuclear proteins, including transcription factors, thereby regulating gene expression. 
Arrows represent positive stimulation and broken lines represent inhibition (see text for 
more details). Abbreviations: EPAC, exchange protein activated by cAMP; GAP, GTPase- 
activating protein; GRF, guanine-nucleotide releasing factor; MEK, MAPK kinase; PI3K, 
phosphoinositide 3-kinase; PKA, protein kinase A; PLC, phospholipase C; RTK, receptor 
tyrosine kinase. Figure acquired from (Marinissen and Gutkind, 2001).
The ROCK and Rho Lifestyle of Chemokine Receptors
A couple of recent studies have suggested that the PI3K pathway may not participate in T 
lymphocyte migration and that their maybe differences in the mechanisms of cell migration 
between lymphocytes (do not require PI3K) and myeloid cells (require PI3K) (Cinamon et 
al., 2001; Smit et al., 2003). A pathway that has gained prominence recently for its
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apparent necessity for chemokine-mediated lymphocyte migration is the Rho-ROCK (Rho- 
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Figure 1.28. Rho-ROCK signalling pathways. Rho activation of ROCKs leads to the 
phosphorylation of several substrates, resulting in various cellular responses. In particular, 
phosphorylation of the myosin binding subunit of myosin light chain phosphatase (MLCP) 
by ROCKs inhibits the dephosphorylation of myosin light chain (MLC), thereby increasing 
myosin II activity and stress-fibre formation and contractility (Riento and Ridley, 2003). 
Abbreviations: CRMP2, collapsin response mediator protein-2; E F -la , elongation-factor 
la ; ERM, ezrin-radixin-moesin; GAP, GTPase activating protein; GFAP, glial fibrillary 
acidic protein; LIMK, LIM (for L in ll, Isll and Mec3) kinase; MARCKS, myristylated 
alanine-rich C-kinase substrate; NHE1, Na-H exchanger-1; NF-L, neurofilament protein.
Rho is a family of small GTPases that were initially cloned on the basis of their similarity 
with the Ras oncogenes. There are currently 18 members that can be further subdivided 
depending upon sequence similarity and biological function and include groups Racl, 
cdc42 and RhoA (Sahai and Marshall, 2002). Rho family GTPases cycle between GDP- 
bound inactive and GTP-bound active forms, with GTP binding promoted by Rho-guanine 
nucleotide exchange factors (Rho-GEFs) and GTP hydrolysis catalysed by Rho-GTPase 
activating proteins (Rho-GAPs) (Fukata et al., 2003; Moon and Zheng, 2003). Rho-family
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GTPases have been observed to regulate the actin cytoskeleton and cell adhesion, and have 
numerous effector molecules (see reviews (Aspenstrom, 1999a; Aspenstrom, 1999b)). One 
such downstream effector of the RhoA, RhoB and RhoC GTPases is the ROCK 
serine/threonine protein kinase. To date their have been 2 ubiquitously expressed ROCK 
isoforms identified, ROCK1 and ROCK2, that are ~ 160 kDa in size. ROCK kinases have 
a plethora of target substrates that contain the m otif R/K-Xaa-S/T or R/K-Xaa-Xaa-S/T, 
including myosin light chain (MLC) -  the major substrate of the Rho-ROCK pathway -  
and thus participates in actomyosin contractility (fig. 1.28) (for in depth reviews of ROCK 
read (Amano et al., 2000; Riento and Ridley, 2003)).
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1.6 Aims of Study
Published research into the signalling pathways activated upon CCR4 ligation is very 
meagre, and there are currently no dedicated papers on this matter, with only a few papers 
demonstrating a calcium flux upon CCR4 ligation and PTX-sensitive migration (Andrew et 
al., 1998; Inngjerdingen et al., 2000; Oh et al.,. 2002; Suzuki et al., 1999). This is in. stark 
contrast to receptors such as CXCR3, and especially CXCR4, in which there are a number 
of published signalling papers (Ganju et al., 1998a; Ganju et al., 2000; Wain et al., 2002).
The aim of this study is to start to elucidate the signal transduction pathways that exist 
downstream of CCR4 upon its ligation with its chemokine ligands, MDC and TARC, and 
more importantly, those pathways that are required for CCR4-mediated directed T cell 
migration. It is apparent from the preceding overview of chemokine function and 
signalling that this family of GPCRs have a pivotal role to play in the general immunity of 
the human organism. Thus any further knowledge of how these chemokines regulate cell 
migration will expectantly provide useful information into these processes and facilitate the 
identification of future therapeutic targets within this field, and more specifically with 
relation to CCR4 (research in this area being highly underdeveloped). Specifically, the 
project will focus investigations in the following areas:
•  The role of PDK in CCR4-mediated signalling and function.
•  Examination of the calcium pathway downstream of ligated CCR4 and the role of 
intracellular calcium mobilisation in directed cell migration.
•  Investigate the mediators that are required for activation of the ERK-MAPK and 
PKB pathways.
•  Elucidate the CCR4-activated signalling cascades that are critical for chemotaxis.
Since this study is primarily concerned with the activity o f CCR4 on T cells, the majority of 
the experiments will be performed in leukaemic T cell lines (principally the CEM T cell 
line) and in more physiologically ‘normal’ T cells (i.e. T lymphoblasts and in vitro 
generated human Th2 cells). This will also allow for a comparison of activities between 




2 . M a t e r i a l s  a n d  M e t h o d s
2.1 Materials
Antibodies
Anti-CD28 (clone 9.3) Mouse Monoclonal Carl June, Uni. Of Pennsylvania, USA |
Anti-CD3 (clone UCHT1) Mouse Monoclonal Doreen Cantrell, School of Life Sciences, Dundee, UK___________
g g S S B B M S M
1 Anti-goat Ig (HRP- 
| conjugated)______________ Rabbit Polyclonal DAKO, Glostrup, Denmark
Goat Polyclonal R & D Systems, Abingdon, UK |
Goat Polyclonal R & D Systems, Abingdon, UK |
A nti-pll08 Goat Polyclonal Santa Cruz Biotechnology, Santa Cruz, USA |
Anti-p85 Rabbit Polyclonal Bart Vanhaesebroeck, Ludwig Institute, London, UK___________
| Anti-phospho GSK-3q/b Rabbit Polyclonal NEB (UK) Ltd, Hitchin, UK |
Rabbit Polyclonal NEB (UK) Ltd, Hitchin, UK |
| Anti-phospho P K J U ^ ^ ^ ^ Rabbit Polyclonal NEB (UK) Ltd, Hitchin, UK [
| Anti-PI3K C 2a Rabbit Polyclonal Bart Vanhaesebroeck, Ludwig Institute, London, UK
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Anti-PKB Goat Polyclonal Santa Cruz Biotechnology, Santa Cruz, USA 1
Anti-PTEN Rabbit Polyclonal Santa Cruz Biotechnology, Santa 
[CTUZj U S A ^ ^ — _ M M — J
1 A nti-rabb itIg (H R P ^
| conjugated)______________ Goat Polyclonal DAKO, Glostrup, Denmark
| PE-conjugated IgGj, K Mouse Monoclonal BD Pharmingen, Oxford, UK
Consumables
| 0.2 ml thin-walled PCR tubes with lids Promega, Southampton, UK_____________
I 1.5 ml Eppendorff centrifuge tubes_________ NUNC, UK
| 30 ml Disposable Pipettes_________________ NUNC, UK
| 96-well plates for chemotaxis_____________ Greiner-bione, Germany________________
1 Butterfly needles________________________ Terumo, Belgium
| Conical 15 ml centrifuge tubes____________ Becton Dickinson, USA_________________
| Cryovials 2ml___________________________ Fisher Scientific, Loughborough, UK
| Gel loading tips 100 pi Fisher Scientific, Loughborough, UK
| Glass cover slips (diameter 23 mm) ' Fisher Scientific, Loughborough, UK
| Haemocytometer________________________ Fisher Scientific, Loughborough, UK
| Parafilm________________________________ Fisher Scientific, Loughborough, UK
| Petri dishes (tissue culture) NUNC, UK
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| PVP-free polycarbonate 5 pm filters________ NeuroProbe Inc, Gaithersburg, MD, USA
| Starsted screw-lid 2 ml centrifuge tubes Starsted, Germany
| Tissue culture 12-well plates______________ NUNC, UK
| Tissue culture flasks (175 cm )____________ NUNC, UK
| Tissue culture flasks (80 cm ) NUNC, UK
| Xomat Kodak flim Kodak, UK
Reagents
| 30% Bis-Acrylamide BioRad, UK
| Adenosine trisphosphate (ATP)_________ Sigma Aldrich, Gillingham, UK
1 Ammonium persulphate (APS)_________ BDH, UK
| Aprotinin _________________________ Sigma Aldrich, Gillingham, UK
| Boric acid___________________________ Sigma Aldrich, Gillingham, UK______
| Brilliant black Sigma Aldrich, Gillingham, UK______
| Butanol_____________________________ Fisher Scientific, Loughborough, UK
| Calcium chloride CaCh_______________ Sigma Aldrich, Gillingham, UK______
| CD45RA+ microbeads Miltenyi Biotec, UK
Fisher Scientific, Loughborough, UK
| Digitonin____________________________ BDH, UK
| Dissociation buffer___________________ Life Technologies, Paisley, UK______
| DTT (dithiothreitol) Promega, Southampton, UK
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| EGTA Sigma Aldrich, Gillingham, UK______
f  Ethanol (EtOH) Fisher Scientific, Loughborough, UK
| Ethyl formate Fisher Scientific, Loughborough, UK
Flo-scint IV scintillation fluid Packard Bioscience, Groningen, Netherlands
| Foetal bovine serum (FBS)____________ Life Technologies, Paisley, UK______
| Fura-2 AM Molecular Probes, Eugene, OR, USA
| Glacial acetic acid____________________ Fisher Scientific, Loughborough, UK
| Glutaraldehyde_______________________ Sigma Aldrich, Gillingham, UK
| Glycerol Fisher Scientific, Loughborough, UK
\ HBSS Life Technologies, Paisley, UK______
| HPLC Parti sphere SAX column Whatman, Maidstone, UK
| Hygromycin B_______________________ Calbiochem, Nottingham, UK________
| Interleukin-2 (IL-2) Chemicon, Hampshire, UK__________
| Ionomycin___________________________ Calbiochem, Nottingham, UK________
| Lauryl sulphate (SDS) Sigma Aldrich, Gillingham, UK______
| L-glutamine_________________________ Life Technologies, Paisley, UK______
Lymphoprep (Ficoll-paque 1.077 g/ml 
density) Nycomed Pharma AS, Oslo, Norway
| Marvel (fat-free dry milk)_____________ Supermarket (Fresh Store, Uni. Bath)
| Mercaptoethanol_____________________ Sigma Aldrich, Gillingham, UK
| M e th y la m in e (2 ^ 3 0 % in H 2 O )^ ^ ^ ^ Fisher Scientific, Loughborough, UK
1 NP-40 (IGEPAL) Fisher Scientific, Loughborough, UK
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| Orthophosphoric acid [32P] 5 mCi/ml Amersham, Little Chalfont, UK
| Penicillin/Streptomycin (P/S) lOOx Life Technologies, Paisley, UK_______
| Petroleum ether (B.P. 40-60 °C) BDH, UK
1 Phorbol 13-myristate 12-acetate (PMA) Calbiochem, Nottingham, UK
| Phosphoric acid______________________ Fisher Scientific, Loughborough, UK
| Poly-L-lysine Sigma Aldrich, Gillingham, UK
| Potassium acetate_____________________ Sigma Aldrich, Gillingham, UK______
| Probenecid__________________________ Sigma Aldrich, Gillingham, UK
| Propan-2-ol__________________________ Fisher Scientific, Loughborough, UK
| Protein G sepharose Pharmacia, UK
| Recombinant human SDF-1 (rhSDF-1) R & D Systems, Abingdon, UK
fRNase AWAY reagent 1Invitrogen, Paisley, UK_____________
RNAsin -  a non-competitive 
ribonuclease inhibitor 49.8 kDa 
recombinant E.coli____________________
Promega, Southampton, UK
| Sodium chloride (NaCL) Sigma Aldrich, Gillingham, UK
| Sodium hydroxide (NaOH)____________ BDH, UK
| Staphylococcal enterotoxin B (SEB) Sigma Aldrich, Gillingham, UK
|TEM ED  —— — — — Sigma Aldrich, Gillingham, UK______
iT ris 1Sigma Aldrich, Gillingham, UK______
| Trypsin^EDTA^ Life Technologies, Paisley UK_______
| Versene Life Technologies, Paisley, UK
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Cells and Media
| Chinese hamster ovary (CHO) K1 cells Dr Z. Brown, Novartis, Horsham, UK______
[D M  EM Life Technologies, Paisley, UK____________ 1
1 h UT-78 Dr Z. Brown, Novartis, Horsham, UK______
f  RPMI 1640 . Life Technologies, Paisley, UK____________
Inhibitors and other Pharmacological Tools
| 8-Br-cADPR Sigma Aldrich, Gillingham, UK
| AG9 Calbiochem, Nottingham, UK_____________
| Dantrolene____________ Calbiochem, Nottingham, UK_____________
1 L-NAME Calbiochem, Nottingham, UK
| Nifedipine____________ Calbiochem, Nottingham, UK_____________
IP e r tu s s i^ to x i^ ^ ^ ^ ™ Sigma Aldrich, Gillingham, UK
IR Q -32-0432 Calbiochem, Nottingham, UK_____________
| Ryanodine____________ Calbiochem, Nottingham, UK_____________
| SB203580 Calbiochem, Nottingham, UK_____________
| TPCK Calbiochem, Nottingham, UK_____________
| U73343 Calbiochem, Nottingham, UK_____________
| Wortmannin___________ Calbiochem, Nottingham, UK_____________
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2.2 Methods 
Cell Culture
The following cell lines were used in this study (descriptions from EC ACC or ATCC 
websites):
■ CEM -  human Caucasian acute T lymphoblastoid leukaemia cell
■ Jurkat J6 -  Leukaemic T lymphoblast cell
■ Hut-78 -  Leukaemic T lymphoblast cell
■ CHOK1 -  Chinese hamster ovary cell
■ CHOKlhCCR4 -  Chinese hamster ovary cell stably transfected with a
plasmid coding to generate functional human CCR4 receptors on its
surface
The following cells were generated from peripheral blood mononuclear cells:
■ T lymphoblasts (T blasts) -  super antigen-activated T cells
■ Th2 lymphocytes -  T helper 2-like cells
Suspension Cells
All suspension cell lines (Jurkat, CEM, HUT-78) were cultured in humidified incubators in 
5 % CO2 at 37 °C in RPMI 1640 medium, supplemented with 10 % (v/v) FBS, 100 U/ml 
penicillin and 100 |ig/ml streptomycin (complete medium). Cells were passaged when a 
concentration of approximately 1-2 x 106 cells/ml was reached. Cells were resuspended in 





CHOK1 and CH OK lhCCR4 cells were cultured in humidified incubators at 37 °C, 5 % 
CO2 and maintained in DMEM (Dulbecco’s Modified Eagles Medium) supplemented with 
10 % (v/v) foetal bovine serum, 100 units/ml penicillin, 100 pg/ml streptomycin, 0,1 pM  
sodium selenite, 4 mg/ml L-proline, 2 mM L-glutamine and, for selection purposes, 200 
pg/ml hygromycin and 1 mg/ml geneticin (complete medium). Cells were passaged when 
fully confluent. For experiments, CHOK1 and CHOKlhCCR4 confluent cells were 
washed, seeded at required density in 1.5 ml centrifuge tubes (in most cases) and incubated 
(37 °C water bath) in fresh medium without foetal bovine serum but with 0.1 % BSA for 1 
hour before stimulation. Growth-arrested cells were treated with the appropriate 
concentrations of stimuli in foetal bovine serum-free medium + 0.1 % BSA.
Cell Counting
Cells were resuspended in 50 ml media (but this varied depending on the suspected number 
of cells present) and a 100 pi sample removed and aliquoted in to a 0.5 ml microcentrifuge 
tube containing 100 pi 0.4 % trypan blue (this checks for cell viability -  it is a negatively 
charged chromophore (contains two azo chromophores) and will not react with the cell 
unless the cell membrane is damaged. A damaged cell results in the dye binding cellular 
proteins and thereby staining the cell blue). Non-viable cells are omitted from the counting 
process -  there ideally should not be any more than 5 % of total cells that are non-viable. 
The tube was gently mixed and -10  pi of the mixture was transferred to one side of a 
haemocytometer. The number of viable cells in one comer square (comprising 16 smaller 
squares) was counted using a light microscope (fig. 2.1).
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VoL of 1 corner 







Figure 2.1. Cell counting using a standard  haemocytometer. Those cells touching the 
bottom and bottom right outside lines are counted, whereas those touching the top and top 
left outside lines are excluded. This gives the number of viable cells counted as 33 (with 2 
non-viable cells).
The number of cells counted should be over 100 and if this was not the case then another 
corner square was counted. The number of cells/ml was calculated using the formula 
below:
Cells/ml = (average count per square) x (dilution factor) x 104 [chamber 
conversion factor]
Therefore, for example in figure 2.1 (using dilution factor described in text):
= 33 x (50 x 2) x 104 
= 3.3 x 107 cells/ml 
(cell viability [3.3 x 107]/[3.5 x 107] x 100 = 94.3 %)
No. or viable cells = 33 
No. of non-viable cells = 2
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Freezing Cells
Cells are frozen in order to provide a stock of cells of a particular age and passage number 
thereby minimising the transformation of cell lines that may occur with long term cell 
culture, and thus providing batches of cells that are similar for all experiments that are 
performed. Cells were grown to an appropriate density (i.e: 1-2 x 106 for suspension cells 
or confluent for adherent cells), washed three times in appropriate media without 
supplements (wash media), and counted using a haemocytometer and the stain trypan blue. 
Trypan blue is a stain (a negatively charged chromophore) that checks cells for their 
viability and will only enter cells whose membranes are damaged. Cells were resuspended 
at a concentration of 2 -  10 x 106 cells/ml in ‘freeze media’ (90 % FBS and 10 % DMSO) 
and 1 ml volumes aliquoted into cryovials. The cryovials were then placed into a ‘Mr 
Frosty’ (filled with the required volume (250 ml) of isopropanol (i.e. propan-2-ol), at room 
temperature, and then placed into a -8 0  °C freezer. The ‘Mr Frosty’ ensures a freezing rate 
of 1 °C/min, thereby reducing the occurrences of artifacts. The following day (16 -  24 
hours later) the cryovials were transferred into canes and placed into liquid nitrogen tanks 
for long-term storage.
Thawing Cells
Appropriate wash media and media with 20 % FBS (instead of normal 10 %), 100 units/ml 
penicillin and 100 pg/ml streptomycin were warmed to 37 °C in a water bath. Cryovials 
containing the desired cells were recovered from liquid nitrogen and thawed immediately 
by partial submersion in a 37 °C water bath for 2 -  3 minutes, with regular agitation. Cells 
were then transferred to 50 ml conical tubes containing pre-warmed wash media and gently 
mixed and centrifuged at 1500 rpm for 5 minutes at rtp. Cells were washed a further two 
times, then resuspended in media containing 20 % FBS (volume of re-suspension depends 
on number of cells, but generally 1 0 - 5 0  ml) and transferred to an appropriate size tissue 
culture flask (25 cm2 flask for ~ 10 mis, 80 cm2 flask for ~ 30 mis, and 175 cm2 flask for ~ 
50+ ml). Over the following days cells were assessed and, once optimal density reached,
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media volume was expanded with cells transferred into larger flasks and resuspended in 
complete media (i.e. media with selective reagents if required).
Polymerase Chain Reaction
The polymerase chain reaction (PCR) is a technique used to amplify virtually any DNA 
segment that lies between two regions of known sequence. The idea of PCR was conceived 
by Kary Mullis (Nobel Laureate 1993) in 1983 at Cetus Corporation (Emeryville, 
California -  merged with Chiron in 1991), but was largely developed by other scientists at 
the corporation, most notably Stephen Scharf and Henry Erlich, and published in 1986 
(Mullis et al., 1986; Scharf et al., 1986). The PCR technique was later sold to Roche 
Molecular Systems for $300 million in 1991 and has since revolutionised molecular 
biology.
The starting material for PCR, the 'target sequence', is a gene or segment of DNA. Heating 
separates the complementary strands of a double-stranded molecule of DNA. Two small 
pieces of synthetic DNA, each complementing a specific sequence at one end of the target 
sequence, serve as primers, with each primer binding to its complementary sequence. DNA 
polymerases (e.g. Taq -  thermostable) start at each primer and copy the sequence of that 
strand. Within a short time, exact replicas of the target sequence have been produced. In 
subsequent cycles, double-stranded molecules of both the original DNA and the copies are 
separated; primers bind again to complementary sequences and the polymerase replicates 
them. In a matter of hours (after many cycles), the target sequence can be amplified many 
million fold with this amplified genetic information then being available for further 
analysis.
Reverse transcriptase-PCR (RT-PCR) is used to amplify products of RNA (any kind -  
mRNA, tRNA, rRNA, etc) to create cDNA, allowing the analysis of gene expression. A 
cDNA is a single-stranded copy of an RNA sequence and synthesized by the retroviral 
enzyme reverse transcriptase (RT). This reverse transcription step is performed prior to 
PCR.
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PCR was applied to amplify DNA encoding for CCR4. The cDNA was generated by 
reverse transcription from mRNA isolated from cells and PCR enabled visualisation of 
DNA segment bands in UV illuminated ethidium bromide gels. With this qualitative 
process, the extent of constitutive transcription of CCR4 was assessed in a range of cell 
types.
Sample mRNA Extraction
Sample mRNA was extracted from CHOKlhCCR4, parental CHOK1, HUT-78, CEM, 
MOLT-4, EL-4, and T-lymphoblast cells. Initially, total cellular RNA was isolated from 
the cells using RNAzol B according to the manufacturers instructions. 1 x 106 cells were 
centrifuged at 13000 rpm  for ~ 5 sec and the supernatant was discarded and the cells were 
homogenized in 400 pi of RNAzol™ B (Biotex, USA). 100 pi of chloroform per 1 ml of 
homogenate was then added, the samples vortexed vigorously for 15 seconds and then 
cooled on ice for 15 minutes. The samples were then centrifuged at 14000 rpm for 15 
minutes, 4 °C. This leads to the formation o f two phases: a lower blue phenol-chloroform 
phase and the RNA-containing upper aqueous phase. The aqueous phase was transferred to 
a clean eppendorff tube and an equal volume of isopropanol was added. The samples were 
cooled on ice for 15 minutes and centrifuged again at 14000 rpm for 15 minutes at 4 °C. 
RNA will then form a precipitate at the bottom of the tube. The supernatants were removed 
and the RNA pellet washed in 1ml 70% ethanol. The pellets were then dried and re­
dissolved in nuclease-free water (Promega, Southampton, UK).
RNA was quantified using a deuterium lamp spectrophotometer, Gene Quant II RNA/DNA 
calculator (Pharmacia, UK). RNA concentration is measured by the absorbance of 1 pi of 
RNA sample diluted in 500 pi of water at 260 nm. The amount of RNA (in pg) present in 
each sample was calculated by the following formula:
A260 x dilution factor (500) x 40* x volume of remaining RNA solution in ml (0.048)
* assumption is that a solution of 40 pg/ml ssRNA (50 pg/ml for dsDNA) has an 
absorbance of 1 at 260 nm.
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ODs were also read at 280 nm and 230 nm to assess the purity of RNA. A value of less 
than 2 for the OD26o:OD28o ratio indicated protein contamination. A low OD26o:OD28o ratio 
indicated guanidine contamination. A ratio between 1.8 and 2.0 was considered acceptable.
1 pg of total RNA was dissolved in 8 pi of nuclease-free water and was treated with 1 pi 
DNase I for possible DNA contamination. DNase I was then inactivated by the addition of 
1 pi EDTA and heated at 65° for 10 minutes.
Reverse Transcription (RT) Step
The resulting solution was then mixed with 2 pi oligo(dT) and denatured at 70 °C for 10 
minutes. The reverse transcription mixtures were made up in 0.2 ml PCR tubes and 
contained 4 pi buffer (supplied with enzyme (Invitrogen)), lp l DTT, 1 pi DNTP’s, 1 pi 
RNAsin and lp l o f reverse transcriptase per sample and, together with the 12 pi mRNA 
sample, gave a final volume of 20 pi per PCR tube. The final concentration in 20 pi of the 
constituents was: 1 pM of oligo(dT)i2-i8, 0.5 mM from each of the deoxynucleoside 
triphosphates dATP, dCTP, dGTP and dTTP, 10 U/pl Superscript II RNase ITReverse 
Transcriptase, and 1 U/pl RNAsin (non-competitive ribonuclease inhibitor).
The tubes were placed in a Perkin Elmer Gene Amp 2400 thermocycler (Warrington, UK) 
and followed a reverse transcription program of: 42 °C for 60 min, 94 °C for 2 min and 4 
°C thereafter. The RT products were either used immediately, or briefly stored at -80° C.
PCR Step
A forward and reverse primer was obtained for the CCR4 gene of interest (using Primer 3 
Design software available on the internet) from Dr. Nicola Jordan (University of Bath). 
The DNA sequence that was amplified by PCR was selected in a way that the primers were 
spanning at least one intron, which would result in the generation of a larger intron- 
containing PCR product in the case of DNA contamination. Each RT template from an 
experimental sample, apart from the genes of interest, were also tested for a positive 
control, the house keeping gene p-actin and a negative control of original RNA before the 
RT step, to check for DNA contamination. Each PCR reaction was carried out in 0.2 ml
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thin PCR tubes in 25 pi total volume containing 0.05 jug cDNA template, 15.9 pi of 
nuclease-free water and the following final concentrations of constituents (in appropriate 
volumes to give a final volume of 25 pi per tube): 200 pM of each of the 4 deoxynucleoside 
triphosphates dATP, dCTP, dGTP and dTTP; 500nM of the forward (sense) primer; 500 
nM of the reverse (antisense) primer; 1.25 Unit of Expand™ High Fidelity enzyme mix, 
which comprised of 2 DNA polymerase enzymes: Taq and a proofreading polymerase Pwo; 
and 1 x Expand™  PCR buffer with Mg2+. The polymerase enzymes and PCR buffers were 
used according to ‘Expand™  High Fidelity PCR System’ manufacturer’s specifications, 
and the thermocycler was given the following programme: 15 sec at 95 °C, 15 sec at 57 °C, 
15 sec at 72 °C repeated for 30 cycles and two holds, one at the beginning of the 
programme for 60 sec/95 °C and one at the end for 6 min/72 °C, prior to cooling to 4 °C 
thereafter. The temperatures set were optimal for the phases of the PCR cycle: 95° C for 
denaturation of the template, 57 °C for annealing of the chemokine receptor oligonucleotide 
primers to the open DNA strand and 72 °C for optimum DNA synthesis by the heat stable 
polymerase enzymes. Dr. N. Jordan optimised cycle composition and number of cycles for 
PCR amplification of chemokine receptor primers in-house. The PCR products were either 
loaded immediately on an agarose gel or briefly stored at 4° C.
Human Gene T >^r0^ U/CLt . Primer SequenceLength (bp) n
CCR4 349 sense: 5' GAAGAAGAACAAGGCGGTGAAGAT 3'
antisense: 5' ATGGTGGACTGCGTGTAAGATGAG 3'
Detection o f PCR Products
A 2% agarose gel was made in TBE (10 mM Tris base, 10 mM Boric acid, 2 mM EDTA, 
pH 8.0), boiled and cooled with the addition of 1 pg/ml ethidium bromide. 5 pi from each 
tube containing the PCR end products were coloured with 5 pi of Blue Juice (15% (w/v) 
Ficoll 400, 0.25% (w/v) bromo-phenol blue in water). A 100 base pair ladder comprising 
of 15 blunt end fragments (100 -  1500 base pair scale) was also coloured with Blue Juice. 
The samples and ladder were loaded onto the agarose-ethidium bromide gel and run by gel
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electrophoresis with 100 V/0.1 mA current (BioRad Instruments). The resulting bands were 
visualised with a UV illuminator and photographed with a Polaroid camera.
Flow Cytometry (FACS) Analysis
Cells were washed twice in PBS and aliquoted into polypropylene FACS tubes at 1 x 106 
cells/tube and resuspended in 95 pi PBS/20% FBS. The cells received either 1 pg of PE- 
conjugated anti-CCR4 mAb (5 pi), or corresponding PE-conjugated IgGi, K isotype control 
(BD PharMingen), or 5 pi PBS/20 %FBS negative (vehicle) control and were incubated for 
30 minutes on ice, in the dark and with regular mixing. Cells were then subsequently 
washed twice and resuspended in 500 pi PBS (or 500 pi 4 % paraformaldehyde, wrapped in 
foil and placed in the fridge for future analysis) and immediately analysed using a FACS 
Vantage (BD Biosciences, San Jose, CA); excitation X 488 nm, emission X 578 nm (band 
pass filter 575/26).
Expansion of Primary Human T Lymphocytes (T Lymphoblasts) in vitro
Bottles of wash media (RPMI 1640) and complete media (RPMI 1640 + 10 % FBS + 100 
units/ml penicillin, 100 pg/ml streptomycin) were warmed to 37 °C in a water bath, and 15 
ml of Lymphoprep was aliquoted into 50 ml transparent conical tubes and allowed to reach 
room temperature in the comparative dark. Peripheral blood was then collected from 
healthy human donors (free of medication, including paracetamol, NSAIDs, etc) in sterile 
heparinised syringes (500 U/ml stock: 2 pl/ml blood). The blood was then diluted 1:1 with 
pre-warmed wash media in a large (175 cm2) tissue culture flask, mixed and, very carefully, 
35 ml of the diluted blood layered on to the Lymphoprep present in the conical tubes 
(without mixing the two). The conical tubes were then spun at 1500 rpm for 30 min at rtp, 
with the brake off, isolating the peripheral blood mononuclear cells (PBMCs) by density 








Figure 2.2. Schem atic diagram  of PBMC separation with Lym phoprep after 
centrifugation. The diagram is representative of the separated layers observed after 
centrifugation with Lymphoprep, along with the colour each layer appears, in an 
undisturbed, transparent conical tube.
After centrifugation, the milky layer containing the mononuclear cells (i.e. lymphocytes 
and monocytes) was carefully removed with a 3 ml long-necked pastette, being carefully 
not to aspirate off any of the Lymphoprep, into a new 50 ml conical tube. The remaining 
volume of the conical tube was filled with wash media and the tube spun at 1500 rpm for 5 
min, rtp. The supernatant was aspirated off and the cells were washed a further three times 
with wash media to ensure that any Lymphoprep present was removed. Following the three 
washes, the pellet containing PBMCs was resuspended in complete media to the original 
blood volume (approximately 1 x 106 cells/ml) and transferred to a large (175 cm2) tissue 
culture flask. The PBMCs were then stimulated (T cells activated to become T 
lymphoblasts) with staphylococcal enterotoxin B (SEB, 1 pg/ml) for 72 hours, and cultured 
in a humidified incubator at 37 °C, 5 % CO2. After three days, the cells were washed three 
times to remove the SEB and resuspended in fresh complete media to original volume and 
growth maintained by supplementing every two/three days with IL-2 (48 Ul/ml) for four
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additions. For experiments (day 1 2 -13  post-isolation), cells were deprived of IL-2 for two 
days and allowed to accumulate in the Go/Gi stage of the cell cycle prior to use. Cells were 
resuspended in RPMI 1640 with 0.1 % BSA for 1 hour prior to use in experiments (unless 
stated otherwise).
In Vitro Generation of Human T Helper 2 (Th2) Cells
Blood samples were collected from healthy adult volunteers and deposited in to 50 ml 
conical tubes containing 1 ml of anti-coagulant (20 mg/ml EDTA in PBS) per 10 ml of 
blood. Blood was diluted 1:1 with pre-warmed RPMI 1640 and 35 ml of diluted blood 
carefully layered on to 15 ml of Ficoll-paque (1.077), and blood separated by density 
gradient centrifugation, as described above. The PBMCs were removed from the gradient 
as previously described, and cells washed 3 x (1600 rpm, 5 min, 12 °C) with MACS buffer 
(PBS + 0.5 % BSA + 2 mM EDTA, pH 7.2, at 4 °C) and cells counted. Cells were 
resuspended in 80 pi MACS buffer/107 cells, and naive CD4+ T cells isolated using 
magnetic cell separation. This involved magnetically labelling cells with CD4+ 
MicroBeads (20 pl/107 cells), incubating the cells + beads in the fridge for 15 min, washing 
2 x with MACS buffer (1600 rpm, 5 min, 12 °C), resuspending the cells in 2 ml MACS 
buffer, and separating (positive selection) on a column that is placed in the magnetic field 
of an AutoMACS separator (Beads and machine from Miltenyi Biotec, Germany). The 
collected CD4+ fraction of cells were then incubated with 20 pl/ml Release Agent (supplied 
with kit) and incubated in the fridge for 10 min. Subsequently, cells were washed (2 x), 
counted, resuspended in MACS buffer at 50 pl/107 cells, and 30 pl/107 cells Stop Reagent 
(supplied with kit) added. A similar process was then repeated for the positive selection of 
CD45RA+ cells within the CD4+ cell fraction. Specifically, CD45RA+ MicroBeads (20 
pl/107 cells) were added to the CD4+ fraction of cells and incubated in the fridge for 15 
min, followed by washing (2 x) and resuspension in 500 pi MACS buffer. Cells were once 
again separated using the AutoMACS machine, with the positive fraction collected (i.e. 
CD4+CD45RA+ cells), washed 2 x in pre-warmed RPMI 1640 and counted. Isolated CD4+ 
CD45RA+ cells were cultured at 106 cells/ml in humidified incubators (5 % CO2 at 37 °C)
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in RPMI 1640 medium, supplemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 pg/ml 
streptomycin, 1% MEM vitamins, 10 pg/ml insulin, 5.5 pg/ml transferrin, 6.7 ng/ml 
selenium, 50 pM  2-mercaptoethanol, 20 U/ml rhIL-2. Cells were polarised to a Th2-like 
phenotype by the addition of rhIL-4 (200 ng/ml) and neutralising anti-IL-12 (1 pg/ml) and 
anti-IFNy (1 pg/ml) Abs (R & D Systems). Activation of cells was initiated by culturing (2 
ml cells/well) in anti-CD3 (1 pg/ml) coated 12 well plates with the above-mentioned media 
for the first 5 days. Cells were then washed and again cultured in the above media, except 
with 50 U/ml rhIL-2 (Chemicon, Chandlers Ford, U.K.), in 175 cm2 tissue culture flasks. 
Cells were used between weeks 3 and 4 post-isolation.
Cell Stimulations and Lysis 
Generating * Whole Cell Lysates* (WCL)
Cells were washed, counted and resuspended in appropriate media (e.g. RPMI 1640 or 
DMEM) for the cell type, supplemented with 0.1 % BSA. For cell numbers refer to the 
figure legends as this varies depending on cell type and antibody being utilised (but not 
normally more than 5 x 106 cells/ml). 1 ml aliquots of cell suspension were added to 1.5 ml 
microcentrifuge tubes and serum starved for 1 h in a 37 °C water bath. If used, cells were 
pre-incubated with inhibitors or vehicle (commonly DMSO or MQH2O) for stated time, 
and then stimulated for indicated times with agonist (e.g. MDC). Reactions were 
terminated and lysates generated by pelleting cells in a centrifuge (pulse to -8000 rpm), 
aspirating off the supernatant, adding 100 pl/106 cells of 1 x sample buffer (see appendix 1 
for recipe -  samples are thus denatured and reduced), and vortexing for 15 sec. Samples 
were then placed on ice and then subsequently boiled for 5 min at 100 °C. Samples were 
stored in a -2 0  °C freezer until required.
Generating Samples for Immunoprecipitation (IP)
As for W CL generation, cells were washed, counted and resuspended in the appropriate 
media for the cell type (supplemented with 0.1 % BSA). Cell numbers were at least 1 x 107
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cells/ml, but refer to figure legends for exact numbers. 1 ml aliquots of cell suspension 
were added to 1.5 ml microcentrifuge tubes and serum starved for 1 h in a 37 °C water 
bath. If utilised, cells were pre-incubated with inhibitors or vehicle for stated time, and 
then stimulated for indicated times with the appropriate agonist. Reactions were terminated 
and lysates generated by pelleting cells in a centrifuge (pulse to -8000 rpm), aspirating off 
the supernatant, and adding 500 p,l ice-cold lysis buffer (see appendix 1). Samples were 
vortexed for -15  sec and placed on ice until next step. Cells were subsequently lysed on a 
rotator at 4 °C for 20 min. Non-soluble material (cell debris) was removed by spinning 
samples in a microfuge for 10 min at 14000 rpm and 4 °C. Supernatants were transferred 
to clean 1.5 ml microcentrifuge tubes.
Immunopreclpitation
Cell lysates (generated by the above method) were pre-absorbed with 20 pi of a 50:50 
slurry o f protein-A or protein-G sepharose (depending on the species source for the 
antibody being used -  see appendix 4) for 30 min on a rotator at 4 °C. Following rotation, 
samples were spun at 14000 rpm (a quick pulse) to pellet the sepharose beads, and the 
supernatant removed and transferred to clean 1.5 ml microcentrifuge tubes. If required, 20 
pi of the lysates were removed to tubes containing 20 pi 2 x sample buffer and boiled for 5 
min (to generate whole cell lysates for control blots) and stored at -2 0  °C. The remaining 
lysate volume was then incubated with 2 -  5 pg antibody on a rotator at 4 °C for 2 hr. 
After 2 hr, 20 pi of a 50:50 slurry of pre-washed protein-A or protein-G sepharose beads 
were added to the lysate-antibody mixture and incubated for a further 1 hr on a rotator at 4 
°C. For immunoblotting, the lysate-bead-antibody mixture was washed 3 x with ice-cold 
lysis buffer (14000rpm, 4 °C, -5  sec). The final wash was removed as completely as 
possible (using a Gilson pipette fitted with a 200 pi gel-loading tip) and the pellet 
resuspended in 20 pi 2 x sample buffer (denaturing and reducing), vortexed for -15  sec, 




SDS-PAGE & Western Blotting (Immunoblotting)
Whole cell lysates or immunoprecipitates were essentially resolved by processes first 
described by Ornstein, Davis, and Laemmli (DAVIS, 1964; Laemmli, 1970; ORNSTEIN, 
1964). Briefly, electrophoresis was carried out using the sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) method. The excess presence of the ionic 
detergent (SDS) and thiol reagent (i.e. 2-mercaptoethanol -  a reducing agent) in the sample 
buffer, along with the process of boiling the samples at 100 °C, has the effect of denaturing 
the proteins by SDS wrapping around the polypeptide backbone and the thiol reagent 
cleaving the disulphide bonds. This results in the proteins being fully dissociated into their 
individual polypeptide subunits. Most polypeptides will bind SDS in a constant weight 
ratio (1.4 g SDS:1 g of polypeptide) in the conditions mentioned above. This leads to the 
negation of the effect of the intrinsic charges of the polypeptides due to the negative 
charges provided by the bound SDS, and thus the SDS-polypeptide complexes all 
essentially have the same negative charge and shape and, consequently, will migrate 
through the gel according to polypeptide size only. A discontinuous buffer system was 
employed, which consisted of a large pore non-restrictive (stacking) gel overlaying a 
smaller pore resolving gel. The principal of separation follows that the pH 6.8 of the 
stacking gel and sample buffer results in the presence of weakly ionised glycine and thus its 
mobility is low. The chloride ions in the running buffer are completely ionised and 
therefore have higher mobility, with the mobility of the proteins being at an intermediate 
between the two different ion types. The application of a voltage causes the leading 
chloride ions to migrate away from the trailing glycine ions setting up a zone of lower 
conductivity, higher voltage gradient and higher pH behind the chloride ions. This zone 
accelerates the glycine to keep it up with the chloride ions and this boundary moves 
through both stacking and resolving gels, with chloride ions overtaking any proteins in 
front. The proteins have a higher velocity than glycine meaning that the proteins are 
concentrated into thin zones (stacks) in order of decreasing mobility. When the proteins 
enter the higher percentage resolving gel their mobilities are reduced so that they migrate 
slower than the glycine ions allowing the proteins to escape the ‘stack’. The increase in pH 
of the resolving gel (pH 8.8) accelerates the trailing ions (glycine) by increasing its net 
negative charge and thus mobility increases. This leads to the glycine ions overtaking some 
of the proteins and migrate directly behind the chloride ions allowing the proteins to
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resolve. Regulation of the pore size of the gel is obtained by the effective use of differing 
concentrations of acrylamide (higher the concentration the smaller the pore size -  the 
stacking gel generally has a pore size larger than the resolving gel), and in the presence of 
polymerising compounds (APS and TEMED -  TEMED is a tertiary amine base that 
catalyses the formation o f oxygen free radicals from APS causing bis-acrylamide (or 
acrylamide) to polymerise) leads to the generation of polymerised acrylamide monomers 
and crosslinked of the chains. The size of the pore size required will depend upon the size 
of the polypeptide of interest.
SDS-PAGE
Whole cell lysate or immunoprecipitates were separated via minigel SDS-PAGE using 
BioRad Mini Protean III equipment (Bio-Rad Laboratories, Hemel Hempstead, UK). All 
gels were 1 mm thick and stacking gels were always 5 % bis-acrylamide. Bis-acrylamide 
percentage for resolving gels varied between the differing proteins of interest (see appendix 
1 & 5 for gel recipes and bis-acrlyamide gel percentages utilised for the varying proteins of 
interest). The glass plates were set-up according to manufacturer’s instructions and the 
resolving gel cast (~ 4.5 ml of Resolving Buffer/gel), overlaid very carefully with MQH2O 
to ensure a smooth and flat gel, and left to polymerise for ~ 30 min. After polymerisation, 
the water was completely removed and Stacking Buffer (with APS and TEMED added 
immediately prior to casting) poured on top of the resolving gel to the top of the small glass 
plate with a comb (containing the appropriate number of teeth (10 or 15)) put in place and 
the gel allowed to set (~ 15 min). Subsequent to stacking gel polymerisation the comb was 
removed and the wells washed 3 x with MQH2O and then filled with Running Buffer (see 
appendix 1 for recipe) and samples added to appropriate wells with a broad molecular 
weight range marker included (Bio-Rad) for ease of protein band identification. Minigels 
were electrophoresed at 70 V until the samples had passed the stacking gel and then the 




The proteins from the electrophoresed minigels were transferred onto nitrocellulose 
membranes by the semi-dry transfer method. The nitrocellulose membrane was placed on 
top of 4 pieces of 3 MM filter paper cut to the same size as the gel (8.5 cm x 5.5 cm), all of 
which were soaked in Semi-Dry Transfer Buffer (see appendix 1 for recipe) and placed on 
the anode of the transfer apparatus. The stacking gel was cut away from the resolving gel 
and the resolving gel rinsed in Semi-Dry Transfer Buffer and carefully placed on to the 
nitrocellulose membrane. 4 more layers of pre-soaked (in transfer buffer) filter paper were 
placed on top of the gel to form a ‘sandwich’. All layers of the ‘sandwich’ were rolled to 
remove all air bubbles. The cathode was plate was applied to the top of the ‘sandwich’ and 
proteins were transferred for 1 hr at 0.8 mA per cm2 of gel.





Anode (+) 3M M  Whatman paper
Running conditions: 
42 mA/cm2 of p i, 1 hr
ASSEMBLED
APPARATUS
Figure 2.3. C onstruction of a single gel m em brane sandwich, with running conditions.
Western Blotting (Immunoblotting/Immunostaining)
Following gel transfer, membranes were washed (2 x) in tris-buffered saline (TBS) and 
protein bands stained with Ponceau S solution (seconds) as an indication of efficient and 
equal transfer of protein bands across the membrane. Ponceau S was removed by washing 
the membranes (1 x) with Semi-Dry Transfer Buffer until the membranes were no longer 
stained. Membranes were then briefly rinsed (3 x) with TBS and blocked for the 
appropriate length of time with either non-fat dry milk powder in TBS or BSA in TBS (for
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blocking conditions of the various antibodies refer to appendix 5) at rtp on a rocking 
platform. After blocking, the membranes were briefly rinsed 3 x in TBS and then 
membranes incubated with primary antibody (once again, refer to appendix 5 for 
conditions) at rtp on a rocking platform. After appropriate incubation time with primary 
antibody, the membranes were washed 5 x 5  min with TBS + 0.1 % Tween-20 (TBST). 
Suitable secondary antibody (conjugated to horse radish peroxidase (HRP)) diluted in 
TBST was then applied to the washed membranes for 1 hr at rtp (with rocking) before 
membranes were washed 3 x with TBST and 2 x with TBS. Protein bands were visualised 
with Amersham Enhanced Chemiluminescence (ECL) reagent (incubation of 1 
min/membrane) according to manufacturer’s instructions and membranes wrapped in cling 
film and exposed to autoradiography film.
Stripping o f Western Membranes
Membranes to be reprobed with primary and secondary antibody (commonly for 
verification of equal loading) were washed 3 x with TBST and submerged in pre-warmed 
(60 °C) Stripping Buffer (refer to appendix 1 for recipe) for 30 min at 60 °C. Following 
rigorous washing of membranes with TBST, membranes were blocked and reprobed with 
appropriate primary and secondary antibodies, as previously described in ‘Western 
Blotting’.
In Vitro Lipid Kinase Assay
Cells were washed, stimulated and immunoprecipitated as previously described in the 
‘Immunoprecipitation’ section, with PI3K lysis buffer used instead of ‘normal’ lysis buffer 
(see appendix 1 for recipes). More specifically, the samples were immunoprecipitated 
using an antibody against the catalytic subunit of the PI 3-kinase of interest (i.e. pllOy, 
p i 108, C 2a, C2P) or p85 (to determine the activity of all class I PI3K isoforms) for 2 h, 
and rotated at 4°C. Samples were then incubated for a further hour with 40 jj.1 50:50 protein 
A slurry. Following protein A incubation period, immunoprecipitates were washed 3 x in 
Buffer A, 3 x in Buffer B, and finally 2 x with Tris-NaCl-EDTA (TNE) buffer (see
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appendix 1 for recipes). The first two buffer washes were carried out by pelleting the beads 
at 14000 rpm for 30 sec, the third group of buffer (i.e. TNE) washes were carried out by 
pelleting the beads at 14000 rpm for 2 min (all washes were carried out at 4 °C). After 
removal of the final wash as completely as possible (by using a Gilson pipette fitted with a 
200 |il gel-loading tip), samples were resuspended in 50 p.1 TNE, 10 p.1 (20 |ng) 
phosphatidylinositol (PI) and 10 p.1 100 mM MgCh. Note that the PI3K inhibitors, 
LY294002 and wortmannin, were incubated with the immunoprecipitates at this point for 
30 mins and 15 mins, respectively, with dilutions of inhibitor in TNE (the PI and M gC^ 
were added after the incubation period with the PI3K inhibitors). Reactions were started by 
the addition of 5 |al ATP Reaction Buffer (see appendix 1) and allowed to proceed for 10 
min at 25°C, with continuous agitation. Reactions were terminated by adding 20 pi 5N 
HC1 and 160 pi chloroform/methanol (1:1) and phases separated by centrifugation at 
14,000rpm for 10 min at rtp. 50 pi of the lower phase was removed and spotted onto 1% 
oxalate-treated thin-layer chromatography (TLC) plates (in 2 x 25 pi loading steps) and 
resolved by TLC in chloroform/methanol/water/ammonium hydroxide (60:47:11.3:2). 
Laned silica gel TLC plates were pre-treated by submerging the plate in 1 % potassium 
oxalate for a few seconds and dried in an oven overnight at 100 °C, before being removed 
and allowed to reach rtp before use (or storage). The solvent tank was pre-equilibriated for 
at least 3 hr prior to the addition of the plate. The plate was removed from the tank when 
the solvent front had reached within 1 cm of the top of the plate. [32P]-labelled lipids were 
visualised by exposure to autoradiography film at -80°C.
Densitometry
Densitometry was performed on IVLK films to provide a more qualitive form of result. 
This method was performed with the use of the Gene Snap 4 and Gene Tools 3.00.22 
programs (SynGene, Cambridge, U.K.). Gene Snap 4 was utilised to take an electronic 
picture of the film (following the program instructions) and the picture imported into Gene 
Tools to perform the density analysis of each band and with automatic background 
deduction incorporated. The generated values were subsequently exported to Microsoft
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Excel 2000 program (Microsoft Corporation, Redmond, WA, U.S.A.) for graphical 
conversion.
Measurement of D3 Phosphoinositide Lipids 
Phospholipid Labelling and Extraction
Cells were washed 3 x with pre-warmed phosphate-free DMEM supplemented with 20 mM 
HEPES and 0.375 % sodium bicarbonate (pH 7.2), incubating cells for 10 min at 37°C in 
between washes to deplete cells of phosphate (cells spun at 1600 rpm, 5 min, rtp). 
Following the final wash, cells were resuspended at 2 x 107 cells/ml in phosphate-free 
DMEM + 5% phosphate-free FBS and labelled with lm Ci [32P] orthophosphate/1 x 108 
cells (i.e. 200 pCi/ml), for 4 h at 37°C. Dialysing against saline for 18 hr attained 
phosphate-free FBS, which was then filter sterilised, aliquoted and stored at -2 0  °C. 
Dialysis tubing was prepared by boiling twice for 5 min in 5 mM EDTA + 200 mM 
Na2CC>3. Proceeding the 4 hr incubation, 32P-labelled CEM cells were then washed 3x in 
pre-warmed phosphate-free DMEM and resuspended at 2 x 107 cells/108 pi in DMEM (or 
97.2 pi DMEM if PI3K inhibitors are used) in 1.5 ml screw-capped Sarstedt tubes. Cells 
were stimulated, as indicated in figure legends, by the addition of 12 pi of lOx agonist (or 
incubated with LY294002 or wortmannin (10.8 pi addition of lOx inhibitor) for 30 and 15 
min, respectively, beforehand), at 37 °C. Reactions were quenched by the addition of ice- 
cold 500 pi chloroform/methanol/H20 (32.6:65.3:2.1 % v:v:v) and vortexing for -15  sec to 
produce a primary extraction phase. Phases were separated by the addition of 200 pi 
freshly prepared chloroform containing 10 pg/ml Folch lipids, and 200 pi of 5 mM 
tetrabutylammonium sulphate (TBAS -  see appendix 1 for recipe), then vortexed for -3 0  
sec and centrifuged at 8000 rpm (-1000 g). The lower phase was carefully removed (using 
a Gilson pipette attached with a 200 pi gel loading tip) to clean 1.5 ml Sarstedt tubes 
containing 400 pi 0.1 M HC1 + 5 mM EDTA, with samples vortexed and centrifuged at 
8000 rpm for a further 5 min to separate phases. The lower phase was removed and 
transferred to clean 1.5 ml Sarstedt tubes and dried in vacuo (medium heat - -1 hr). The
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dried lipids were then deacylated by the addition of 1 ml 25 % (w/v) aqueous 
methylamine/methanol/N-butanol (4:4:1 v/v/v) and incubated in a 53 °C water bath for 40 
min, and then rapidly cooled on ice for a further 5 min before samples dried in vacuo 
overnight (medium heat). The deacylation generates glycerophosphatidylinositol (GroPI) 
derivatives that are soluble in water. Thus, 500 pi MQH2O was added to the dried samples 
followed by 600 pi N-butanol/petroleum ether (bp 40 -  60 °C)/ethyl formate (20:4:1 v/v/v). 
After vigorous vortexing, samples were centrifuged at 8000 rpm for 5 min to separate 
phases, and the upper layer removed and discarded. The aqueous phase was washed by 
adding a further 600 pi of the above-mentioned N-butanol/petroleum ether/ethyl formate 
solution, centrifuged at 8000 rpm for 5 min, with the upper organic phase discarded as 
before. The lower aqueous phase was dried in vacuo overnight (medium heat) and samples 
then stored at -8 0  °C until analysed by high performance liquid chromatography (HPLC) 
(Ward, 2000).
High Performance Liquid Chromatography (HPLC) Analysis
The deacylated samples were analysed by anion-exchange HPLC analysis using a 12.5 cm 
Partisphere SAX column (Whatman, Maidstone, UK). The dried lipids were redissolved in 
90 pi MQH2O by vortexing (and by the use of a sonicating water bath), with non-soluble 
material sedimented at 14000 rpm for 1 min. The sample was automatically applied with a 
Jasco Intelligent sampler 851-AS to an anion exchange Whatman Partisphere SAX column 
at a flow rate of 1 ml/min. The lipids were eluted from the column using a gradient based 
on Buffer A (MQH2O) and Buffer B (1.25 M ammonium phosphate [(N H ^H P O ^, pH 3.8 
(adjusted with HPO4 at 25 °C)), with both buffers filtered and degassed (with bubbling 
nitrogen for 30 min) prior to use. The mobile phase gradient was fed into the column by a 
Jasco Intelligent HPLC pump PU-980 connected to a Ternary gradient unit LG-980-02 and 
was as follows: 0 min, 0 % Buffer B (B); 5 min, 0 % B; 45 min, 12 % B; 60 min, 30 % B; 
61 min, 100 % B; 65 min, 100 % B; 66 min, 0 % B; 90 min, 0 % Buffer A and B. The 
eluate was fed into a Canberra Packard A-500 Flo-One on-line beta-radiodetector where it 
was mixed with 3 volumes (i.e 3 ml/1 ml eluate) of Flo-Scint IV scintillation fluid. The 
results were analysed by the Flo-One data program (Radiomatic, USA). Retention times 
for individual GroPIs have been described elsewhere (fig. 2.4) (Ward, 2000).
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Figure 2.4. HPLC elution profile of deacylated [32P]-labelled phosphoinositides 
derived from  an activated leukaemic T cell line (Ward, 2000).
Chemotaxis Assay -  NeuroProbe Reusable MB Series 96-Well Chemotaxis 
Chambers (CEM Cells)
CEM chemotaxis assays were conducted in 96-well reusable chemotaxis chambers 
(NeuroProbe, Gaithersburg, MD, U.S.A.). Cells were washed twice and resuspended in 
RPMI 1640 media + 0.1 % BSA at 1 x 106 cells/ml and serum starved for 1 hr at 37 °C. 
The chamber was assembled according to manufacturer’s instructions (fig. 2.5), with 365 pi 
of agonist (diluted in RPMI 1640 + 0.1 % BSA) added to the lower wells (avoiding 
formation of air bubbles) and a polyvinylpyrrolidine-free polycarbonate membrane (5 pm 
pores) filter was carefully stuck firmly to the plate. The gasket was positioned onto pins on 
underside of chamber lid and lid gently closed with even pressure across the top of the 
chamber. 200 pi of cell suspension were added to the upper wells, then covered with 
parafilm and incubated at 37 °C (5 % CO2) for 90 minutes. Following incubation, the 
upper wells were aspirated off and 200 pi of versene was added to each well for 20 minutes
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at 4 °C. The versene was then aspirated off and the chamber dismantled. The 96-well plate 
and attached membrane were spun at 1500 rpm for 10 minutes to pellet cells and the 
supernatant carefully aspirated off. The cells were resuspended in 100 pi RPMI 1640 + 0.1 
% BSA. Cell numbers were determined from standard curves of the same cells using 20 pi 
Cell Titer 96 A Q ueous reagent per well with plates incubated at 37 °C for colour changes to 
develop before the plate is read at 490 nm on a Dynatech MR5000 plate reader (Dynatech 
Laboratories, Billingshurst, U.K.). Results were presented as a chemotactic index (fold 
increase over basal) with statistical analysis performed using Student’s t test.
Pipette Tip 
Contact Point 2A—
Contact Point 2B 







Figure 2.5. The MB Series 96-well reusable chemotaxis cham ber and assembly
(individual images from www.neuroprobe.com).
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Chemotaxis Assay -  NeuroProbe Disposable ChemoTx System (Th2 cells)
Th2 cell chemotaxis was conducted with the faster and recently available disposable 
ChemoTx plates (more consistent/reliable than the chambers used for CEM cell 
chemotaxis, but were not available at the beginning of those studies) (NeuroProbe, 
Gaithersburg, MD, U.S.A.). Cells were washed twice and resuspended in RPMI 1640 
media (without phenol red) + 0.1 % BSA at 1 x 107 cells/ml. Cells were labelled with 5 
pg/ml calcein-AM (Molecular Probes, Leiden, Netherlands) for 30 minutes at 37 °C on a 
rocker. Cells were then washed (x 2) and resuspended at 4 x 106 cells/ml in above- 
mentioned media and starved for lhr at 37 °C. The bottom wells of the plate were carefully 
loaded with 29 pi of agonist, avoiding the formation of air bubbles, and then carefully 
overlaid with the 5 pm membrane/filter. 25 pi (equivalent to 100,000 cells/well) of cell 
suspension were dispensed on top of the filter for each well and the plate covered with the 
supplied lid and placed in a humidified incubator at 37 °C for 75 minutes (fig. 2.6). After 
incubation period, washing away with PBS and scraping the filter top with 3MM 
chromatography paper removed non-migrated cells. The plate + filter were read on a 
fluorescent plate reader (Fluoroskan Ascent plate reader, Thermo Labsystems, Finland) 
using a filter pair of 485 nm (excitation) and 538 nm (emission). Results were presented as 
a chemotactic index with statistical analysis performed using Student’s t test.
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Fluorometric Imaging Plate Reader (FLIPR) Assay -  Calcium Mobilisation
Agonists were prepared in Assay Buffer (HBSS/20 mM HEPES (without Phenol Red 
indicator) + 0.1 % BSA w/v) at 3 x required final concentration and aliquoted (> 60 pi) in 
to a round bottom 96-well plate. Fluo-4 AM (50 pg) was dissolved in 22 pi DMSO 
followed by the addition of 22 pi of the non-ionic surfactant pluronic F-127 acid (20 % 
solution in DMSO) to aid solubilisation of the AM ester. Both Fluo-4 and pluronic F-127 
supplied by Molecular Probes (Eugene, Oregon, U.S.A.). The Fluo-4 mix was then added 
to 22 mis of Assay Buffer with Brilliant Black (100 pM final) and probenecid (2.5 mM 
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Figure 2.7. Analysing results generated using the FLIPR system. The figure represents 
a typical result obtained on the FLIPR machine for unstimulated (vehicle-treated) and 
stimulated cell samples. The fold increase over control (FIOC) was calculated as shown, 
with the MAX-MIN value derived from the maximum fluorescence counts obtained upon 
stimulation (vehicle or ligand) divided by the minimum fluorescence counts observed prior 
to stimulation.
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CEM/Th2 cells were washed in Assay Buffer and resuspended at 1 x 106 cells/ml in 
Loading Buffer. If antagonists are being used, then cells are resuspended in Assay Buffer 
with inhibitor for required preincubation time (taking into account the subsequent 30 min 
Fluo-4 incubation time) before the addition of the Fluo-4 mix with probenecid and Brilliant 
Black (Sigma Aldrich, Gillingham, U.K.). The anion-exchange protein inhibitor 
probenecid was used to prevent the extrusion of Fluo-4 from the cells by organic ion 
transporters. 100 pi of cell suspension (100,000 cells) were added to each well of a black- 
walled, clear-bottomed, poly-D-lysine coated plate and incubated for 30 min at 37 °C, 5 % 
CO2 and 95 % O2. The presence of Brilliant Black (a quenching agent) in the Loading 
Buffer negates the need for washing. After loading, the plate was spun at 1200 rpm for 5 
min at RT. The cell plate was loaded into the FLIPR (Molecular Devices Ltd, Wokingham, 
U.K.) and a signal test was taken (also allows the determination of any effect of the 
inhibitors upon Fluo-4 loading of the cells) and laser power adjusted to obtain a basal level 
of -10,000 Fluorescence Intensity Units (FIU). The cells were then excited at 488 nm using 
the FLIPR laser and fluorescence emission determined used a CCD camera with a bandpass 
interference filter (510-560 nm). Fluorescence readings were taken at 1 s intervals for 60 s 
and a further 150 readings were taken at 2 s intervals. Agonist (50 pi) was added (dispense 
speed 30 pl/sec) after 1 min using the FLIPR. Raw fluorescence data was exported for each 
well and tabulated versus time within Microsoft Excel (Microsoft Corporation, Redmond, 
WA, U.S.A.). Data was then imported into Origin 6.0 (Microcal Software Inc., 
Northampton, MA, U.S.A.) and the peak response over basal determined, as a fold increase 
(fig. 2.7), and curves fitted with the logistic non-linear curve fit equation:
, where:
y l+ fl/X o )!’ 
p =  power
x0 = centre (i.e. EC50)
A t = initial Y  value (i.e. min. response)
A2 = final Y value (i.e. max. response)
and where y  (Xq) =  (A j +  A 2)  /  2  
and ( X j / x ^ - C p - O / C p  +  l )
N.B. the x-axis has to be set to a logarithmic scale.
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‘Concorde* Calcium (MERLIN) Assay
Measurement and visualisation of free intracellular calcium in CHOKlhCCR4 cells was 
performed using the Concorde (MERLIN) system. Cells were grown on thin (No. 1, 22 
mm diameter) coverslips (BDH) until approximately 20% confluent. Cells were then 
washed (x 2) with media and starved for 1 hour (37 °C) prior to washing (x 3) in 
physiological salt solution (PSS -  see appendix 1). Cells were then loaded with 5 (iM 
Fura-2-AM (in PSS) for 30 minutes in the dark. Excess Fura-2 was removed by washing 
the cells three times in PSS and cells left for 15 minutes in the dark. The coverslip was 
then transferred to an experimental chamber (at 37 °C) mounted on the stage of an inverted 
microscope (Zeiss Axiovert 100). The bathing medium consisted of 250 pi PSS. Levels of 
intracellular-free calcium were then measured using the MERLIN high-speed ratiometric 
imaging system (MERLIN 2.0, Life Science Resources Ltd, Cambridge, UK) and inverted 
microscope equipped with an UltraPix FK1000 cooled digital camera and a 
SpectraMASTER high-speed monochromator (both purchased from Life Science Resources 
Ltd). Cells were stimulated with MDC or TARC (after approximately 60 sec of basal 
recording) whilst alternately excited with 340 and 380 nm wavelengths. Fura-2 
fluorescence emission intensity was measured at X 510 nm and the 340/380 nm 
fluorescence ratios (Rf) were calculated for individual cells and the mean calculated. 
Results were expressed in a variety of formats and are explained, in detail, in the 
appropriate figure legends.
N.B. Fura-2 AM is an example of an excitation-shifted or dual excitation indicator and 
therefore is a dual wavelength probe. Thus, when Fura-2 is not bound to calcium the 
excitation maximum is 372 nm (but commonly use 380 nm) but when calcium is present 
the excitation maximum shifts to 340 nm. The emission maximum is always 510 nm. This 
means that Fura-2 is a useful indicator in ratio-metric calcium assays, such as the ‘Concord’ 
assay. However, the FLIPR system does not use a ratio-metric system allowing for the use 
of the calcium indicator Fluo-4. Fluo-4 has the big advantage of a very large fluorescence 
intensity increase in response to calcium binding allowing for a more sensitive analysis, 
ideal for the FLIPR system.
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Arno-GFP Localisation by Confocal Microscopy
HUT-78 cells were transiently transfected with DIMRIE-C reagent (Invitrogen, Paisley, 
UK). 0.5 ml of pre-warmed (37 °C) serum-free Optimem medium (Life Technologies, 
Paisley, UK) was added to each well of a six-well plate followed by the addition of 6 pi 
DIMRIE-C reagent. In a separate tube, 8 pg/ml plasmid DNA (Arno-GFP (gift from Dr. P. 
Cullen, University of Bristol, UK)) solution was made-up in serum-free Optimem and 500 
pi added to each well of the six-well plate (giving 4 pg/ml DNA final). Wells were mixed 
gently and the DNA and liposomal reagent were left to complex for 30 min at rtp. HUT-78 
cells were washed and resuspended at 2 x 107 cells/ml in serum-free Optimem, and then 
200 p i of this cell suspension (4 x 106 cells) was added to each well of six-well plate and 
mixed. The plate was incubated at 37 °C/5% CO2 for 4 hours, after which a further 2 ml of 
Optimem + 15% FBS was added to each well and incubated for a further 20 hours. 
Coverslips were coated with 3 ml of 5 ug/ml poly-L-lysine solution (in 100 mM borate 
buffer (sodium borohydride), pH 8.3) for 2 hours at rtp (or overnight at 4 °C), and then 
washed 2 x in PBS before use. Following the 20 hr incubation, the transfected cells were 
washed 2 x in RPMI 1640 and serum-starved for 2 hours. 1 ml of cells (4 x 106cells/ml) 
were then transferred to a clean six-well plate containing the poly-L-lysine coated 
coverslips and allowed to adhere for 30 min at 37 °C. Cells were then stimulated for 
indicated times with 10 nM MDC or vehicle. Following required stimulation time, the 
media was aspirated off with reactions terminated and cells fixed by the addition of freshly 
prepared 2 ml of ice-cold 4% paraformaldehyde/1% glutaraldehyde (in PBS) solution for 
10 min at rtp. Coverslips were then washed 3 x in PBS and carefully mounted onto a slide 
with 20 pi Mowiol (Calbiochem, Nottingham, UK) mounting medium (containing the anti- 
quenching reagent DABCO (Sigma, Gillingham, UK)) and left to dry in the dark overnight, 
at rtp. Slides were examined on an Olympus inverted stage confocal microscope (Olympus 





3.1 Results I: Role of PI3K in CCR4-Mediated Responses
Introduction
Ligation o f chemokine receptors with their respective ligands leads to the activation of 
various intracellular signalling pathways with resultant induction of a cellular function, 
such as cell spreading, proliferation, cytokine secretion and cell migration to name a few. 
One of the most widely studied chemokine-activated signalling cascades is the PI3K- 
associated pathway, which has been implicated as essential for a cells ability to detect a 
chemokine gradient and directionally migrate in response to chemokine receptor ligation on 
a variety o f cells (Funamoto et al., 2002; Iijima and Devreotes, 2002; Sadhu et al., 2003b; 
Sadhu et al., 2003a; Wang et al., 2002b; Weiner et al., 2002). The PI3K family consists of 
several evolutionary conserved lipid kinases, divided into 3 classes, thought to play a role 
in a multitude of cellular functions and responses (reviewed in the ‘Introduction’ and more 
comprehensively in (Fruman and Cantley, 2002; Vanhaesebroeck et al., 2001)).
There is currently no published data on the activation and role, if any, of PI3K downstream 
of the activated CCR4 receptor in any cell type. In this chapter, we show that the CCR4 
ligands, MDC and TARC, are able to activate the PI3K pathway resulting in the 
accumulation of PI(3,4,5)P3 and the phosphorylation of the downstream effector PKB. 
However, the activation of PI3K isoforms appears to be dispensable for MDC and TARC- 
mediated migration of T cells.
Validation of Cell Models for Expression of CCR4
It is important to determine the presence and extent of expression of the receptor of interest 
(in this case CCR4), since receptor presence defines the capacity of the cell to respond to 
the receptor’s ligands (i.e. MDC and TARC). In order to demonstrate that the cells utilised
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throughout this thesis express CCR4, PCR and FACS analyses were carried out to establish 
both message and cell surface CCR4 protein expression, respectively. PCR analysis 
demonstrated that CCR4 mRNA was present in 5 of the 7 cell types tested, with the CHO 
parents and the EL-4 mouse T cell leukaemic line lacking CCR4 message (fig. 3.1). Flow 
cytometry (FACS) analysis revealed that those cells, CHOKlhCCR4, MOLT-4, CEM, 
HUT-78 and T-lymphoblasts, that tested positive for possessing CCR4 mRNA, express cell 
surface CCR4 to varying extents (fig. 3.2). CHOKlhCCR4, T-lymphoblasts (T-blasts) and 
HUT-78 cells exhibit noticeable levels of CCR4 cell surface expression. However, MOLT- 
4 cells demonstrate minimal quantities of cell surface CCR4. This thesis has principally 
utilised the CEM cell line and human peripheral blood-derived T cells differentiated in 
vitro toward a Th2 phenotype. CEM cells constitutively exhibit substantial amounts of cell 
surface CCR4 (fig. 3.2A). Various studies have established the expression of CCR4 on 
human Th2 cells (Bonecchi et al., 1998; DAmbrosio et al., 1998; Zhang et al., 2000). Fig. 
3.2, B highlights the effectiveness of the method used here to generate CCR4-expressing 
Th2-like cells, although the amplitude of CCR4 expression is not as great as that observed 
on CEM cells.
Expression of the PI3K isoforms and the Regulators of their Lipid 
Products
It is imperative for this results chapter to establish the expression of the PI3K isoforms 
found in the cell types employed in this work. As expected, the T lymphocyte classes of 
cells (CEM, Th2, T-lymphoblast, and Jurkat) express each of the isoforms immunoblotted 
for, namely p i 108, pllO y, C 2 a  and C2p (fig. 3.3). The relative expression of these 
isoforms between the cell lines varies, except for pllOy, which is similar across the cell 
range. The p i 105 isoform appears to be substantially lower in the two cell lines, CEM and 
Jurkat, when compared to the ‘primary’ T cells Th2 and T-lymphoblast (fig. 3.3, top blot), 
even taking into account the variability in protein quantities between the samples. The 
same samples have been used for all 4 PI3K isoform blots, thus although there was no 
protein assay performed on the cell lysates to demonstrate similar levels of total protein, 
blots were stripped and reprobed for (3-actin (a cytoskeletal protein that is a widely used 
housekeeping gene internal control for quantitative RT-PCR reactions, and at the protein
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level for Western blot analysis) to ascertain the equality of protein amounts loaded across 
the lanes. Additionally, the two class II PI3K isoforms, C 2a  and C2p, appear to 
demonstrate comparable levels of expression across the cell range, but taking into account 
the substantially higher protein levels loaded for the peripheral blood-derived T cells, then 
this would suggest that expression is actually significantly lower in Th2 and T-lymphoblast 
cells. Unsurprisingly, CH OK lhCCR4 cells lack the leukocyte-restricted PI3K isoforms 
pllO y and p i 108, along with PI3K-C2p. The two lipid phosphatases PTEN and SHIP 
regulate the levels of D3 phosphoinositide lipids, and therefore play a pivotal role in the 
PI3K pathway. Jurkats lack both phosphatases SHIP and PTEN, whilst CEMs lack just 
PTEN at the protein level, as previously described by Freebum et al. (Freebum et al., 
2002). The ‘normal’ T cells (T-lymphoblast and Th2) express both lipid phosphatases, with 
CHOKlhCCR4 cells lacking the 5-inositolphosphatase SHIP (fig. 3.3, bottom two blots).
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Figure 3.1. PCR analysis of CCR4 mRNA expression in various cell types. PCR was
performed on mRNA extracted from each of the cell types. All cells demonstrate the 
presence of CCR4 mRNA except CHOK1 parents and EL-4 cells. p-actin band 
demonstrates the generation of cDNA in the positive samples. Result of 1 experiment.
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Figure 3.2. Expression of cell surface CCR4 on various cell types. Expression of CCR4 
was assessed by immunostaining 1 x lO6 cells lpg of R-phycoerythrin-conjugated mouse 
anti-human CCR4 mAb (1G1), or PE-conjugated IgGi, K isotype control Ab, or vehicle 
(Th2 and CEM cell analysis only), followed by flow cytometry analysis, as described in 
Materials and Methods. The data are representative of more than 3 different experiments 
with Th2 data representative of at least three different sets of differentiated cells.
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Figure 3.3. The expression of PI3K isoforms and lipid phosphatases in cells exhibiting 









Figure 3.3. The expression of PI3K isoforms and lipid phosphatases in cells exhibiting 
cell surface CCR4 expression. Cells were washed and incubated in RPMI-1640 media, 
(or DMEM for CHOKlhCCR4 cells), containing 0.1% BSA and incubated at 37°C for 1 hr. 
Cell lysates were resolved by SDS-PAGE and transferred to nitrocellulose membranes. 
Membranes were immunoblotted with the indicated antibodies, and protein was visualised 
by ECL, as described in M aterials and Methods. The data are representative of at least 
three separate experiments. Blots were stripped and reprobed with P-actin to determine 
extent of equal loading as described in M aterials and Methods, with the stripped and 
reprobed blot for pi 105 presented (which is also representative of the P-actin levels 
obtained for the other 5 blots).
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Activation of the PI3K Pathway 
Measurement o f PKB Phosphorylation
The major downstream effector of PI3K activity is PKB, a serine/threonine kinase, whose 
recruitment, phosphorylation arid subsequent activation are entirely dependent upon the 
lipid products o f PI3K (Vanhaesebroeck and Alessi, 2000), and consequently, is an indirect 
measure of PI3K activity. Several studies have reported the activation of PKB following 
stimulation of chemokine receptors other than CCR4 (Bonacchi et al., 2001; Smit et al., 
2003; Sotsios et al., 1999), and PKB itself has been proposed to be involved in the 
polarisation of neutrophils responding to a chemotactic gradient (Hannigan et al., 2002; 
Servant et al., 2000). Thus, PKB phosphorylation can be monitored as an indirect 
measurement of PI3K activity.
CEM cells characteristically display a constitutive level of phosphorylated PKB due to the 
absence of the 3' -  phosphoinositide lipid phosphatase PTEN (Freebum et al., 2002). 
However, MDC stimulated phosphorylation of PKB (on Ser 473) above basal levels in a 
concentration-dependent manner (fig. 3.4, A). MDC-induced increases in PKB 
phosphorylation in a time-dependent manner with responses detectable at 30 sec post­
stimulation reaching a maximum at 5 mins and returning toward basal levels at 30 min. 
(Fig. 3.4, B).
In order to determine if the PKB phosphorylation events witnessed in CEM cells are not a 
cell line specific phenomenon, various other CCR4-expressing cell lines, both T cell and 
non-T cell, were used. As was observed upon CCR4 ligation in CEM cells, MDC was 
capable of instigating the phosphorylation o f PKB (on Ser 473) in all 3 CCR4-expressing 
cell types (fig. 3.5). Although this phosphorylation was time-dependent, the kinetics varied 
quite considerably between the different cell types. The leukaemic T cell line HUT-78 and 
the T-lymphoblasts exhibited similar kinetics, with the rapid (< 1 min) and transient (no 
detectable levels at 5 min) phosphorylation o f PKB upon MDC stimulation (fig. 3.5, A and 
B). The CCR4 transfected CHOK1 cells however displayed a much slower onset of PKB 
phosphorylation ( 5 -  > 30 min) (fig. 3.5, C). CCR4 untransfected CHOK1 parent cells do 
not signal in response to MDC or TARC (fig. 3.6).
107
GtResuks*)
Figure 3.4. MDC stim ulates the phosphorylation of the PI3K effector PKB in a dose 
dependent m anner in CEM  cells.
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Figure 3.4. MDC stim ulates the phosphorylation of the PI3K effector PKB in a dose- 
dependent m anner in CEM  cells. Levels of phospho-PKB protein were determined by 
western blot analysis. CEM cells were incubated in low serum (2% FBS) for 16 hrs at 2 x 
106 cells/ml. Prior to experimentation, CEM cells were washed three times in RPMI, and 
resuspended at 4 x 106 cells/ml and serum-starved for 1 hour. Cells were then stimulated at 
37°C with A, indicated concentrations of MDC for 5 mins, or B, MDC (30nM) for the 
indicated times, and cells lysed by the addition of 1 x sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with 
a phospho-specific PKB Ab with affinity for the Ser 473-phosphorylated, active form, of 
PKB, and protein was visualised with ECL. Stripping and reprobing blots with anti-PKB 
Ab confirmed equal loading, as described in M aterials and Methods. Data representative 
of 3 separate experiments.
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Figure 3.5. MDC stim ulates the phosphorylation of PKB in various types of cells, with 
varying kinetics.
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Figure 3.5. MDC stim ulates the phosphorylation of PKB in various types of cells, with 
varying kinetics. Levels of phospho-PKB protein were determined by western blot 
analysis. Prior to experimentation, cells were washed three times in media, and 
resuspended at 5 x 106 cells/ml and serum-starved for 1 hour. Cells (A, HUT-78, or B, T- 
lymphoblast, or C, CHOKlhCCR4) were then stimulated at 37°C with MDC for indicated 
times, and cells lysed by the addition of 1 x sample buffer. Cell lysates were resolved by 
SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with a phospho- 
specific PKB Ab with affinity for the Ser 473-phosphorylated, active form, of PKB, and 
protein was visualised with ECL. Stripping and reprobing blots with anti-PKB Ab 




Figure 3.6. CHOK1 paren t cells (i.e. CCR4 untransfected CHOK1 cells) do not signal 
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Figure 3.6. CHOK1 paren t cells (i.e. CCR4 untransfected CHOK1 cells) do not signal 
in response to MDC. Expression of CCR4 was assessed by immunostaining 1 x 106 cells 
lpg of R-phycoerythrin-conjugated mouse anti-human CCR4 mAb (1G1), or PE- 
conjugated IgGi,* isotype control Ab, followed by flow cytometry analysis, as described in 
Materials and Methods. Levels of phospho-ERKl/2 protein were determined by western 
blot analysis. CHOK1 were washed three times in DMEM, and resuspended at 5 x 106 
cells/ml and serum-starved for 1 hour. Cells were then stimulated at 37°C with MDC (10 
nM) or TARC (10 nM) for indicated times, B, and cells lysed by the addition of 1 x sample 
buffer. Cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes, 
and immunoblotted with a phospho-specific ERK1/2 Ab with affinity for the Thr 202/Tyr 
204 phosphorylated, active form, of ERK, and protein was visualised with ECL. Stripping 
and reprobing blots with anti-ERK Ab confirmed equal loading, as described in Materials 
and Methods. Data representative of 2 separate experiments.
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CCR4 Ligation Stimulates the Accumulation of PI(3,4,5)P3 in CEM Cells
An alternative method of determining the extent of PI3K activation is to assess the 
accumulation of one of its lipid products, namely PI(3,4,5)P3. Although the method of 
measuring this lipid is substantially more time-consuming and utilises large amounts of 
gamma radioactivity, it is a more direct measure of PD K  activity. Consequently, 32P- 
labelled CEM cells were used to investigate the effect of MDC stimulation upon the levels 
of this phospholipid. Treatment of CEM cells with MDC led to a time-dependent increase 
in PI(3,4,5)P3 levels, with a maximum response seen at 2 -  5 min (fig. 3.7).
Activation o f PI3K Isoforms and their Sensitivity Towards PI3K Inhibitors
In order to further define the PI3K response it is necessary to establish the PI3K isoforms 
involved and the effect that the PI3K inhibitors employed in the remainder of this chapter 
have on the individual isoforms. To verify this, we ascertained whether 
immunoprecipitates o f the various class I and II PI3K isoforms derived from MDC- 
stimulated CEM cells exhibited enhanced in vitro lipid kinase activity above that of 
unstimulated levels. GPCRs are known to be able to activate p llO y  (PI3Ky) directly via 
their associated GPy proteins. Accordingly, MDC stimulated an increase in the in vitro 
activity of p llO y that was immensely rapid and transient, with detectable stimulation 
occurring only at 30 sec (fig. 3.8, A). Additionally, immunoprecipitating the p85 
regulatory/adapter subunit of the class IA isoforms, (thereby assessing the activity of 
p i 10a, P and 8), demonstrated an increase in activity at around 1-2 mins (fig. 3.8, B ), 
suggesting an increase in activity o f one of the class IA isoforms. Furthermore, p i 108 (an 
isoform shown to be required for neutrophil chemotaxis) was rapidly activated in response 
to MDC with an increase in activity observed at 1 min (fig. 3.8, C). Both the class IA and 
IB isoforms were sensitive to LY294002 and wortmannin with p i 108 being particularly 
sensitive to wortmannin. The class II PI3K isoforms, C 2 a  and C2p, showed no detectable 
levels of stimulation above those of the considerably high basal levels of activity (fig. 3.9, 
A and B). However, C2p basal kinase activity showed resistance to the PI3K inhibitor 
LY294002, with only a moderate level of inhibition at 30 jxM, but concentration-dependent 
sensitivity to wortmannin. C 2 a  demonstrated noticeable sensitivity to both LY294002 and 
wortmannin at the higher concentrations.
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Figure 3.7. MDC stim ulates the time-dependent accum ulation of PI(3,4,5)P3 in CEM 
cells.
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Figure 3.7. MDC stim ulates the tim e-dependent accum ulation of PI(3,4,5)P3 in CEM 
cells. Lipid analysis was carried out using a total of 2 x 107 32P-labelled CEM cells that 
were stimulated at 37°C with MDC (10 nM) for indicated times. Phospholipids were 
extracted and deacylated with the glycerophosphorylinositol derivatives of PI(3,4,5)P3 
analysed by HPLC, as described under Materials and Methods. Data is representative of at 
least 2 separate experiments.
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Figure 3.8. M DC-m ediated CCR4 ligation in CEM cells leads to the activation of the 
Class I PI3K  isoforms, p i  105 and pllOy.
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Figure 3.8. M DC-mediated CCR4 ligation in CEM  cells leads to the activation of the 
Class I PI3K isoforms, pllO S and pllOy. A total of 1 x 107 CEM cells were stimulated at 
37°C for various times (labels in min) with 10 nM MDC. Cells were lysed and lysates 
were subjected to immunoprecipitation with A, an anti-pl lOy Ab, B, an anti-p85 Ab, and C, 
an anti-pl 108 Ab. Immunoprecipitates were washed and, where indicated, treated with 
LY294002 or wortmannin (30 and 15 min, respectively), and analysed for PI kinase 
activity, as described in Materials and Methods. Lipids were detected by exposure to film 
at -70°C, and, additionally, analysed by densitometry to determine PI(3)P generation 
(graphs). Results are representative of at least two separate experiments. C = vehicle 
control (stimulated with vehicle for same length of time as MDC with LY/Wort treatment
i.e. 1, 0.5 and 5 min for pi lOy, p85 and pi 108, respectively).
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Figure 3.9. Class II PI3K isoforms are not stim ulated upon MDC stim ulation of CEM 
cells.
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Figure 3.9. Class II PI3K isoforms are not stim ulated upon MDC stim ulation of CEM 
cells. A total of 1 x 107 CEM cells were stimulated at 37°C for various times with 10 nM 
MDC. Cells were lysed and lysates were subjected to immunoprecipitation with A, an anti- 
C 2a Ab, and B, an anti-C2(3 Ab. Immunoprecipitates were washed and, where indicated, 
treated with LY294002 or wortmannin, and analysed for PI kinase activity, as described in 
Materials and Methods. Lipids were detected by exposure to film at -70°C, and, 
additionally, analysed by densitometry to determine PI(3)P generation (graphs). Results 
are representative of at least two separate experiments. C = vehicle control (stimulated 
with vehicle for same length of time as MDC with LY/Wort treatment i.e. 0.5 and 5 min for 
C 2a and C2(3, respectively).
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Regulation of PI3K Activity with Pharmacological Inhibitors
To confirm the inhibitory effects observed on individual PI3K isoform activity in IVLK 
assays (fig. 3.8 and 3.9) with the PI3K inhibitors are translated to in vitro lipid 
accumulation, the lipid-labelling assay was performed. Cells were labelled with 32P- 
orthophosphate and pretreated with the chemically distinct PI3K inhibitors LY294002 (30 
min) and wortmannin (15 min) at concentrations revealed to inhibit the kinase activity of 
all the tested PI3K isoforms. The importance of the inhibitors being chemically distinct is 
that they have different secondary target kinases (i.e. non-specific effects). This allows the 
elimination of possible non-PI3K activity inhibition on cellular events if both inhibitors 
demonstrate similar effects. MDC-stimulated PI(3,4,5)P3 accumulation was diminished 
upon pretreatment with either LY294002 (fig. 3.10, A) or wortmannin (fig. 3.10, B) in a 
concentration-dependent manner, further confirming PI3K activity inhibition at the 
concentrations of PI3K inhibitors employed.
Additionally, phosphorylation of PKB (an additional marker of PI3K activation) on Ser 473 
in response to MDC is abrogated with the use of LY294002 (fig. 3.11, A) in CEM cells. 
Furthermore, this effect was witnessed in the other CCR4-expressing cell types -  HUT-78, 
T-lymphoblasts, and CHOK1 (fig. 3 .1 1 ,5 -  D).
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Figure 3.10. Accum ulation of PI(3,4,5)P3 is abrogated in a concentration-dependent 
m anner with the use of P13K inhibitors.
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Figure 3.10. Accumulation of PI(3,4,5)P3 is abrogated in a concentration-dependent 
m anner with the use of PI3K inhibitors. A total of 2 x 107 32P-labelled CEM cells were 
stimulated at 37°C with A, pretreated for 30 mins with indicated concentrations of the PI3K 
inhibitor LY294002 before stimulation with MDC (10 nM) for 5 mins, and B, pretreated for 
15 mins with indicated concentrations of the PI3K inhibitor wortmannin and subsequent 
stimulation with MDC (10 nM) for 5 mins. Phospholipids were extracted and deacylated 
with the glycerophosphorylinositol derivatives of PI(3,4,5)P3 analysed by HPLC, as 




Figure 3.11. Inhibition of M DC-stimulated PKB phosphorylation with LY294002 in a 
range of CCR4 expressing cells.
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Figure 3.11. Inhibition of M DC-stimulated PKB phosphorylation with LY294002 in a 
range of CCR4 expressing cells. Levels of phospho-PKB protein were determined by 
western blot analysis. Prior to experimentation, cells were washed three times in media, 
and resuspended at 5 x 106 cells/ml and serum-starved for 1 hour. Cells (A, CEM, or B, 
HUT-78, or C, T-Lymphoblast, or D, CHOKlhCCR4) were then stimulated at 37°C with 
MDC for indicated times (in the presence or absence of LY294002, 30 min preincubation), 
and cells lysed by the addition of 1 x sample buffer. Cell lysates were resolved by SDS- 
PAGE, transferred to nitrocellulose membranes, and immunoblotted with a phospho- 
specific PKB Ab with affinity for the Ser 473-phosphorylated, active form, of PKB, and 
protein was visualised with ECL. Stripping and reprobing blots with anti-PKB Ab 
confirmed equal loading, as described in Materials and Methods. Data representative of 3 
separate experiments. Key: P, 100 nM PMA 5 min; CM, CEM cell lysate sample.
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Role of PI3K in Chemokine-Directed T Cell Migration
One functional response of a cell to activation with a chemokine is directed cell migration. 
Hence, we investigated whether MDC could stimulate chemotaxis of CEM cells. Several 
studies have demonstrated the ability of MDC to elicit the migration of a variety of CCR4 
expressing cells (Chantry et al., 1999; Iellem e t al., 2001; Imai et al., 1999). Accordingly, 
MDC stimulated the chemotaxis of CEM cells in a concentration-dependent manner with 
classic bell-shaped characteristics (fig. 3.12).
The involvement of PI3K in chemokine-mediated T cell chemotaxis has been reported for 
various receptors (Curnock et al., 2003; Hirsch et al., 2000; Sotsios et al., 1999). By means 
of pretreating the cells with LY294002 and wortmannin, we demonstrate that they have no 
negative impact upon MDC-mediated CEM cell chemotaxis, even at concentrations as high 
as 30 pM  and 300 nM, respectively (fig. 3.13, A). Yet there was a detrimental effect on 
basal migration with 30 pM  LY294002. However, when aliquots of the remaining 
(unused) treated cells were immunoblotted for the effect of MDC on pPKB Ser 473 there 
was an abrogation of the MDC stimulated phosphorylation of PKB with both LY294002 
and wortmannin at the two highest concentrations (lOpM, 30pM and lOOnM, 300nM 
respectively) (fig. 3.13, B top blots). It has been suggested that phosphorylation at Thr 308 
is required for full PKB activation (Scheid et al., 2002). Using an antibody that recognises 
PKB phosphorylation at Thr 308 there is a similar pattern to that observed with the pPKB 
Ser 473 Ab (fig. 3.13, B bottom blots). MDC had no effect on random migration (fig. 3.14).
Role of PI3K in Differentiated Human Th2 Cells
In order to determine whether the effects we are witnessing in a leukaemic T cell line are an 
accurate reflection of the events in peripheral blood-derived T lymphocytes, we examined 
CCR4 in Th2 cells, where expression of CCR4 is well documented (Bonecchi et al., 1998; 
DAm brosio et al., 1998; Zhang et al., 2000). As was observed in CEMs, MDC brought 
about increases in PKB phosphorylation in a time and concentration-dependent manner 
(fig. 3.15). However, the kinetics of PKB phosphorylation were more rapid and transient to 
that observed for MDC stimulation of CEM cells, with detectable increases in PKB Ser 473 
phosphorylation occurring between 0.5-2 mins and returning to basal levels within 5 mins.
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Figure 3.12. MDC stim ulates the directed migration of CEM cells in a concentration- 
dependent m anner.
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Figure 3.12. MDC stim ulates the directed migration of CEM cells in a concentration- 
dependent m anner. CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a 
reusable MB series 96-well chemotaxis chamber, above lower wells containing varying 
concentrations of MDC, as described in Materials and Methods. Chemotaxis across a 5 pm 
membrane was determined after 1.5 hr incubation at 37°C in 5% CO2. The data are derived 
from a single experiment with quintuplicate replicates that is representative of three other 
experiments. Data are expressed as the mean chemotactic index (± SEM), which is the 
ratio of cells migrating toward MDC vs. cells randomly migrating. Data were analysed by 
ANOVA and Student’s t test, with Bonferroni correction, for significance of MDC- 
stimulated migration compared with randomly migrating cells (*, p < 0.0005; **, p < 
0.0001; ***, p < 0.00005). The horizontal line at a chemotactic index of 1 represents 
unstimulated basal migration and is shown for ease of comparison with stimulated levels.
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Figure 3.13. MDC-stimulated CEM cell chemotaxis is insensitive to PI3K inhibitors.
CEM cells (2 x 105 cells/200 j-tl) were added to the upper wells of a reusable MB series 96- 
well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells were 
preincubated with the stated concentrations of LY294002 (LY) or wortmannin (wort) for 
30 or 15 minutes respectively, A, as described in Materials and Methods. Chemotaxis 
across a 5 pm  membrane was determined after 1.5 hr incubation at 37°C in 5% CO2. The 
data are derived from a single experiment with quintuplicate replicates that is representative 
of three other experiments. Data are expressed as the number of cells migrated. Data were 
analysed by ANOVA and Student’s t test, with Bonferroni correction, to compare 
responses in the presence and absence of PI3K inhibitors within control and MDC- 
stimulated groups (*, p < 0.01). A table of the actual values is presented below the graph 
for the reader to peruse. A sample of cells from those treated and untreated with the PI3K 
inhibitors for the chemotaxis assay was taken and stimulated with MDC (10 nM) for 
indicated times (C = vehicle 5 min), and lysates generated, B. These lysates were resolved 
by SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with anti- 
phospho PKB473 Ab and anti-phospho PKB308 Ab. The blots were stripped and reprobed 
with anti-PKB Ab to verify equal loading and efficiency of protein transfer.
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Figure 3.14. MDC has no effect on chemokinesis in CEM  cells.
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Figure 3.14. MDC has no effect on chemokinesis in CEM cells. CEM cells (2 x 105 
cells/200 pi) incubated (5 min) with varying concentrations of MDC, as indicated, were 
added to the upper wells of a reusable MB series 96-well chemotaxis chamber, above lower 
wells containing varying concentrations of MDC alone, as indicated in the graphic. The 
assay was then performed according to the chemotaxis protocol detailed in Materials and 
Methods. Chemotaxis/chemokinesis across a 5 pm membrane was determined after 1.5 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
quintuplicate replicates that is representative of two other experiments. Values in table 
represent the data displayed in the graph, presented as chemotactic index (taking 0 
chemokine on top and bottom as basal i.e. chemotactic index of 1).
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Figure 3.15. MDC stim ulates the rapid  and transient phosphorylation of the PI3K 
effector PKB in a concentration-dependent m anner in hum an Th2 cells.




Figure 3.15. MDC stim ulates the rapid and transient phosphorylation of the P13K 
effector PKB in a concentration-dependent m anner in hum an Th2 cells. Th2 cells 
were generated, as described in Materials and M ethods, and prior to experimentation were 
washed three times in RPMI, and resuspended at 5 x 105 cells/500 pi and serum-starved for 
1 hour. Cells were then stimulated at 37°C with indicated concentrations of MDC for 1 
min, or MDC (lOnM) for the indicated times and cells lysed by the addition of 1 x sample 
buffer. Cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes, 
and immunoblotted with a phospho-specific PKB Ab with affinity for the Ser473- 
phosphorylated form of PKB, and protein was visualised with ECL. Stripping and 
immunoblotting with an anti-PKB Ab, as described in Materials and M ethods, confirmed 
equal loading.
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Th2 cells exhibit the same migratory characteristics as those of CEM cells towards MDC
MDC stimulated the chemotaxis of Th2 cells in a dose-dependent fashion with a maximum 
migration reached at 50-100 nM (fig. 3.16, A). LY294002 and wortmannin treated Th2 
cells were still wholly responsive to MDC when monitoring chemotaxis (fig. 3.17, A), yet 
the phosphorylation of PKBSer473 was prohibited at similar concentrations by the PI3K 
inhibitors LY294002 and wortmannin (fig. 3.16, B , and 3.17, B).
Do Both CCR4 Ligands Act in a Comparable Manner with Respect to 
PI3K?
The CCR4 receptor has an additional ligand to that of MDC, namely TARC. Akin to 
MDC, TARC exclusively binds CCR4 suggesting that there must be differences between 
the two chemokines in their functional roles, and therefore signalling through CCR4. 
However, with regard to PI3K, TARC appears to display similar properties to MDC. 
TARC is able to stimulate the phosphorylation of PKB with similar kinetics as MDC (fig. 
3.18). However, the extent of phosphorylation is not as high as observed with MDC. 
Furthermore, TARC-mediated chemotaxis of Th2 cells is insensitive to pretreatment with 
LY294002 (identical to MDC) and displays a similar ability to MDC in the extent of cell 
migration achieved (fig. 3.19, R, and fig. 3.20). Conversely, TARC is unable to stimulate 
the directed migration of CEM cells to anywhere near the same extent as to that observed 
with MDC (fig. 3.19, A), and consequently, there is difficulty in examining the effects of 
inhibitors upon CEM cell migration in response to TARC (max. chemotactic index of 2).
A PKB Inhibitor has no Effect on CEM Cell Chemotaxis
The PKB inhibitor PKBi (lL -6-Hydroxymethyl-c/»>0-inositol 2-[(R)-2-0-m ethyl-3-0- 
octadecylcarbonate]) has been demonstrated to have 40-fold selectivity for PKB (IC50 = 2 
|iM ) over PI3K (IC50 = 83 |J.M) (Hu et al., 2000). As would be expected from the lack of 
effect with PI3K inhibition, 10 |iM  PKBi pretreatment had no detrimental impact on CEM 
chemotaxis mediated by MDC (fig. 3.21), although PKB kinase assays are required to 
confirm the compound is having the desired inhibitory effect on PKB.
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Figure 3.16. MDC induces the concentration-dependent directed m igration of Th2 
cells. Th2 cells were generated, as described in M aterials and Methods, washed three times 
in RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Cells (1 x 105 cells/25 pi) 
were added to the upper wells of a disposable ChemoTx chemotaxis plate, above lower 
wells containing varying concentrations of MDC, A, as described in Materials and 
Methods. Chemotaxis across a 5 pm membrane was determined after 1.25 hr incubation at 
37°C in 5% CO2. The data are derived from a single experiment with triplicate replicates 
that is representative of three other experiments. Data are expressed as the mean 
chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. cells 
randomly migrating. Data were analysed by ANOVA and Student’s t test, with Bonferroni 
correction, to compare MDC-induced migration to basal (*, p < 0.05; **, p < 0.001). The 
horizontal line at a chemotactic index of 1 represents unstimulated basal migration and is 
shown for ease of comparison with stimulated levels. Western blot analysis was performed 
by resuspending Th2 cells at 5 x 105 cells/500 pi and then serum-starved for 1 hour. Cells 
were then stimulated at 37°C with 10 nM MDC for indicated times in the presence or 
absence of LY294002 (30 min preincubation) and lysed by the addition of 1 x sample 
buffer. Cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes, 
and immunoblotted with a phospho-specific PKB Ab with affinity for the Ser473- 
phosphorylated form of PKB, and protein was visualised with ECL. Stripping and 
immunoblotting with an anti-PKB Ab, as described in Materials and Methods, confirmed 
equal loading. S = SDF-1/CXCL12 10 nM, 1 min (positive control).
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Figure 3.17. LY294002 and w ortm annin display no consequence on M DC-induced 
Th2 cell chemotaxis, but attenuate the M DC-mediated phosphorylation of PKB at
Ser.473
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Figure 3.17. LY294002 and w ortm annin display no consequence on M DC-induced 
Th2 cell chemotaxis, but attenuate the M DC-mediated phosphorylation of PKB at
Ser473. Th2 cells were washed and resuspended in RPMI/0.1% BSA for 1 hour at 37°. 
Where indicated, graph A, cells were preincubated with varying concentrations of 
LY294002 (LY) or wortmannin (wort) for 30 or 15 minutes respectively. Cells (1 x 105 
cells/25 pi) were added to the upper wells of a disposable ChemoTx chemotaxis plate, 
above lower wells containing MDC (100 nM), as described in Materials and Methods. 
Chemotaxis across a 5 pm membrane was determined after 1.25 hr incubation at 37°C in 
5%  CO2. The data are derived from a single experiment with triplicate replicates that is 
representative of three other experiments. Data are expressed as the mean chemotactic 
index (± SEM), which is the ratio of cells migrating toward MDC vs. cells randomly 
migrating (+/- inhibitor). The horizontal line at a chemotactic index of 1 represents 
unstimulated basal migration and is shown for ease of comparison with stimulated levels. 
B, Th2 cells were washed three times in RPMI, and resuspended at 5 x 105 cells/500 pi and 
serum-starved for 1 hour. As indicated, cell samples were pretreated with either LY294002 
or wortmannin for 30 or 15 mins, respectively. Cells were then stimulated at 37°C with 
MDC (lOnM) for 1 min or with vehicle for 1 min (C), before cells were lysed by the 
addition of 1 x sample buffer. Cell lysates were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes, and immunoblotted with anti-phosphoPKBSer473, and protein was 
visualised with ECL. The blots were stripped and reprobed with anti-PKB Ab to verify 
equal loading and efficiency of protein transfer.
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Figure 3.18. TARC stimulates the phosphorylation of PKB.
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Figure 3.18. TARC stimulates the phosphorylation of PKB. Levels of phospho-PKB 
protein were determined by western blot analysis. Prior to experimentation, cells were 
washed three times in media, and resuspended at 5 x 106 cells/ml and serum-starved for 1 
hour. Cells (A, CEM, or B , T-Lymphoblast) were then stimulated at 37°C with TARC or 
MDC (10 or 30 nM) for indicated times, or for 5 min with indicated concentrations, and 
cells lysed by the addition of 1 x sample buffer. Cell lysates were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes, and immunoblotted with a phospho-specific PKB 
Ab with affinity for the Ser 473-phosphorylated, active form, of PKB, and protein was 
visualised with ECL. Stripping and reprobing blots with anti-PKB Ab confirmed equal 









m anner. A, CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a reusable 
MB series 96-well chemotaxis chamber, above lower wells containing varying 
concentrations of TARC, as described in Materials and Methods. Chemotaxis across a 5 
pm membrane was determined after 1.5 hr incubation at 37°C in 5% CO2. The data are 
derived from a single experiment with quintuplicate replicates that is representative of three 
other experiments. Data are expressed as the mean chemotactic index (± SEM), which is 
the ratio of cells migrating toward TARC vs. cells randomly migrating. The horizontal line 
at a chemotactic index of 1 represents unstimulated basal migration and is shown for ease 
of comparison with stimulated levels. B, Th2 cells were generated, as described in 
M aterials and Methods, washed three times in RPMI, and resuspended in RPMI/0.1% BSA 
for 1 hour at 37°. Cells (1 x 105 cells/25 pi) were added to the upper wells of a disposable 
ChemoTx chemotaxis plate, above lower wells containing varying concentrations of MDC 
or TARC, as described in Materials and Methods. Chemotaxis across a 5 pm membrane 
was determined after 1.25 hr incubation at 37°C in 5% CO2. The data are derived from a 
single experiment with triplicate replicates that is representative of three other experiments. 
Data are expressed as the mean chemotactic index (± SEM), which is the ratio of cells 
migrating toward MDC/TARC vs. cells randomly migrating.
TARC is able to chemotax Th2 cells in a concentration-dependent
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Figure 3.20. TARC-mediated Th2 cell chemotaxis is unaffected by PI3K inhibition.
Th2 cells were washed and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Where 
indicated, graph A, cells were preincubated with varying concentrations of LY294002 or 
wortmannin for 30 or 15 minutes respectively. Cells (1 x 105 cells/25 pi) were added to the 
upper wells of a disposable ChemoTx chemotaxis plate, above lower wells containing 
TARC (100 nM), as described in Materials and Methods. Chemotaxis across a 5 pm 
membrane was determined after 1.25 hr incubation at 37°C in 5% CO2. The data are 
derived from a single experiment with triplicate replicates that is representative of three 
other experiments. Data are expressed as the mean chemotactic index (± SEM), which is 
the ratio of cells migrating toward TARC vs. cells randomly migrating (+/- inhibitor). The 
horizontal line at a chemotactic index of 1 represents unstimulated basal migration and is 
shown for ease of comparison with stimulated levels. Data were analysed by Student’s t 















Figure 3.21. Sensitivity of CCR4-mediated CEM  cell chemotaxis to a PKB inhibitor.
CEM cells (2 x 105 cells/200 jul) were added to the upper wells of a reusable MB series 96- 
well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells were 
preincubated with 10 pM PKBi for 3 hours, as described in Materials and Methods. 
Chemotaxis across a 5 pm membrane was determined after 1.5 hr incubation at 37°C in 5% 
CO2. The data are derived from a single experiment with quintuplicate replicates that is 
representative of three other experiments. Data are expressed as the mean chemotactic 
index (± SEM), which is the ratio of cells migrating toward MDC vs. cells randomly 
migrating (+/- inhibitor). Data were analysed by ANOVA and Student’s t test to compare 
responses in the presence and absence of inhibitor (p < 0.05). The horizontal line at a 
chemotactic index of 1 represents unstimulated basal migration and is shown for ease of 




• CCR4 is expressed to varying degrees in a number of transformed and non­
transformed T cells. In addition, untransfected CHOK1 cells fail to signal in 
response to either MDC or TARC, unlike the CCR4 transfected CHOK1 cells.
• All of the tested T cell types express the PI3K isoforms p i 108, PI3Ky, C 2 a  and 
C2P. However, CH OK lhCCR4 cells lack p i 108, PI3Ky and C2(3. The HUT-78 T 
cell line along with T-lymphoblasts and Th2 cells express both PTEN and SHIP lipid 
phosphatases. The leukaemic T cell line CEM lacks PTEN and CHOKlhCCR4 cells 
lack SHIP. Jurkats lack both SHIP and PTEN.
• Ligation of CCR4 with MDC results in the phosphorylation of PKB in a 
concentration-dependent manner. The kinetics of this chemokine-mediated event 
varied between the different cell types, from rapid and transient to a slower onset and 
more prolonged PKB phosphorylation. This phosphorylation was sensitive to PI3K 
inhibition.
•  MDC stimulation of CEM cells leads to the PI3K-dependent accumulation of 
PI(3,4,5)P3. Furthermore, CCR4 activation results in the increased activity of all the 
class I (both I a  and I b )  PI3K isoforms tested for, but there were no detectable 
increases in the activity of class II PI3K isoforms. However, the kinase activities of 
all these PI3K isoforms were sensitive, to varying degrees, to both LY294002 and 
wortmannin.
•  The concentration-dependent MDC-mediated directed CEM cell migration was 
insensitive to both LY294002 and wortmannin.
•  Th2 cells behave in a similar manner to CEM cells with regard to CCR4-mediated 
events: MDC is able to activate the PI3K-PKB pathway and elicit the PI3K- 
independent chemotaxis of Th2 cells.
•  Studies performed to date indicate that TARC behaves in a similar manner to MDC 
pertaining to the role of PI3K in directed T cell migration.
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3.2 Discussion I 
PI3K Involvement in CCR4 Signal Transduction and Chemotaxis
This section has investigated the role of PI3K in the regulation of MDC/CCR4-mediated 
PKB phosphorylation and chemotaxis of T cells. In addition, a brief investigation into the 
comparison of TARC with MDC was also performed. With the use, principally, of human 
Th2 cells and the leukaemic T cell line CEM, it has been demonstrated that MDC-mediated 
CCR4 ligation leads to the activation of class IA and IB PI3K isoforms with the subsequent 
accumulation of PI(3,4,5)P3 and phosphorylation of the major PI3K effector PKB. 
However, with the use of two chemically distinct PI3K inhibitors, wortmannin and 
LY294002, used at concentrations that were observed to inhibit the kinase activity of all the 
tested PI3K isoforms, as well as PI(3,4,5)P3 accumulation and PKB phosphorylation (at 
both Thr 308 and Ser 473 residues), there is no negative effect on MDC-mediated Th2 or 
CEM cell chemotaxis. Furthermore, studies with TARC have indicated that this 
phenomenon of PI3K-independent CCR4-mediated T cell chemotaxis is not restricted to 
just that migration induced by MDC. Although it appears that neither CEM cells nor Th2 
cells require PI3K activity for chemotaxis it would seem that there are some fundamental 
differences between their responses to the CCR4 ligands.
Disparate PKB Phosphorylation Profiles of the Various Cell Types
The kinetics for PKB phosphorylation are far more rapid and transient in Th2 cells, as well 
as in HUT-78 and T-lymphoblasts, than those observed in CEM and CHOKlhCCR4 cells. 
The most logical explanation for this observation is the cellular presence or absence of the 
lipid phosphatases PTEN and SHIP. The inositol lipid 3-phosphatase PTEN, which 
hydrolyses PI(3,4,5)P3 to PI(4,5)P2, has been demonstrated to be absent from a variety of 
leukaemic T cell lines, including CEM (Astoul et al., 2001; Freebum et al., 2002; Shan et 
al., 2000), and this has been confirmed here. In addition, it has been established that the 
lipid 5-phosphatase SHIP, which hydrolyses PI(3,4,5)P3 to PI(3,4)P2, is absent from the 
Jurkat T leukaemic cell line, but present in CEM cells (Freeburn et al., 2002). Further to 
this, it has been determined within the results presented here that CHOK1 cells lack SHIP,
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not entirely unexpected due to the fact it is considered to be exclusively expressed by 
haemopoietic cells (Damen et al., 1996; Liu and Dumont, 1997), unlike SHIP2 (Pesesse et 
al., 1997; Sly et al., 2003). The cell types that express both PTEN and SHIP (T- 
lymphoblasts, HUT-78 and Th2 cells) display rapid and transient phosphorylation of PKB, 
whereas the cells lacking PTEN (CEM) or SHIP (CHOK1) demonstrate a much slower 
onset of PKB phosphorylation as well as this being more persistent. Moreover, the cells 
lacking PTEN display high basal levels of phosphorylated PKB, consistent with that seen in 
Jurkat cells (Cumock et al., 2003). Cells possessing PTEN had very low or undetectable 
levels of basal PKB phosphorylation. PTEN is required to ‘turn o f f  the PI3K response by 
attenuating the levels of D3-phosphorylated inositol lipids. Thus, in the PTEN-expressing 
cell types, MDC (and TARC) is able to elicit the phosphorylation of PKB that is readily 
detected due to the low basal levels and this response is ‘turned o f f  by the activity of 
PTEN. However, in PTEN deficient cells (e.g. CEM), there is likely a build-up of D3- 
phosphorylated lipids that eventually leads to the detectable increase in PKB 
phosphorylation that is more persistent due to the inability to down-regulate the 3- 
phosphoinositide lipids. Yet, the levels of phospho-PKB are reduced relatively quickly 
compared to those levels stimulated by SDF-1/CXCL12 (CXCR4) that are very prolonged 
(Cumock et al., 2003). This may be due to the presence of SHIP in CEM cells in which its 
activation leads to the degradation of PI(3,4,5)P2 and therefore the accumulation of 
PI(3,4)P2 (due to absence of PTEN), and subsequently curtail PKB activity.
Though there is some controversy over the lipid products required for PKB 
phosphorylation, centering on whether PI(3,4)P2 or PI(3,4,5)P3 is the critical substrate 
required for cellular localisation. There are studies suggesting that PI(3,4)P2 is the 
principal substrate for the PH domain of PKB (Franke et al., 1997; Freeh et al., 1997; 
Klippel et al., 1997), and this would correlate well with the observation in CEM cells of 
high basal phospho-PKB levels. The likelihood is that the presence of both SHIP and 
PTEN are required for the sufficient regulation of PKB activity, and studies have 
demonstrated that SHIP appears to play at least some role in the regulation of PI3K 
effectors (Freebum et al., 2002; Isakoff et al., 1998; Lemmon and Ferguson, 2000). 
Although CHOK1 cells lack SHIP but possess PTEN and display significant basal 
phospho-PKB levels seemingly confirming a role of SHIP in PKB regulation, this is 
perhaps not the case and is due to experimental conditions. CHOK1 cells are adherent cells
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but were stimulated in this study as a suspension cell therefore possibly increasing the 
levels of phospho-PKB due to stress and other such factors. Moreover, this cell type does 
not normally express SHIP (unlike the cell lines mentioned above with regard to PTEN) 
and thus it is probable that PKB activity is regulated via other phosphatases (either lipid 
e.g. SHIP2, or PKB-specific phosphatases (incidentally, this may also be the case in the T 
cell lines mentioned above)). The prolonged phosphorylation in CHOK1 cells of PKB in 
response to CCR4 ligation is likely to be due to many factors, with perhaps the biggest 
factor being the introduction of a receptor not normally expressed in this cell type. The 
introduction of a receptor to a cell by stable transfection does not ensure that the receptor 
couples to downstream signalling pathways in a correct manner. This is why there is 
always the requirement to carry out studies in cell types endogenously expressing the 
receptor of choice. A transfected cell line is, however, useful in indicating the possible 
signalling pathways that are activated in endogenously CCR4 expressing cells, with the 
added benefit of determining the authenticity of the response. This was highlighted by the 
inability of CHOK1 parent cells (untransfected with CCR4) to signal in response to MDC 
or TARC. This confirms the responses observed in CHOKlhCCR4 cells upon 
MDC/TARC stimulation are solely generated by ligated CCR4.
In addition to the differences between the cell types utilised in this study with regard to the 
expression of lipid phosphatases, there are also the variances observed in PI3K isoform 
expression to take into consideration. CHOK1 cells lacked p i 105, p llO y  and C2p PI3K 
isoforms that the T cells all possessed. This is not unexpected, as p i 108 and PI3Ky (pi lOy) 
are known to be leukocyte restricted (although recent studies suggest they may be more 
broadly expressed than first thought), however, C2p is widely distributed and its absence 
slightly more surprising (Chantry et al., 1997; Sawyer et al., 2003; Vanhaesebroeck et al., 
1997b). The remaining class Ia isoforms ( a  and p) are widely expressed and essential for 
survival (El Sheikh et al., 2003; Sasaki et al., 2002). The upshot of these observations is 
that the delayed PKB phosphorylation in CHOKlhCCR4 cells may be due to the restricted 
PI3K isoform availability for the chemokine receptor to activate. PI3Ky is the sole PI3K 
isoform activated by GPCR and, as demonstrated here (although weakly), to be activated 
by chemokine receptors (Brock et al., 2003; Jones et al., 2003; Leopoldt et al., 1998). 
Likewise, p i  108 has been demonstrated, both here and in other systems, to be activated
135
discussion *)
downstream of chemokine receptors, although its activation is not restricted to GPCRs (Jou 
et al., 2002; Okkenhaug et al., 2002; Sadhu et al., 2003b). The lack of these two isoforms 
in CHOK1 cells is likely to be significant. While highly speculative, the rapid 
phosphorylation of PKB witnessed in T-lymphoblasts and Th2 cells may in part be due to 
their apparent hefty levels of p i  108 expression compared to the CEM and Jurkat cell lines.
The IVLK assays are hard to derive any conclusive evidence about the extent and kinetics 
of PI3K isoform activation due to the high basal levels of activity but p i 108 does appear to 
be substantially activated upon MDC stimulation in CEM cells. The limitations of the 
IVLK data are two-fold: firstly, the substrate used is PI. Thus the generated product is 
PI(3)P and therefore not necessarily an accurate indicator regarding the generation of the 
lipids PI(3,4)P2 and PI(3,45)P3; secondly, the lipid generation is not measured within the 
cell, removing factors such as access to target lipid substrates. Despite these 
constrainments, the IVLK assay is useful in determining a general increase in individual 
PI3K isoform activity and sensitivity to PI3K inhibitors (at least those that compete at the 
ATP-binding site). This clarification may help to explain the rapid and transient kinetics 
witnessed with CEM cells in IVLK assays yet the more latent kinetics observed with both 
PI(3,4,5)P3 accumulation in lipid labelling studies and the phosphorylation of PKB. An 
additional observation is the high basal activity displayed by each of the PI3K isoforms in 
CEM cells (and also observed in Jurkat cells -  general data from Ward group). This high 
kinase activity compared to ‘normal’ cells, such as T-lymphoblasts, cannot necessarily be 
accounted for by defects in the cells ability to regulate D3 PI lipids. It is possible that there 
may be a positive feedback mechanism occurring where increases in D3 Pis leads to 
recruitment o f PH domain-containing proteins that are then able to further activate PI3K.
This process will continue, and eventually reaching equilibrium, unless the D3 Pis are 
negatively regulated, which cannot occur if crucial lipid phosphatases are missing, resulting 
in abnormally high basal PI3K activity.
An alternative mechanism of PI3K activity regulation by PTEN is through direct 
management of upstream activators. It has recently been demonstrated that PTEN regulates 
PDGF receptor (and possibly other receptors) signalling through direct interaction, and 
dephosphorylates the activated tyrosine phosphorylated receptor and subsequent activation 
of downstream substrates (Mahimainathan and Ghosh, 2004). PTEN has displayed the
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ability to dephosphorylate a number of proteins, including She and FAK in integrin- 
activated T cells (Gu et al., 1999; Leslie et al., 2000; Myers et al., 1997; Tamura et al., 
1998; Tamura et al., 1999). Furthermore, there was evidence to suggest that PTEN may 
negatively regulate PDGF receptor in the absence of ligand (through constitutive 
association via PTEN’s C2 domain), and upon ligand binding to the receptor PTEN 
dissociates allowing tyrosine phosphorylation and activation of receptor and substrates to 
occur (Mahimainathan and Ghosh, 2004). Therefore, in the absence of PTEN these PI3K 
activation pathways remain, at least in part, unregulated and thus cells lacking PTEN 
protein exhibit increased basal PI3K activity. PTEN may be regulated in normal 
circumstances through a feedback mechanism. One proposed model suggests that the 
elevated PI(3,4,5)P2 levels activate a kinase (maybe PKB or CKII (casein kinase II)) that 
phosphorylates PTEN at Ser 380 and Ser 385 (and possibly threonine residues as well) in 
the C-terminal ‘tail* and protects the protein from degradation (Birle et al., 2002; Torres et 
al., 2003; Torres and Pulido, 2001; Vazquez et al., 2000). When the PI(3,4,5)P3 levels are 
reduced to basal amounts there is reduced PTEN phosphorylation and increase in PTEN 
degradation. A small amount of basal PI3K activity is required to maintain cell viability.
Activation o f P13K is Redundant for CCR4-Mediated T Cell Migration
In the past few years there has been an escalating body of evidence implicating a role, to 
varying degrees, for the PI3K family of enzymes in the directional migration of 
leukocytes/Dictyostelium in response to a chemokine gradient (Vanhaesebroeck et al., 
1999). The class IA isoforms have been shown to have a role in SDF-1-mediated Jurkat 
chemotaxis (Curnock et al., 2003) and essential for Dictyostelium migration (Funamoto et 
al., 2002; Iijima and Devreotes, 2002). Recently, the development of a selective p i 108 
isoform inhibitor has led to the seemingly essential role of this isoform in neutrophil 
chemotaxis (Sadhu et al., 2003b; Sadhu et al., 2003a) and involvement in breast cell 
migration (Sawyer et al., 2003). However, the use of p i 10y 1' mice has also implicated a 
role of this class IB isoform in neutrophil (and macrophage) chemotaxis (Hannigan et al., 
2002; Hirsch et al., 2000; Li et al., 2000; Sasaki et al., 2000), although migration is not 
completely attenuated (50-90%), and with a surprising lack o f effect on lymphocyte 
migration. This suggests either another isoform (pi 108?) or a PI3K-independent pathway
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may additionally be involved (Chodniewicz and Zhelev, 2003a; Chodniewicz and Zhelev, 
2003b). Despite the development of PI3K isoform knockout mice and the generation of 
PI3K inhibitors (some isoform specific), studies have primarily concentrated on the 
chemotaxis of granular leukocytes and Dictyostelium. In spite of this, there is increasing 
evidence to suggest that perhaps PI3K isoforms do not provide the directional cues for T 
lymphocyte migration! A recent study by Smit, et al. (Smit et al., 2003) demonstrated that 
CXCR3 chemotaxis of PBMCs in response to CXCL11/I-TAC was insensitive to either 
LY294002 or wortmannin at concentrations up to 30 pM and 300 nM, respectively. These 
chemotaxis results display a similar resistance to the PI3K inhibitors as the data presented 
within this thesis. Additionally, PI3K inhibitors had little effect on in vivo T lymphocyte 
arrest and adhesion to high endothelial venules in exteriorised Peyer’s patches (Constantin 
et al., 2000) or on the SDF-1(CXCL12) and ELC (CCL19)/SLC (CCL21) transendothelial 
migration in laminar flow chambers (Cinamon et al., 2001). Smit has suggested that 
perhaps class II PI3K isoforms may still be involved. Although we demonstrate activation 
of class LA and IB isoforms in T cells with MDC, we observe no stimulation of the class II 
isoforms. This may well be due to the inability of the assay to reliably detect any 
stimulated increases above the considerably high basal levels witnessed in these cells. 
There is currently no published data that has ascertained the presence of C2(3 downstream 
of activated chemokine receptors. Contrastingly, C 2 a  has been demonstrated to be 
activated downstream of the CCR2 receptor (Turner et al., 1998). However, even taking 
this in to consideration, in our hands we were able to attenuate the C 2 a  basal activity with 
both LY294002 and wortmannin quite considerably at the respective concentrations of 30 
pM and 300 nM. C2(3 basal activity is largely resistant to LY294002 (even at 30 pM) but 
activity is still severely compromised with 300 nM wortmannin (Foster et al., 2003). It 
would therefore be expected if  C2oc/(3 were involved there would be a detectable inhibitory 
effect upon T cell chemotaxis at the utilised concentrations of these PI3K inhibitors. The 
third PI3K isoform C2y has an expression profile restricted to the liver, thus is not relevant 
to this work (Misawa et al., 1998; Ono et al., 1998; Rozycka et al., 1998).
A variety of studies have demonstrated a role for the 3’-phosphoinositide phosphatase 
PTEN in localising to the trailing and lateral edges of migrating cells with exclusion from 
the leading edge, a region where PI3K and its products and their effectors (particularly 
PKB) have been observed to localise (fig. 3.22) (Funamoto et al., 2002; Iijima et al., 2004;
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Iijima and Devreotes, 2002; Li et al., 2003b). Over-expression or deficiency of PTEN 
attenuates or ameliorates leukocyte motility respectively, whilst deficiency of SHIP, 
another key regulatory phosphatase, has demonstrated to bring about enhanced motility 
(Fox et al., 2002; Kim et al., 1999a; Tamura et al., 1998). There are however several lines 
of evidence to suggest that relocalisation of PTEN to the posterior of the cell is not a 
prerequisite for migration of all cell types. Firstly, the CEM cell line utilised in this study 
lack PTEN yet the mechanisms of cell motility, with respect to PI3K requirements, appear 
to be identical to MDC-induced Th2 cell migration, which contain both PTEN and SHIP. 
Secondly, evidence that suggests perhaps posterior localisation of PTEN may not be an 
event shared by all migrating cells is substantiated by HL60 cells (a human promyelocytic 
leukaemia cell) (Xu et al., 2003) and Jurkat cells (Cumock et al., 2003; Sotsios et al., 1999), 
in which both cell lines lack PTEN and SHIP yet polarise and migrate seemingly normally 
in response to chemokines. Furthermore, the use of a PKB inhibitor in a CEM cell 
chemotaxis assay has no effect upon cell migration. Yet the use of the same inhibitor had 
an effect upon the rate of neutrophil pseudopod extension and migration (Chodniewicz and 
Zhelev, 2003a), thus further highlighting the potential differences in PI3K requirements 
between myeloid and lymphoid cells.
Additionally, although the lipid kinase activity of these PI3K isoforms may be severely 
diminished with the use of PI3K inhibitors, we cannot rule out the possibility that the 
associated adapter subunits (i.e. p55, p85, p lO l) are perhaps playing important additional 
functional roles, participating in protein -  protein interactions, distinct from those required 
for activation of the catalytic subunits. Each of the p85 subunits of the class LA proteins 
contain two SH2, one SH3 and two proline-rich domains providing a great potential for 
protein interaction. It has been demonstrated that SDF-1/CXCL12 is able to stimulate the 
tyrosine phosphorylation of Gab-2 and its co-association with SHP-2 and the p85 adapter 
subunit. Additionally, using a mutated dominant SHP-2 construct that lacked the 
phosphatase domain resulted in the attenuation of SDF-l/CXCL12-mediated chemotaxis 
(Whittaker and Ward, unpublished data). Also, studies have established that SHP-2 can 
control integrin-mediated cell migration through its interaction with focal adhesion kinase 
(FAK) (Manes et al., 1999; Oh et al., 1999; Yu et al., 1998a), and SDF-1/CXCL12 is known 
to tyrosine phosphorylate a number of focal adhesion complex components (Ganju et al., 
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Figure 3.22. Proposed role of PI3K in gradient sensing and subsequent cell migration.
The ligation of the GPCR with chemokine leads to the activation of Ras (or PI3Ky directly 
-  not depicted) and the subsequent accumulation of PI(3,4,5)P3 lipids, due to increased 
PI3K activity. It has been demonstrated in Dictyostelium  that this accumulation of 3’- 
phosphoinositides is restricted to the leading edge of the cell due, at least in part, to the 
localisation of PTEN (and possibly SHIP) to the lateral and trailing edges of the cell. 
PI(3,4,5)P3 lipids attract PH domain-containing proteins including guanine-nucleotide 
exchange factors (GEFs) that activate small GTPases of the Rho family (e.g. Ras, Rac, 
Rho, cdc42). These Rho GTPases are able to amplify the signal by activating PI3K 
isoforms themselves. The GTPases activate many different pathways that lead to actin 
polymerisation (or depolymerisation -  not portrayed) and events such as 
lamellipodia/filopodia formation and cell movement (crawling). Abbreviations: GAPs, 
GTPase activating proteins; PH, pleckstrin homology; PTEN, phosphatase and tensin 
homology deleted on chromosome ten protein; PTKs, protein tyrosine kinases; SHIP, SH2- 
containing inositol 5-phosphatase.
the localisation/recruitment/activation of the PI3K catalytic subunits, it cannot not be ruled 
out that the p85 subunit is recruiting proteins that are having a positive effect upon cell 
migration without the need of the kinase activity of the associated pi 10 catalytic subunits
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(Ueki et al., 2003). Indeed, it was suggested in a recent study that SHP-2 may 
dephosphorylate p i 90 RhoGAP leading to release from lipid rafts and therefore favouring a 
sustained activation of the small GTPase Rho (Sordella et al., 2003), which may then have 
an influence on migration.
Possible Alternatives to PI3K-Dependent Pathways in CCR4-Mediated T 
Cell Migration
The small GTPases Rho, Ras, Rac and cdc42 have been shown to play pivotal roles in the 
remodelling of the actin cytoskeleton and, consequently, effects on a cells ability to polarise 
and migrate. Rho-associated coiled-coil forming protein kinase (ROCK), an effector of 
Rho, enhances myosin light chain (MLC) phosphorylation and thereby regulates actin- 
myosin contraction (Etienne-Manneville and Hall, 2002), and has been shown to be 
involved in uropod (posterior of cell) function in migrating neutrophils (Xu et al., 2003). A 
recent study demonstrated, with the use of a ROCK inhibitor (Y-27632), that CCR7- 
mediated polarisation and migration of T-lymphocytes requires ROCK (Bardi et al., 2003). 
This correlates with our observations that inhibition of ROCK also attenuates MDC- 
mediated T lymphocyte migration (data shown in ‘Results II’). Chodniewicz (Chodniewicz 
and Zhelev, 2003a) demonstrated in neutrophils that 80% of pseudopod extension rate (in 
response to stimulation with the chemoattractant fMLP) required a PI3Ry-dependent, 
(similar to levels seen with neutrophil migration from PDKy'7' mice), pathway and that the 
remaining 20% was PI3K-independent, with Y-27632 able to inhibit this remaining 20%. 
This study suggested that in neutrophils it appears that there are two distinct PTX-sensitive 
pathways, one PI3Ky-dependent and one PI3K-independent. It is possible that T 
lymphocytes migrating in response to CCR4 ligation (and perhaps CXCR3) do not rely 
upon a PI3K-dependent pathway but upon at least one or more PI3K-independent 
pathways, of which one involves Rho-ROCK activity. The possible PI3K-independent 
pathways will be discussed at greater depth in the ‘Discussion II’ section.
Additional evidence of cell-specific migration mechanisms occurring within the leukocyte 
family is highlighted with DOCK2 7 mice. Upstream of the Rac small GTPases lies the 
scaffolding protein DOCK2. Lymphocytes from DOCK2 7 mice revealed a severe lack of a
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migratory response to SDF-1/CXCL12, BLC/CXCL13, ELC/CCL19 and SLC/CCL21, yet 
monocyte/macrophages migrated normally to SDF-1/CXCL12 and MCP-1/CCL2, 
indicating cell specific mechanisms. It is unclear how DOCK2 is recruited and evidence 
suggests there could well be PI3K-dependent and independent mechanisms at work 
(DOCK2 pathways reviewed in (Reif and Cyster, 2002)). Additionally, a recently 
published paper suggests a reciprocal interaction between Rac and Rho in fibroblasts that is 
required for cytoskeletal reorganization (Gasteier et al., 2003). More specifically, this 
study revealed the Rac-dependent activation of the Rho-cascade via a diaphanous-related 
forming named FHOD1 (formin homology 2 domain containing 1) in inducing cytoskeletal 
changes. FHOD1 effects required the Rho-ROCK cascade, yet Rac (and not Rho or cdc42) 
bound to FHOD1 inducing its recruitment to actin filaments and membrane ruffles 
(Gasteier et al., 2003). This suggests a possible mechanism for the involvement of both a 
DOCK2 and ROCK-dependent pathway in T lymphocyte directed cell migration without 
the need of PI3K activity. It could be that there are at least two pathways that are required 
for T cell chemotaxis, that may or may not be mutually exclusive: one pathway for 
lamellipodia formation at the anterior of the cell (requiring DOCK2?); and a pathway 
required for uropod formation at the posterior (ROCK-dependent?). A cell requires the 
extension at the front to be tightly coordinated temporally with contraction in the middle 
and retraction at the back for effective movement and prevention of either process will 
severely affect a cells migration. Consequently, it is more likely that the pathways are 
intertwined with one another in some way to make this movement finely coordinated, with 
a negative feedback interaction between these pathways in order to get a coordinated 




The data presented in this first results section indicates that CCR4-mediated T-lymphocyte 
cell migration is independent of detectable PI3K catalytic activity. The ability of MDC to 
activate PI3K isoforms (class Ia / I b )  suggests a role for them to play in currently non­
characterised CCR4-mediated functional responses (such as cell proliferation/anti- 
apoptosis). Although it appears that neither CEM cells nor polarised Th2 cells require 
PI3K activity for chemotaxis it would seem that there are some fundamental differences 
between their responses to the CCR4 ligands. The kinetics for PKB phosphorylation are far 
more rapid and transient in the non-transformed T cells (and HUT-78 cells), with the 
transient nature possibly explained by the presence of PTEN. In addition, and perhaps 
more interestingly of all, TARC and MDC are able, in equal measures, to induce the 
chemotaxis of Th2 cells, yet TARC is far less effective in instigating CEM cell chemotaxis 
than MDC. This phenomenon is unexplainable and to date we have been unable to find a 
difference in the signalling pathways mediated by TARC and MDC in these cells that may 
provide an explanation. This data suggests, along with the other recent studies mentioned, 
the involvement of PI3K in chemokine-mediated migration of T lymphocytes is, in all 
probability, context dependent. Some possible PI3K-independent mechanisms have been 
discussed but these pathways remain very ambiguous, and will be discussed, along with 
other possible options, in the remaining part of this thesis.
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Key Future Experiments I
1. Perform in vitro PI3K assays in Th2 cells -  basal PI3K activity would be expected 
to be lower allowing for better assessment of the extent of their activation.
2. Utilise PI3K isoform knockout models to ascertain the role of PI3K in CCR4- 
mediated directional T cell migration -  currently studies have largely only been 
performed in granulocytes and not with either of the CCR4 ligands.
3. Use siRNA technology to make certain the role, if any, of PI3K in CCR4-mediated 
T cell migration -  there has recently been an increase in the accessibility of this 
technology and it offers a number of advantages over current techniques: firstly, it is 
cheaper and far easier than generating knockout models; secondly, the method 
allows the control o f expression. Thus the cells develop and are cultured with the 
gene o f interest before its ‘knocked out’, allowing for suitable controls, and possibly 
preventing any abnormalities occurring during development/maturation due to the 
loss of the target gene.
4. Study the role of the PI3K isoforms and downstream effectors in cell polarisation 
and migration by the use of real time confocal microscopy -  the availability of 
selective antibodies (raised in different species) against all the PI3K isoforms and 
many of the effectors would allow the localisation and any mobilisation of these 
molecules to be viewed, providing strong evidence for the role of PI3K in T cell 
migration.
5. Attempt to determine why TARC is ineffective in causing the migration of CEM 
cells yet displays similar potency in attracting human Th2 cells as MDC. This 
would involve in many types of experiments, including western blot analysis to 
elucidate any differences in signalling pathways and chemotaxis experiments.







Having established that the PI3K pathway is activated by both MDC and TARC but is yet 
surprisingly dispensable for CCR4-mediated T cell migration, investigations were 
performed to determine the requirement of various other signalling molecules for 
chemotaxis.
Chemokine receptors, as with all GPCRs, act as ligand-dependent GDP exchange factors 
with receptor ligation leading to the exchange of GDP for GTP in the receptor-associated 
GDP-bound G protein. This leads to the Ga and Gpy subunits dissociating and activating 
various signalling cascades, with the receptor reverting to a low affinity state (Arai and 
Charo, 1996; Kuang et al., 1996). A number of studies have demonstrated the activation of 
a number of components of various signalling pathways for most chemokines and in 
multiple cell types, including the PI3K and ERK-MAPK pathways (Ashida et al., 2001b; 
Bonacchi et al., 2001; Chandrasekar et al., 2003a; Smit et al., 2003; Soriano et al., 2003; 
Sotsios et al., 1999; Wain et al., 2002).
However, thus far there has been very little research on the signalling pathways 
downstream of CCR4, and this has led us to investigate the CCR4-mediated signal 
transduction pathways and the cascades that may be involved in T lymphocyte migration. 
In this study, we demonstrate that ligation of CCR4 leads to activation of the ERK-MAPK 
pathway, in addition to the PI3K pathway, and that neither of these cascades is required for 
directed T cell migration. However, phospholipase C (PLC) is required, but interestingly, 
migration is independent of classical/novel protein kinase C isoforms and calcium 
mobilisation. The Rho-ROCK pathway also appears to be essential for migration. These 
alternative PLC- and ROCK-mediated pathways are discussed.
To aid the reader, there will be ‘pathway & inhibitor guides’ throughout this results section 
to assist the reader in understanding the pathways being analysed within that current sector.
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4.1 Characterisation of CCR4-Mediated Intracellular Calcium 
Mobilisation 
Introduction
Calcium is a ubiquitous intracellular signal that accompanies cells throughout their entire 
lifespan, from their origin at fertilisation to the end of their life cycle. There has been a 
rapid advancement of the calcium field since the 1950s, when interest in the signalling role 
of calcium started. This has led to significant roles for calcium in a plethora of processes 
covering fertilization, proliferation, apoptosis, contraction and secretion, development, 
learning and memory (Berridge et al., 2000; Berridge et al., 2003). Calcium, at the cellular 
level, is derived from two sources -  external and internal. It enters from outside the cell by 
passing through channels that span the plasma membrane, such as voltage-operated calcium 
channels and receptor-operated calcium channels. Or it can be released from internal 
calcium stores, through channels in the endoplasmic reticulum (Berridge et al., 1998).
CCR4-Mediated Calcium Mobilisation
All ligated signalling chemokine receptors have demonstrated the intracellular mobilisation 
of calcium and is thus a widely used indicator of chemokine receptor activation (Jordan et 
al., 1999; Struyf et al., 2001; Sullivan et al., 1999a; Yoshida et al., 1999). CCR4 has been 
shown to mobilise calcium in a range of cell types that it is expressed on, including 
platelets, NK cells and Th2 cells (Abi-Younes et al., 2001; Andrew et al., 1998; 
Inngjerdingen et al., 2000). Figures 4.1 -  4.4 demonstrate the MDC- and TARC- 
stimulated intracellular calcium mobilisation in CHOKlhCCR4 cells. This mobilisation is 
extremely rapid in onset and very transient, with levels returning back to basal within 20 
seconds. CHOKlhCCR4 calcium analysis was performed using a microscopy technique 
that measured emission intensity at X 510 nm after excitation at both X 340 nm and X 380 
nm in Fura-2-loaded cells. Upon calcium binding, the fluorescent excitation maximum of 
the indicator undergoes a blue shift from 363 nm (Calcium-free) to 335 nm (Calcium- 
saturated), while the fluorescence emission maximum is relatively unchanged at -510  nm.
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Graphical analysis of fluorescent intensity at 510 nm for 340 nm and 380 nm will therefore 
generate 2 graphs that are mirror images of one another (fig. 4.2, B , and fig. 4.4, B). 
Results are expressed as the ratio of the fluorescent emission intensity corresponding to the 
two excitations, with a pseudocolour format utilised for visualisation purposes (fig. 4.2, A, 
and fig. 4.4, A). This method allows for the spatial analysis of calcium mobilisation to be 
determined. Figure 4.5 displays intensity plots at different time points for a single cell 
stimulated with TARC. Although the resolution is poor, it is reasonably clear that the 
calcium flux is emanating from the centre of the cell.
This thesis is focused on CCR4-mediated signalling pathways in T cells. Using another 
method o f calcium flux analysis (FLIPR), which allows for much more of a high- 
throughput analysis, MDC- and TARC-induced calcium mobilisation in CEM and Th2 
cells was measured. As was observed for CHOKlhCCR4 cells, MDC and TARC both 
elicited rapid intracellular calcium mobilisation in CEM cells (fig. 4.6). However, in 
contrast, this concentration-dependent mobilisation was much less transient than in 
CHOKlhCCR4 cells and a return to basal levels was achieved only after at least 90 
seconds. It is also apparent that, as is the case for PKB phosphorylation and other 
signalling/functional responses, MDC is a more potent stimulator of intracellular calcium 
flux than TARC (fig. 4.7).
Use of Pertussis Toxin to Ascertain the Extent of CCR4-Mediated 
Calcium Mobilisation Reliance Upon God
Chemokines predominantly signal through GPCRs that are coupled to the heterotrimeric G 
proteins Gcxipy, although other Got proteins have been demonstrated to couple to some 
chemokine receptors (Arai and Charo, 1996; Damaj et al., 1996; Vila-Coro et al., 1999). 
Thus, the majority of chemokine-mediated responses are sensitive to the Goti inhibitor 
pertussis toxin (PTX). PTX catalyses the ADP-ribosylation of Goti, thus preventing the G 
protein heterotrimers from interacting with receptors. The a i subunits remain in their 
GDP-bound state, unable to initiate pathway activation. Pretreatment of CEM cells with 
100 ng/ml PTX abolished MDC- or TARC-stimulated intracellular calcium flux (fig. 4.8).
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Figure 4.1. M DC-m ediated calcium mobilisation in C H O K lhC C R 4 cells. 
A
MDC 10 n.M 
(60 sec)
i * t  1 1 ! i I i ! l i  f * 1
0 20 40 60 80 100 120 140
Tim e (sec)













Figure 4.1. M DC-m ediated calcium mobilisation in C H O K lhC C R 4 cells. Levels of 
intracellular-free calcium were measured using the MERLIN imaging system and Zeiss 
Axiovert S I00 inverted microscope equipped with an UltraPix FK1000 cooled digital 
camera and a SpectraMASTER high-speed monochromator. Cells were grown on 
coverslips to approximately 20% confluency. Prior to experimentation, cells were washed 
and resuspended in physiological salt solution (PSS) and loaded with Fura-2, as described 
in Materials and Methods. Cells were stimulated with MDC (10 nM) whilst alternately 
excited with 340 and 380 nm wavelengths. Fura-2 fluorescence emission intensity was 
measured at X 510 nm and the 340/380 nm fluorescence ratios (Rf) were calculated for 
individual cells (A) and the mean calculated (B). Results are expressed as fold increase 




Figure 4.2. Visualisation of MDC-induced calcium mobilisation in CHOKlhCCR4 cells.
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Figure 4.2. Visualisation of M DC-mediated calcium mobilisation in C H O K lhC C R 4 
cells. Levels of intracellular-free calcium were visualised using the MERLIN imaging 
system and Zeiss Axiovert S I00 inverted microscope equipped with an UltraPix FK1000 
cooled digital camera and a SpectraMASTER high-speed monochromator. Cells were 
grown on coverslips to approximately 20% confluency. Prior to experimentation, cells 
were washed and resuspended in PSS and loaded with Fura-2, as described in Materials 
and Methods. The intensity for fluorescent light emission (X = 510 nM) using excitation at 
340 and 380 nm was monitored at the level of each single fura-2-loaded cell of the field 
(A), with MDC (10 nM) added at 60 sec. A representative graph of emission intensity at X 
340 nm and X 380 nm excitation is presented for a single cell (B). Results are expressed in 
a pseudocolour format and are indicative of the calculated Rf values for each cell. These 
results are representative of more than three separate experiments.
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Figure 4.3. TARC-mediated calcium mobilisation in CHOK1HCCR4 cells. 
A
TARC 30 nM 
(69 sec)
B
100 150 200 250
T im e (sec)









Figure 4.3. TARC-mediated calcium mobilisation in C H O K lhC C R 4 cells. Levels of 
intracellular-free calcium were measured using the MERLIN imaging system and Zeiss 
Axiovert S I00 inverted microscope equipped with an UltraPix FK1000 cooled digital 
camera and a SpectraMASTER high-speed monochromator. Cells were grown on 
coverslips to approximately 20% confluency. Prior to experimentation, cells were washed 
and resuspended in physiological salt solution (PSS) and loaded with Fura-2, as described 
in Materials and Methods. Cells were stimulated with TARC (30 nM) whilst alternately 
excited with 340 and 380 nm wavelengths. Fura-2 fluorescence emission intensity was 
measured at A, 510 nm and the 340/380 nm fluorescence ratios (Rf) were calculated for 
individual cells (A) and the mean calculated (B). Results are expressed as fold increase 




Figure 4.4. Visualisation of TARC-induced calcium flux in C H O K lhC C R 4 cells.
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Figure 4.4. Visualisation of TARC-induced calcium flux in C H O K lhC C R 4 cells.
Levels of intracellular-free calcium were visualised using the MERLIN imaging system and 
Zeiss Axiovert S100 inverted microscope equipped with an UltraPix FK1000 cooled digital 
camera and a SpectraMASTER high-speed monochromator. Cells were grown on 
coverslips to approximately 20% confluency. Prior to experimentation, cells were washed 
and resuspended in PSS and loaded with Fura-2, as described in Materials and Methods. 
The intensity for fluorescent light emission (X, = 510 nM) using excitation at 340 and 380 
nm was monitored at the level of each single fura-2-loaded cell of the field (A), with TARC 
(10 nM) added at 69 sec. A representative graph of emission intensity at X 340 nm and X 
380 nm excitation is presented for a single cell (B). Results are expressed in a 
pseudocolour format and are indicative of the calculated Rf values for each cell. These 
results are representative of more than three separate experiments.
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Figure 4.5. Spatial analysis of TARC-induced calcium mobilisation in CHOK1HCCR4
cells.
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Figure 4.5. Spatial analysis of TARC-induced calcium mobilisation in C H O K lhC C R 4 
cells. Levels of intracellular-free calcium were visualised using the MERLIN imaging 
system and Zeiss Axiovert S I00 inverted microscope equipped with an UltraPix FK1000 
cooled digital camera and a SpectraMASTER high-speed monochromator. Cells were 
grown on coverslips to approximately 20% confluency. Prior to experimentation, cells 
were washed and resuspended in PSS and loaded with Fura-2, as described in Materials 
and Methods. The intensity for fluorescent light emission = 510 nM) using excitation at 
340 and 380 nm was monitored at the level of a single fura-2-loaded cell, with TARC (10 
nM) added at 69 sec.
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Figure 4.6. MDC- and TARC-induced calcium flux in CEM  cells is rapid, transient 
























































Figure 4.6. MDC- and TARC-induced calcium flux in CEM  cells is rapid, transient 
and concentration-dependent, as determ ined by FLIPR analysis. Levels of 
intracellular-free calcium were determined using a 96-well plate FLIPR system. Prior to 
experimentation, cells were washed and resuspended in loading buffer, labelled with Fluo- 
4, and plated out at 80, 000 cells/well onto poly-L-lysine coated plates, as described in 
Materials and Methods. The cells were then excited at 488 nm using the FLIPR laser and 
change in fluorescence emission of Fluo-4 determined using a CCD camera with a band­

















Figure 4.7. C om parison of MDC- and TARC-mediated calcium mobilisation in CEM 
cells. Levels of intracellular-free calcium were determined using a 96-well plate FLIPR 
system. Prior to experimentation, cells were washed and resuspended in loading buffer, 
labelled with Fluo-4, and aliquoted out at 80, 000 cells/well onto poly-L-lysine coated 
plates, as described in Materials and Methods. The cells were then excited at 488 nm using 
the FLIPR laser and change in fluorescence emission of Fluo-4 determined, in response to 
chemokine stimulation, using a CCD camera with a band-pass interference filter (510-560 
nm). Results are expressed as fold increase over unstimulated (vehicle) cells (± SEM), with 
curve fitting performed using the logistic non-linear curve fit equation in Origin. Results 
are representative of more than 3 separate experiments.
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Figure 4.8. MDC- and TARC-mediated calcium mobilisation in CEM cells is sensitive 
to PTX treatm ent.
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Figure 4.8. MDC- and TARC-mediated calcium mobilisation in CEM cells is sensitive 
to PTX treatm ent. Levels of intracellular-free calcium were determined using a 96-well 
plate FLIPR system. Cells were pretreated with 100 nM pertussis toxin (PTX) overnight 
(16 hr). Prior to experimentation, cells were washed and resuspended in loading buffer, 
labelled with Fluo-4, and aliquoted out at 80, 000 cells/well onto poly-L-lysine coated 
plates, as described in M aterials and Methods. The cells were then excited at 488 nm using 
the FLIPR laser and change in fluorescence emission of Fluo-4 determined, in response to 
chemokine stimulation, using a CCD camera with a band-pass interference filter (510-560 
nm). Results are expressed as fold increase over unstimulated (vehicle) or PTX-treated cells 
(± SEM), as appropriate. Results are representative of 3 separate experiments.
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Requirement of Janus Kinases for CCR4-Mediated Calcium Mobilisation 
in CEM Cells
The janus kinase (JAK) family of tyrosine kinases is well known to be activated by many 
cytokines and growth factors. These JAKs are activated directly by the activated receptors 
and go on to phosphorylate and activate signal transducers and activators of transcription 
(STATs). These receptor-associated STATs then dimerise and translocate to the nucleus 
and regulate gene expression. In the last few years a number of papers have demonstrated 
that chemokine receptor dimerisation leads to the activation of the JAK-STAT pathway 
(Mellado et al., 2001; Rodriguez-Frade et al., 1999b; Rodriguez-Frade et al., 1999a; Vila- 
Coro et al., 1999; Wong et al., 1997; Wong et al., 2001). JAK2/3 activation has been 
demonstrated to be required for chemokine-mediated induction of intracellular calcium 
mobilisation in a variety of cell types, including T cells (Mellado et al., 1998; Soriano et al., 
2003). To determine if there was any involvement of JAK2/3 in CCR4-mediated calcium 
flux in T cells, the widely used JAK2/3 inhibitor AG490 was preincubated with CEM cells, 
with a range of concentrations, for one hour. There was little effect of AG490 at 10 pM 
and 50 pM compared to MDC-only stimulated calcium mobilisation responses, especially 
at the lower chemokine concentrations (fig. 4.9). However, preincubation of CEM cells 
with 100 pM AG490 attenuated the MDC-mediated calcium flux by around 50% at 100 nM 
MDC. Intracellular calcium mobilisation mediated by TARC displayed similar patterns to 
that observed for MDC (fig. 4.10). Both JAK2 and JAK3 have been characterised 
downstream of activated chemokine receptors such as CXCR4 and CCR5 (Vila-Coro et al., 
1999; Wong et al., 2001; Zhang et al., 2001). AG490 is known to demonstrate inhibition of 
both JAK2 and JAK3. In order to elucidate if both JAK2 and JAK3 are having an effect on 
calcium mobilisation or if it is just one of them, a JAK3 inhibitor that has no effect on 
JAK2 activity was used. Pretreatment of CEM cells with the JAK3 inhibitor WHI-P154 
had no effect on MDC-induced calcium responses and demonstrated an exact profile to that 
observed with the negative control for AG490, AG9 (an inactive tyrphostin) (fig. 4.11).
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Figure 4.9. The JA K 2 tyrosine kinase is not essential for an in tracellular calcium flux 
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Figure 4.9. The JA K 2 tyrosine kinase is not essential for an intracellular calcium flux 
in CEM  cells in response to CCR4 ligation with MDC. Levels of intracellular-free 
calcium were determined using a 96-well plate FLIPR system. Prior to experimentation, 
cells were washed and resuspended in loading buffer and pretreated with AG490 for 1 hr at 
indicated concentrations. Cells were then labelled with Fluo-4 and aliquoted out at 80, 000 
cells/well onto poly-L-lysine coated plates, as described in Materials and Methods. The 
cells were then excited at 488 nm using the FLIPR laser and change in fluorescence 
emission of Fluo-4 determined, in response to MDC stimulation, using a CCD camera with 
a band-pass interference filter (510-560 nm). Results are expressed as fold increase over 
unstimulated (vehicle/inhibitor) cells (± SEM), with curve fitting performed using the 




Figure 4.10. The JA K 2 tyrosine kinase is not essential for an in tracellular calcium 
flux in CEM  cells in response to CCR4 ligation with TARC.
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Figure 4.10. The JA K 2 tyrosine kinase is not essential for an intracellular calcium
flux in CEM  cells in response to CCR4 ligation with TARC. Levels of intracellular-free 
calcium were determined using a 96-well plate FLIPR system. Prior to experimentation, 
cells were washed and resuspended in loading buffer and pretreated with AG490 for 1 hr at 
indicated concentrations. Cells were then labelled with Fluo-4 and aliquoted out at 80, 000 
cells/well onto poly-L-lysine coated plates, as described in Materials and Methods. The 
cells were then excited at 488 nm using the FLIPR laser and change in fluorescence 
emission of Fluo-4 determined, in response to TARC stimulation, using a CCD camera 
with a band-pass interference filter (510-560 nm). Results are expressed as fold increase 
over unstimulated (vehicle/inhibitor) cells (± SEM), with curve fitting performed using the 




Figure 4.11. CCR4-mediated intracellular calcium mobilisation does not rely upon
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Figure 4.11. CCR4-mediated in tracellu lar calcium mobilisation does not rely upon 
JAK3 in CEM cells. Levels of intracellular-free calcium were determined using a 96-well 
plate FLIPR system. Prior to experimentation, cells were washed and resuspended in 
loading buffer and pretreated with specified inhibitors (WHI-P154 = JAK3; AG9 = 
negative control for AG490) for 1 hr at indicated concentrations. Cells were then labelled 
with Fluo-4 and aliquoted out at 80, 000 cells/well onto poly-L-lysine coated plates, as 
described in Materials and Methods. The cells were then excited at 488 nm using the 
FLIPR laser and change in fluorescence emission of Fluo-4 determined, in response to 
MDC stimulation, using a CCD camera with a band-pass interference filter (510-560 nm). 
Results are expressed as fold increase over unstimulated (vehicle/inhibitor) cells (± SEM), 
with curve fitting performed using the logistic non-linear curve fit equation in Origin. 
Results are representative of 2 separate experiments.
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CCR4-Stimulated Calcium Mobilisation is PLC-Dependent and Uses IP3 
Receptor Calcium Stores
Calcium releases from the internal stores of the ER are controlled by a variety of channels 
that include the IP3 receptor (IP3R), ryanodine receptor (RR) and nicotinic acid adenine 
dinucleotide phosphate receptor (NAADPR) (Bootman et al., 2001; Genazzani and Thorn, 
2002; Rizzuto et al., 2002). The most intensely studied of these channels is that of the 
IP3R. IP3, along with DAG, is a product of the hydrolysis of the membrane phospholipid 
PI(4,5)P2 by the lipid enzyme PLC. PLCp can be activated by the Gpy subunits after 
chemokine receptor ligation (Jiang et al., 1997; Li et al., 2000; Wu et al., 1992). To 
determine whether the increase in intracellular calcium following ligation of the CCR4 
receptor requires the enzymatic function of PLC isoforms, experiments utilised the 
pharmacological inhibitor of PLC, U73122 (not specific for any one isoform). The MDC- 
induced calcium response was concentration-dependently curtailed following an hour 
pretreatment of CEM cells with U73122 (fig. 4.12). At the highest concentration of 
inhibitor (1.5 pM) the calcium flux was abolished. As would be expected, TARC-mediated 
calcium mobilisation demonstrated a similar sensitivity to U73122 as to that observed for 
MDC (fig. 4.13). The results presented here support the observation of previous studies 
that have reported U73122 to have an IC5 0  between 500 nM and 2.1 pM (Smith et al., 1996; 
Stam et al., 1998; Yule and Williams, 1992). U73343 is the inactive analogue of U73122 
and consequently has no effect upon CCR4-induced intracellular calcium mobilisation (fig. 








Having determined that PLC is required for calcium mobilisation, it was then necessary to 
confirm that IP3 was the mediator of this response. 2-aminoethoxydiphenyl borate (2- 
APB) has been described as an inhibitor of calcium release from IP3R stores without 
affecting binding of IP3 to IP3R. It has no effect on calcium release from RR stores and has 
an IC50 of 42 pM, with studies using the compound at up to 100 pM (Ascher-Landsberg et 
al., 1999; Maruyama et al., 1997; Werry et al., 2003). Treatment of CEM cells with 75 pM 
2-APB led to the abrogation of both MDC- (fig. 4.15, A) and TARC- (fig. 4.15, B) induced 
intracellular calcium mobilisation.
Ryanodine Receptor Stores do not Contribute Towards CCR4-Mediated 
Intracellular Calcium Mobilisation in CEM Cells.
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R yan od in e (m M ) 
D an tro len e C affeine
The RR calcium stores are released by calcium itself that has been itself released from other 
sources, normally the IP3R stores (Bootman et al., 2001; Islam, 2002). Therefore, to test 
whether 2-APB is just inhibiting the release of calcium from the upper most channel (i.e. 
IP3R) in a cascade or that IP3R stores are the only calcium stores contributing to the 
CCR4-mediated calcium response, it is necessary to inhibit the RRs and other calcium 
induced calcium release (CICR) channels. The RRs are termed because ryanodine is a high 
affinity ligand for the CICR channel and will promote the channel’s activation at low 
concentrations. However, at high concentrations (100 pM -  10 mM) ryanodine inhibits the 
channel whilst in its open state (Ehrlich et al., 1994). In addition, at millimolar 
concentrations, caffeine is an activator of RRs (Friel and Tsien, 1992). Therefore, the 
combined treatment of caffeine (to open the RR channels) and ryanodine (to block) is 




MDC- and TARC-induced calcium release from intracellular stores is substantially 
potentiated in the presence of 10 mM caffeine, but caffeine has no effect on its own in 
CEM cells (fig. 4.16). Ryanodine has no effect upon CCR4-mediated calcium responses 
alone but does abolish the effect of caffeine on CCR4-mediated intracellular calcium 
release (fig. 4.16). The cell permeable RR blocker dantrolene has no effect on either MDC- 
or TARC-induced calcium release at 100 pM (fig. 4.17, A and B).
Nifedipine
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Cyclic adenosine diphosphate-ribose (cADPR) is a second messenger, generated from its 
precursor NAD+ (nicotinamide adenine dinucleotide) possibly by receptor-activated ADP- 
ribosyl cyclases (ARC), which can gate the RRs and cause the release of calcium (Galione 
and Churchill, 2000). A metabolite of an alternative pyridine nucleotide, nicotinamide 
adenine dinucleotide diphosphate (NADP+), by possibly a similar process is nicotinic acid 
adenine dinucleotide phosphate (NAADP). NAADP is able to mobilise intracellular 
calcium stores distinct from those for IP3R and RR (Genazzani and Billington, 2002; Patel 
et al., 2001). Mobilisation of intracellular calcium in NK cells through the cADPR has 
been demonstrated for IL-8, SDF-1, RANTES and MDC, with DCs mobilising calcium in a 
cADPR-dependent manner in response to CCL2, CCL19, CCL21 and CXCL12 
(Inngjerdingen et al., 1999; Partida-Sanchez et al., 2004). 8-Br-cADPR is an effective 
inhibitor of cADPR-mediated calcium release (with no effect on ryanodine-mediated 
calcium release) but had no impact on either MDC- or TARC-induced intracellular calcium 
release in CEM cells (fig. 4.18 and fig 4.19) (Guse et al., 1995). Nifedipine is an L-type 
calcium channel blocker but has been shown at very high concentrations to inhibit 
NAADP-mediated calcium release from intracellular stores, with no effect on IP3- or 
cADPR-mediated release (Yusufi et al., 2002). 50 pM nifedipine pretreatment of CEM 
cells had a small negative effect upon MDC- and TARC-induced calcium responses at 50 
nM and 100 nM chemokine concentrations (fig. 4.18 and fig. 4.19).
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Role of PI3K in CCR4-Mediated Calcium Responses
PI3K has been shown to be required for the initiation of calcium entry through calcium- 
permeable non-selective cation channel 2 (NSCC-2) and store-operated calcium channels 
(SOCCs) (Kawanabe et al., 2002; Kawanabe et al., 2003). However, using LY294002 to 
inhibit PI3K activity, there was no effect on MDC- or TARC-induced calcium responses in 
CEM cells, even at inhibitor concentrations as high as 50 pM  (fig. 4.20 and fig. 4.21).
PKC Sensitive Calcium Mobilisation in Response to CCR4 Ligation
PKC has been demonstrated to have effects on chemokine-mediated calcium mobilisation 
due to effects on receptor internalisation. Activating PKC has been shown to abrogate 
chemokine-mediated calcium responses due to receptor internalisation (Guinamard et al., 
1999; Schondorf et al., 1993). Figure 4.22, A and B, illustrate that PKC activation, with 
PMA, abrogated calcium mobilisation. An increase in calcium flux was seen when PKC 
was inhibited with the broad-spectrum (classical and novel isoform) PKC inhibitor RO-32- 
0432, or when PKC expression was down-regulated by overnight pretreatment with PMA 
(fig. 4.22).
CCR4-Mediated Calcium Responses in Th2 Cells
To determine whether CEM cells act in a comparable manner to more physiologically 
normal CCR4 expressing T cells, in vitro generated Th2 cells were analysed for their 
calcium responses upon CCR4 ligation. MDC and TARC were both able to elicit 
intracellular calcium mobilisation in Th2 cells and these responses showed similar 
sensitivities to the PLC and JAK2/3 inhibitors, U73122 and AG490, to those observed for 
CCR4-mediated calcium responses in CEM cells. U73122 abrogated the calcium responses 
to MDC and TARC, whereas AG490 had a diminutive effect (fig. 4.23 and fig. 4.24).
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Figure 4.12. Inhibition of PLC attenuates the M DC-induced calcium mobilisation in 
CEM  cells. Levels of intracellular-free calcium were determined using a 96-well plate 
FLIPR system. Prior to experimentation, cells were washed and resuspended in loading 
buffer and pretreated with U73122 for 1 hr at indicated concentrations. Cells were then 
labelled with Fluo-4 and aliquoted out at 80, 000 cells/well onto poly-L-lysine coated 
plates, as described in Materials and Methods. The cells were then excited at 488 nm using 
the FLIPR laser and change in fluorescence emission of Fluo-4 determined, in response to 
MDC stimulation, using a CCD camera with a band-pass interference filter (510-560 nm). 
Results are expressed as fold increase over unstimulated (vehicle/inhibitor) cells (± SEM), 
with curve fitting performed using the logistic non-linear curve fit equation in Origin. 
Results are representative of 3 at least separate experiments.
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Figure 4.13. Inhibition of PLC attenuates the TARC-induced calcium mobilisation in 
CEM cells. Levels of intracellular-free calcium were determined using a 96-well plate 
FLIPR system. Prior to experimentation, cells were washed and resuspended in loading 
buffer and pretreated with U73122 for 1 hr at indicated concentrations. Cells were then 
labelled with Fluo-4 and aliquoted out at 80, 000 cells/well onto poly-L-lysine coated 
plates, as described in M aterials and Methods. The cells were then excited at 488 nm using 
the FLIPR laser and change in fluorescence emission of Fluo-4 determined, in response to 
TARC stimulation, using a CCD camera with a band-pass interference filter (510-560 nm). 
Results are expressed as fold increase over unstimulated (vehicle/inhibitor) cells (± SEM), 
with curve fitting performed using the logistic non-linear curve fit equation in Origin. 
Results are representative of at least 3 separate experiments.
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Figure 4.14. The inactive analogue of U73122 has no effect on CCR4-mediated 
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Figure 4.14. The inactive analogue of U73122 has no effect on CCR4-mediated 
calcium mobilisation in CEM  cells. Levels of intracellular-free calcium were determined 
using a 96-well plate FLIPR system. Prior to experimentation, cells were washed and 
resuspended in loading buffer and pretreated with U73122 or U73343 for 1 hr at indicated 
concentrations. Cells were then labelled with Fluo-4 and aliquoted out at 80, 000 cells/well 
onto poly-L-lysine coated plates, as described in Materials and Methods. The cells were 
then excited at 488 nm using the FLIPR laser and change in fluorescence emission of Fluo- 
4 determined, in response to MDC (A) or TARC (B) stimulation, using a CCD camera with 
a band-pass interference filter (510-560 nm). Results are expressed as fold increase over 
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Figure 4.15. CCR4-induced in tracellu lar calcium flux requires calcium release from 
IP3 receptor stores. Levels of intracellular-free calcium were determined using a 96-well 
plate FLIPR system. Prior to experimentation, cells were washed and resuspended in 
loading buffer and pretreated with 2-APB (75 pM) for 1 hr. Cells were then labelled with 
Fluo-4 and aliquoted out at 80, 000 cells/well onto poly-L-lysine coated plates, as described 
in Materials and Methods. The cells were then excited at 488 nm using the FLIPR laser 
and change in fluorescence emission of Fluo-4 determined, in response to MDC (A) or 
TARC (B) stimulation, using a CCD camera with a band-pass interference filter (510-560 
nm). Results are expressed as fold increase over unstimulated (vehicle/inhibitor) cells (± 
SEM), with curve fitting performed using the logistic non-linear curve fit equation in 
Origin. Results are representative of at least 3 separate experiments.
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Figure 4.16. Caffeine pre-treatment potentiates intracellular calcium mobilisation
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Figure 4.16. Caffeine pre-treatm ent potentiates in tracellu lar calcium mobilisation 
upon CCR4-ligation on CEM  cells. Levels of intracellular-free calcium were determined 
using a 96-well plate FLIPR system. Prior to experimentation, cells were washed and 
resuspended in loading buffer and pretreated with caffeine, ryanodine or both for 1 hr at 
indicated concentrations. Cells were then labelled with Fluo-4 and aliquoted out at 80, 000 
cells/well onto poly-L-lysine coated plates, as described in Materials and Methods. The 
cells were then excited at 488 nm using the FLIPR laser and change in fluorescence 
emission of Fluo-4 determined, in response to MDC, TARC or caffeine stimulation, using a 
CCD camera with a band-pass interference filter (510-560 nm). Results are expressed as 
change in fluorescence (± SEM). Results are representative of 3 separate experiments.
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Figure 4.17. The ryanodine receptor inhibitor dantrolene has no negative effect upon 
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Figure 4.17. The ryanodine receptor inhibitor dantrolene has no negative effect upon 
CCR4-mediated intracellular calcium mobilisation in CEM cells. Levels of 
intracellular-free calcium were determined using a 96-well plate FLIPR system. Prior to 
experimentation, cells were washed and resuspended in loading buffer and pretreated with 
danrolene (100 pM) for 1 hr. Cells were then labelled with Fluo-4 and aliquoted out at 80, 
000 cells/well onto poly-L-lysine coated plates, as described in Materials and Methods. 
The cells were then excited at 488 nm using the FLIPR laser and change in fluorescence 
emission of Fluo-4 determined, in response to MDC (A) or TARC (B) stimulation, using a 
CCD camera with a band-pass interference filter (510-560 nm). Results are expressed as 
fold increase over unstimulated (vehicle/inhibitor) cells (± SEM), with curve fitting 
performed using the logistic non-linear curve fit equation in Origin. Results are 
representative of 2 separate experiments.
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Figure 4.18. cADPR calcium stores play no m ajor contribution tow ards MDC 
induced cytosolic calcium increases in CEM  cells.
3 0 -
2 5 - ■ MDC
•  + 8-Br-cADPR (50jjJVI)
A + Nifedipine (50pM)
I  20"
3 -U






1E-8 IE-7IE-11 IE-10 IE-9
MDC Concentration (M)
Figure 4.18. cADPR calcium stores play no m ajor contribution towards MDC- 
induced cytosolic calcium increases in CEM  cells. Levels of intracellular-free calcium 
were determined using a 96-well plate FLIPR system. Prior to experimentation, cells were 
washed and resuspended in loading buffer and pretreated with 8-Br-cADPR (50 pM) or 
nifedipine (50 pM) for 1 hr. Cells were then labelled with Fluo-4 and aliquoted out at 80, 
000 cells/well onto poly-L-lysine coated plates, as described in Materials and Methods. 
The cells were then excited at 488 nm using the FLIPR laser and change in fluorescence 
emission of Fluo-4 determined, in response to MDC stimulation, using a CCD camera with 
a band-pass interference filter (510-560 nm). Results are expressed as fold increase over 
unstimulated (vehicle/inhibitor) cells (± SEM), with curve fitting performed using the 




Figure 4.19. cADPR calcium stores play no m ajor contribution towards TARC 




+ 8-Br-cADPR (50pM) 














1E-11 IE-8 lEr7IE-10 IE-9
TARC Concentration (M)
Figure 4.19. cADPR calcium stores play no m ajor contribution tow ards TARC- 
induced cytosolic calcium increases in CEM cells. Levels of intracellular-free calcium 
were determined using a 96-well plate FLIPR system. Prior to experimentation, cells were 
washed and resuspended in loading buffer and pretreated with 8-Br-cADPR (50 pM) or 
nifedipine (50 pM) for 1 hr. Cells were then labelled with Fluo-4 and aliquoted out at 80, 
000 cells/well onto poly-L-lysine coated plates, as described in Materials and Methods. 
The cells were then excited at 488 nm using the FLIPR laser and change in fluorescence 
emission of Fluo-4 determined, in response to TARC stimulation, using a CCD camera 
with a band-pass interference filter (510-560 nm). Results are expressed as fold increase 
over unstimulated (vehicle/inhibitor) cells (± SEM), with curve fitting performed using the 




Figure 4.20. PI3K inhibition has no effect on M DC-induced intracellular calcium 
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Figure 4.20. PI3K inhibition has no effect on M DC-induced in tracellu lar calcium 
mobilisation in CEM cells. Levels of intracellular-free calcium were determined using a 
96-well plate FLIPR system. Prior to experimentation, cells were washed and resuspended 
in loading buffer and pretreated with LY294002 for 30 min at indicated concentrations. 
Cells were then labelled with Fluo-4 and aliquoted out at 80, 000 cells/well onto poly-L- 
lysine coated plates, as described in Materials and Methods. The cells were then excited at 
488 nm using the FLIPR laser and change in fluorescence emission of Fluo-4 determined, 
in response to MDC stimulation, using a CCD camera with a band-pass interference filter 
(510-560 nm). Results are expressed as fold increase over unstimulated (vehicle/inhibitor) 
cells (± SEM), with curve fitting performed using the logistic non-linear curve fit equation 
in Origin. Results are representative of 3 separate experiments.
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Figure 4.21. PI3K inhibition has no effect on TARC-induced in tracellular calcium 
mobilisation in CEM cells.
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Figure 4.21. PI3K inhibition has no effect on TARC-induced in tracellu lar calcium 
mobilisation in CEM cells. Levels of intracellular-free calcium were determined using a 
96-well plate FLIPR system. Prior to experimentation, cells were washed and resuspended 
in loading buffer and pretreated with LY294002 for 30 min at indicated concentrations. 
Cells were then labelled with Fluo-4 and aliquoted out at 80, 000 cells/well onto poly-L- 
lysine coated plates, as described in Materials and Methods. The cells were then excited at 
488 nm using the FLIPR laser and change in fluorescence emission of Fluo-4 determined, 
in response to TARC stimulation, using a CCD camera with a band-pass interference filter 
(510-560 nm). Results are expressed as fold increase over unstimulated (vehicle/inhibitor) 
cells (± SEM), with curve fitting performed using the logistic non-linear curve fit equation 
in Origin. Results are representative of 3 separate experiments.
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Figure 4.22. A ttenuation of CCR4-mediated in tracellular calcium mobilisation can be 
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Figure 4.22. A ttenuation of CCR4-mediated in tracellular calcium mobilisation can be 
achieved through activation of PKC. Levels of intracellular-free calcium were 
determined using a 96-well plate FLIPR system. A sample of cells were treated with 100 
nM PMA overnight. Prior to experimentation, cells were washed and resuspended in 
loading buffer and pretreated with RO-32-0432 (10 pM) or PMA (100 nM) for 30 min, as 
indicated. Cells were labelled with Fluo-4 and plated out at 80, 000 cells/well onto poly-L- 
lysine coated plates, as described in Materials and Methods. The cells were then excited at 
488 nm using the FLIPR laser and change in fluorescence emission of Fluo-4 determined, 
in response to MDC (A) or TARC (B) stimulation, using a CCD camera with a band-pass 
interference filter (510-560 nm). A selection of cells were stimulated with 100 nM PMA 




Figure 4.23. In tracellu lar calcium mobilisation, mediated by MDC, requires PLC 
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Figure 4.23. In tracellular calcium mobilisation, mediated by MDC, requires PLC 
activation in Th2 cells. Levels of intracellular-free calcium were determined using a 96- 
well plate FLIPR system. Prior to experimentation, cells were washed and resuspended in 
loading buffer and pretreated with U73122 (1 pM) or AG490 (50 pM) for 1 hr. Cells were 
then labelled with Fluo-4 and aliquoted out at 90, 000 cells/well onto poly-L-lysine coated 
plates, as described in Materials and Methods. The cells were then excited at 488 nm using 
the FLIPR laser and change in fluorescence emission of Fluo-4 determined, in response to 
MDC stimulation, using a CCD camera with a band-pass interference filter (510-560 nm). 
Results are expressed as fold increase over unstimulated (vehicle/inhibitor) cells (± SEM), 
with curve fitting performed using the logistic non-linear curve fit equation in Origin. 
Results are representative of 3 separate experiments.
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Figure 4.24. The TARC-induced in tracellular calcium flux displays sim ilar 
sensitivities to inhibitors as that observed for MDC in Th2 cells.
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Figure 4.24. The TARC-induced intracellular calcium flux displays sim ilar 
sensitivities to inhibitors as that observed for MDC in Th2 cells. Levels of intracellular- 
free calcium were determined using a 96-well plate FLIPR system. Prior to 
experimentation, cells were washed and resuspended in loading buffer and pretreated with 
U73122 (1 pM) or AG490 (50 pM) for 1 hr. Cells were then labelled with Fluo-4 and 
aliquoted out at 90, 000 cells/well onto poly-L-lysine coated plates, as described in 
Materials and Methods. The cells were then excited at 488 nm using the FLIPR laser and 
change in fluorescence emission of Fluo-4 determined, in response to TARC stimulation, 
using a CCD camera with a band-pass interference filter (510-560 nm). Results are 
expressed as fold increase over unstimulated (vehicle/inhibitor) cells (± SEM), with curve 
fitting performed using the logistic non-linear curve fit equation in Origin. Results are 
representative of 3 separate experiments.
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4.2 Signal Transduction and Directed Cell Migration 
MDC- and TARC-Stimulated ERK1/2 Phosphorylation
The ERK-MAPK pathway is a relatively well-characterised and studied cascade that is 
activated downstream of a plethora of receptor types. The chemokine family of receptors 
are no different to other groups, with ERK phosphorylation/activation demonstrated in 
response to a number of chemokines (Kim et al., 2003; Kremer et al., 2003; Lentzsch et al., 
2003; Uchida et al., 2003), but not for MDC or TARC. The ERK1/2-MAPK pathway has 
been implicated in the regulation of cell growth and differentiation, with its activation 
commonly construed from its phosphorylation (Lewis et al., 1998). The PI3K-PKB and 
ERK-MAPK modules are two of the pre-eminently studied pathways in a number of 
experimental systems, including within the chemokine field. The following results have 
examined the effect of various pharmacological inhibitors, utilised in chemotaxis assays, on 
these two cascades. These results, along with published data, will allow for a more detailed 
analysis and construction of the signalling pathways that are potentially downstream of 
CCR4 and their requirements in directed T cell migration.
MDC and TARC were both able to stimulate the time- and concentration- dependent 
phosphorylation of ERK 1/2 in CHOKlhCCR4 cells, with maximum responses observed 
between 2 and 5 minutes with optimal chemokine concentrations above 50 nM (fig. 4.25, 
A). ERK1/2 phosphorylation was additionally witnessed in the leukaemic T cell line CEM 
and T-lymphoblasts in response to CCR4 ligation (fig. 4.25, B and C). However, the 
kinetics were slightly more rapid in the T lymphocyte cell types, with peak phosphorylation 
occurring around 2 minutes. In all three cell types, MDC was consistently more effective 
than TARC in mediating ERK1/2 phosphorylation. The phorbyl ester 12-myristate 13- 
acetate (PMA) was used as a positive control for ERK phosphorylation.
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CCR4-Mediated GEM Cell Chemotaxis is PTX-Dependent
Chemokines were named on a functional basis, due to their ability to direct migration of 
specific target cell types up their concentration gradient. Hence, the cardinal effect 
resulting from CCR4 ligation and signalling will be chemotaxis, regardless of cell type. 
Yet the pathways that are involved in this process are poorly characterised and it is 
becoming increasingly evident that these required cascades vary between cell- and 
receptor-type. However, to date all chemokine-mediated directed cell migration has been 
shown to be sensitive to PTX and pretreatment of CEM cells with 100 ng/ml PTX 
abrogated MDC-mediated chemotaxis (fig. 4.26, A). The phosphorylation/activation of 
ERK1/2 and PKB in response to MDC is also dependent upon G ai coupling to CCR4 (fig. 
4.26, B and C). A noteworthy observation is the lack of effect of PTX on basal levels of 
PKB phosphorylation in CEM cells, demonstrating that the treatment was not having an 
adverse effect on levels of PKB activation in general (fig. 4.26, C).
The role of PI3K in ERK1/2 phosphorylation is controversial. A number of groups have 
shown that chemokine-stimulated ERK1/2 activation in a variety of leukocytes is sensitive 
to PI3K inhibition (Knall et al., 1996; Knall et al., 1997; Smit et al., 2003; Sotsios et al., 
1999), whilst others disagree and demonstrate that phosphorylation of ERK1/2 is refractory 
to PI3K inhibition (Cumock et al., 2003; Shyamala and Khoja, 1998; Wain et al., 2002). 
Pretreatment of CHOKlhCCR4, CEM and T-lymphoblast cells with 10 pM LY294002 has 
no effect on MDC-mediated ERK1/2 phosphorylation (fig. 4.27). The effect of PI3K 
inhibition on PKB phosphorylation and CCR4-induced T cell migration has been discussed 
earlier (see ‘Results I’).
Role of PLC, Calcium and PKC on MDC-Mediated Directed CEM Cell 
Migration
The activation of PLC sensitive signalling pathways have been demonstrated for a number 
of chemokines, including CXCL8/CXCR2, CCL15/CCR1 and CCL2/CCR2 (Bacon et al., 
1995; Kim et al., 2003; Kuang et al., 1996; Li et al., 2000). Additionally, two recent 
studies has demonstrated the importance o f PLC, using the inhibitor U73122, for
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CXCL12/CXCR4- and CXCL1 l/CXCR3-mediated chemotaxis of T cells (Smit et al., 
2003; Soriano et al., 2003). U73122 pretreatment of CEM cells concentration-dependently 
inhibited MDC-induced chemotaxis with abrogation occurring with 3 pM U73122 (fig. 
4.28, A). Furthermore, U73122 inhibited PKB phosphorylation in response to MDC with 
U73433, the inactive isomer, having no effect (fig. 4.28, B). Smit, et al. (Smit et al., 2003) 
demonstrate U73122 having a moderate reduction on CXCL11 stimulated ERK1/2 
phosphorylation in T-lymphocytes and with complete inhibition observed in CXCR3 
transfected COS-7 cells. In CEM cells, MDC-stimulated ERK1/2 phosphorylation was 
slightly curtailed at higher concentrations of U73122 but there was also an accompanying 
increase in basal levels of phosphorylation (fig. 4.28, B). The net effect was a similar level 
of phosphorylation observed for both unstimulated and stimulated cells at 10 pM U73122.
2-APB
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So far the chemotaxis data has displayed a similar sensitivity towards the inhibitors as was 
observed for CCR4-induced calcium flux responses. Studies to date have suggested that in 
the absence of adhesive molecules calcium is not required for chemotaxis (Alteraifi and 
Zhelev, 1997; Elferink et al., 1992; Fabbri et al., 1997; Kuijpers et al., 1992). Conversely, 
chemotaxis of neutrophil in the presence of adhesive molecules appears to depend on 
intracellular calcium (Alteraifi and Zhelev, 1997; Hofman et al., 1999; Mandeville and 
Maxfield, 1997). Analysis of CEM cell chemotaxis with U73122 has hinted that calcium 
and/or DAG are likely to be required for CCR4-mediated migration. Pretreating CEM cells 
with 2-APB, at concentrations that abrogate CCR4-mediated intracellular calcium 
mobilisation (fig. 4.15), had no impact upon MDC-induced chemotaxis (fig. 4.29, A). This 
correlates with the theory that calcium is not required for directed cell migration in the
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absence o f adhesive molecules. Moreover, 2-APB treatment had no influence on PKB 
phosphorylation in response to MDC but did severely reduce ERK1/2 phosphorylation 
events in a concentration-dependent manner (fig. 4.29, B).
So far, use of inhibitors has indicated that calcium is a dispensable signal for cell migration, 
whilst the PLC inhibitor has a significant effect on migration. One explanation for this data 
could be that the DAG/PKC pathway plays an important role. The most widely studied 
DAG effector is PKC. The PKC is a very well studied kinase in many different 
experimental settings, including chemotaxis. It has been demonstrated that various PKC 
isoforms are required for chemotaxis of various cell types in response to a variety of stimuli 
(Camevale and Cathcart, 2003; Entschladen et al., 2000; Etienne-Manneville and Hall, 
2001; Laudanna et al., 1998). G66976 is a selective inhibitor for the classical protein 
kinase Cs (i.e. a , (3 and y) and effective at nanomolar concentrations, whilst novel PKC 
isoform activity (i.e. 8, e, r\ and 0) is unaffected, even at micromolar concentrations 
(Martiny-Baron et al., 1993). Reassuringly, pretreatment of CEM cells with G66976, at 
concentrations up to 300 nM, had no influence on MDC-induced directed cell migration 
(fig. 4.30, A). Indeed, Go6976 had no detrimental effect on ERK1/2 and PKB 
phosphorylation in response to MDC stimulation either (fig. 4.30, B). This data compares 
favourably with the lack of requirement for calcium mobilisation for MDC-induced CEM 
cell chemotaxis, as the classical PKC isoforms require both calcium and DAG for 
activation. In contrast, the novel PKC isoforms require only DAG for their activation. 
Unfortunately, there are no pharmacological tools to specifically constrain the activity of 
these isoforms individually. However, there are a number of inhibitors that display 
inhibitory effects over both the classical and novel isoforms. One of these, RO-32-0432, 
has been described as a broad-spectrum PKC isoform inhibitor, although it does display a 
10-fold and 4-fold more selective action for PK C a (IC50 = 9 nM) and PKC(3 (IC50 = 28 
nM) over PKCe (IC50 = 108 nM), respectively (Wilkinson et al., 1993). Pretreatment of 
CEM cells with 10 pM  RO-32-0432 (30 min) completely abated MDC-driven CEM cell 
chemotaxis (fig. 4.31, A), whilst ERK1/2 phosphorylation was refractory to the inhibitory 
effects of this compound (fig. 4.31, B). However, PKB phosphorylation in response to 
MDC was partially down-regulated after RO-32-0432 treatment (fig. 4.31, B). There is a 
single pharmacological inhibitor available to study the effect of an individual novel PKC
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isoform, namely rottlerin and PKC8. This inhibitor displays up to 10-fold greater 
selectivity for PKC8 (IC50 = 3 - 6  pM) over other isoforms (IC50 = 30 -  42 pM) 
(Gschwendt et al., 1994). PKC8 has recently been implicated having a role in the 
chemotaxis of human osteogenic sarcoma (HOS) cells to CCL15 (CCR1) (Ko et al., 2002; 
Li et al., 2003a). Rottlerin inhibited MDC-mediated CEM cell chemotaxis in a 
concentration-dependent manner, with complete inhibition observed at 10 pM  rottlerin (fig. 
4.32, A). ERK1/2 phosphorylation was refractory to PKC8 inhibition, and in contrast to 
RO-32-0432, so was PKB phosphorylation (fig. 4.32, B ). PKC8 has been shown to be a 
ubiquitously expressed enzyme and immunoblotting cell lysates for PKC8 confirmed the 
expression of this isozymes in CEM cells (fig. 4.32, C) (Liu and Heckman, 1998).
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Figure 4.25. MDC and TARC stim ulate the phosphorylation of the ERK-M APK in a 
concentration- and time-dependent manner.
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Figure 4.25. MDC and TARC stim ulate the phosphorylation of the ERK-M APK in a 
concentration- and time-dependent m anner. Levels of phospho-ERKl/2 protein were 
determined by western blot analysis. Prior to experimentation, cells were washed three 
times in appropriate media, and resuspended at 4 x 106 cells/ml and serum-starved for 1 
hour. CHOKlhCCR4 (A), CEM (B ) or T-lymphoblast (C) cells were then stimulated at 
37°C with indicated concentrations of ligand for 2 mins or for the indicated times, and cells 
lysed by the addition of 1 x sample buffer. PMA (lOOnM and 5 min), P, was used as a 
positive control for ERK 1/2 phosphorylation. Cell lysates were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes, and immunoblotted with a phospho-specific 
ERK 1/2 Ab with affinity for the Thr 202- and Tyr 204-phosphorylated, active form, of 
ERK 1/2, and protein was visualised with ECL. Stripping and reprobing blots with anti- 
ERK1/2 Ab confirmed equal loading, as described in Materials and Methods. Data 
representative of 3 separate experiments.
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Figure 4.26. CCR4-mediated signalling events and chemotaxis are pertussis toxin- 
sensitive. CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a reusable MB 
series 96-well chemotaxis chamber, above lower wells containing 1 or 3 nM MDC. Cells 
were preincubated with the 100 ng/ml pertussis toxin (PTX) for 16 hours, A, as described in 
Materials and Methods. Chemotaxis across a 5 pm membrane was determined after 1.5 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test with a Bonferroni correction to compare responses in the presence and 
absence of PTX (*, p < 0.0001; **, p < 0.00005). The horizontal line at a chemotactic 
index of 1 represents unstimulated basal migration and is shown for ease of comparison 
with stimulated levels. CHOKlhCCR4 (B) and CEM (Q  cells treated and untreated with 
pertussis toxin were stimulated with MDC (10 nM) for indicated times (C = vehicle 5 min; 
P = 100 nM PMA 5 min), and lysates generated. These lysates were resolved by SDS- 
PAGE, transferred to nitrocellulose membrane, and immunoblotted with anti-phospho 
ERK 1/2 Ab or anti-phospho PKB473 Ab. The blots were stripped and reprobed with the 
appropriate pan-Ab to verify equal loading and efficiency of protein transfer. Results are 
representative of 3 separate experiments.
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Figure 4.27. M DC-induced phosphorylation of ERK1/2 does not require PI3K 
activity.
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Figure 4.27. MDC-induced phosphorylation of ERK1/2 does not require PI3K 
activity. Levels of phospho-ERKl/2 protein were determined by western blot analysis. 
Prior to experimentation, cells were washed three times in appropriate media, and 
resuspended at 4 x 106 cells/ml and serum-starved for 1 hour. Cells were then stimulated at 
37°C with MDC for indicated times (in the presence or absence of 10 pM LY294002, 30 
min preincubation), and cells lysed by the addition of 1 x sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with 
a phospho-specific ERK 1/2 Ab with affinity for the Thr 202- and Tyr 204-phosphorylated, 
active form, of ERK 1/2, and protein was visualised with ECL. Stripping and reprobing 
blots with anti-PKB Ab confirmed equal loading, as described in Materials and Methods. 
Data representative of 3 separate experiments. Key: P, 100 nM PMA 5 min. The X 
indicates there was no sample in that lane.
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Figure 4.28. CCR4-mediated CEM  cell chemotaxis and ERK1/2 phosphorylation 
require PLC activation.
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Figure 4.28. CCR4-mediated CEM cell chemotaxis and ERK1/2 phosphorylation 
requires PLC activation. CEM cells (2 x 105 cells/200 jul) were added to the upper wells 
of a reusable MB series 96-well chemotaxis chamber, above lower wells containing 1 nM 
MDC. Cells were preincubated with indicated concentrations of U73122 for 1 hour, A, as 
described in Materials and Methods. Chemotaxis across a 5 pm membrane was determined 
after 1.5 hr incubation at 37°C in 5% CO2. The data are derived from a single experiment 
with quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test with a Bonferroni correction to compare responses in the presence and 
absence of U73122 (*, p < 0.05; **, p < 0.000005). The horizontal line at a chemotactic 
index of 1 represents unstimulated basal migration and is shown for ease of comparison 
with stimulated levels. CEM (B) cells treated and untreated with U73122, or the negative 
control U73343, were stimulated with MDC (10 nM) for indicated times (C = vehicle), and 
lysates generated. These lysates were resolved by SDS-PAGE, transferred to nitrocellulose 
membrane, and immunoblotted with anti-phospho ERK 1/2 Ab or anti-phospho PKB473 Ab. 
The blots were stripped and reprobed with the appropriate pan-Ab to verify equal loading 
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Figure 4.29. M DC-induced CEM  cell chemotaxis does not require calcium 
mobilisation. CEM cells (2 x 105 cells/200 jj.1) were added to the upper wells of a reusable 
MB series 96-well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells 
were preincubated with indicated concentrations of 2-APB for 1 hour, A, as described in 
Materials and Methods. Chemotaxis across a 5 (im membrane was determined after 1.5 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s / test (p < 0.05) to compare responses in the presence and absence of 2-APB. 
The horizontal line at a chemotactic index of 1 represents unstimulated basal migration and 
is shown for ease of comparison with stimulated levels. CEM {B) cells treated and 
untreated with 2-APB were stimulated with MDC (10 nM) for indicated times (C = 
vehicle), and lysates generated. These lysates were resolved by SDS-PAGE, transferred to 
nitrocellulose membrane, and immunoblotted with anti-phospho ERK 1/2 Ab or anti- 
phospho PKB473 Ab. The blots were stripped and reprobed with the appropriate pan-Ab to 




Figure 4.30. Classical PKC isoform activity is not required for CCR4-mediated CEM 
cell chemotaxis. a
h i







T re a tm e n t
B
af»> f-Ao Ac Ac/ /  / /
c 2 C  2 C 2 C 2




c 5 C  5 C 5 C 5










Figure 4.30. Classical PKC isoform activity is not required for CCR4-mediated CEM 
cell chemotaxis. CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a 
reusable MB series 96-well chemotaxis chamber, above lower wells containing 1 nM 
MDC. Cells were preincubated with indicated concentrations of Go6976 for 30 min, A, as 
described in Materials and Methods. Chemotaxis across a 5 pm membrane was determined 
after 1.5 hr incubation at 37°C in 5% CO2. The data are derived from a single experiment 
with quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test (p < 0.05) to compare responses in the presence and absence of 
G66976. The horizontal line at a chemotactic index of 1 represents unstimulated basal 
migration and is shown for ease of comparison with stimulated levels. CEM (B) cells 
treated and untreated with G56976 were stimulated with MDC (10 nM) for indicated times 
(C = vehicle), and lysates generated. These lysates were resolved by SDS-PAGE, 
transferred to nitrocellulose membrane, and immunoblotted with anti-phospho ERK 1/2 Ab 
or anti-phospho PKB473 Ab. The blots were stripped and reprobed with the appropriate 
pan-Ab to verify equal loading and efficiency of protein transfer. Results are representative 
of 3 separate experiments.
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Figure 4.31. MDC-induced CEM cell chemotaxis is sensitive to a broad spectrum  
PKC isoform inhibitor. CEM cells (2 x 105 cells/200 pi) were added to the upper wells of 
a reusable MB series 96-well chemotaxis chamber, above lower wells containing 1 nM 
MDC. Cells were preincubated with indicated concentrations of RO-32-0432 for 30 min, 
A, as described in Materials and Methods. Chemotaxis across a 5 pm membrane was 
determined after 1.5 hr incubation at 37°C in 5% CO2. The data are derived from a single 
experiment with quintuplicate replicates that is representative of three other experiments. 
Data are expressed as the mean chemotactic index (± SEM), which is the ratio of cells 
migrating toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by 
ANOVA and Student’s t test with a Bonferroni correction (*, p < 0.00005) to compare 
responses in the presence and absence of RO-32-0432. The horizontal line at a chemotactic 
index of 1 represents unstimulated basal migration and is shown for ease of comparison 
with stimulated levels. CEM (B) cells treated and untreated with RO-32-0432 were 
stimulated with MDC (10 nM) for indicated times (C = vehicle), and lysates generated. 
These lysates were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and 
immunoblotted with anti-phospho ERK 1/2 Ab or anti-phospho PKB473 Ab. The blots were 
stripped and reprobed with the appropriate pan-Ab to verify equal loading and efficiency of 
protein transfer. Results are representative of 3 separate experiments.
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Figure 4.32. Rottlerin pre-treatment inhibits MDC-induced CEM cell chemotaxis.
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Figure 4.32. Rottlerin pre-treatm ent inhibits M DC-induced CEM cell chemotaxis.
CEM cells (2 x 105 cells/200 |nl) were added to the upper wells of a reusable MB series 96- 
well chemotaxis chamber, above lower wells containing 1 nM MDC. A, Cells were 
preincubated with indicated concentrations of rottlerin for 30 min, as described in Materials 
and Methods. Chemotaxis across a 5 pm membrane was determined after 1.5 hr incubation 
at 37°C in 5% CO2. The data are derived from a single experiment with quintuplicate 
replicates that is representative of three other experiments. Data are expressed as the mean 
chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. cells 
randomly migrating (+/- inhibitor). Data were analysed by ANOVA and Student’s t test 
with a Bonferroni correction (*, p < 0.00005; **, p < 0.000005) to compare responses in 
the presence and absence of rottlerin. The horizontal line at a chemotactic index of 1 
represents unstimulated basal migration and is shown for ease of comparison with 
stimulated levels. B, CEM cells treated and untreated with rottlerin were stimulated with 
MDC (10 nM) for indicated times (C = vehicle), and lysates generated. These lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with 
anti-phospho ERK 1/2 Ab or anti-phospho PKB473 Ab. The blots were stripped and 
reprobed with the appropriate pan-Ab to verify equal loading and efficiency of protein 
transfer. C, CEM cell lysates with varying amounts of protein (i.e. cell numbers) were 
additionally immunoblotted for expression of PKC8, with a PKC8 Ab. Results are 
representative of 3 separate experiments.
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Recent attention has focused on the role of Rho GTPase and its downstream effector Rho- 
dependent kinase (ROCK) in chemokine-elicited migration, as it appears to be required for 
CCR7 and CXCR4 T lymphocyte migration in response to CCL19/CCL21 and CXCL12 
respectively (Bardi et al., 2003; Vicente-Manzanares et al., 2002). Pretreatment of CEM 
cells with the ROCK inhibitor Y-27632 markedly inhibited MDC-induced chemotaxis in a 
concentration-dependent manner (fig. 4.33, A). Y-27632 had no effect on the ability of 
MDC to elicit the phosphorylation of ERK1/2 or PKB (fig. 4.33, B ).
ROCK is known to inhibit myosin light chain phosphatase and to directly phosphorylate 
myosin light chain (Raftopoulou and Hall, 2004). Hence, we verified that Y-27632 did 
indeed inhibit the intended ROCK target by monitoring cellular levels of phospho- 
MLC2Ser19 in lysates derived from resting and CCL22-stimulated CEM cells. CCL22 
induced a sustained phosphorylation of MLC over a 30 minute period, which was 
completely attenuated by pre-treatment with Y-27632 (fig. 4.34).
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The Two Protease Inhibitors TLCK and TPCK Abrogate Directed T Cell 
Migration
These two chloromethyl ketones have a broad-spectrum of activity against various serine 
proteases. TLCK and TPCK (effective concentrations of both are 10 -  100 pM) have been 
demonstrated to inhibit NF-kB activation, with subsequent transcription of the iNOS gene, 
and p70s6K activation (Breithaupt et al., 1996; Grammer and Blenis, 1996; Kim et al., 1995; 
Schini-Kerth et al., 1997). NF-kB has been demonstrated to be activated by chemokine 
receptor ligation and, with the use of TLCK/TPCK and SN50 (a peptide inhibitor of NF- 
kB), been shown to be required for optimal migratory responses (Altura and Gebrewold, 
2002; Barna and Kew, 1995; Cherla and Ganju, 2001; Ko et al., 2002; Zernecke et al.,
2001). Studies in various systems have suggested a plethora of mechanisms for the 
activation of the NF-kB pathway, including via PKC8 (Page et al., 2003). Treatment of 
CEM cells with TLCK or TPCK, at various concentrations for 1 hour prior to chemokine 
exposure in a modified Boyden chamber, completely inhibited directed T cell migration in 
a concentration-dependent manner (fig. 4.35, A and B). In addition, both compounds 
inhibited PKB phosphorylation in response to MDC, and TLCK had a slight detrimental 
effect on ERK 1/2 phosphorylation (fig. 4.36). In contrast, TPCK pretreatment of CEM 
cells had no ramifications on chemokine stimulated ERK1/2 phosphorylation but did 
ameliorate basal levels to those of MDC-stimulated intensities at the higher concentrations 
of inhibitor (fig. 4.36). The NOS inhibitor L-NAME has been utilised in a study that 
reported the requirement of NO in CXCL12/CXCR4-mediated Jurkat T cell chemotaxis 
(Cherla and Ganju, 2001). However, L-NAME pretreatment of CEM cells had no 
influence on either MDC-mediated chemotaxis or ERK 1/2 phosphorylation, even at 
concentrations as high as 2 mM (fig. 4.37, A and B).
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So far several inhibitors have demonstrated inhibitory outcomes on both ERK 1/2 and CEM 
cell chemotaxis in response to MDC. However, this gives little indication to the actual 
requirement of ERK1/2 for directed cell migration. MEK1/2 is the upstream activator of 
ERK 1/2 and its only known substrate. A widely used inhibitor of MEK to study ERK 1/2- 
mediated responses is PD98059. PD98059 does not compete for the ATP-binding site of 
MEK or its association with ERK 1/2 but is instead thought to inhibit through an allosteric 
mechanism (Alessi et al., 1995; Dudley et al., 1995). There are conflicting reports for the 
involvement of MEK/ERK in chemokine-mediated cell migration. Published studies have 
attenuated CXCL12-, CCL20-, CCL2-, CCL7-, CCL8-, CCL11- and CCL11-induced actin 
polymerisation and/or cell migration of leukocytes (Sotsios et al., 1999; Sullivan et al., 
1999b; Wain et al., 2002). Whilst other studies have demonstrated that CXCL12-, CXCL1- 
, CCL2- and CXCL11-induced leukocyte chemotaxis does not depend on ERK1/2 
activation (Ashida et al., 2001a; Cherla and Ganju, 2001; Smit et al., 2003; Wang et al., 
2002a). PD98059 treated CEM cells chemotaxed normally to MDC (fig. 4.38, A), whilst 
the same concentration of PD98059, as expected, abolished ERK 1/2 phosphorylation in 
response to MDC in CEM (fig. 4.38, B ), CHOKlhCCR4 (fig. 4.38, C) and T-lymphoblast 
(fig. 4.38, D ) cells. There was no unfavourable impact on PKB phosphorylation in any of 
the cell types tested (fig. 4.38, C and D ).
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Figure 4.33. M DC-induced CEM cell chemotaxis is sensitive to a ROCK inhibitor.
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Figure 4.33. MDC-induced CEM cell chemotaxis is sensitive to a ROCK inhibitor.
CEM cells (2 x 105 cells/200 jul) were added to the upper wells of a reusable MB series 96- 
well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells were 
preincubated with indicated concentrations of Y-27632 for 1 hour, A, as described in 
Materials and Methods. Chemotaxis across a 5 Jim membrane was determined after 1.5 hr 
incubation at 37°C in 5%  CO2. The data are derived from a single experiment with 
quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test with a Bonferroni correction (*, p < 0.0005; **, p < 0.00005; ***, p < 
0.000005) to compare responses in the presence and absence of Y-27632. The horizontal 
line at a chemotactic index of 1 represents unstimulated basal migration and is shown for 
ease of comparison with stimulated levels. CEM (B) cells treated and untreated with Y- 
27632 were stimulated with MDC (10 nM) for indicated times (C = vehicle), and lysates 
generated. These lysates were resolved by SDS-PAGE, transferred to nitrocellulose 
membrane, and immunoblotted with anti-phospho ERK1/2 Ab or anti-phospho PKB473 Ab. 
The blots were stripped and reprobed with the appropriate pan-Ab to verify equal loading 
and efficiency of protein transfer. Results are representative of 3 separate experiments.
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Figure 4.34. MDC phosphorylates M LC2 in CEM cells in a ROCK-dependent 
m anner.
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Figure 4.34. MDC phosphorylates M LC2 in CEM cells in a ROCK-dependent 
manner. Levels of phospho-MLC2 protein were determined by western blot analysis. 
Prior to experimentation, cells were washed three times in appropriate media, and 
resuspended at 4 x 106 cells/ml and serum-starved for 1 hour. Cells were then stimulated at 
37°C with MDC for indicated times (in the presence or absence of 10 pM Y-27632, 60 min 
preincubation), and cells lysed by the addition of 1 x sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with 
a phospho-specific MLC2 Ab with affinity for the Ser 19-phosphorylated form of MLC2, 
and protein was visualised with ECL. Stripping and reprobing blots with anti-p-actin Ab 
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Figure 4.35. Both TLCK and TPCK are able to attenuate CCR4-mediated CEM cell 
chemotaxis. CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a reusable 
MB series 96-well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells 
were preincubated with indicated concentrations of TLCK, A, or TPCK, B, for 1 hour, as 
described in Materials and Methods. Chemotaxis across a 5 pm membrane was determined 
after 1.5 hr incubation at 37°C in 5% CO2. The data are derived from a single experiment 
with quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test with a Bonferroni correction (*, p < 0.05; **, p < 0.005; ***, p < 
0.00005) to compare responses in the presence and absence of TLCK or TPCK. The 
horizontal line at a chemotactic index of 1 represents unstimulated basal migration and is 
shown for ease of comparison with stimulated levels.
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Figure 4.36. M DC-induced PKB but not ERK 1/2 phosphorylation is sensitive to 
TLCK  and TPCK  pre-treatm ent.
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Figure 4.36. M DC-induced PKB but not ERK 1/2 phosphorylation is sensitive to 
TLCK and TPCK  pre-treatm ent. Levels of phospho-PKB or -ERK 1/2 protein were 
determined by western blot analysis. Prior to experimentation, cells were washed three 
times in appropriate media, and resuspended at 4 x 106 cells/ml and serum-starved for 1 
hour. Cells were then stimulated at 37°C with MDC for indicated times (in the presence or 
absence of indicated concentrations of TLCK or TPCK, 60 min preincubation), and cells 
lysed by the addition of 1 x sample buffer. Cell lysates were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes, and immunoblotted with anti-phospho ERK 1/2 Ab 
or anti-phospho PKB473 Ab. The blots were stripped and reprobed with the appropriate 
pan-Ab to verify equal loading and efficiency of protein transfer. Results are representative 
of 3 separate experiments.
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Figure 4.37. NOS is not involved in M DC-mediated CEM  cell chemotaxis. CEM cells 
(2 x 105 cells/200 jil) were added to the upper wells of a reusable MB series 96-well 
chemotaxis chamber, above lower wells containing 1 nM MDC. Cells were preincubated 
with indicated concentrations of L-NAME for 1 hour, A, as described in Materials and 
Methods. Chemotaxis across a 5 |im membrane was determined after 1.5 hr incubation at 
37°C in 5% CO2. The data are derived from a single experiment with quintuplicate 
replicates that is representative of three other experiments. Data are expressed as the mean 
chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. cells 
randomly migrating (+/- inhibitor). Data were analysed by ANOVA and Student’s t test to 
compare responses in the presence and absence of L-NAME (p < 0.05). The horizontal line 
at a chemotactic index of 1 represents unstimulated basal migration and is shown for ease 
of comparison with stimulated levels. CEM (B) cells treated and untreated with L-NAME 
were stimulated with MDC (10 nM) for indicated times (C = vehicle; P = 100 nM PMA 5 
min), and lysates generated. These lysates were resolved by SDS-PAGE, transferred to 
nitrocellulose membrane, and immunoblotted with anti-phospho ERK 1/2 Ab. Results are 
representative of 3 separate experiments.
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Figure 4.38. M EK inhibition has no effect upon M DC-induced CEM cell chemotaxis. 
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Figure 4.38. M EK inhibition has no effect upon M DC-induced CEM cell chemotaxis.
CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a reusable MB series 96- 
well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells were 
preincubated with indicated concentrations of PD98059 for 1 hour, A, as described in 
Materials and Methods. Chemotaxis across a 5 pm membrane was determined after 1.5 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test to compare responses in the presence and absence of PD98059 (p < 
0.05). The horizontal line at a chemotactic index of 1 represents unstimulated basal 
migration and is shown for ease of comparison with stimulated levels. CEM (B), 
CHOKlhCCR4 (C) or T-lymphoblast (D) cells treated and untreated with PD98059 were 
stimulated with MDC (10 nM) for indicated times (C = vehicle; P = 100 nM PMA 5 min; J 
= Jurkat cell lysate sample), and lysates generated. These lysates were resolved by SDS- 
PAGE, transferred to nitrocellulose membrane, and immunoblotted with anti-phospho 
ERK 1/2 Ab or anti-phospho PKB473 Ab. The blots (B) were stripped and reprobed with 
pan-ERKl/2 to verify equal loading and efficiency of protein transfer. Results are 
representative of 3 separate experiments.
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Effect of Various Other Kinase Inhibitors on CCR4-Induced Chemotaxis
A couple of other molecules that have been demonstrated in published papers to be 
required for directed cell migration were also studied in chemotaxis assays, namely JAK2/3 
and p38. JAK2/3 has been shown to be essential for CXCL12-mediated T cell chemotaxis 
by inhibition with 50 pM AG490 (Soriano et al., 2003), yet 100 pM  AG490 had no effect 
on CEM cell chemotaxis in response to MDC (fig. 4.39, A). Likewise, p38 (a MAPK) has 
been implicated in directed cell migration (Adachi et al., 2001; Ashida et al., 2001a; Cara et 
al., 2001), but pretreating CEM cells with SB203580, at a concentration used in the above­
referenced studies and others, had no effect on MDC-mediated T cell chemotaxis (fig. 4.39, 
A). However, both MDC and TARC are able to phosphorylate p38 in CEM cells in a time- 
dependent manner upon chemokine stimulation (fig. 4.39, B).
Th2 Cell Chemotaxis Requires Similar Pathway Activation to CEMs
CEMs are a transformed human leukaemic T cell line that, by definition, is not a 
physiologically normal cell type. As in the first results chapter ( ‘Results I’), human Th2 
cells were generated from PBMCs that were differentiated in vitro into Th2-like cells and 
used in chemotaxis assays to confirm that data obtained with CEM cells were likely to be 
‘normal’ events. MDC- and TARC-mediated Th2 cell chemotaxis was wholly sensitive to 
PTX (fig. 4.40) and U73122 pretreatment (fig. 4.41), but insensitive to 2-APB-mediated 
inhibition of intracellular calcium mobilisation (fig. 4.41). Incidentally, the negative 
analogue of U73122, U73343, had no repercussions on chemotaxis after pretreatment of the 
Th2 cells (fig. 4.41). In addition, 10 pM  RO-32-0432 abolished CCR4-induced Th2 cell 
chemotaxis (fig. 4.42, A), and partially negated MDC-induced PKB phosphorylation in T- 
lymphoblasts (fig. 4.42, B). Both RO-32-04 and rottlerin pretreatment had no detrimental 
influence on ERK1/2 and PKB phosphorylation in response to MDC stimulation in T- 
lymphoblasts, respectively (fig. 4.42, B). The serine protease inhibitors TLCK and TPCK 
had massive ramifications on Th2 cell chemotaxis upon preincubation, with an almost 
complete cessation of any cell movement (fig. 4.43). In contrast, CCR4-mediated Th2 cell 
chemotaxis was refractory to the inhibitory effects of AG490 (JAK2/3) and WHI-P154 
(JAK3) on their target kinases (fig. 4.44). These results correlate very positively with those 
obtained for CEM cells, with little difference in sensitivity to the utilised inhibitors.
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Figure 4.39. Sensitivity of CCR4-mediated CEM  cell chemotaxis to various inhibitors.
CEM cells (2 x 105 cells/200 pi) were added to the upper wells of a reusable MB series 96- 
well chemotaxis chamber, above lower wells containing 1 nM MDC. Cells were 
preincubated with indicated concentrations of AG490 or SB203580 for 1 hour, A , as 
described in Materials and Methods. Chemotaxis across a 5 pm membrane was determined 
after 1.5 hr incubation at 37°C in 5% CO2. The data are derived from a single experiment 
with quintuplicate replicates that is representative of three other experiments. Data are 
expressed as the mean chemotactic index (± SEM), which is the ratio of cells migrating 
toward MDC vs. cells randomly migrating (+/- inhibitor). Data were analysed by ANOVA 
and Student’s t test to compare responses in the presence and absence of inhibitor (p < 
0.05). The horizontal line at a chemotactic index of 1 represents unstimulated basal 
migration and is shown for ease of comparison with stimulated levels. Levels of phospho- 
p38 protein were determined by western blot analysis. CEM cells were washed three times 
in appropriate media, and resuspended at 4 x 106 cells/ml and serum-starved for 1 hour. 
Cells were then stimulated at 37°C with MDC or TARC for indicated times and cells lysed 
by the addition of 1 x sample buffer. Cell lysates were resolved by SDS-PAGE, transferred 
to nitrocellulose membranes, and immunoblotted with anti-phospho p38 Ab, with affinity 
for Thr 180- and Tyr 182-phosphorylated form. Results are representative of 2 separate 
experiments.
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Figure 4.40. MDC- and TARC-mediated Th2 cell chemotaxis is sensitive to pertussis 
toxin pretreatm ent. Th2 cells were generated, as described in Materials and M ethods, 
washed three times in RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Cells 
were preincubated with 100 ng/ml pertussis toxin (PTX) for 16 hours. Cells (1 x 105 
cells/25 pi) were added to the upper wells of a disposable ChemoTx chemotaxis plate, 
above lower wells containing 100 nM MDC or 100 nM TARC, as described in Materials 
and Methods. Chemotaxis across a 5 pm membrane was determined after 1.25 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
triplicate replicates that is representative of three other experiments. Data are expressed as 
the mean chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. 
cells randomly migrating. Data were analysed by ANOVA and Student’s t test with a 
Bonferroni correction to compare responses in the presence and absence of PTX (*, p < 
0.001). The horizontal line at a chemotactic index of 1 represents unstimulated basal 
migration and is shown for ease of comparison with stimulated levels.
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Figure 4.41. CCR4-mediated Th2 cell chemotaxis is PLC-dependent but calcium 
independent. Th2 cells were generated, as described in Materials and Methods, washed 
three times in RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Cells were 
preincubated with U73122, U73343 or 2-APB for 1 hour, at indicated concentrations. Cells 
(1 x 105 cells/25 pi) were added to the upper wells of a disposable ChemoTx chemotaxis 
plate, above lower wells containing 100 nM MDC or 100 nM TARC, as described in 
Materials and Methods. Chemotaxis across a 5 pm membrane was determined after 1.25 
hr incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
triplicate replicates that is representative of three other experiments. Data are expressed as 
the mean chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. 
cells randomly migrating. Data were analysed by ANOVA and Student’s t test with a 
Bonferroni correction to compare responses in the presence and absence of inhibitor (*, p < 
0.005; **, p < 0.0005). The horizontal line at a chemotactic index of 1 represents 
unstimulated basal migration and is shown for ease of comparison with stimulated levels.
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Figure 4.42. CCR4-mediated Th2 cell chemotaxis is sensitive to the inhibition of PKC 
isoforms.
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Figure 4.42. CCR4-mediated Th2 cell chemotaxis is sensitive to the inhibition of PKC 
isoforms. Th2 cells were generated, as described in Materials and Methods, washed three 
times in RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Cells were 
preincubated with 10 pM RO-32-0432 for 30 min. Cells (1 x 105 cells/25 pi) were added to 
the upper wells of a disposable ChemoTx chemotaxis plate, above lower wells containing 
100 nM MDC or 100 nM TARC, as described in Materials and Methods. Chemotaxis 
across a 5 pm membrane was determined after 1.25 hr incubation at 37°C in 5% CO2. The 
data are derived from a single experiment with triplicate replicates that is representative of 
three other experiments. Data are expressed as the mean chemotactic index (± SEM), 
which is the ratio of cells migrating toward MDC vs. cells randomly migrating. Data were 
analysed by ANOVA and Student’s t test with a Bonferroni correction to compare 
responses in the presence and absence of RO-32-0432 (*, p < 0.005; **, p < 0.0005). The 
horizontal line at a chemotactic index of 1 represents unstimulated basal migration and is 
shown for ease of comparison with stimulated levels. Levels of ERK1/2 and PKB 
phosphorylation in T-lymphoblasts were carried out by Western blot analysis. T- 
lymphoblasts (day 12-13) were washed three times in RPMI, and resuspended at 5 x 106 
cells/ml and serum-starved for 1 hour. Cells were then stimulated at 37°C with MDC or for 
indicated times, in the presence or absence of RO-32-0432 or 10 pM Rottlerin (30 min 
preincubation), and cells lysed by the addition of 1 x sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with 
anti-phospho ERK1/2 Ab or anti-phospho PKB473 Ab. The blots (B) were stripped and 
reprobed with pan-PKB to verify equal loading and efficiency of protein transfer. Results 
are representative of at least 2 separate experiments.
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Figure 4.43. Both TLCK and TPCK are able to attenuate CCR4-mediated CEM  cell 
chemotaxis. Th2 cells were generated, as described in Materials and Methods, washed 
three times in RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Cells were 
preincubated with TLCK or TPCK for 1 hour, at indicated concentrations. Cells (1 x 105 
cells/25 pi) were added to the upper wells of a disposable ChemoTx chemotaxis plate, 
above lower wells containing 100 nM MDC or 100 nM TARC, as described in Materials 
and Methods. Chemotaxis across a 5 pm membrane was determined after 1.25 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
triplicate replicates that is representative of two other experiments. Data are expressed as 
the mean chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. 
cells randomly migrating. Data were analysed by ANOVA and Student’s t test with a 
Bonferroni correction to compare responses in the presence and absence of inhibitor (*, p < 
0.0005). The horizontal line at a chemotactic index of 1 represents unstimulated basal 
migration and is shown for ease of comparison with stimulated levels.
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Figure 4.44. JAK activity is not required for CCR4-mediated Th2 cell chemotaxis.
Th2 cells were generated, as described in Materials and Methods, washed three times in 
RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 37°. Cells were preincubated 
with AG490 or WHI-P154 for 1 hour, at indicated concentrations. Cells (1 x 105 cells/25 
pi) were added to the upper wells of a disposable ChemoTx chemotaxis plate, above lower 
wells containing 100 nM MDC or 100 nM TARC, as described in M aterials and Methods. 
Chemotaxis across a 5 pm membrane was determined after 1.25 hr incubation at 37°C in 
5% CO2. The data are derived from a single experiment with triplicate replicates that is 
representative of three other experiments. Data are expressed as the mean chemotactic 
index (± SEM), which is the ratio of cells migrating toward MDC vs. cells randomly 
migrating. Data were analysed by ANOVA and Student’s t test with a Bonferroni 
correction to compare responses in the presence and absence of inhibitor (p < 0.05). The 
horizontal line at a chemotactic index of 1 represents unstimulated basal migration and is 
shown for ease of comparison with stimulated levels.
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Anti-Human MDC Treatment Potentiates MDC-mediated Th2 Cell 
Chemotaxis
The finding that pretreating Th2 cells with 10 pg/ml anti-human MDC Ab actually 
increased MDC-mediated chemotaxis was serendipitous (fig. 4.45). It was initially thought 
that the Ab being used was an anti-CCR4 Ab, being utilised to demonstrate that the TARC- 
and MDC-induced Th2 chemotactic responses were being mediated via CCR4. However, 
the alarming results of a 100% increase in chemotaxis for MDC, yet no effect on TARC 
responses, in the presence of anti-hMDC Ab soon led to the correct identity of the Ab.
MDC Stimulates the Phosphorylation of PYK2
PYK2 is a non-receptor tyrosine kinase structurally related to focal adhesion kinase (FAK) 
and largely has restricted expression to cells derived from the haematopoietic lineages 
(Avraham et al., 2000; Gelman, 2003). CXCL8, CCR5 and CXCR4 have demonstrated 
phosphorylation of PYK2 in response to their respective chemokine ligands and this 
tyrosine kinase has been implicated in having an important role to play in a cells ability to 
migrate (Davis et al., 1997; Di, V et al., 2004; Dikic et al., 1998; Femandis et al., 2004; 
Ganju et al., 1998b; Ganju et al., 1998a). MDC stimulated the exceptionally rapid and 
transient tyrosine phosphorylation of PYK2, with phosphorylation occurring within and up 
to 1 minute post-stimulation (fig. 4.46, A). This phosphorylation was insensitive to PI3K, 
MEK and PKC inhibition (4.46, B).
MDC Induces the Phosphorylation of Both GSK-3a/p and p90RSK
The serine/threonine kinase p90RSK is widely expressed and activated by ERK1/2, PDK-1 
and PKC, with roles in cell cycle regulation, GSK-3 phosphorylation and regulation of gene 
expression via effects on transcriptional regulators such as NF-kB (Frodin and Gammeltoft, 
1999; Jensen et al., 1999). Two papers have confirmed p90RSK phosphorylation can be 
stimulated by chemokines, namely CXCL12 and CCL5 (Lee et al., 2002; Zhang et al.,
2002). MDC stimulated the phosphorylation of p90RSK, with kinetics similar to that of
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ERK1/2 phosphorylation ( 2 - 5  min), in CH OKlhCCR4 cells that was sensitive to PTX 
pretreatment (fig. 4.47, A).
GSK-3 is a multifunctional serine/threonine kinase involved in many different pathways 
and initially identified as an enzyme that regulates glycogen synthesis downstream of PKB 
(Doble and Woodgett, 2003; Frame and Cohen, 2001; Harwood and Braga, 2003; 
Harwood, 2001). However, only a single study has determined GSK-3 phosphorylation 
occurs downstream of a chemokine receptor, CXCL12/CXCR4 in a neuronal cell line 
(Chalasani et al., 2003). A recent study has suggested a role for GSK-3 in migration of 
astrocytes and has been implicated in controlling lamellipodia formation in keratinocytes 
(Etienne-Manneville and Hall, 2001; Koivisto et al., 2003). MDC stimulated the 
LY294002- and RO-32-0432-sensitive phosphorylation of G SK -3a/p in T-lymphoblasts 
(fig. 4.47, B). PD98059 had no noticeable impact on this phosphorylation and LY294002 
did not completely diminish the GSK-3 response (fig. 4.47, B ).
Relocalisation of Amo-GFP in Response to MDC Stimulation
Amo (ARF nucleotide-binding-site opener) is a guanine-nucleotide exchange factor (GEF) 
for both ARF1 (ADP-ribosylation factor 1) and ARF6 in vitro, but specificity in vivo is 
likely to be more constrained to ARF6 (Macia et al., 2001; Turner and Brown, 2001). 
ARF6 targets include PLD and R acl, with implicated roles in diapedesis of leukocytes, 
epithelial cell migration and receptor recycling (Claing et al., 2001; Donaldson, 2003; 
Powner and Wakelam, 2002; Santy and Casanova, 2001; Weber et al., 2001). The HUT-78 
leukaemic T cell line (used because it is easier to transfect than CEMs) was transiently 
transfected with GFP-labelled Amo and stimulated with 10 nM MDC for time points up to 
2 minutes. Reactions were stopped and cells fixed for analysis using a confocal 
microscope. Unstimulated cells displayed a punctate cytosolic localisation of Amo-GFP 
that, upon stimulation with MDC, became distinctly membrane localised at 1 min before 




MDC and TARC Stimulate the Phosphorylation of UPE
CEM cells were stimulated with MDC and TARC over a time-course and cell lysates were 
generated for Western blot analysis. The blots were then immunoblotted for 
phosphorylated levels of a protein called FKHR (Forkhead in Rhabdomyosarcoma), a 
transcription factor activated downstream of PKB and involved in cell survival and 
regulation of the cell cycle. However, phospho-FKHR (MW 75 kDa; specific fo Ser 256 
phosphorylation) could not be consistently detected but instead an additional band at 
approximately 200 kDa was identified (fig. 4.49, A). This presence of this unidentified 
protein (termed ‘Unidentified Phosphorylated Entity’ or UPE) appears to be activation- 
induced and possibly shows phosphorylation between 5 and 10 minutes post-CCR4 
ligation. This UPE phosphorylation was sensitive to PTX pretreatment of the CEM cells 
for both MDC and TARC-mediated responses (fig. 4.49, B).
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Figure 4.45. 50% increase in MDC-induced Th2 cell chemotaxis on p retreatm ent of 
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Figure 4.45. 50% increase in M DC-induced Th2 cell chemotaxis on pretreatm ent of 
the cells with an anti-hM DC Ab. Th2 cells were generated, as described in M aterials and 
Methods, washed three times in RPMI, and resuspended in RPMI/0.1% BSA for 1 hour at 
37°. Cells were preincubated with 10 pg/ml anti-hMDC Ab for 1 hour. Cells (1 x 105 
cells/25 pi) were added to the upper wells of a disposable ChemoTx chemotaxis plate, 
above lower wells containing 100 nM MDC or 100 nM TARC, as described in M aterials 
and Methods. Chemotaxis across a 5 pm membrane was determined after 1.25 hr 
incubation at 37°C in 5% CO2. The data are derived from a single experiment with 
triplicate replicates that is representative of three other experiments. Data are expressed as 
the mean chemotactic index (± SEM), which is the ratio of cells migrating toward MDC vs. 
cells randomly migrating. Data were analysed by ANOVA and Student’s t test with a 
Bonferroni correction to compare responses in the presence and absence of anti-hMDC Ab 
(*, p < 0.001). The horizontal line at a chemotactic index of 1 represents unstimulated 
basal migration and is shown for ease of comparison with stimulated levels.
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Figure 4.46. CCR4 ligation with MDC leads to the phosphorylation of PYK2 in HUT-
78 cells.
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Figure 4.46. CCR4 ligation with MDC leads to the phosphorylation of PYK2 in HUT- 
78 cells. Levels of phospho-PYK2 protein were determined by western blot analysis. Prior 
to experimentation, cells were washed three times in appropriate media, and resuspended at 
4 x 106 cells/ml and serum-starved for 1 hour. Cells were then stimulated at 37°C with 
MDC or 10 pg/ml UCHT-1 (anti-CD3 Ab) for indicated times, A, and in the presence of 
indicated concentrations of LY294002 (30 min preincubation), PD98059 (60 min 
preincubation) or RO-32-0432 (30 min preincubation), B , and cells lysed by the addition of 
500 pi ice-cold lysis buffer. PYK2 was then immunoprecipitated out by the addition of 3 
pg/ml PYK2 Ab for 2 hours, followed by 20 pi of a 50:50 protein G slurry for 1 hour. 
Pelleted beads were then resuspended in 15 pi 2 x sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with 
anti-phospho tyrosine Ab (4G10 clone). Results are representative of at least 2 separate 
experiments (C = vehicle).
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Figure 4.47. CCR4 ligation leads to the phosphorylation of both GSK-3 and p90RSK
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Figure 4.47. CCR4 ligation leads to the phosphorylation of both GSK-3 and p90RSK.
Levels of phospho-GSK-3 or -p90RSK protein were determined by western blot analysis. 
Prior to experimentation, cells were washed three times in appropriate media, and 
resuspended at 5 x 106 cells/ml and serum-starved for 1 hour. CHOKlhCCR4, A, or T- 
lymphoblasts, B, were then stimulated at 37°C with MDC for indicated times (in the 
presence or absence of indicated concentrations of LY294002, RO-32-0432 (both 30 min 
preincubation), PD98059 (60 min preincubation), or pertussis toxin (PTX, 16 hour 
preincubation) and cells lysed by the addition of 1 x sample buffer. Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with 
anti-phospho GSK-3cx/p Ab, with affinity for Ser 21 (of a ) and Ser 9 (of p) phosphorylated 
forms, or anti-phospho p90RSK Ab, with affinity for Ser 380-phosphorylated form. Results 
are representative of at least 2 separate experiments (C = vehicle; P = 100 nM PMA 5 min).
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Figure 4.48. Localisation of A rno-GFP to the plasma m em brane in HUT-78 cells 
upon stim ulation with MDC.
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Figure 4.48. Localisation of Arno-GFP to the plasma m em brane in HUT-78 cells 
upon stim ulation with MDC. HUT-78 cells were transiently transfected with Amo-GFP 
and stimulated in a time-dependent manner with 10 nM MDC, with cells fixed in 
paraformaldehyde/glutaraldehyde. Images of the cells were obtained by confocal 
microscopy. Areas of green indicate localisation of Arno-GFP. Data are from a single 
experiment and representative of 2 separate experiments.
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Figure 4.49. CCR4-ligation on CEM cells leads to the pertussis toxin-sensitive 
phosphorylation of UPE.
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Figure 4.49. CCR4-ligation on CEM  cells leads to the pertussis toxin-sensitive 
phosphorylation of UPE. Levels of phospho-‘Unidentified Phosphorylated Entity’ were 
determined by western blot analysis. Prior to experimentation, CEM cells were washed 
three times in appropriate media, and resuspended at 5 x 106 cells/ml and serum-starved for 
1 hour. Cells were then stimulated at 37°C with MDC or TARC, A, for indicated times and 
in the presence or absence of 100 ng/ml pertussis toxin (PTX, 16 hour preincubation), B, 
and cells lysed by the addition of 1 x sample buffer. Cell lysates were resolved by SDS- 
PAGE, transferred to nitrocellulose membranes, and immunoblotted with anti-phospho 
FKHR Ab, with affinity for the Ser 256-phosphorylated form of FKHR. Results are 




•  CCR4-ligation leads to intracellular calcium mobilisation in CHOKlhCCR4, CEM 
and Th2 cells.
•  This calcium mobilisation requires G ai and PLC activity, and IP3R calcium stores. 
Other sources of calcium, both intracellular and extracellular appear to contribute little 
towards this CCR4-induced calcium response.
•  JAKs and PI3K have no significant role in these calcium responses, whilst caffeine 
has the ability to potentiate calcium flux. PKC activity has an unfavourable effect on 
calcium mobilisation.
•  Th2 cells display similar responses as to those observed in CEM cells regarding 
intracellular calcium mobilisation and sensitivities towards pharmacological inhibitors.
•  MDC and TARC stimulate the phosphorylation of ERK1/2 in a concentration- and 
time-dependent manner. With kinetics more rapid in the T cells than in 
CHOKlhCCR4.
•  PKB and ERK phosphorylation, along with MDC-mediated CEM cell chemotaxis is 
PTX sensitive.
• Directed CEM cell migration induced by MDC is sensitive to PLC inhibition but 
refractory to the abolition of intracellular calcium mobilisation. ERK1/2 
phosphorylation is partially sensitive to U73122 treatment.
• Classical PKC isoform inhibition has no impact on CCR4-mediated chemotaxis but 
broad-spectrum and PKC8 inhibitors have a severe detrimental response.
•  MDC stimulates MLC2 phosphorylation, and abrogation of this effect with a ROCK 
inhibitor attenuates chemotaxis.
•  TLCK and TPCK have harmful effect on PKB phosphorylation and chemotaxis in 
response to MDC stimulation. However, NOS, MEK/ERK, JAK and p38 appear to be 
redundant for CCR4-mediated CEM cell chemotaxis.
•  Data from Th2 cell migration in response to MDC correlated exceptionally well with 
data obtained from CEM cells.
214
<'cRcsuhsll
• Anti-human MDC Ab potentiates Th2 cell migration in response to MDC but not 
TARC.
• CCR4 ligation leads to the phosphorylation of PYK2, GSK-3ot/(3 and p90RSK.
• MDC stimulates the membrane localisation of Amo-GFP in HUT-78 cells and the 




CCR4-Mediated Intracellular Calcium Mobilisation
The rise in intracellular calcium represents a common activation pathway upon triggering 
cells with chemokine ligands. However, the mechanisms that lead to this release of 
calcium are poorly understood. There have been a number of advances in the last few years 
within the calcium field itself, with the discovery of sphingosine-, NAADP- and cADPR- 
mediated calcium release mechanisms, and it appears that these pathways are able to 
overlap considerably with the more established IP3R, RR and extracellular influx routes. 
This has led to many complex models being proposed on how the various mechanisms may 
be intertwined based on studies performed in a variety of systems. In contrast, chemokine- 
induced calcium mobilisation is largely used as an indicator of agonistic activity for 
chemokines upon exposure to various cell types, with very little interest/research into the 
underlying mechanisms. Unsurprisingly, the results presented within demonstrated the 
rapid and transient mobilisation of calcium in CHOKlhCCR4, CEM and Th2 cells in 
response to CCR4 ligation. MDC and TARC have previously been shown to instigate a 
calcium flux in Th2 cells (Andrew et al., 1998; D'Ambrosio et al., 1998), NK cells 
(Inngjerdingen et al., 2000), and various CCR4 transfected cell lines (Imai et al., 1997; Imai 
et al., 1998). The kinetics for these studies varies from 30 seconds up to -100  seconds for 
the span of time that the calcium concentration is above resting levels. The Th2 studies 
cited above, however, are very comparable to the results presented here for both CEM and 
Th2 cell calcium responses (about 90 seconds). The more rapid ‘on-off calcium responses 
observed for CHOKlhCCR4 cells is possibly due to the differences in technique employed 
and to cell type. MDC was consistently more effective than TARC in eliciting calcium 
mobilisation and this is consistent with their respective abilities in 
phosphorylating/activating other signalling mediators, such as PKB and ERK.
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Figure 4.50. Schematic showing the potential chem okine-activated calcium mobilising 
pathways. Note that not all possible pathways are displayed in order to minimize the 
complexity. Other pathways include the sphingosine-1-phosphate cascade that has been 
demonstrated to be activated downstream of GPCRs. Abbreviations not defined in text: 
ARC, ADP-ribosyl cyclases.
As is the case for the vast majority of chemokine-mediated responses, PTX treatment had 
the effect of abolishing the chemokine-mediated calcium flux in both CEM and Th2 cells, 
indicating that CCR4 is coupled to the Gai protein (Schorr et al., 1999). Although PTX 
fails to distinguish between ai- and Py-stimulated pathways, it is likely that the py subunits 
are responsible for eliciting the calcium response observed with MDC and TARC. The 
PLC inhibitor U73122 completely attenuated the CCR4-mediated calcium response but ai 
has never been shown to couple to PLCp, whereas the py subunits are known to be capable 
of stimulating the PLCp2 and p3 isoforms that are activated by chemokine receptors (Jiang 
et al., 1997; Li et al., 2000; Rhee and Bae, 1997; Wing et al., 2001; Wu et al., 1993).
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Where investigated, it is evident that the majority of chemokine-mediated calcium 
responses are wholly-sensitive to PLC inhibition, thereby indicating a requirement for IP3- 
mediated calcium release (Maghazachi, 1997; Scandella et al., 2003; Schorr et al., 1999; 
Soriano et al., 2003). However, this inhibition does not confirm that IP3R calcium stores 
are the sole contributors to the calcium response, and merely that they are essential for the 
instigation of a calcium flux. Figure 4.50 is a simplified diagram of some of the 
interactions that occur between the different calcium pools.
Role of cADPR-Mediated Calcium Mobilisation
Indeed, it has been demonstrated that CXCL12 may utilise the cADPR pathway in NK cells 
in addition to the IP3R cascade, and the same study suggested that MDC- (and CXCL8) 
mediated intracellular calcium mobilisation was solely via the cADPR pathway and that the 
IP3R pools contributed very little to the overall calcium response (Inngjerdingen et al., 
1999). Treating the cells with an anti-RR Ab abolished this MDC-mediated calcium flux 
suggesting that cADPR is acting via the RR stores, as would be expected. The mechanism 
surrounding cADPR-mediated responses are still very unclear. It is known that cADPR 
represents more of a modulator rather than a messenger as its introduction into a cell will 
normally have no immediate effect, suggesting that it functions by increasing the sensitivity 
of RRs to rises in calcium, propagating a CICR effect (Cui et al., 1999; Empson and 
Galione, 1997; Hashii et al., 2000). How cADPR does this is unknown. One proposal is 
that it binds directly to RRs and stimulates calcium release, although cADPR appears not to 
bind directly to the RR and likely functions through an intermediary protein, such as the 
FKBP12.6 (FK506-binding protein 12.6) that does associate with RRs (Lee, 1997; Noguchi 
et al., 1997). Another recent suggestion is that it activates the SERCA pump thereby 
enhancing the calcium load within the ER lumen -  a process that is known to increase the 
sensitivity of RRs (Koizumi et al., 1999; Lukyanenko et al., 2001). In contrast to the 
Inngjerdingen et al. study, inhibition of the cADPR pathway and RRs had no appreciable 
effect on CCR4-mediated calcium release in CEM cells. This maybe down to differences 
in cell type utilised between the two studies. Inngjerdingen et al. showed that there was a 
relatively large delay (~ 30 sec) between the addition of MDC and the mobilisation of 
calcium. This is in contrast to other studies, in various cell types, observing CCR4-
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mediated calcium mobilisation that show an immediate effect of the ligand in producing a 
calcium flux. The technique employed by Inngjerdingen also required the permeabilisation 
of the cells in order to treat with various inhibitory tools and this may have had negative 
consequences upon the signalling mechanisms. The same group suggest that the 
stimulation of this pathway is via the G as protein (not a i) (Maghazachi, 2000). This is 
clearly contradictory to the results presented within this thesis. However, a recent paper 
has suggested a role of CD38, an ADP-ribosyl cyclase, in chemokine-stimulated DC 
calcium mobilisation and chemotaxis (Partida-Sanchez et al., 2004).
NAADP Does not appear to Contribute to CCR4-Induced Calcium Responses
In contrast to IP3Rs and RRs, the NAADP release mechanism is not sensitive to calcium 
and therefore does not support CICR. To date, there have been no studies into the role of 
this pathway in chemokine-mediated calcium mobilisation. This is likely due to the fact 
that there is a distinct lack of tools to investigate this pathway. The pharmacological 
inhibitors that do exist are not specific to the NAADPR, and all were developed, and are 
effective, as L-type calcium channel inhibitors (Patel et al., 2001). It is proposed that 
NAADP may function to sensitise the IP3Rs and RRs by providing a small amount of 
calcium that triggers the receptors, or by releasing a bolus of calcium that is taken up by 
other stores in the lumen and sensitises the IP3R/RRs this way (Berridge et al., 2003). 
Nifedipine, an L-type calcium channel blocker, has been proven to inhibit NAADP- 
mediated calcium release but had no effect on MDC- or TARC-induced calcium responses 
(Yusufi et al., 2002). This suggests there is no role of this cascade in the response, which is 
further backed up by the complete inhibition observed with 2-APB and U73122, which 
would not be expected if NAADP were contributing to the calcium flux as it appears to not 
lie downstream of the IP3 cascade but parallel.
RR Involvement Downstream o f Ligated CCR4
Inhibition of RRs with dantrolene and inhibitory concentrations of ryanodine had no impact 
on CCR4-mediated CEM cell calcium mobilisation. However, caffeine surprisingly 
potentiated the CCR4-stimulated calcium mobilisation whilst having no effect on its own.
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The RR possesses calcium-binding high-affinity activation and low-affinity inhibition sites 
with competition between the two. A full-blown calcium release by caffeine requires a 
small calcium release, initiated by caffeine itself, which then acts on RRs triggering a large 
calcium release (Islam, 2002). The second step of this can be inhibited if the initial small 
rise in calcium is mopped up by calcium-binding proteins, such as calreticulin and 
calsequestrin, that are abundant in leukocytes (Pettit and Fay, 1998). Because caffeine was 
incubated with the cells for 30 min prior to analysis it is likely that any calcium response 
generated upon initial exposure to caffeine had been adequately buffered so as not to 
display high basal levels of cytosolic calcium, but caffeine was unable to stimulate the 
realease of calcium when it was added during analysis. Caffeine may still have been 
having the effect of increasing the calcium affinity of the calcium activation site of RR so 
that the calcium released by IP3R stores is activating the RRs and subsequently amplifying 
the CCR4-mediated calcium response. This would also explain the ability of ryanodine in 
inhibiting this effect with no ramifications on the non-caffeine influenced response.
Role of JAKs, PI3K and PKC in Intracellular Calcium Mobilisation
A couple o f groups have published a number o f papers implicating a role of the Janus 
kinases in chemokine-mediated signal transduction. The JAKs are a well-known signalling 
intermediary in cytokine-induced signal transduction; however, their role in chemokine 
signalling is controversial. It has been postulated that JAKs lie upstream of everything in 
the signal cascade elicited by chemokines, and that by inhibiting JAKs, by definition, 
activation of all other pathways are similarly inhibited (Mellado et al., 1998; Rodriguez- 
Frade et al., 1999a; Soriano et al., 2003). These studies demonstrate abrogation of JAK- 
activated downstream effectors with 50 (iM AG490. Published studies have focused 
mainly on CCR2-, CCR5- and CXCR4-mediated responses in monocytes and T cells, 
respectively. However, even at 100 jiM, pretreatment of CEM or Th2 cells with AG490 
was far from abolishing the CCR4-mediated calcium flux, whilst JAK3 inhibition (also 
implicated in some studies) alone had no effect whatsoever. This was also the case for 
CCR8 T cell migration and calcium flux (Wain and Ward, unpublished data). Additionally, 
another study has refuted a role for JAKs in CXCR4-mediated signalling (Majka et al., 
2000a). Thelen and Baggiolini (Thelen and Baggiolini, 2001) proposed a number of
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reasons why receptor dimerization and the JAK-STAT pathway are unlikely to be 
functionally relevant for chemokine receptors. One o f the more appealing arguments 
against involvement of the JAK-STAT pathway are the kinetics of calcium mobilisation. 
Chemokines initiate a calcium response within 1 sec of their addition to the cellular 
environment, but cytokines have a 20 -  30 sec delay. This is likely due to the time required 
for receptor oligomerisation to occur (involving plasma membrane movement) and then 
subsequent activation of JAKs, G-proteins and PLC isoforms, etc. Therefore, it would be 
expected that if chemokines were utilising this JAK mechanism that the kinetics for 
calcium mobilisation would be more delayed than previously shown, which is not the case. 
Additionally, the vast majority of calcium responses are PTX-dependent, and with respect 
to certain receptors, such as CCR4, all responses investigated have been demonstrated to be 
PTX sensitive. There seems little benefit from having an additional signalling entity that 
solely recruits PTX-sensitive G-proteins. It has been suggested by Mellado et al. that 
combination of chemokines (i.e. CCL2/CCR2 and CCL5/CCR5) switch the calcium flux 
response from PTX-sensitive to insensitive. Indeed, in many disease situations there are 
multiple chemokines released at a similar time and this may present a more plausible 
explanation for the need of receptor dimerization-mediated JAK signalling. Differences in 
the requirement for JAKs may be explained in part by the use of different cell types with 
most of the CXCR4 T cell work done in MOLT-4 cells (a human acute T lymphoblastoid 
leukaemia cell line). However, all migratory events to date have been sensitive to PTX 
treatment, indicating that any PTX-insensitive events are superfluous for chemotaxis. This 
area needs to be more intensely investigated by more groups (currently 3 groups have 
produced the vast majority of the published work, with only -10  primary papers published 
in this area in total) before a more balanced judgement can be formulated. The use of 
phospho-specific Abs against JAKs will help to determine if they are downstream of CCR4.
PI3K has been shown to be pivotal in the CX3CR1-mediated calcium response in 
transfected CHO cells, with wortmannin and LY294002 completely attenuating any 
CX3CL1-induced calcium response, whilst PLC inhibition had no effect (Kansra et al., 
2001). This is thought to occur through an unknown receptor-operated channel. PI3K is 
known to have an excitatory role on L- and N-type calcium channels (voltage-operated 
calcium channels) via the py subunits, but blockade of these channels had no effect on the
221
discussion tt
influx of calcium (Blair and Marshall, 1997; Viard et al., 1999). Besides, leukocytes are 
not excitatory cells and thus not voltage-activated, therefore discounting any effect of N- or 
L-type calcium channels in a chemokine-mediated calcium response in T cells. This is 
confirmed with the lack of effect of nifedipine (an L-type channel blocker) on CCR4- 
induced CEM cell calcium mobilisation. It is generally considered that calcium influx 
pathways contribute little, if at all, to the immediate chemokine-mediated calcium 
responses, but calcium release-activated calcium current (CRAC) channels may have a part 
to play in sustaining an elevated calcium level (Schondorf et al., 1993; Schorr et al., 1999). 
These channels are activated due to intracellular calcium store depletion in response to, for 
example, IP3 activity on IP3R (these channels are also called store-operated channels 
(SOCs)). Some of these SOCs (along with some ROCs and other channel types) form part 
of the transient receptor potential (TRP) gene superfamily of calcium permeable cation 
channels and thought to be the most promising molecular candidates for the otherwise 
unknown leukocyte calcium influx channels (Li et al., 2002). These TRP channels have 
been demonstrated to be activated by DAG in addition to PI3K and other mediators 
(Gamberucci et al., 2002). However, PMA treatment had a detrimental impact on calcium 
responses initiated by MDC or TARC in CEM cells and LY294002 treatment had no 
influence on calcium flux. In addition, the inhibition of PKC increased the intracellular 
mobilisation of calcium further opposing the possibility of TRP channel activity in CCR4- 
stimulated calcium responses in T cells. It is highly likely that this effect of PKC on 
calcium response is due to effects on receptor internalisation (Guinamard et al., 1999; 
Schondorf et al., 1993). It has been demonstrated that phorbol esters stimulate the 
phosphorylation o f CXCR4 and that this leads to the rapid internalisation of the receptor 
that can be blocked by PKC inhibitors (Haribabu et al., 1997; Signoret et al., 1997). The 
potentiation in calcium response observed with PKC inhibitors on MDC/TARC-responses 
is likely due to the inhibition of ligand-dependent phosphorylation of CCR4 leading to 
internalisation via the activation of PKC. However, experiments need to be conducted to 
confirm the downregulation of CCR4-receptor expression in response to PMA and 
MDC/TARC and the reversal of this phenomenon with PKC inhibitors.
Overall, the MDC- or TARC-mediated calcium response is a reasonably rapid ‘on-off 
affair, suggesting that there is little, if  any, role of a calcium influx mechanism in a CCR4-
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induced calcium flux in T cells. It would appear that the majority of the response is 
mediated via IP3R stores, with no contribution from other intracellular calcium release 
mechanisms. However, more thorough investigations into the role of TRPs, and other 
influx channels, needs to be conducted for chemokine-elicited calcium responses to be able 
to draw more conclusive deductions about the role of calcium influx pathways.
CCR4-Induced T Cell Migration
How a Cell Crawls
Extracellular matrix
Focal adhesions





5. Deadhesion of Focal Contacts in Uropod. 
Cell Body Shortening
Figure 4.51. Model of cell locomotion. 1). A resting cell detects a chemoattractant 
gradient and becomes activated. 2). The cell protrudes a lamellipod towards the source of 
the chemokine. 3). New focal contacts (mediated by integrins) are formed under the 
extended lamellipod. 4). The cell exerts force on the cytoskeleton via contraction 
(direction of force is displayed by red and pink arrows). 5). The old focal contacts at the 
rear of the cell detach under the exerted force, resulting in net translocation of the cell.
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Cell locomotion can be considered as a process that involves 5 steps, with the overall 
process appearing as a crawling movement. This process requires cycles of actin 
polymerisation and depolymerisation. Upon a resting cell being stimulated by a 
chemokine, the signal generated leads to the amplification of barbed ends of actin (known 
as microspikes or filopodia) that elongate to form filaments (lamellipodia) that can protrude 
many micrometres long from the cell body at the leading edge. This protruding edge then 
adheres to the substratum (extracellular matrix) via focal complexes, followed by 
development of contractile force on the cytoskeleton due to the contraction of the 
cytoplasmic actomyosin. The old focal contacts at the trailing edge (uropod) of the cell 
detach, resulting in the cell’s net translocation (fig. 4.51). In general, cdc42 regulates 
filopodia, Rac is required for lamellipodia formation and Rho is involved in the control of 
cell contraction. However, the identification of the pathways that lie upstream and 
downstream of these small GTPases, and any cross talk that occurs between them, are 
largely unknown and appear to vary greatly depending on the experimental system. This 
section will try to identify signalling mediators and propose pathways that may be required 
for CCR4-induced T cell chemotaxis.
Calcium Mobilisation is not required for CCR4-Mediated T Cell Chemotaxis
As has previously been discussed, the vast majority of chemokine-mediated events are 
PTX-sensitive, with all investigated migratory events sensitive. CCR4-mediated actions 
produced no surprises in this area with ERK1/2, PKB, p90RSK and UPE phosphorylation 
dependent upon G ai coupling to CCR4, in addition to CEM and Th2 cell chemotaxis.
There have been many roles for calcium in cell motility and polarity proposed, from the 
regulation of actin-binding proteins to the stimulation o f myosin II-based contraction 
(Stossel, 1993). MLCK activates myosin II, which provides the force necessary for 
lamellipod extension and uropod retraction, and calcium/CaM binding directly activates 
MLCK. Although chemokines have been demonstrated to mobilise calcium, the 
requirement of a measurable calcium flux for chemokine-mediated cell migration remains 
ambiguous. It seems likely that the need for calcium mobilisation for migration is 
dependent upon the type of cell and stimulating chemokine. In the giant newt eosinophil
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and Dictyostelium cells, upon stimulation there is an initial calcium release from the central 
store caused by IP3, followed by a fall in calcium concentration in the part o f the cell 
nearest the chemoattractant source. This generates a small calcium gradient and probably 
contributes towards the cell’s polarisation (Brundage et al., 1991; Brundage et al., 1993; 
Gilbert et al., 1994; Yumura et al., 1996). A similar gradient in the distribution of 
calcium/CaM has also been demonstrated in the fibroblast (Hahn et al., 1992). A 
measurable calcium gradient has been difficult to demonstrate or is absent in smaller cell 
types such as human neutrophils (Laffafian and Hallett, 1995). However, some studies 
report that transient increases in calcium mobilisation are required for chemotaxis in these 
cell types, such as CXCR4- (haemopoietic stem cells) and CCR7- (DCs) mediated 
migration (Henschler et al., 2003; Scandella et al., 2003). Whilst other studies suggest that 
chemotaxis does not rely upon a calcium flux, such as CCR2 in monocytes (Turner et al.,
1995). Indeed, calcium mobilisation appears to be inconsequential for CCR4-mediated T 
cell chemotaxis, as results demonstrate in this thesis with the lack of effect o f 2-APB on 
migration, yet the compound inhibits calcium flux. Although MLCK can be activated by a 
calcium/CaM-dependent mechanism, its activation has also been demonstrated to occur via 
the Rho-ROCK pathway (Vicente-Manzanares et al., 2002).
Roles of PKC and ROCK for Directed T Cell Migration in Response to CCR4 Ligands
Cell migration is a complex process with multiple signalling pathways likely to be required 
for a cell to assume a characteristic polarised morphology, extend membrane processes 
(lamellipodia) at the leading edge of the cell, and then pull the rear of the cell forward. Rho 
is a small GTPase whose activity has been implicated heavily in this cell polarisation 
process. The first effector of Rho to be discovered was the Rho-associated coiled-coil 
forming protein kinase (ROCK) II (also known as ROKa), with another family member, 
ROCKI (ROKp), since discovered (Ishizaki et al., 1996; Leung et al., 1995; Leung et al., 
1996; Matsui et al., 1996; Nakagawa et al., 1996). ROCKs phosphorylate various 
substrates, such as myosin light chain (MLC) phosphatase (MLCP), MLC and LIM (L in ll, 
Isll and Mec3) kinase (LIMK). ROCKs are able to phosphorylate MLC, independently of 
calcium, on the same residue that is phosphorylated by MLCK (Ser 19) (Amano et al., 
1996; Totsukawa et al., 2000). This phosphorylation of the regulatory MLC (also known as
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MLC2) of myosin II induces its interaction with actin, leading to activation of myosin 
ATPase and the subsequent enhancement of cell contractility (required for uropod 
detachment). MLCP is responsible for the dephosphorylation of MLC, and so negatively 
regulates actomyosin-based contractility. ROCK phosphorylates the myosin-binding 
subunit (MBS) of MLCP at Thr 697 (inhibitory), Ser 854 and Thr 855 (phosphorylation of 
this particular residue leads to MLCP dissociating from myosin), but the exact mechanisms 
of inhibition are not known (Feng et al., 1999; Kawano et al., 1999; Kimura et al., 1996; 
Velasco et al., 2002). Another ROCK substrate are the serine/threonine LIMKs that then 
phosphorylate and inhibit cofilin. Cofilin is an actin-binding and -depolymerising protein 
that regulates the turnover of actin filaments, thus inhibition leads to an increase in the 
number of actin filaments (Maekawa et al., 1999). Despite this evidence for a role of 
ROCK in cell motility there have only been a couple of papers published concerning the 
role of ROCK in chemokine-mediated directed cell migration. In both studies a 
pharmacological inhibitor (Y-27632) of ROCKI and II was used to ascertain its importance 
in chemotaxis. CXCR4- and CCR7-mediated chemotaxis of T lymphocytes was abrogated 
with the inhibitor (Bardi et al., 2003; Vicente-Manzanares et al., 2002) and Vicente- 
Manzanares demonstrated that MLC phosphorylation in response to CXCL12 was 
dependent upon RhoA. CEM cell chemotaxis in response to MDC displayed a similar 
sensitivity towards ROCK inhibition with Y-27632. Furthermore, MDC stimulated an 
increase in the phosphorylation of MLC that was abated with Y-27632 pretreatment. 
Interestingly, the inhibition of MLC phosphorylation was complete and thus well below the 
basal levels. This would suggest that ROCK is doing more than just inhibiting MLCP, 
which is regarded as the most likely mechanism of action for ROCK in actin 
polymerisation, and must be playing a proactive role in the phosphorylation of MLC, either 
directly or possibly indirectly via MLCK (Vicente-Manzanares et al., 2002).
Although the G protein py subunits have been demonstrated to activate various Rho 
guanine nucleotide exchange factors (GEFs), including p ll4R hoG E F  (Niu et al., 2003), 
and thus activating the Rho-ROCK pathway, recent evidence provides a link for PKC in 
MLC phosphorylation, independent of activating Rho. Results presented within have 
established that PLC is critical for CCR4-mediated chemotaxis (a phenomenon displayed 
by other chemokine receptors as well (Smit et al., 2003; Soriano et al., 2003)). Having
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determined that calcium mobilisation seems not to be required for CCR4-mediated 
migration, it would therefore appear that the second product of PLC-mediated PI(4,5)P2 
hydrolysis, namely DAG, has a pivotal role to play. A recently published paper, utilising 
oligodeoxyribonucleotides (ODN) to specifically inhibit PKCp and various 
pharmacological inhibitors, provided evidence that PKCp was required for monocyte 
chemotaxis in response to CCL2 (Camevale and Cathcart, 2003). In addition, PKC£ was 
shown to be essential for neutrophil chemotaxis in response to the chemokine CXCL8 
(Laudanna et al., 1998). However, PKCp is a classical PKC isoform that requires both 
DAG and calcium for its activity and would thus suggest it is an unlikely candidate as a 
PKC isoform in CEM cell migration towards MDC. This is confirmed with the lack of 
effect of the classical PKC inhibitor G66976 on this migratory event. Since DAG appears 
to be involved it is possible that a novel PKC isoform maybe mediating CEM cell 
chemotaxis, although a role for PKC£ in CCR4-mediated CEM cell migration cannot be 
ruled out. This conclusion would seem to be confirmed with the sensitivity of MDC- 
induced T cell migration being sensitive to the broad-spectrum (classical and novel 
isoform) PKC inhibitor RO-32-0432. It is not understood how PKC isoforms regulate cell 
motility/migration. One hypothesis maybe that PKC is having effects on actin 
reorganisation/polymerisation. Effectors of PKC isoforms are the MARCKS 
(myristoylated alanine-rich C kinase substrate) family o f proteins (Arbuzova et al., 2002). 
It has been shown that MARCKS can bind to and cross-link actin in vitro and that 
activation of the PKC pathway leads to the local release of actin by MARCKS, resulting in 
a local softening of the actin cytoskeleton and increased plasticity (favourable for migration 
through tight spaces) (Hartwig et al., 1992). MARCKS has also been found to co-localise 
with F (filamentous)-actin in the lamellipodia (Myat et al., 1997). This regulation of actin 
by MARCKS may alternatively occur via PI(4,5)P2 availability. MARCKS has been 
shown to sequester PI(4,5)P2 and this lipid may be released by PKC activity allowing the 
lipid to become locally available for actin-binding proteins, a hypothesis that is supported 
by the fact that MARCKS can inhibit PLC-induced PI(4,5)P2 hydrolysis and this can be 
reversed by PKC (Wang et al., 2001). Alternatively, PKC may be involved in the 
phosphorylation of MLC. The protein kinase C-potentiated inhibitor protein of 17 kDa 
(CPI-17) specifically inhibits MLCP when it is phosphorylated at Thr 38. A very recent 
study established that all PKC isoforms were able to interact with CPI-17 in vivo, via their
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cysteine-rich domains, and that they were responsible for the phosphorylation o f the Thr 38 
residue of CPI-17 (Zemlickova et al., 2004). Additionally, PKC has been shown to be 
required for the activity of ROCK, without affecting Rho-ROCK complex formation 
(Barandier et al., 2003). Moreover, EGFR-mediated myosin heavy chain A and B (MHC- 
A, -B) phosphorylation is dependent upon PKC activity (Straussman et al., 2001), and 
EGF-induced MLC phosphorylation required PKC8 (myosin II is a hexamer composed of 
two heavy chains and two pairs of light chains) (Iwabu et al., 2004). Incidentally, although 
PDK-1 is the upstream kinase for the activation loop of PKC isoforms, it has been reported 
that PDK-1 can mediate this phosphorylation event independent of PI3K and Iwabu et al. 
present data indicating that PI3K inhibition had no effect on PKCS activity (Dempsey et al., 
2000; Iwabu et al., 2004; Sonnenburg et al., 2001). The importance of the PKCS isoform 
was highlighted within this thesis with the observation that the PKCS selective inhibitor 
rottlerin completely attenuated CEM cell chemotaxis in response to MDC. This was in 
accordance with another study that demonstrated that CCL15/CCR1 chemotaxis relied 
upon PKCS activation (Ko et al., 2002). Rottlerin is a controversial inhibitor as it has been 
reported to display no inhibitory activity against PKCS whatsoever (Davies et al., 2000), 
whilst other groups have contradicted this data (Saraiva et al., 2003). Finally, PKCS has 
been shown to activate NF-kB in neutrophils and epithelial cells (Page et al., 2003; 
Vancurova et al., 2001), and NF-kB activity is required for CCL15/CCR1- and 
CXCL12/CXCR4-mediated chemotaxis (Cherla and Ganju, 2001; Ko et al., 2002). 
Activation and nuclear translocation of NF-kB requires phosphorylation, ubiquitination, 
and subsequent degradation of its cytoplasmic inhibitor IkBcx via the IkB kinase (IKK) 
pathway. Both TLCK and TPCK have been reported to prevent the degradation of IkBoc 
and thus preventing NF-kB activation (Henkel et al., 1993; Zemecke et al., 2001). TLCK 
and TPCK treatment of CEM cells abolished their migratory response towards MDC. 
Although these inhibitors are broad-spectrum protease inhibitors they give an idea as to the 
requirement of NF-kB in cell migration as demonstrated by other groups that have then 
gone onto use more selective NF-kB inhibitory methods (Cherla and Ganju, 2001). It is not 
known how NF-kB is contributing towards the chemotactic response. Cherla et al. propose 
that it is via the NOS pathway, with NOS inhibition detrimental to CXCL12-induced T cell 
chemotaxis, but pretreatment with L-NAME had no effect on CCR4/CEM cell chemotaxis 
(Cherla and Ganju, 2001). Therefore, it is more likely reliant upon the transcription of new
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genes and subsequent translation into proteins. This hypothesis is supported by the 
detrimental effects of actinomycin D (RNA synthesis inhibitor (prevents RNA polymerase 
moving along DNA -  transcription) and cyclohexamide (protein synthesis inhibitor - 
translation) on CCL15-induced cell migration (Ko et al., 2002).
However, it is possible that the DAG product o f PI(4,5)P2 hydrolysis is responsible for 
mediating migration by more than just activation of the PKC pathway. The last few years 
have seen an increasing amount of data on the additional signalling pathways promoted by 
DAG. One of these pathways is the activation of Rap-GEFs termed calDAG-GEFs. As the 
name suggests, these GEFs are regulated by calcium and/or DAG, via distinct binding 
domains (Stork, 2003). RapGTPase can be activated by the calDAG-GEFI (RasGRP2) and 
calDAG-GEFIII family members, and a recent study demonstrated that CXCL12-mediated 
B cell migration was dependent upon Rap activation, and in turn this activation was reliant 
on PLC activity (McLeod et al., 2002). Interestingly, calcium appeared not to participate in 
the activation of Rap in this study, correlating with CCR4-CEM cell chemotaxis being a 
calcium-independent migration event. The downstream effectors of Rap that may be 
involved in chemotaxis are not known. Effectors for Rap include PLCe, p38, PI3K/PKB, 
Raf as well as possibly inhibiting PI3K/PKB, Raf and p38 (Stork, 2003). Recently, reports 
have indicated that Rap co-localises with F-actin and blocking its activation inhibited actin 
polymerisation (Caloca et al., 2004; McLeod et al., 2004). Also, CXCL12-stimulated Pyk2 
tyrosine phosphorylation was attenuated with Rap inhibition (McLeod et al., 2004). Pyk2 
is a non-receptor tyrosine kinase and member of the focal adhesion kinase (FAK) family. 
CCR4 ligation resulted in the PTX-sensitive tyrosine phosphorylation of Pyk2 and 
inhibition abrogates CXCL8-induced neutrophil chemotaxis, B cell and macrophage 
migration (Di, V et al., 2004; Guinamard et al., 2000; Okigaki et al., 2003).
Involvement o f Alternative Pathways in CCR4-Mediated CEM Cell Migration
Work presented within this thesis additionally investigated the involvement of the p38- 
MAPK, JAK, and ERK-MAPK protein kinases in directed T cell migration in response to 
CCR4 ligands. The p38-MAPK has been shown to be required for CCL1 l/CCR3-mediated 
eosinophil chemotaxis, monocyte and neutrophil chemotaxis (Adachi et al., 2003; Ashida et
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al., 2001b; Coxon et al., 2003). Although CCR4-ligation led to phosphorylation of p38, a 
selective inhibitor against this MAPK had no effect on CCR4-mediated cell migration. 
This effect compares favourably with other studies suggesting a lack of a role for p38 in 
cell migration (Fernandis et al., 2004; Ko et al., 2002).
Additionally, another MAPK family member ERK1/2 has been implicated in chemotactic 
events (Adachi et al., 2003; Brahmbhatt and Klemke, 2003; Coxon et al., 2003), and 
likewise with p38, inhibition of MEK1/2 (whose only known effector is ERK1/2) had no 
effect on CEM cell chemotaxis towards MDC, despite curtailing MDC-induced ERK 
phosphorylation events. The lack of effect of ERK inhibition on migratory events by the 
use of the MEK inhibitor PD98059 has been widely reported in the literature (Bardi et al., 
2003; Cherla and Ganju, 2001; Fernandis et al., 2004; Fine et al., 2001; Ko et al., 2002; 
Vicente-Manzanares et al., 2002; Wang et al., 2002a). The JAKs have been extensively 
talked about previously in this discussion and, similar to effects on calcium mobilisation, 
their inhibition had no detrimental outcome on the chemotactic ability of CEM cells to 
migrate towards MDC, further discounting a role of these tyrosine kinase in the signalling 
and functional responses mediated by CCR4.
Finally, a very interesting response was obtained when Th2 cells were pretreated with an 
antibody against hMDC, resulting in an almost 100% increase in MDC-induced chemotaxis 
but with no effect upon TARC-stimulated chemotaxis. This spectacle is currently 
unexplainable and a number of experiments are required to be performed in order to try to 
understand this response. The antibody (anti-hMDC mAb, R & D Systems) is neutralising 
towards MDC activity with an ND50 of 0.5 -  2 lig/ml (utilised at 10 jxg/ml in assay). It is 
possible that the T cells themselves are producing MDC and that by preincubating them 
with anti-hMDC is mopping up secreted MDC and thus increasing the sensitivity of the 
receptor towards MDC when exposed to the gradient. If this is the case then it is 
interesting that mopping up the secreted MDC has no beneficial effect on TARC responses 
(T cells cannot produce TARC). One explanation is that the two chemokines are acting via 
different receptors, with TARC acting on an additional receptor for mediating chemotaxis 
of Th2 cells. This would help to explain why the in vitro generated Th2 cells chemotax to 
TARC but CEM cells do not (to any great extent), despite CEMs expressing CCR4 and
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chemotaxing to MDC, as well as producing signalling responses to TARC. This could be 
easily confirmed/dismissed by the use of a neutralising antibody towards CCR4.
Signalling Pathways Leading to ERK and PKB Phosphorylation
As has previously been mentioned, the ERK-MAPK and PKB signalling cascades are two 
of the most widely studied signalling pathways, with both ‘routes’ and their downstream 
effectors implicated in a wide-range of cellular functions, including cell proliferation and 
survival. The ERK and PKB pathways are generally considered to be reasonably distinct 
from each other, although there have been reports that there is a level of cross-talk between 
the two. While these cascades are relatively well characterised in various systems there is 
not a lot known about how chemokine receptors regulate each pathway. Thus this section 
will discuss the results obtained for CCR4-mediated activation/phosphorylation of ERK 
and PKB and attempt to relate it to current knowledge for other chemokine receptors.
Characterisation o f the CCR4 Activated ERK-MAPK Pathway
Not unexpectedly, CCR4 ligation led to the phosphorylation of ERK1/2 (both isoforms will 
subsequently be referred to as ERK) in a range of different cells, with broadly similar 
kinetics that is in contrast to those observed for PKB phosphorylation. As expected, 
incubation of cells with the selective MEK1/2 (referred to as MEK from this point forward) 
inhibitor PD98059 led to a complete abolishment of CCR4-induced ERK phosphorylation. 
This confirms the involvement of the Raf-MEK-ERK pathway in CCR4-mediated 
signalling. MEK is the only generally acknowledged substrate of Raf kinases, with MEK’s 
only known substrate being that of ERK, whilst ERK has over 70 substrates, many of them 
nuclear transcription factors (O'Neill and Kolch, 2004). However, the molecular machinery 
that is responsible for activation of the Raf-MEK-ERK pathway, in response to chemokine 
stimulation, is lacking clarity and appears to almost certainly vary between the chemokine 
receptors and cell systems being studied.
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Having established that ERK phosphorylation is sensitive to PTX treatment, in vivo 
evidence indicates that activation of ERK by Gai-coupled receptors is likely to employ the 
py subunits o f the heterotrimeric G-protein complexes (Koch et al., 1994; Luttrell et al.,
1996). These py subunits can then activate a range of molecules that lead to ERK 
activation. CXCL12-mediated stimulation of ERK in T lymphocytes has consistently been 
demonstrated to be a prolonged event (Ganju et al., 1998a; Kremer et al., 2003; Tilton et 
al., 2000) that relies upon the tyrosine kinase ZAP-70 and the scaffold/adaptor protein SLP- 
76 (SH2 domain-containing leukocyte protein of 76 kDa) (Kremer et al., 2003). However, 
rapid and transient ERK phosphorylation does not rely upon ZAP-70 and SLP-76, thus it is 
probable that these proteins are not responsible for CCR4-mediated ERK activation, which 
is transient. Alternative non-receptor tyrosine kinases that have been implicated in ERK 
phosphorylation, downstream of GaiPy, are those of the Src family (Luttrell et al., 1996; 
Ma et al., 2000). Src (and other family members e.g. Lck and Lyn) have been implicated in 
the activation of the ERK pathway downstream of CXCR3 (Bonacchi et al., 2001) and 
demonstrated to be activated downstream of CXCR4 and CXCR2 (Inngjerdingen et al., 
2002; Okabe et al., 2002; Ptasznik et al., 2002; Yamasaki et al., 2001). Moreover, Src 
tyrosine kinases have been shown to associate with Pyk2 and subsequent activation of the 
ERK pathway, among others, suggesting a potential role for CCR4-mediated Pyk2 
phosphorylation in T lymphocytes (Avraham et al., 2000; Yamasaki et al., 2001). It is 
possible that Src activation by py subunits does not involve a direct interaction and that 
perhaps PI3Ky serves as an intermediary (Hawes et al., 1996; Lopez-Ilasaca et al., 1997). 
Indeed, there are a number of studies that report chemokine-mediated ERK 1/2 
phosphorylation is sensitive to treatment with PI3K inhibitors (Kansra et al., 2001; Knall et 
al., 1996; Sotsios et al., 1999). However, LY294002 and wortmannin treatments had no 
impact on MDC-stimulated ERK phosphorylation, therefore seemingly discounting a role 
for PI3K in this system.
In contrast, PLC inhibition and the attenuation of intracellular calcium mobilisation had 
small but significant ramifications on ERK phosphorylation downstream of ligated CCR4. 
It is possible that the mobilised calcium (generated by PLC activity) is required for Pyk2 
activity and the subsequent formation of Shc-Grb2-Sos complexes that then activate Ras (a 
small GTPase) and the Raf-MEK-ERK pathway (that can incidentally be achieved via Src
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and without the need for Pyk2) (Marinissen and Gutkind, 2001). She and Grb2 are SH2 
domain-containing adaptor proteins and Src is able to phosphorylate She thus recruiting 
Grb2 and the RasGEF called Sos (son of sevenless). Alternatively, the rise in intracellular 
calcium could be activating Ras guanine-nucleotide releasing factor (RasGRF) or calDAG- 
GEFS with subsequent Ras stimulation. Although PKC isoforms have been established to 
activate the ERK pathway (in a Ras-independent manner) in various cell systems, including 
chemokine systems, the use of PKC inhibitors against the classical and novel PKC isoforms 
had no repercussions on CCR4-stimulated ERK phosphorylation (Ghosh et al., 2004; Kim 
et al., 2003; Woo et al., 2002). It is also possible that DAG, a product of PLC-mediated 
PI(4,5)P2 hydrolysis, alone is activating RasGRPl (Ras guanine-nucleotide releasing 
protein (calDAG-GEFII)) and/or RasGRP3. Both of these Ras activating proteins have 
been shown to be high-affmity DAG/phorbol-ester receptors and involved in the activation 
of the Ras-Raf-MEK-ERK pathway (Lorenzo et al., 2000; Lorenzo et al., 2001). Indeed, in 
thymocytes it has been demonstrated that a lack o f RasGRPl leads to the unresponsiveness 
of the cells in Ras signalling assays and proliferation experiments upon TCR ligation 
(Dower et al., 2000). Another possibility that relies on DAG is that of Rap-mediated ERK 
activation. This mechanism is Ras-independent with Rap activating Raf. However, the 
role of Rap varies between cell types and stimuli, with Rap capable of activating or 
inhibiting this route to ERK activation. Also, it is known that Rap is able to stimulate the 
activation of B-Raf, but B-Raf is not present generally in peripheral T cells, although its 
introduction leads to an ability for Rap to activate the ERK pathway (Dillon et al., 2003). 
There needs to be more investigation into the role of Rap in activating/inhibiting ERK in T 
cells, but current data would suggest that Rap is inhibitory downstream of the TCR 
(Appleman et al., 2001; Carey et al., 2000). Intriguingly, this may provide an explanation 
for the increase in basal levels of phosphorylated ERK upon treatment with the higher 
concentration of the PLC inhibitor U73122. It is possible that the basal inhibition of ERK 
phosphorylation is removed by inhibiting the basal levels of DAG thus inactivating Rap 
and leading to the unregulated activation of R af and the consequent activation of MEK and 
ERK. It is also apparent that a chymotrypsin-like serine protease is involved in the 
homeostatic regulation of ERK as demonstrated by the increased levels of ERK 
phosphorylation observed with TPCK treatment in CEM cells. In contrast the trypsin-like 
serine protease inhibitor TLCK had no impact on ERK activity.
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One of the first identified 70+ effectors of ERK was p90RSK (RSK, MAPKAP-K1). This 
kinase is involved in the regulation of the cell cycle, gene transcription (including that of 
chemokines), and protein synthesis (Frodin and Gammeltoft, 1999; Zhang et al., 2002). 
MDC was able to stimulate the PTX- and PD98059-sensitive phosphorylation of p90RSK, 
thereby identifying one such substrate of ERK that is activated upon CCR4 ligation. The 
only pharmacological inhibitor that produced a complete attenuation of ERK 
phosphorylation in response to CCR4 ligation was that of PD98059, as expected. Thus it is 
likely that there are a number of pathways upstream of Raf that contribute to the activation 
of the MEK-ERK cascade. Figure 4.52 is a schematic of the possible pathways, based 
upon the data presented within and from the current literature, which lead to ERK 
activation upon stimulation with MDC or TARC.
MDC
TARC CC R4
Figure 4.52. Schematic diagram  of the possible pathways dow nstream  of CCR4 that 
lead to ERK-M APK activation. See text for more details.
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Characterisation of the CCR4 Activated PI3K-PKB Pathway
The author refers the reader to ‘Results I* and ‘Discussion I’ for an in depth analysis into 
the kinetics of PKB phosphorylation, and its dependency on PI3K activity, upon ligation of 
CCR4 with either MDC or TARC. This section will discuss the possible pathways that 
lead to PI3K activation and subsequent PKB phosphorylation.
As with all the other CCR4-mediated signalling cascades investigated within this thesis, 
CCR4-induced PKB phosphorylation is sensitive to PTX treatment indicating the 
requirement for CCR4 to couple to the G ai protein. There are likely to be a number of 
routes that lead to the activation of PI3K and subsequent activation of PKB. The most 
straight forward of these would involve the direct activation of PI3Ky by the py subunits. 
PI3Ky is the only isoform that can be activated in this way by GPCRs and it was earlier 
shown that PI3Ky is indeed activated by MDC in CEM cells. This activation of PI3Ky will 
lead to an increase in PI(3,4)P2 and PI(3,4,5)P3 lipids, recruitment of PDK-1 and 
subsequent recruitment/activation of PKB and its downstream effectors (Brock et al., 2003; 
Wymann et al., 2003a). The activation of the class IA PI3K isoforms cannot occur directly 
via the Gpy proteins but instead can occur via a classical pathway involving the recruitment 
and activation of a Src tyrosine kinase (by either G ai or py) that then tyrosine 
phosphorylates the adaptor protein She with subsequent recruitment of Grb2 and the 
RasGEF Sos (Ma et al., 2000; Stephens et al., 1993). This leads to the activation of Ras 
that can then activate, via its association with the catalytic domain, the class LA PI3K 
isoforms (Kodaki et al., 1994; Rodriguez-Viciana et al., 1994; Vanhaesebroeck et al., 
1997a). Ras and the adaptors play a role in recruiting PI3K to the plasma membrane where 
it can phosphorylate its main substrate PI(4,5)P2. However, the exact mechanisms 
surrounding class IA PI3K recruitment downstream of chemokine receptors is ill-defined 
(Cantley, 2002; Ward and Cantrell, 2001). Furthermore, it has been established that Ras 
can additionally activate PI3Ky (Suire et al., 2002). This finding may be crucial as it has 
been determined within this thesis that phosphorylation of PKB is dependent upon PLC 
activity, suggesting that PI3Ky does not contribute to PKB activation if it is solely activated 
in a direct manner by the GPy subunits. In contrast however to ERK phosphorylation, 
calcium mobilisation was surplus to requirements with regard to CCR4-mediated PKB
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phosphorylation. Therefore, not unexpectedly, the selective classical PKC inhibitor had no 
effect on levels of phosphorylated PKB, but the broad-spectrum PKC inhibitor RO-32-0432 
did have a slight negative impact. This indicates that a novel PKC isoform is involved in 
PKB activation and the options would appear to be restricted to PKC0, PKCrj or PKCe, as 
the PKC8 inhibitor rottlerin had no impact. The role of PKC isoforms in the PI3K-PKB 
cascade remains ambiguous but there are studies that examine this relationship. Classical 
and novel PKC isoforms have been described as influencing in a positive manner the 
phosphorylation of PKB (Bauer et al., 2003; Gliki et al., 2002; Kim et al., 2004; Matsumoto 
et al., 2001). Although there is a requirement for PLC (and likely its products) it cannot be 
ruled out that a DAG-dependent pathway separate from novel PKC isoform activity is 
involved. Since RO-32-0432 displays activity against the atypical PKC^ (no data available 
for PKC£), it is possible that an atypical isoform is involved in modulating the activity of 
PKB. Indeed, atypical isoforms have been implicated as being negative regulators of PKB 
activity (Doombos et al., 1999; Mao et al., 2000) but, importantly for this study, have also 
been described as having a positive role (Li et al., 2004a; McConkey et al., 2004). It is not 
clear how PKC is mediating these effects. One explanation is that PKC is constitutively 
bound to PKB and induces its recruitment to the membrane as has recently been shown to 
occur for PKC0 upon activation of CD3 in T cells, whilst other PKC isoforms are involved 
in the transactivation of PKB (Bauer et al., 2003; Konishi et al., 1994). It is also possible 
that PKC is only having an impact at the level of Ser 473 phosphorylation and is not 
affecting Thr 308 phosphorylation (Kroner et al., 2000), although this is in contrast to the 
data presented by Kim et al. (Kim et al., 2004). PDK-1 is known to be involved in the 
activation (by phosphorylation of the activation loop) of PKC isoforms, with certain 
isoforms observed to directly interact with PDK-1, in various circumstances and this 
mechanism would fit in nicely with the observation that PKB phosphorylation is fully 
dependent on PI3K activity (Cenni et al., 2002; Chou et al., 1998; Dutil et al., 1998). RO- 
32-0432 did not completely attenuate PKB phosphorylation at the Ser 473 residue and 
maximal effects were seen at sub-maximal utilised concentrations. This would suggest that 
PKC is not required for complete activation of PKB. Therefore, an alternative explanation 
for the role of DAG is required as PLC activity is essential for PKB phosphorylation. It is 
possible that DAG is activating a RasGEF, such as the CalDAG-GEFs or RasGRPs, with 
subsequent activation of Ras and recruitment of PI3K. These pathways have been
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discussed earlier in this discussion and will not be covered again. An absolute requirement 
o f PLC activity for PKB activation has been demonstrated in two other systems, with one 
o f these studies determining calcium was the essential product and the other established a 
role for PKC (Amin et al., 2003; Tang et al., 2002).
Surprisingly, both TLCK and TPCK abrogated MDC-induced PKB phosphorylation. A 
paper published in 2001 detailed the ability of TPCK to disrupt PDK-1 signalling by 
preventing PDK-1 from phosphorylating its regulatory sites in PKB (phosphorylation at Ser 
473 and Thr 308 was inhibited indicating PDK-2 inhibition as well) (Ballif et al., 2001). It 
is not known about the sensitivity of PDK to TLCK. It is generally considered that IkB 
kinase is a downstream target of PKB. However, another intriguing paper has suggested 
that NF-kB is upstream of PKB and inhibition of NF-kB (with TPCK and SN-50) led to the 
inhibition of PKB whilst PDK inhibition had no effect upon NF-kB activity (Meng et al., 
2002). Additionally, this report demonstrated that over expression of p65 (of NF-kB) leads 
to higher PKB phosphorylation (24 hr) and an increase in PKB mRNA (at 12 hr). 
Phosphorylation of PKB in this study was slow (TNF = 1 5  min; LPS = 60 min) and 
prolonged and would suggest that although NF-kB may well be able to activate PKB in 
certain situations it is unlikely to be responsible for MDC- and TARC-mediated PKB 
phosphorylation, which is a very rapid event. As such, it is more likely that TPCK and 
TLCK are mediating their effects via the disruption of P D K -l’s (and 2 ’s) ability to 
phosphorylate PKB.
An established substrate of PKB is GSK-3 and, unusually, this leads to the inactivation of 
GSK-3, with a subsequent increase in the activity of glycogen synthase (Cohen and Frame, 
2001). MDC-stimulated phosphorylation of G SK -3a/p was indeed sensitive to LY294002 
but this was not absolute. However, treatment of cells with the PKC inhibitor RO-32-0432 
prior to MDC stimulation did result in the abolition of G SK -3a/p phosphorylation. This is 
not a surprise with PKC an established activator of GSK-3 (Christian et al., 2002; Fang et 
al., 2002; Tsujio et al., 2000). Figure 4.53 is a schematic of the pathways that possibly 
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Figure 4.53. Schematic diagram  of the potential CCR4-mediated signalling cascade 
tha t leads to PKB phosphorylation. ‘Other effectors’ include Ik B  kinase, eNOS, mTOR, 
Bad, FKHR, caspase 9 (last 3 are inhibited). -Effectors’ include p70S6K, Rac/RhoGEFs, 
Tec kinases (e.g. Btk, Itk, Tec). See text for more details of the cascade. Dotted aqua lines 
indicate pathways that have not been supported by data presented within this thesis with 




Possible Role of Arno and Identity of UPE
Identifying a Role for Amo
Amo (ARF nucleotide binding site opener) is a GEF for the GTPases ARF1 and ARF6 . 
These ARF GTPases are best known for their role in vesicle transport, with ARF1 
localising primarily to the Golgi complex where it initiates carrier vesicle formation by 
nucleating the assembly of coat protein complexes (Donaldson and Klausner, 1994). 
Contrastingly, ARF6 has been localised to the plasma membrane/endosomal system, where 
it regulates the recycling of membrane proteins (Chavrier and Goud, 1999). It has been 
demonstrated that ARF6 also regulates the availability of P-arrestin to GPCRs with receptor 
activation leading to receptor desensitisation by p-arrestin (which has been liberated from 
activated ARF6) sterically hindering the ability of the receptor to activate its cognate G 
protein (Hunzicker-Dunn et al., 2002). Additionally, ARF6 has been shown to be required 
for membrane ruffling and lamellipodia formation, with ARF6 colocalising with Racl and 
required for R acl recycling to the plasma membrane (Radhakrishna et al., 1999; Song et 
al., 1998; Van Aelst and D'Souza-Schorey, 1997). Amo is a 47 kDa protein that possesses 
a C-terminal PH domain. The selectivity of this PH domain appears to be broad as it has 
been demonstrated that it binds PI(4,5)P2 and PI(3,4,5)P3 (Chardin et al., 1996; Paris et al., 
1997; Venkateswarlu et al., 1998). This perhaps suggests that although PD K  activity is not 
required for T cell chemotaxis in response to MDC or TARC, it does not rule out a role for 
Amo and ARF6 . Arno has been shown to colocalise with ARF6 in actin-rich lamellipodia 
at the cell periphery, but only upon treatment with phorbol ester (Frank et al., 1998). Amo 
has been shown to stimulate epithelial cell migration through stimulation of Racl and PLD, 
however in the few PLD assays performed MDC was unable to initiate a detectable 
increase in PLD activity in CCR4 transfected CHO cells (data not presented) (Santy and 
Casanova, 2001). Although this would suggest that Arno is not working through the PLD 
pathway it is necessary to perform a more in depth analysis into PLD activation in T cells 
before any substantial conclusions can be drawn. The review by Turner & Brown goes into 
more detail about the possible role of Amo and PLD in cell motility (Turner and Brown, 
2001). It is impossible to define the exact role Amo and its substrates ARF1/6 are 
performing in CCR4-mediated signal transduction, but it is possible that Amo/ARF could
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be involved in one or more of the mechanisms mentioned above and only future studies 
would help to clarify this.
Possible Candidates fo r  the Identity o f  UPE
The kinetics for UPE phosphorylation are relatively slow at 5 -  10 minutes. This would 
suggest that UPE is reasonably far down the CCR4-initiated signalling cascade in T cells. 
Additionally, it is a very large molecule at about 200 kDa helping to considerably cut down 
on the number of potential candidates. Since the antibody used was against FKHR 
(FOX Ol) phosphorylated at Ser 256 then potential candidates will include members of the 
FOXO family of transcription factors: AFX (FOX 04) and FKHR-L1 (F0X 03a). These 
transcription factors all posses the conserved serine residue at the N-terminal end of the 
DNA-binding domain. However, AFX and FKHR-L1 are only 65 and 97 kDa, 
respectively, ruling out these factors as possible candidates. The serine residue at 256 lies 
within a consensus sequence for phosphorylation by PKB, therefore possible candidates for 
UPE should include this consensus region, such as caspase 9 (47 kDa), Bad (23 kDa), 
IK K a (not clear (85 kDa)), GSK-3oc/p (54/46 kDa), PDE3B (124 kDa), mTOR (289 kDa), 
IRS-1 (175 kDa), Raf (74 kDa), eNOS (140 kDa) and BRCA1 (220 kDa). Of these 
proteins, IRS-1, mTOR and BRCA1 are potential candidates with regard to their size. 
However, IRS-1 (insulin receptor substrate-1) is a little too small and unlikely to be 
activated downstream of a chemokine receptor in T cells; mTOR (molecular target of 
rapamycin) is a distinct possibility but an anti-phospho mTOR Ab has been used and there 
was considerable basal levels of phosphorylated protein (data not shown); BRCA1 (breast- 
cancer-susceptibility-gene-1 product) is a possibility. BRCA1 is a nuclear phosphoprotein, 
thought to be a tumour suppressor, expressed in T lymphocytes and is encoded by the 
BRCA-1 gene and activated by PKB (Green and Schuler, 2000; Vanhaesebroeck and 
Alessi, 2000). Another possibility is tuberin (200 kDa, also known as TSC2), a product of 
the tumour suppressor gene TSC2, involved in regulating cell proliferation and tumour 
development. Tuberin is directly phosphorylated by PKB and is believed to be inhibited by 
this event, and thereby possibly stimulating the mTOR pathway (Li et al., 2004b). This is 
perhaps a more viable candidate for UPE as mTOR has been implicated in chemokine 
signalling (Hwang et al., 2003). However, it is perhaps more likely that it is none of the 




The second section of this thesis has concentrated primarily on the pathways that may be 
required for CCR4-mediated T cell chemotaxis. It has been demonstrated that CCR4 
signalling and chemotaxis requires the coupling of the receptor to the G ai protein and that 
the Janus kinases appear to have no part to play. MDC and TARC are able to mobilise 
calcium from intracellular IP3R-sensitive stores and that other mechanisms of calcium 
release appear to have little or no contribution towards the total cytoplasmic levels. PLC is 
a pivotal enzyme that is required for calcium, PKB signalling and chemotaxis, however, its 
involvement in the ERK-MAPK pathway is ambiguous. Intracellular calcium mobilisation 
is redundant with respect to a cell’s ability to directionally migrate towards MDC. 
Moreover, a calcium flux is not required for the phosphorylation of PKB although it does 
contribute to a certain extent in the activation of ERK. The other product of PI(4,5)P2 
hydrolysis by PLC, DAG, appears to be a pivotal player in chemotaxis and PKB signalling 
and likely to involve effectors that are not only members of the PKC family. However, 
although CCR4-ligation leads to activation of the ERK-MAPK pathway (and PKB 
pathway, as discussed previously) it is not involved in events required for cell migration. 
Instead, it has been established that the Rho-ROCK-MLC pathway is at least one cascade 
that is indispensable for CCR4 directed T cell migration. In addition, there have been a 




Key Future Experiments II
1. Perform a more detailed analysis of the role of PKC and/or DAG in the signalling 
and chemotactic responses. This will involve using DAG and OAG (a DAG that 
activates only calcium-dependent PKCs (l-Oleoyl-2-acetyl-sn-glycerol)) to 
stimulate or downregulate (through prolonged exposure) PKC isoforms. 
Additionally, look at cell localisation of the PKCs (this was investigated briefly but 
could observe no changes) and their phosphorylation state in Th2 cells 
(phosphorylated basal levels are too high in CEMs). Also, to utilise siRNA 
technology and/or peptide inhibitors to selectively inhibit individual PKC isoforms. 
Using DAG/OAG in presence of PKC inhibition will help to determine the presence 
of non-PKC-mediated pathways, in addition to targeting specific DAG effectors.
2. Investigate more thoroughly the role of NF-kB in the chemotactic response and, if 
any, the genes that are transcribed.
3. Characterise the effectors of the calcium pathway e.g. calmodulin, NFAT, etc.
4. Investigate the Rho-ROCK-MLC pathway more thoroughly and establish the role of 
the ‘other’ GTPases cdc42 and Rac in actin polymerisation and cell migration 
utilising techniques, including confocal microscopy, to determine co-associations.
5. Characterise pathways other than PKB and ERK that are activated upon CCR4 
ligation. Determine the range of effectors activated by the ERK and PKB pathways, 
as well as their transcription factors. Attempt to relate this to their role in CCR4 
function.
6 . Determine role of DOCK2 in CCR4-mediated cell migration of T cells.
7. Establish the identity of UPE through protein isolation/purification and sequencing.
8. Ascertain the role of Amo/ARF in CCR4-mediated responses and whether it is 
required for cell motility.
9. Verify whether MDC and TARC stimulate identical signalling pathways, and if 
CCR4-mediated T cell chemotaxis utilises the same signalling cascades as other 
CCR4-expressing cells e.g. monocytes, DCs, thymocytes.
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5. O ver a ll  D isc u ssio n  & C o n clu sio n s
5.1 Potential Roles of Calcium, ERK and PKB in CCR4 Functions
It has been established through the course of this thesis that each of the calcium-, ERK- and 
PKB-associated signalling cascades is dispensable for CCR4-mediated directed T cell 
migration. However, it is unlikely that the activation of these pathways are a redundant 
feature of chemokine activity and more plausible that, despite their name, chemokines have 
a much broader repertoire with regard to their functional role than simply an ability to elicit 
a cell migratory response. The following few sub-sections will very briefly discuss the 
potential role these three pathways may have in a cell’s actions.
Calcium
Calcium is an incredibly versatile intracellular signal that regulates a plethora of different 
cellular functions. Mobilised calcium exerts its effects via EF-hand proteins (see appendix 
9) that bind calcium with high affinity to helix-loop-helix motifs that are repeated from two 
to twelve times. A ubiquitous and abundant EF-hand protein is calmodulin (CaM) that 
interacts with and regulates various proteins including calmodulin-dependent kinases 
(CaMKs), calcineurin, NFAT and AP-1. When intracellular calcium levels are low CaM 
assumes a closed-conformation that prevent it from binding to protein kinases. An increase 
in intracellular calcium leads to CaM binding 4 calcium ions and subsequent 
conformational change allowing CaM to relieve the autoinhibition of its target kinases. 
One such target of CaM is calcineurin (protein phosphatase 2B), a serine/threonine 
phosphatase that binds directly to the transcription factor NFAT (nuclear factor of activated 
T cells) leading to its dephosphorylation allowing it to translocate from the cytosol to the 
nucleus (Hogan et al., 2003; Ikura et al., 2002). Additionally, CaMKs can activate the 
transcription factor CREB (cAMP response element binding protein) and SRF (serum 
response factor) (fig. 5.1). It has been shown that NFAT regulates the expression of 
various cytokines, such as IL-2, IL-4, IL-12 and T N F a (Luo et al., 1996; Rao et al., 1997). 
Calcineurin has also been demonstrated to be involved in the negative regulation of
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CXCR4 expression in T cells (Cristillo and Bierer, 2003), and NFAT is involved in the 
regulation of chemokine (CCL4, CCL2) production by GPCR (fMLP) activation (and 
required the synergistic interaction of the ERK pathway) (Ali et al., 2000). Currently there 
is sparse data regarding the role of chemokine-activated NFAT (if it is even activated) but it 
is possible that chemokine stimulation may lead to changes in expression of various 
chemokine receptors and chemokine expression profiles i.e. T cell differentiation, and 
involved in T cell proliferation via increased secretion of cytokines e.g. IL-2. Any effect 
calcium is having on transcription is in addition to the effects it has in mediating classical 
PKC, Pyk2 and other kinase activation. Calcium is additionally thought to have a 
substantial role in cell adhesion and it is possible that in transendothelial migration studies, 
where adhesion will be a part, calcium may be required for chemokine-mediated migration 
(Hofman et al., 1999; Rouleau et al., 2003).
Adhesion
Gene Transcription
Figure 5.1. A selection of possible calcium-influenced pathways activated by CCR4 in 
T cells. See text for more details. Abbreviations (not explained in text): cPKC, classical 
PKC isoforms; CBP, CREB-binding protein;® = phosphorylated serines.
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ERK
The ERK-MAPK cascade is a major player in regulating gene expression in eukaryotic 
cells, with ERK able to activate a plethora of substrate proteins that include MSK1/2 
(mitogen- and stress-activated kinase 1/2), p90RSK, MNK1/2 (MAP kinase interacting 
kinase 1/2), SRF, AP-1, CREB, Histone H3, Ets, Elk-1, STAT1-3 and c-myc/n-myc (Waas 
et al., 2004). Transcription factors such as Elk-1, c-myc and CREB are generally thought 
to be involved in cell proliferation and differentiation and various chemokines have been 
demonstrated to activate these transcription factors (e.g. Elk-1, CREB, AP-1, c-myc) (Kim 
et al., 2003; Lentzsch et al., 2003; Majka et al., 2000b; Rincon, 2001; Schaeffer and Weber, 
1999; Suzuki et al., 2001; Yang et al., 2001; Zhang et al., 2002). Thus, chemokines may 
serve to amplify the immune response and as a consequence, in certain cases, prolong the 
inflammatory reaction via the activation of the ERK-MAPK pathway. Additionally, ERK 
activation of p90RSK can lead to the inhibition of the pro-apoptotic protein Bad, thereby 
promoting cell survival.
PKB
Following its activation, PKB transduces signals that regulate multiple biological processes 
via an abundance of effectors (see ‘Introduction’ for a sample of these). PKB is widely 
considered to be involved in processes that include apoptosis, gene expression and cellular 
proliferation. Indeed, a number of chemokines have been shown to inhibit apoptosis in a 
PI3K-PKB-dependent manner, including CCL25 (CCR9), CXCL12 and CCL19/21 (CCR7) 
(Hideshima et al., 2002; Sanchez-Sanchez et al., 2004; Youn et al., 2002). Furthermore, 
CXCL12 has been determined to phosphorylate (thereby inhibiting) Bad in a PI3K- 
dependent manner in T cells (Hideshima et al., 2002; Suzuki et al., 2001). The anti- 
apoptotic effects of CCL19/21 were established to be via the activation of NF-kB in mature 
DCs, probably via a PD K  regulated pathway (Sanchez-Sanchez et al., 2004). Additionally, 
a number of chemokines can promote proliferation in a PI3K-dependent manner, including 
CXCL16 (Chandrasekar et al., 2003a). Finally, CX3CL1 is able to induce its own 
expression via the PI3K-PKB-NF-kB signalling cascade (Chandrasekar et al., 2003b). It is 
conceivable that CCR4 ligation is likely to deliver a pro-survival signal to the cell and
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generate a proliferative response. CCR4-mediated PKB activation can also potentially 
have a role to play in other processes, such as vesicular trafficking (Chan et al., 1999).
5.2 Potential Signalling Pathways Required for CCR4-Mediated T 
Cell Chemotaxis
As has been discussed earlier, there is likely to be more than one signalling cascade 
required for cell motility in response to a chemotactic gradient. The motile cell performs a 
crawling movement with pseudopodia, detachment and contraction closely co-ordinated 
with one another to provide a smooth and efficient process. This thesis has found at least 
one pathway that is essential, namely the Rho-ROCK pathway. Other pathways that have 
been established to be required for a cell’s ability to move in response to various stimuli 
(not necessarily to chemokines) include the cdc42 and Rac pathways, which are purported 
to control filopodia and lamellipodia formation, respectively, via actin 
polymerisation/depolymerisation processes (Haddad et al., 2001). These cascades are 
complex and beyond the scope of this thesis. In brief, the cdc42 GTPase binds to the 
Wiskott-Aldrich syndrome protein (WASP), which recruits ARP2/3 (actin-related protein 
2/3) complex and initiates the barbed-end growth of actin filaments by enhancing 
nucleation. Similarly, Rac binds the WASP family protein WAVE, which also recruits 
ARP2/3 to form new barbed ends. Rac is additionally able to recruit the serine/threonine 
kinase PAK (p21 -activated kinase) that co-localises with F-actin in membrane ruffles and 
to lamellipodia, where it helps mediate actin assembly. PAK can additionally 
phosphorylate LIM kinase (LIMK) that then phosphorylates and inactivates cofilin, thereby 
inhibiting cofilin’s actin depolymerising and severing activity. The activity of cofilin is 
required though to eventually block lamellipod extension and this maybe via a PLC- 
dependent phosphatase (and may also require PKC activity) that relieves the inhibition of 
cofilin (Matsui et al., 2001; Zhan et al., 2003). Blocking actin depolymerisation will inhibit 
polarised (but not random) lamellipodia extension demonstrating the importance of 
concomitant depolymerising activity in the lamellipod (Cramer, 1999; Zebda et al., 2000). 
CXCL12 has been reported to activate LIMK and subsequent phosphorylation of cofilin in 
T cells and is required for chemotaxis (Nishita et al., 2002). Finally, the 140 kDa formin
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mDia can regulate actin polymerisation through its interaction with the actin-polymerising 
protein profilin. Profilin has been shown to be involved in T cell migration through 
regulation of the F-actin/G-actin ratio, thereby modulating the availability of actin for other 
effectors (e.g. such as those involved in lamellipodia formation) (Vicente-Manzanares et 
al., 2003). There are a number of excellent reviews that cover the roles of cdc42/rac 
signalling in migration and the reader is encouraged to read these in order to obtain an 
overall understanding of the complexities of the pathways that are likely to be involved in T 
cell chemotaxis (Burridge and Wennerberg, 2004; Chung et al., 2001; Matozaki et al., 
2000; Raftopoulou and Hall, 2004; Samstag et al., 2003; Sanchez-Madrid and del Pozo, 
1999; Small et al., 2002). Figure 5.2 incorporates these cascades, along with the essential 
pathways reported within this thesis, in to a schematic diagram of potential/required CCR4 
signal transduction in T cell chemotaxis. The proposed mechanism of 



















Figure 52. Potential pathways involved in CCK4-mediated 1 cell chemotaxis. Activation ot molecules highlighted in pink is essential tor CCK4-mediated 1 cell chemotaxis (trom results presented within 
thesis), whilst molecules highlighted in green have been shown to be downstream of ligated CCR4. Dotted lines represent possible indirect routes. This is by no means a comprehensive model of the signalling 
cascades and the level of cross-talk in T cell chemotaxis, but does highlight some of the major routes and potential interactions. Abbreviations (not defined within text): CAS, Crk-associated substrate; ELMO, 
engulfment and cell motility (CED-12); LIMK, Lin-11 Isl-1 Mec-3 kinase; MHC, myosin heavy chain; WAVE, WASP family verprolin-homologous protein.
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Figure 5.3. D endritic nucleation/array (process of forming actin filament branches) 
treadm illing model for protrusion of the leading edge. (1) Extracellular signals activate 
receptors. (2) The associated signal transduction pathways produce active Rho-family 
GTPases and PIP2 that (3) activate WASp/Scar proteins. (4) WASp/Scar proteins bring 
together Arp2/3 complex and an actin monomer on the side of a pre-existing filament to 
form a branch. (5) Rapid growth at the barbed end of the new branch (6) pushes the 
membrane forward. (7) Capping protein terminates growth within a second or two. (8) 
Filaments age by hydrolysis of ATP bound to each actin subunit (white subunits turn 
yellow) followed by dissociation of the _ phosphate (subunits turn red). (9) ADF/cofilin 
promotes phosphate dissociation, severs ADP-actin filaments and promotes dissociation of 
ADP-actin from filament ends. (10) Profilin catalyses the exchange of ADP for ATP 
(turning the subunits white), returning subunits to (11) the pool of ATP-actin bound to 
profilin, ready to elongate barbed ends as they become available. (12) Rho-family GTPases 
also activate PAK and LIM kinase, which phosphorylates ADF/cofilin. This tends to slow 
down the turnover of the filaments (Pollard and Borisy, 2003).
249
(Overall °<$iscussien S< &endusums
53  Overall Conclusion
As has been mentioned before, the pathways stimulated upon CCR4 ligation have not been 
examined, which provided an exciting window of opportunity in which to investigate. The 
results presented within this thesis have established, for the first time, a number of CCR4- 
induced signalling cascades, including that of the PI3K-PKB, ERK-MAPK and Rho- 
ROCK-MLC pathways, in T lymphocytes (or for any cell). Furthermore, a reasonably 
comprehensive examination of CCR4-mediated intracellular calcium mobilisation has been 
performed, and established that a calcium flux is redundant in the chemotactic response to 
MDC. This study also provides, for the first time, strong evidence for the lack of 
participation of PI3K in certain chemokine-mediated T cell migratory events (in this case 
CCR4). In comparison to results published for other receptors, it is clear that chemokines 
generally activate similar cascades with minor variations. However, the relevance of these 
cascades towards a cell’s migratory response appears to vary quite considerably, with the 
most notable differences being the requirement (or lack of) PI3K and DOCK2 activity. It is 
very likely that as the chemokine signalling field develops more and more, variations will 
be observed in the signalling cascades that are activated/inhibited, along with disparities in 
those pathways required for cell migration. It will be intriguing to learn whether CCR4 
signalling is similar in lymphocytes as in myeloid cells (e.g. monocytes) and whether there 
is a similar lack of necessity for lipid PI3K activity. It will also been interesting to 
elucidate whether PI3K is participating in chemotaxis independently of its lipid kinase 
activity. The work presented within has utilised, to a great extent, a variety of 
pharmacological inhibitors. It needs to be stressed that the majority of inhibitors are 
limited by their specificity, but if used at rational concentrations they can provide a good 
indication of a target molecule’s requirement in a signalling pathway/response. 
Throughout this thesis inhibitors have been used at concentrations deemed to be selective 
for their target, as reported in the literature.
It is clear that, although this thesis has provided a greater understanding in to the pathways 
that regulate cell migration, there are still a vast number of unanswered questions 
remaining concerning the cascades involved in chemotaxis and the role of various 
pathways in non-chemotactic events. However, this thesis has hopefully provided some 
strong foundations for which future work can be built on.
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Appendix /, (Recipes
6.1 Appendix 1: Recipes
Recipes for SDS-PAGE and Western Blotting
4 x  Resolving Gel Buffer





p H  8 .8
4 x  Stacking Gel Buffer





p H  6 .8
Formulae fo r  SDS-PAGE Gel Solutions made with resolving and stacking gel buffers 
containing 0.4% SDS (SDS at a fina l concentration o f 0.1% fo r all gels):
■
y. ______
5.0 ml 5.0 ml 5.0 ml 5.0 ml 5.0 ml 5.0 ml 3.0 ml
150 |Lil 1 150 p.1 | 150 pi | 150 pi 1 150 |il | 150 pi 150 pi
10% Ammonium Persulphate (APS) 





25 mM Tris 15.15





39 mM glycine 2.93
SDS 0.375
Methanol 200 ml
Transfer conditions: 0.8 mA/cm2, i.e. 163.2 mA for 4 x (8.5 x 6.0) cm gels.
10 x Washing/Blocking Buffer
g/L
10 m M Tris 12.11 p H 7.5
100 mM NaCl 58.44
0.1 % Tween-20 (TBST only, omit for TBS) 10.0 ml
For blocking add appropriate reagent e.g. 5% (w/v) non-fat milk powder, or 1% (w/v) BSA 
(see Appendix 5).
10% Sodium Azide




100 mM 2-mercaptoethanol (stock: 14.3 M)
2% SDS
62.5 mM Tris-HCl (stock: 200 mM, pH 6.8 -  24.22 g/1 L MQH20 )
m q h 2o
Recipes for Cell Stimulations
2 x Sample Buffer













20 mM Tris (121.1 MW) 0.242
137 mM NaCl (58.44 MW) 0.801
10 mM NaF (41.99 MW), 2.00 ml
500 mM stock: 420 mg/20 ml MQH20
1 mM EDTA (372.2 MW), 1.00 ml
100 mM stock: 372.24 mg/10 ml MQH20
10% glycerol (w/v) 10.00
1 % NP-40 (w/v) 1.00
1 mM Sodium orthovanadate (189.3 MW), 0.2 (ll/ml
500 mM stock: 0.09195 g in 1.0 ml MQH20
1 mM PMSF (174.2 MW), 2 |xl/ml
500 mM stock: 0.0871 g in 1.0 ml DMSO
Aprotinin (2 mg/ml stock in MQH20 )  2 p,l/ml
Leupeptin (2 mg/ml stock in MQH20 )  2 pl/ml














Recipes for In Vitro Lipid Kinase Assay
Lysis Buffer
g/L
20 mM Tris (121.1 MW) 0.242
137 mM NaCl (58.44 MW) 0.801
1 mM MgCl2 (203.3 MW), 1.0 ml
100 mM stock: 203.3 m g/10 ml MQH20
1 mM CaCl2 (219.1 MW), 1.0 ml
100 mM stock: 219.1 mg/10 ml MQH20
10% Glycerol (w/v) 10.00
1 % NP-40 (w/v) 1.00
1 mM Sodium orthovanadate (189.3 MW), 0.2 |xl/ml~^
500 mM stock: 0.09195 g in 1.0 ml MQH20
1 mM PMSF (174.2 MW), 2 pl/ml
500 mM stock: 0.0871 g in 1.0 ml DMSO
Aprotinin (2 mg/ml stock in MQH20 )  2 pl/ml
Leupeptin (2 mg/ml stock in MQH20 )  2 pl/ml













KH2P 0 4 0.20
NP-40 (w/v) 10.00





100m M Tris 1.21 pH 7.4
5 mM LiCl (42.39 MW), 100 mM stock: 42.39 mg/10 ml MQH20  5.0 ml




10 Mm Tris 0.121 pH 7.4
150 mM NaCl 0.88
5 mM EDTA (372.24 MW), 5.0 ml
100 mM stock: 372.24 m g/10 ml MQH20
100 pM  Sodium orthovanadate, 500 mM stock 0.2 pl/ml (add on day of
use)
ATP Kinase Buffer
0.88 mM ATP, 8.8 mM stock: 8.8 pi (100 mM stock)/100 pi 10 mM Tris
20 mM MgCl2, 200 mM MgCl2 stock: 20.33 g/20 mis MQH20
5 pCi/5 pi [y32P]-ATP: e.g. (stock: 10 pCi/1 pi) for 10 samples require 50 pCi in 50 pi 
.*.5 pi y-ATP + 5 pi 8.8 mM ATP + 5 pi 200 mM MgCl2 + 35 pi 10 mM Tri * 
= 50 pCi/50 pi
* Note: make solution up to volume with 10 mM Tris (pH 7.4)
SNHCl(lOOml)
43 ml concentrated HC1 (36% pure, 1.18 g/ml density) + 57 ml MQH20  
TLC Tank Resolving Buffer (120.3 ml)
Chloroform 60.0 ml
Methanol 47.0 ml
MQH20  11.3 ml
Ammonium hydroxide 2.0 ml
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Recipes for Lipid Labelling
Media
Sterile phosphate-free DMEM (1 L) supplemented with sodium bicarbonate (49 ml of 7.5% 
stock) and 20 mM HEPES.
Primary Extraction Phase Solution
Chloroform 32.6 ml
Methanol 65.3 ml
MQH20  2.1m l
10 fJg/ml Folch Lipids (prepared just before use)
1 mg Folch lipids (from bovine brain, Folch fraction I lipids) in 100 ml chloroform
2.4 M HCl, 5 mM Tetrabutylammonium Sulphate (TEAS) (prepared just before use)
MQH2O 39.7 ml
HCl (concentrated) 10.3 ml
TBAS 85 mg
0.1 M HCl,  5 mM EDTA (prepared just before use)
MQH20  47.07 ml
100 mM EDTA 2.50 ml









Petroleum ether (bp 40 - 60°C) 16 ml
Ethyl formate 4 ml
1.25 M Ammonium Phosphate
(NH4)2H P 0 4 165.08 g/1 L MQH20  pH 3.8 *
* Note: pH adjusted with phosphoric acid (H3PO4). Buffer is filtered through 2 pm  filters 
prior to use, and if not used immediately, degassed by re-filtering and bubbling through N2 
for 30 min before using.
Recipes for Concorde/MERLIN Calcium Assay 
Physiological Salt Solution (PSS)
g/500 ml (lOx stock) -  pH 7.5
1.35 M Sodium chloride 39.45
54 mM Potassium chloride 2.00
20 mM Magnesium chloride 2.03
100 mM HEPES 11.91
2 mM* Calcium chloride 2 ml of 1 M stock/1 L*
10 mM* Glucose 1.8g/l L*
*CaCl2 and glucose are added to the 1 x PSS solution just prior to use, thus amounts and 




500 jig Fura-2 is dissolved in 99.8 jllI pluronic F-127 acid (20% (w/v) DMSO) to give a 5 
mM stock (1000 x working concentration). A working concentration is obtained by the 
addition of 10 jllI 5 mM Fura-2 to 10 ml PSS. Cells are ‘loaded’ with 1 ml of this solution 
for 30 min in the dark.
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° ^ N H ,
Targ et  N otes
JAK2/3 Inhibitor of JAK2
phosphorylation. Also
inhibits EGFR kinase (IC50 = 
100 nM) and JAK3. Light 
sensitive.
Inactive An inactive compound that is 
used as a negative control for 
AG490 and other tyrphostins. 
Light sensitive.
IP3R C a2+ Inhibits IP3-induced calcium 
release (IC50 = 42 |iM ) 
without affecting IP3 binding 
to its receptor. Does not 







calcium release from 
caffeine-insensitive stores. 
Has no effect on the release 





Increases the calcium affinity 
of the calcium activation site 
of the RR at millimolar 
concentrations. In certain 
circumstances, caffeine will 
also induce the release of 
calcium from RR stores.
Inhibits binding of ryanodine 
but not of IP3. Binds to the 
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cPKC Selective for the calcium-
dependent PKCs (IC50 = 2-6 
Nm). Does not affect nPKC 
or aPKC activity. Inhibition 
is via competition with ATP 
and not protein substrate.




A stereospecific inhibitor of 
NO formation from L- 
arginine that is light sensitive. 
Competitive and a slowly 
reversible inhibitor of NOS 
(IC50 = 500 nM).
PI3K Inhibits (reversibly) PI3K 
(IC50 = 1.4 juM), with greater 
potency for the class I PI3K 
isoforms over the class II 
members. Acts at the ATP- 
binding site of PI3K.
H,COOC .COOCH;
H3C





blocker of L-type Ca 





MEK A light sensitive inhibitor of 
MAPK kinase (MEK). Acts 
by binding to the inactivated 
form of MEK, thereby 
OCH3 preventing its
phosphorylation by c-Raf or 
MEK kinase (IC50 = 2-7 pM). 
May act via an allosteric 
mechanism.
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Pertussis Toxin
An exotoxin (holotoxin) 
consisting of 952 residues 
forming six subunits (S l- 
S5). Catalytic A subunit = 
SI; Cell binding B oligomer 
= S2, S3, S4 (x 2) and S5.
G ai Catalyses ADP-ribosylation
of guanine nucleotide-binding 
regulatory proteins G ai, G ao 
and G ar. Thus preventing 
the G protein heterotrimers 
from interacting with 
receptors. The a  subunits 
remain in their GDP-bound 





PKB Blocks PKB (IC50 = 2 pM) 
with more than 40-fold 
selectivity over PI3K (IC50 = 
83 pM). Inhibition appears 
to be mediated through 




PKC A selective cell permable
(light sensitive) PKC 
inhibitor (via ATP-binding 
competition, IC50 = 9 - 1 0 0  
nM) of both classical and 
novel isoforms (but with 
slightly better activity against 




PKCS(?) Initially identified as PKC8 
isoform selective inhibitor 
(ATP-binding site, IC50 = 3-6 
pM ) with up to 10-fold 
selectivity over other 
isoforms. However, recent 





R R C a2+
c h , ch3 ho
I I nw »un3
Able to both inhibit and 
activate RRs. RR receptors 
have a low- and high-affinity 
site for ryanodine. 
Nanomolar concentrations 
sensitise the RR to CICR 
with micromolar amounts 
inhibiting.
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0 ~ 0 ~ oH
p38
IH rt— \  O
K M ,
NF-kB?










inhibitor of p38 MAPK (IC50 
= 16 nM (350 nM in cells)). 
Light sensitive. Binds ATP 
site in the enzyme’s inactive 
state.
A light sensitive inhibitor of 
p38, with less potency than 
SB202190 (IC50 = 34 nM 
(600 nM in cells)). However, 
exhibits the same mode of 
action as SB202190.
Inhibits trypsin-like serine 
proteases. Blocks activation 
of NF-kB and subsequent 
induction of the iNOS and 
COX2 genes. Effective 
concentration = 10 -  100 juM. 
Blocks activation of p70S6K 
by all mitogens. Inactivates 
trypsin irreversibly. No 
effect on chymotrypsin.
Inhibits chymotrypsin-like 
serine proteases. Blocks 
activation of NF-kB and 
subsequent induction of the 
iNOS and COX2 genes. 
Effective concentration = 1 0  
- 1 0 0  pM. Blocks activation 
of p70S6K by all mitogens. 
No effect on trypsin.
An aminosteroid that inhibits 
G protein-mediated PLC 
activation (IC50 = 1 - 2  pM  in 
cells), possibly in a non­
competitive manner.
The inactive analogue of 
U73122 and consequently 
used as a negative control.
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WHI-P154 JAK3 A potent, cell-permeable, 
specific inhibitor of JAK3 
(IC50 = 5.6 pM). Has no 
effect on either JAK1 or 
JAK2. Inhibition is via 
binding to the catalytic site of 
JAK3. Light sensitive.
Wortmannin
CH3u  y CH
PI3K A potent and light-sensitive 
non-competitive and
irreversible inhibitor of all 
classes of PI3K, with greater 
potency against the class I 
PI3K isoforms (IC50 = 2 - 4  
nM). Structurally dissimilar 
to LY294002, and therefore 
useful for separating non- 
PI3K inhibitory activity from 
that of PI3K when used with 
LY294002. Activity is via 




ROCKI/II A highly potent, cell- 
permeable and selective 
inhibitor of Rho-associated 
protein kinases (both ROCK I 
and II = 140 nM). Inhibition 
is competitive with respect to 
ATP. Light-sensitive.
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6.3 Appendix 3: Inhibitor Practical Information
m m a
2 APB lP3R-mediated calcium 
release
2.25 -  75 liM 1 hr
JAK2/3 Lip lo 100 uM 1 In
Caffeine* R R - mediatcd ca Id  u rnrelease 10 mM 30 min
30 -  300 nMG56976 Classical PKC 0 miu
.Y294002 30 miu3 -  30 m M
PKBi
PD98059 Ml K 1/2 3 - 20 p M
Classical and novel PKC 30 minRO-32-0432 10 uM
Ryanodine RR-mediated calcium release 100 jiM 30 min
t l c k Serine proteases (NF-k'B) 3 -  100 uM hr
b h I HS!W
U73122 PLC 0 .3 -  IOrM I hr
WHI-P 54 JAK3 50 liM
Y-27632 ROCK I -  10 pM
* Caffeine utilised at an activating concentration.
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6.4 Appendix 4: Antibody Affinities
Binding Strengths of Immunoglobulins to Protein A and Protein G
H um an
IgG, + + + +
IgG2 + + + +
IgG3 — + +
IgG4 + + + +
IgM + —
IgA + —














IgG2a — + +
IgG2b — +
IgG2c + + +
R abbit IgG + + + +
Horse IgG + + +
Pig IgG + + + +
Sheep IgG,
— + +
IgG2 + + + +
Goat IgG + + + +
Chicken — ----
Cow IgG, + +
IgG2
+ + = Strong binding 
+ = Moderate binding
-  = No binding
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6.5 Appendix 5: Western Blotting Conditions
Pan-F.RK 1/2 
(Ab = 1 in 1000) 1 0 44/42
19c BSA in TBS
+ azide. 1 % BSA + azide in TBST. 3hrs. rtp.
5 '7c milk in TBST, 1 hr, 
rtp. Anti-rabbit Ig = 1 in 
KXMM)
Pan-CiSK-?n/p 
(A b= 1 in 1000) 10 51/46 + azide, overnight, rtp.
19? BSA + azide in 
TBST. 3hr. rip.
5‘ . milk in TBST. Ihr. 




(Ab -  1 in l(HX))_________
7.5 90 5% milk in TBS. 3hrs, rtp.
35i BSA +• azide in 
TBST. overnight, 
rtp._______ _
591 milk in TBST. Ihr. 




(Ah= 1 in l(KX))
1 0 60 1% milk in TBS. 1 hr. rtp.
19, BSA + azide in 
TBST, overnight,
rtP- . .
59; milk in TBST, Ihr. 
rtp. Anti-rabbit Ig = 1 in 
71XX).
Phospho p38
(Thr 180/Tyr 182) |()
<Ab= I in I (XX))
Pliospho MLC.2 
, (S er 19) 15
f Ah -  1 in 1000)
1 % milk in TBS. ™ T S A * ' ttif ”' '  ^ n',,k l" U:Vi 1,, TBST,Overnight ftp. Antl-rablnl Ig -
: ooo.
38 5He milk in TBS. 1 hr. rtp.
I r/t BSA + azide in 
TBST, overnight. 
np_________
V!< milk in TBST. I hr. 
rtp. Anti-rabbit lg = I in 
7(XX).
c t e .  n  - m e  1 ■*'' B S A  +  v U l d e i  i l l  , r . 5% imJk m TBS. ^  ,8  ... . TBST, overnirlu.
Mystery Protein i.e. 
phospho FKHR 
(Ser256)
(Ab = 1 in 1000)
PhOspbotyi osjnc (cion, 
4 0  JO)
(Ah -  i in 10b0)
PTHN
(Ab = I in 1000)
-2 0 0
7.5 or 5 (FKHR = 
75)
5% milk in TBS, 
2hr, rtp.
39? BSA + azide in 
TBST. overnight, 
rtp.
5% milk in TBST. I hr, 






J % BSA in TBS 
t- azide. 
ovemighi. np.
5% milk in TBS, 
I hr, rtp.
. . * 8 S A . * k W  5^  m H kinTBST, Ihr.
Tnsi,3i»;flp. Z "
19, BSA + azide in 
I TBST, overnight, 
rtp.
5% milk in TBST. I hr. 
rtp. Anti-rabbit Ig = I in 
7000.
PI3K-C2a 
(Ab = 1 in 1000) 7.5 170
591 milk in TBS, 
1 hr, rtp.
in TBST, overnight, 
rtp. rip. Anti-rabbit lg=  1 in 10000.r-
PI 3 K-pi 108 
(Ab = I in 1000) 7.5 110
1% BSA in TBS. 
1 hr. rtp.




(Ab = 1 in 1000) 7.5 78
5% milk in TBS, 
1 hr, rtp.
19. BSA + azide in 
TBST, overnight, 
rep.
594 milk in TBST. Ihr.
np. Anti-rabbit Ig = 1 in 
7000.
* azide is at 0.05% .
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1 A = 10‘10 m
(Angstrom) 10"8 cm 
1CT4 |im  
10'1 nm
Centigrade —> Fahrenheit























X X Chi'F V PsiQ CO Omega
Fahrenheit —*■ Centigrade 
°C = 0.555 x ( ° F - 32)
Purity of DNA
Pure DNA: A260/A280 ^  1.8
An A260/A280 < 1-8 indicates that the 
preparation is contaminated with proteins 
and aromatic substances (e.g. phenol).
An A260/A280 > 2.0 indicates a possible 
contamination with RNA.
Centrifugal force «-► revolutions per minute:
rpm =  1000/ H.CF_
V 1.12 x R
/rp m  \ 2 
R C F =  1.12 x R  ( io o o )
Where:
rpm = revolutions per minute 
RCF = relative centrifugal force 
R = radius of motor in mm
at room temperature.
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6.7 Appendix 7: Amino Acid Characteristics
A m in o
A c id
3 Single C hem ical P rop erties C o m p o s it io r  
o f  S ide / C\  








Alanine Ala A 89 GCU
GCG
GCC GCA Hydrophobic -CHj







Asparagine Asn N 132 AAU A AC Hydrophillic -CIL-CONH,
Aspartic Acid 
(Aspartate)
Asp D 133 GAU GAC Hydrophiilic -CHj-COOH
Cysteine Cys C 121 UGU UGC -CH2-SH
Glutamine Gin Q 146 CAA CAG Hydrophillic -CHrCIL-CONH:
Glutamic Acid 
(Glutamate)
Glu E 147 GAA GAG Hydrophiilic -CH,-CH,-COOH
Glycine Gly G 75 GGU
GGG
GGC GGA -H
Histidine His H 155 CAU CAC Hydrophillic -c h 2-c ,n ,h /
(C.iNjH /  = imidazole)
Isoleucine lie I 131 AUU AUC AUA Hydrophobic -CH(CHj)-CH2-CHj







Lysine Lys K 146 AAA AAG Hydrophillic -(CH2)4-NH2
Methionine Met M 149 AUG Hydrophobic -CH2-CH2-S-CHj




Proline Pro P 115 ecu
CCG
CCC CCA -(CH2)3
((CH2)3 = proline ring)







Threonine Thr T 119 U  I
ACG
ACC ACA Hydrophillic -CH(CH.i)-OH




Tyrosine Tyr Y 181 UAU UAC Hydrophobic -CH2-C6H«-OH 
(C«H« = benzene)
Valine Val V 117 GUU
GUG
GUC GUA Hydrophobic -CH-(CHj)2
Basic amino acids are shown in blue, acidic amino acids in red, neutral amino acids in black, 
and amino acids with uncharged, polar residues in green. Average MW =110 Da.
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6.8 Appendix 8: Schematic Kinase Structures & Phosphorylation
Non-Receptor Tyrosine Kinases
FAK _ _  FAK, Pyk2
Src
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PI3K Isoforms
pllO a, fr 8p85 Binding
SH3HT&Kcdc42 Bini
Class I
[ i l l C 2  > C  PIK
Class I I
Auto-phosphorylation 
site (not In a, only p and
p85a  5(SerlM,))

























]— 1 Kinase ^  Domain
Tyr27*












Ser371, T h r3** S e r" 4 Ser411* 11'424 
T h r " 1
Auto-inhibitory domain
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  K in ase Domain
1 H D ----------
Thr2*2,
Tyr2",
00—  E R K , JN K , p38
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PKA
P K P










 Cc24ike^— {Cl a)—
Thr508 Thr*‘*l Ser***
m i i l E  C 3 ■  Kinase Domain _  Novel
Thr5*® Thr71" Ser7»
A typical
T h r T hr5*®
Activation ▲ \  Hydrophobic
l0°P | motif
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G TPases







Switch I Switch H
r 'S
Ras, Roc, Rho, cdc42







Inhibits Gab2 Tyr domain-binding domain-binding 
phosphorylation y reg(on region
—^ 3 ^ —o — i s o — — q-15©-
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Diagrams display the domains present in each protein, with regions of interest highlighted 
along with residues that have been demonstrated to play an important role in the protein’s 
function when phosphorylated (indicated w ith© ).
Domain Abbreviations: AC, acidic domain; AP, alanine- and proline-rich domain; BD, 
binding domain; CaLB, calmodulin-binding domain; CD, common docking domain (also 
known as cytoplasmic retention sequence (CRS)); CH I, collagen homology domain 1; CR, 
conserved region; CRD, cysteine-rich domain; CT, C-terminal; D, docking domain; DD, 
dimerisation domain; E, effector-binding domain; EDS, ERK docking site; EF, EF hand 
domain; FAT, focal adhesion targeting domain; FERM/4.1, band 4.1/ezrin/radixin/moesin 
domain; L, linker domain; Loop, loop domain; MD, membrane-binding domain; NES, 
nuclear export sequence; NT, N-terminal; NTD, nuclear targeting domain; P/G, P/G box; 
PD, proline-rich domain; PH, pleckstrin-homology domain; PID, PIP2-interacting domain; 
PS, pseudosubstrate; PIK, phosphatidylinositol kinase domain; PTB, phosphotyrosine- 
binding domain; PTPase, protein tyrosine phosphatase; PX, phox homology domain; R, 
regulatory domain; RBD, ras-binding domain; RoBD, rho-binding domain; SH2, src- 
homology 2 domain; SH3, src-homology 3 domain; ?, membrane-associating domain?
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6.9 Appendix 9: Protein Interaction Domains
D o m a in  B i n d in g  S p e c if ic it y  P r o t e in  E x a m p l e s  
o r  R o l e
D e s c r i p t i o n
SH2 Phospho-tyrosine Btk, p85, Grb2, SHIP Src-homology 2 (SH2) domains 
are modules of approximately 
100 amino acids that 
bind specific phosphotyrosine- 
containing peptide motifs (e.g 
p85 SH2 recognises pYXXM 
in target proteins), normally 
between 3-6 residues in size.
PTB Phospho-tyrosine She, IRS-1
14-3-3 Phospho-ser/thr 14-3-3 5
Phosphotyrosine binding (PTB) 
domains are modules ranging 
from 100 -  150 amino acids 
that commonly bind Asn-Pro- 
X-Tyr (NPXpY) motifs (e.g. in 
the insulin receptor), but 
require more amino-terminal 
residues for high affinity 
binding (~ 12 residues in total).
In mammals there are nine 
closely related 14-3-3 proteins 
that are 30 kDa in size and bind 
phosphoseri ne-contai ni ng 
motifs in binding partners (e.g. 
MEKK, c-Raf, PKC).
FHA Phospho-ser/thr AF-6, Rad 53 The Forkhead-Associated 
(FHA) domain is 65 -  100 
amino acids long, containing 
several highly conserved key 
residues, which bind pTXXX 
peptides among others.
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PH Phospholipid PK B, PLC, PDK A wide variety of proteins that 
associate with membranes 
contain pleckstrin homology 
(PH) domains. Some PH 
domains bind specific 
phosphoinositides (e.g. PLC 
and PI(4,5)P2, PKB and 3’- 
phosphoinositides) leading to 
relocation at membranes.
FERM Phospholipid Radixin, Ezrin, Moesin Named after the initial 4
proteins the it was found in, the 
FERM domain is about 150 
amino acids and is found in a 
variety of cytoskeletal- 
associated proteins. FERM 
domain is required PI(4,5)P2- 
regulated membrane binding of 
ERM. FERM domain of 
Radixin additionally recognises 
IP3 as a ligand.
FYVE Phospholipid Hrs-2, FGD1, SARA The FYVE (Fab-1, YOTB,
Vacl and EEA1) domain has 
been identified in more than 60 
proteins and is a small, 
cysteine-rich Zn2+ binding 
domain of roughly 60 amino 
acids. It displays specificity for 
PI(3)P and consequently has 
implicated FYVE domain- 
containing proteins
downstream of PI3K.
ENTH Phospholipid Epsin 1, A P180 The Epsin NH2-terminal 
homology (ENTH) domain is a 
membrane-binding motif of 
approximately 140 amino acids 
with selectivity for PI(4,5)P2. 
ENTH domain containing 
proteins have been implicated 
as clathrin adaptors in 
endocytosis.
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PX Phospholipid PLD 1/2, PI3K
C 1 Phospholipid PKC isoforms, c-Raf
C2 Phospholipid PKCp, Perforin 1
WW Pro-rich sequence FBP-11, YAP
GYF Pro-rich sequence CD2BP2, Smy2
One of the most recently 
identified members of the 
phospholipid binding domains. 
Phox Homology (PX) domains 
are ~ 120 amino acids and 
function predominantly as D3- 
phosphorylated
phosphoinositide [PI(3)P] 
binding modules, targeting the 
PX domain-containing proteins 
to the membranes.
Domains that are enriched in 
cysteines of approximately 50 
amino acids and are involved in 
the recruitment of proteins to 
the membrane. Cl domains 
generally bind DAG or phorbyl 
esters.
A region of 130 or so amino 
acids that is involved in binding 
phospholipids in a calcium- 
dependent or independent 
manner. Found in more than 
100 proteins with functions 
ranging from signal 
transduction to vesicular 
trafficking.
Small 38 -  40 amino acid 
residue modules that potentially 
bind overlapping sites with 
SH3 domains.
Glycine-tyrosine-phenylalanine 
(GYF) is a proline-rich peptide- 
binding domain but is 
structurally unrelated to SH3 or 
WW domains. CD2BP2 binds 
a proline-rich peptide sequence 
in tail region of CD2.
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SH3 Pro-rich sequence p85, Grb2, Src
EVH1 Pro-rich sequence WASP, MENA
DD Apoptosis NF-kB p i00, DAPK
BIR Apoptosis IAP-1, Survivin
Found in numerous proteins, 
the Src-homology 3 (SH3)
domains bind to proline-rich 
peptides that form a left-handed 
poly-Pro type II helix, with the 
minimal consensus Pro-X-X- 
Pro. Src SH3 can bind a motif 
within p85 PI3K.
A module of -110 amino acids 
found in some scaffolding 
proteins involved in the control 
of the actin cytoskeleton. 
Ena/Vasp Homology domain 1 
(EVH1) recognise proline-rich 
motifs in components of the 
cytoskeleton, such as vinculin 
and Zyxin.
Death domains (DD) are 80 -  
100 residue motifs involved in 
apoptosis signalling. Found in 
both receptors (e.g. TNF 
family) and cytoplasmic 
proteins, they heterodimerize 
with death domains of distinct 
proteins (e.g. FADD adaptor) 
via electrostatic interactions.
The Baculovirus IAP Repeat 
(BIR) domain is a -70  amino 
acid zinc-binding module. It 
has been demonstrated to be 
necessary for the interaction of 
Inhibitors of Apoptosis (IAP) 
proteins with diverse 
proapoptotic factors, promoting 
cell survival.
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Apoptosis FADD, Procaspase-10 The Death Effector Domain
(DED) is found in inactive 
procaspases and proteins that 
regulate caspase activation. 
DEDs recruit procaspases into 
complexes with adaptor 
molecules containing a second 
DED that is directly associated 
with activated TNF receptors.
Apoptosis Procaspase-2, APAF-1 Caspase Recruitment Domains
(CARDs) act in a similar 
manner to that of the DED 
domains. They are modules of 
90 -  100 amino acids, and like 
DEDs, mediate the 
heterodimerisation of adaptor 
proteins and procaspases via 
their respective CARDs.
Apoptosis Bcl-2, BAX, Bcl-xL Bcl-2 Homology (BH1-4) 
domains are found in proteins 
that inhibit apoptosis. These 
proteins can form homo- or 
heterodimers via these various 
BH domains found in both 
interacting molecules.
Protein interactions pi 15RhoGEF, RGS4 The RGS (Regulator of G
(known specificity) Protein Signalling) is typically
about 120 amino acids in 
length. RGS domains act 
allosterically by stabilizing the 
transition intermediate of the 
GTP binding pocket of the 
alpha subunit of heterotrimeric 
G proteins. This results in the 
acceleration of the intrinsic 
GTPase activity of that alpha 
subunit.
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FAP, PSD-95, Dsh PDZ domains bind to 4 -  5 
residues of their target proteins 
(normally transmembrane 
receptors or ion channels) with 
high affinity. The consensus 
sequence is found in the C- 
terminus of target proteins and 
contains frequently contain a 
hydrophobic molecule (e.g. Val 
or lie), and the second and third 
residues determine specificity. 
Additionally, PDZ domains are 




Hrs, STAM, Vps27 Vps27p, Hrs and Stam (VHS) 
domain is approximately 150 
amino acids in size and bind 
target molecules via other 
domains, including Hrs with 
Hrs FYVE domain. The 
domain may play a role in 
receptor tyrosine kinases 
signalling and endocytosis.
Protein interactions DAPK, Shank 
(variable specificity)
Although ANK domains have 
been found in more than 600 
proteins, to date it is unknown 
what constitutes an ANK 
domain target. Targets of ANK 
domains include p53 and 
CDK6, and the cytoskeletal 
protein Ankyrin is almost 
entirely composed of these 
short 33 amino acid repeats.
Protein interactions B-Catenin, APC protein The Armadillo (ARM) 40
(variable specificity) amino acid repeat is named 
after the Drosophila protein it 
was found in (p-catenin is the 
human homologue). It has 
subsequently been found in 
more than 100 proteins with no 
common features among the 
target proteins identified.
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SAM Protein interactions 
(variable specificity)
Slp-76, CNK, Scm The Sterile Alpha Motif (SAM) 
has been implicated in the 
formation of homo- and 
heterotypic oligomers.
WD40 Protein interactions 
(variable specificity)
Gp, Prp4, Sec 13 The common functional theme 
of WD40 domains is to serve as 
a stable platform to which 
proteins can bind. WD40 
proteins do not have catalytic 
activity unlike the non-WD40 
propeller family of proteins. A 
notable protein that contains 
the WD40 domain is that of the 
G-protein P chain that allows it 
to bind the G-protein a,y- 
chains.
BRCT Protein interactions 
(variable specificity)
DNA ligase III, BARD BRCA1 C-terminus (BRCA1)
domains are found mostly in 
proteins involved in cell cycle 
checkpoint functions
responsive to DNA damage.
CC Protein interactions Statl, Fos, Jun
(variable specificity)
Coiled-coils (CC) domains 
function as oligomerisation 
domains for a number of 
proteins. It is thought that 5% 
of proteins encoded in 
sequenced genomes contain 
coiled-coils (two or more a- 
helices wrapped around each 
other with a superhelical twist). 
CCs can form homo- or 
heterotypic oligomers.
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Protein interactions LIMK, Enigma 
(variable specificity)
Identified initially in 3 
developmental^ regulated 
transcription factors Lin-1, Isl-1 
and Mec-3 (LIM) and now 
identified in more than 300 
proteins, the LIM domain is a 
zinc-binding, cysteine-rich 
motif consisting of 2 tandemly 
repeated zinc fingers. LIM 
domain containing proteins 




Skp2, TAP, Rnalp Leucine-Rich repeats (LRR) 
are 22 -  28 amino acid motifs 
involved in protein -  protein 
interactions and form crescent­
shaped structures acting as a 
scaffold for protein 
interactions.
Calcium Calmodulin, Calcineurin Approximately 40 residues in
size and is involved in binding 
intracellular calcium. Structural 
EF-hand domains seem to play 
a role in buffering intracellular 
calcium levels.
Cytoskeleton Cofilin, Drebrin, ADF The Actin-Depolymerising 
Factor (ADF) domain is found 
in proteins involved in F-actin 
severing. ADF proteins bind to 
monomeric and filamentous 
actin and sever actin filaments 
leading to faster actin turnover.
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CH Cytoskeleton Calponin, Vav The calponin homology (CH) 
domain is present in 
cytoskeletal and signal 
transduction proteins. Tandem 
CH (type 1 & 2) domains, at 
the amino terminus, bind F- 
actin and cross-link filaments 
into bundles and networks. 
Type 3 CH domains are found 
in proteins that regulate muscle 
contraction, such as calponin, 
as well as in signalling 
proteins, such as Vav, and may 
not interact directly with actin. 
Instead they act as regulatory 
domains or protein-protein 
interaction scaffolds to 
modulate the activity of 
proteins.
DH RhoGTPase RhoGEFs, Tiam- Dbl homology (DH) or
RhoGEF domains induce Rho 
family GTPases to displace 
GDP, thereby effectively
activating the Rho GTPase by 
allowing binding to GTP. The 
DH domain is usually 
proceeded by a PH domain, 
which appears to enhance 
catalytic efficiency. Also 
found in Rac/cdc42 binding
proteins
Dbl.
such as Tiaml and
Structural diagrams were obtained from Cell Signaling Technologies (www.cellsignal.com).
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Antigen presenting cell 
(APC)
Cell required for, but not actually mediating, a specific immune response. Often used to describe antigen- 
presenting cells (APC; see below).
A molecule that releases H+ ion (proton).
Immunity mediated by lymphocytes and characterized by antigen-specificity and memory.
Movement of a molecule across a membrane or other barrier driven by energy other than that stored in the 
concentration gradient or electrochemical gradient of the transported molecule.
Any substance that non specifically enhances the immune response to antigen.
The strength of binding (affinity constant) between a receptor (e.g. one antigen-binding site on an antibody) 
and a ligand (e.g. epitope on an antigen).
The aggregation of particulate antigen by antibodies. Agglutination applies to red blood cells as well as to 
bacteria and inert particles covered with antigen.
65 kDa serine/threonine protein kinase, also known as protein kinase B (PKB). Critical mediator of cell 
survival and major effector o f PI3K activity.
Variants of a polymorphic gene at a given genetic locus; alternative forms of a genetic locus; a single allele 
for each locus is inherited separately from each parent (e.g. at a locus for eye color the allele might result in 
blue or brown eyes).
Relating to one of a series of two or more alternate forms of a gene that occupy the same position or locus 
on a specific chromosome.
The phenomenon whereby, following successful rearrangement of one allele o f an antigen receptor gene, 
rearrangement o f the other parental allele is suppressed, thereby ensuring each lymphocyte expresses only a 
single specificity of antigen receptor.
An antigen responsible for producing allergic reactions by inducing IgE formation.
'Changed reactivity' of the host when meeting an 'agent* on a second or subsequent occasion mediated by 
IgE - IgE-mediated hypersensitivity, e.g. asthma, eczema, hay fever and food allergy.
The allelic variation (genetic differences) observed among members of the same species.
A tissue transplant (graft) between two genetically non-identical (allogenic) members of a species.
Reactive with foreign tissue type.
Antigenic determinants that are present in allelic (alternate) forms. When used in association with 
immunoglobulin, allotypes describe allelic variants o f immunoglobulins detected by antibodies raised 
between members of the same species (i.e. An allelic variant of an antigen, which, because it is not present 
in all individuals, may be immunogenic in members o f the same species which have a different version of 
the allele).
Any of a class of 20 molecules that are combined to form proteins in living things. The sequence of amino 
acids in a protein and hence protein function are determined by the genetic code. Consist of both a 
carboxylic acid group as well as an amino acid group.
A substance (e.g. C3a, C4a or C5a) capable o f directly triggering mast cell degranulation (histamine 
release).
An often fatal immediate hypersensitivity reaction to antigenic challenge, triggered by IgE or 
anaphylatoxin-mediated mast cell degranulation, leading to anaphylactic shock due to vasodilatation and 
smooth muscle contraction.
Potentially reversible specific immunological tolerance in which the lymphocyte becomes functionally 
nonresponsive.
Serum protein (immunoglobulin) formed in response to immunization, composed of constant and variable 
regions. The variable region has a special configuration that matches that of the antigen and binds to it, the 
constant region helps to eliminate it. Antibodies are generally defined in terms of their specific binding to 
the immunizing antigen.
A phenomenon in which target cells, coated with antibody, are destroyed by specialized killer cells (NK 
cells, neutrophils and macrophages), which bear receptors for the Fc portion of the coating antibody (Fc 
receptors). These receptors allow the killer cells to bind to the anti-body-coated target.
Any molecule capable of being recognized by an antibody or T-cell receptor. An antigen is a substance that 
can trigger an immune response. Many antigens are foreign proteins. An allergen is a special type of 
antigen that causes an IgE antibody response. Antigens may also be immunogens if they are able to trigger 
an immune response (resulting in production of an antibody as part of the body's defence against infection 
and disease), or haptens if not.
A specialized type of cell, bearing cell surface class IIMHC (major histocompatibility complex) molecules, 
involved in processing and presentation of processed antigenic peptide to the T cell receptor on CD4 T 
cells, e.g. macrophages, dendritic cells, B cells. Note, however, that most types o f cell are able to present 



































Large molecules are broken down (processed) within macrophages into peptides and presented within the 
groove of MHC molecules.
The specific antigen-binding receptor on T or B lymphocytes; these receptors are transcribed and translated 
from rearrangements of V genes.
The part of an immunoglobulin molecule that binds antigen specifically.
A single antigenic site or epitope on a complex antigenic molecule or particle; a cluster of epitopes (see 
‘epitope’).
The non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA 
synthesis.
Programmed cell death (“suicide”) as signaled by the nuclei (and characterized by endonuclease digestion 
of DNA) in normally functioning human and animal cells when age or state of cell health and condition 
dictates.
68 kDa cytoplasmic serine/threonine protein kinase that is activated by Ras-GTP and phosphorylation. 
Asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems. People with 
asthma have acute episodes (when the air passages in their lungs get narrower, and breathing becomes more 
difficult). Sometimes episodes o f asthma are triggered by allergens, although infection, exercise, cold air 
and other factors are also important triggers.
IgE-raediated hypersensitivity, i.e. asthma, eczema, hay fever and food allergy.
A term used to describe IgE-mediated anaphylactic responses in humans, usually genetically determined.
A triphosphate ester of adenine that participates in the transfer o f energy in hundreds of individual cellular 
reactions.
A tissue transplant from one area to another on a single individual.
A disease caused by the immune system "rejecting" self tissues.
An immune response to "self1 tissues or components. Such an immune response may have pathological 
consequences leading to autoimmune diseases.
From the same individual.
A pattern o f Mendelian inheritance whereby an affected individual possesses one copy of a mutant allele 
and one normal allele. In contrast, recessive diseases require that the individual have two copies o f the 
mutant allele. Individuals with autosomal dominant diseases have a 50-50 chance of passing the mutant 
allele and hence the disorder onto their children.
Any chromosome other than a sex chromosome.
The binding strength between two molecules (e.g. antibody and antigen) taking into account the valency of 
the interaction (i.e. the summation of multiple affinities -  e.g. when a polyvalent antibody binds to a 
polyvalent antigen). Thus the avidity will always be equal to or greater than the intrinsic affinity (see 
affinity).
Membrane-bound immunoglobulin on the surface of B cells that specifically recognizes intact antigen and 
triggers a B cell immune response.
Lymphocytes that are produced in the bone marrow. When B cells are stimulated by antigens, they are 
converted into antibody-forming plasma cells; these cells carry immunoglobulin and class II MHC (major 
histocompatibility complex) antigens on their surfaces.
A 23 kDa member of the Bcl-2 family that is pro-apoptotic.
A molecule that accepts H+ ion (proton).
Two nitrogenous bases (adenine and thymine or guanine and cytosine) held together by weak bonds. Two 
strands of DNA are held together in the shape of a double helix by the bonds between base pairs.
A polymorphonuclear leukocyte (and a type of granulocyte), whose granules contain heparin, histamine and 
other vasoactive amines. Within tissues, these cells are known as mast cells.
210/190 kDa A hybrid tyrosine kinase that is a product of the fusion between c-ABL and the BCR gene.
A member of the arrestin family, which has been implicated in mediating the desensitization and 
internalization of GPCRs. Constitutively phosphorylated by ERK1/2 and localized in the cytosol. When 
recruited to the plasma membrane after agonist stimulation, P-arrestin is rapidly dephopshorylated -  
essential for receptor internalization but not desensitization.
A 12kDa protein, not itself encoded within the MHC, but forming part of the structure of MHC class I- 
encoded molecules.
A planar secondary structure element of proteins that is created by hydrogen bonding between the backbone 
atoms in two different polypeptide chains or segment o f a single folded chain.
An artificially produced hybrid antibody in which each of the two antigen-binding arms is specific for a 
different antigenic epitope. Such antibodies, which can be produced either by chemical cross-linkage or by 
recombinant DNA techniques, can be used to link together two different antigens or cells, e.g. a cytotoxic 
T-cell and a tumor cell.
A functional term for an antibody molecule capable of blocking the interaction of antigen/stimulant with 
other antibodies or with cells.









































68-95 kDa member of the Raf family of serine/threonine kinases expressed primarily in the brain and in the 
nervous system. A MAPK kinase kinase (MAPKKK).
77 kDa Bruton’s Tyrosine Kinase (Btk); a member of the Tec family, is a cytoplasmic protein tyrosine 
kinase that is phosphorylated and activated after antigen stimulation of the BCR.
120 kDa transmembrane protein involved in cellular adhesions.
99-125 kDa cell adhesion kinase beta (also known as RAFTK, FAK2 or Pyk2); a protein tyrosine kinase 
that is part of the Focal Adhesion Kinase (FAK) family. It is involved in many signaling cascades linking 
cell surface events to the cytoskeleton.
-2 2  kDa intracellular calcium-binding protein consisting of at least two different peptide chains.
A member of the family of Ca(2+)-dependent intracellular 28 kDa cysteine proteases.
50-60 kDa calmodulin-dependent protein kinase II; a serine/threonine kinase that is activated in the 
presence o f increased Ca(2+).
Adenosine 3’5 ’ cyclic monophosphate; a second messenger with a role in gene transcription, neuronal 
functions, and cell proliferation. Also regulates GSK-3 and transcription factors such as STAT.
An active process whereby cross-linking of cell surface molecules (e.g. by antibody) leads to aggregation 
and subsequent migration of the molecules to one pole of the cell.
Any molecule which when conjugated to a non-immunogenic molecule (e.g. a hapten) makes the latter 
immunogenic by providing epitopes for helper T-cells which the hapten lacks.
Membrane transport protein that binds to a solute and transports it across the membrane by undergoing a 
series of conformational changes.
C y s t e in e  p r o t e a s e s  w it h  a s p a r t a t e  s p e c if ic it y .
49 kDa cysteine aspartyl protease-2; an initiator caspase for apoptosis. Also known as ICH-1 and NEDD-2
33 kDa cysteine aspartyl protease-3; an effector caspase for apoptosis. Also known as LICE, CPP32, 
YAMA, apopain and SCA-1.
55 kDa cysteine aspartyl protease-8; an initiator caspase for apoptosis. Also known as MACH, FLICE, and 
Mch5.
59 kDa cysteine aspartyl protease-9; an initiator caspase for apoptosis. Also known as ICE-LAP6, Mch6, 
and APAF-3.
"Cluster Designation/Differentiation": international nomenclature for leukocyte cell surface molecules 
which are identified by a given group of monoclonal antibodies (CD number).
The alpha chain of the IL-2 receptor expressed on activated T cells.
A co-stimulatory molecule on the surface of T lymphocytes that signals activation by binding to B7 
molecules on antigen presenting cells.
A trimeric complex of y, 6  and e chains which together with a ££ or T|T | homodimer, or a £ r |  heterodimer 
acts as a signal transducing unit for the T-cell receptor.
Cell surface glycoprotein, usually on helper T-cells that recognizes MHC class II molecules on antigen- 
presenting cells (acts as a T cell signalling/co-receptor molecule).
A cell surface molecule on B cells and APCs that recieves a signal for T cell help (via CD40Ligand).
A transmembrane tyrosine phosphatase that is constitutively bound to CD45AP (CD45-associated protein). 
CD45 controls TCR signaling, regulates tyrosine phosphorylation of CD22 and mediates activation of SHP- 
1; Leukocyte common antigen
Cell surface glycoprotein, usually on cytotoxic T-cells, that recognizes MHC class I molecules on target 
cells (acts as a T cell signalling/co-receptor molecule).
34 kDa cyclin-dependent kinase-1; a serine/threonine protein kinase that is the catalytic sub-unit o f cyclin 
B, controlling the onset of mitosis.
33 kDa cyclin dependent kinase-2; associates primarily with Cyclin A during G l-S  transition.
36 kDa cyclin dependent kinase-4; associates with Cyclin D l, D2 and D3 and phosphorylates the Rb 
protein
31 kDa Cyclin dependent kinase-5; found in active form only in neuronal cells. Activated by association 
with cyclin-like neuronal proteins.
DNA molecule made as a copy of mRNA and therefore lacking the introns that are present in genomic 
DNA. cDNA is synthesized from an RNA template using reverse transcriptase.
A culture of a particular type of cell that can be reproduced indefinitely, thus making the cell line 
"immortal".
Killing (lysis) of a target cell by an effector lymphocyte.
Immune reaction mediated by T cells; in contrast to humoral immunity, which is antibody mediated. Also 
referred to as delayed-type hypersensitivity.
The activation of T-cells, B-cells and other cells involved in the immune response.
A short-lived transcription factor that is a member of the activator protein-1 (AP-1) family. It is activated by 


























ConA (concanavalin A) 
Conjugate 
Connective tissues





Form hydrophilic pores that extend across the lipid bilayer; when these pores open, they allow specific 
molecules to pass through them
A family of structurally-related chemotactic cytokines which selectively induce chemotaxis and activation 
of leukocytes (and other cells). They also play important roles in lymphoid organ development, cell 
compartmentalization within lymphoid tissues, Thl/Th2 development, angiogenesis and wound healing. 
Migration of cells along (up) a concentration gradient of an attractant (chemotactic factors).
An organism or recombinant DNA molecules created by joining DNA fragments from two or more 
different organisms.
Composite of genetically distinct individuals, e.g. following an allogeneic bone marrow graft.
The self-replicating genetic structures of cells containing the cellular DNA that bears in it nucleotide 
sequence (the linear array of genes), and thus carries part (or all) of that hereditary information of an 
organism.
36 kDa short-lived transcription factor that is a member of the activator protein-1 (AP-1) family. It has been 
found to both induce and inhibit apoptosis and promote trophic changes in peripheral organs.
Proteins encoded by genes in the major histocompatibility complex (q.v.). Class I molecules are designated 
HLA-A, B, or C. Class II molecules are designated DP, DQ or DR: Class I MHC - found on all nucleated 
cells, "self molecules"; Class II MHC - found on macrophages, B and T cells.
The process by which a B-cell changes the class but not specificity o f a given antibody it produces, e.g. 
switching from an IgM to an IgG antibody.
A process by which contact with antigen (i.e. self antigen or artificially introduced antigen) at an early stage 
of lymphocyte differentiation leads to the cell death by apoptosis of lymphocytes of a particular specificity.
The prevalent concept that specificity and diversity of an immune response are the result of selection by 
antigen of specifically reactive clones from a large repertoire of preformed lymphocytes, each with 
individual specificities.
A genetically homogeneous population derived from a single cell (progenitor).
The process of asexually producing a group of cells (clones), all genetically identical, from a single 
ancestor. In recombinant DNA technology, the use o f DNA manipulation procedures to produce multiple 
copies o f a single gene or segment of DNA is referred to as cloning DNA.
DNA molecule originating from a virus, a plasmid, or the cell of a higher organism into which another 
DNA fragment of appropriate size can be integrated without loss o f the vectors capacity for self-replication; 
vectors introduce foreign DNA into host cells, where it can be reproduced in large quantities. Examples are 
plasmids, cosmids, and yeast artificial chromosomes; vectors are often recombinant molecules containing 
DNA sequences from several sources.
A transcription factor that is involved in the mitogenic signaling pathway, apoptosis, and is believed to 
regulate telomerase activity; a cellular homologue o f avian myelocytomatosis virus oncogene.
Sequence of three nucleotides in a DNA or messenger RNA sequence that represents the instruction for 
incorporation of a specific amino acid into a growing polypeptide chain.
Cofilin and ADF (actin depolymerisation factor) are members of a family of actin-binding proteins that play 
pivotal roles in cytokinesis and possibly chemotaxis. Cofilin promotes the regeneration of actin filaments 
by severing pre-existing filaments, and nucleating new actin polymers. Activity o f cofilin is inhibited by 
LIMK.
Related in nature.
The joining of segments of DNA to generate essentially new genetic information, as occurs with Ig genes 
during the development of B cells. Combinatorial joining allows multiple opportunities for 2 sets of genes 
to combine in different ways.
The hypervariable amino acid sequences within antibody and T-cell receptor variable regions which interact 
with complementary amino acids on the antigen or peptide-MHC complex.
Base-pairing between a larger purine base (adenine or guanine) and a smaller pyrimidine base (cytosine or 
thymine) while DNA is in its double-helix. (A/T, G/C)
A T-cell mitogen.
Covalently-linked complex of two or more molecules (e.g. fluorescein conjugated to antibody).
Any supporting tissue that lies between other tissues and consists of cells embedded in a relatively large 
amount of extra-cellular matrix. Functions include support, storage, and protection.
The invariant carboxyl-terminal portion of an antibody molecule, as distinct from the variable region which 
is at the amino-terminal of the chain.
Contact dermatitis is an inflammation of the skin or a rash caused by contact with various substances of a 
chemical, animal or vegetable nature. The reaction may be an immunologic response or a direct toxic effect 
o f the substance. Among the more common causes o f a contact dermatitis reaction are detergents left on 
washed clothes, nickel (in watch straps, bracelets and necklaces, and the fastenings on underclothes), 
chemicals in rubber gloves and condoms, certain cosmetics, plants such as poison ivy, and topical 
medications.
The number of copies of a transgene that is integrated into the host genome.
Additional receptor molecules that contribute to the T or B cell receptor signalling complex.
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70 kDa cyclooxygenase-2 (also known as prostaglandin-endoperoxide synthase-2); an "emergency enzyme" 
that functions to repair and defend cells.
See Raf.
45 kDa cAMP response element-binding transcription factor.
40 kDa SH2 and SH3 domain-containing adaptor protein.
The ability of an antibody, specific for one antigen, to react with a second antigen; a measure of relatedness 
between two different antigenic substances.
60 kDa Carboxyl-terminal Src Kinase (Csk); a cytosolic protein tyrosine kinase that functions to 
phosphorylate and inactivate Src family kinases.
A molecule that competes with CD28 reducing costimulation (also known as CD152).
Nucleotide that is generated from ATP in response to hormonal stimulation of cell-surface receptors; serves 
as a universal signaling molecule; a secondary messenger in signaling pathways.
Low molecular weight secreted and soluble proteins that stimulate or inhibit the differentiation, 
proliferation or function of immune cells.
Binds to cells.
Contents of a cell that are contained within its plasma membrane but, in the case of eucaryotic cells, outside 
the nucleus.
System of protein filaments in the cytoplasm of a eucaryotic cell that gives the cell shape and the capacity 
for directed movement.
Contents of the main compartment of the cytoplasm, excluding membrane-bounded organelles such as 
endoplasmic reticulum and mitochondria.
Kills cells.
T-cells (usually CD8) which kill target cells following recognition of foreign peptide (antigen) within the 
groove of an MHC class I molecule on the target cell membrane.
A small segment o f immunoglobulin heavy-chain and T-cell receptor DNA, coding for the third 
hypervariable region of most receptors.
1,2-diacyl-n-glycerol (DAG); an intracellular second messenger, is found in the phospholipid bilayer o f the 
cell membrane and controls lipid structure and PKC and phospholipase activation.
A T cell-mediated reaction to antigen, which takes 24-48 hours to develop fully, and which involves release 
of cytokines from T cells and recruitment of monocytes and macrophages. Also called cell-mediated 
immunity.
A cell with finger-like processes specialised for antigen presentation.
Part of the antigen molecule that binds to an antibody-combining site or to a receptor on T cells (see hapten 
and epitope).
A cell surface antigenic determinant found only on cells of a certain lineage and at a particular 
developmental stage; used as an immunologic marker.
The number of chromosomes in most cells except the gametes. In humans, the diploid number is 46. 
Covalent intrachain bonds found in protein molecules; covalent linking of two -SH groups of neighboring 
cysteine residues in a folded polypeptide chain. These bonds are rarely, if ever found in the cytosol.
Found in the immunoglobulin heavy chain gene and T-cell receptor □ and □ gene loci between the V and J 
gene segments. Encode part of the third hypervariable region in these antigen receptor chains.
The molecule that encodes genetic information. DNA is a double-stranded molecule held together by weak 
bonds between base pairs o f nucleotides. The four nucleotides in DNA contain the bases: (A), guanine (G), 
cytosine (C), and thymine (T). In nature, base pairs form only between A and T and between G and C; thus 
the base sequence of each single strand can be deduced from that o f its partner.
DNA sequence that has been altered by design for the addition of a transgene, targeted mutation, 
replacement, or any one of a number of methods that yield a recombinant DNA sequence.
An enzyme that participates in DNA replication by unwinding the double helix near the replication fork. 
Fills in nicks and gaps made in polynucleotide strands.
Catalyzes the addition, o f a deoxyribonucleotide to the 3' end of a DNA chain.
Process whereby two complementary nucleic acid strands form a double helix during an annealing period; a 
powerful technique for detecting specific nucleotide sequences.
Enzymes that make reversible cuts in a double helical DNA molecule for the purpose of removing knots or 
unwinding excessive twists.
Process in which molecules of RNA are synthesized in which a strand of DNA acts as a template.
A major tyrosine-phosphorylated, GAP-associated protein present in cells transformed by different tyrosine 
kinases. Overexpression has been shown to inhibit Ras activity.
Certain combinations of helices and sheets which pack together to form a compactly folded globular unit. 
Normally binds elF4E, inhibiting cap-dependent translation. Regulated by the PI3K-PKB and mTOR 
pathway(s).





































Fc receptor (FcR) 
Fibroblast
Separation technique in which an electric field is applied to a solution containing a protein molecule; the 
protein will migrate at a rate depending on its net charge and on its size and shape.
The exposure of cells to rapid pulses of high-voltage current which renders the plasma membrane of the 
cells permeable and thus allowing transfection.
A transcription factor and component of the ternary complex that binds SRE and mediates gene regulation 
in response to serum and growth factors. Activated by ERK.
A cell of the early embryo that can replicate indefinitely and which can differentiate into other cells; stem 
cells serve as a continuous source of new cells.
Specialized animal cell that secretes a hormone into the blood; usually part of a gland, such as the thyroid or 
pituitary gland.
Cellular ingestion of macromolecules by invagination of plasma membrane to produce an intracellular 
vesicle which encloses the ingested material.
From within.
Enzymes that hydrolyze internal phosphodiester bonds in a polynucleotide chain or nucleic acid molecule.
Labyrinthine, membrane-bounded compartment in the cytoplasm of eucaryotic cells, where lipids are 
synthesized and membrane-bound proteins are made.
Intracellular smooth surfaced vesicles in which endocytosed material passes on its way to the lysosomes. 
Pathogenic cell wall-associated lipopolysaccharides of Gram-negative bacteria.
Highly specific protein catalysts, they speed up the reactions by reducing the activation energy for a 
particular chemical change.
A class o f granulocyte (and polymorphonuclear leukocyte), the granules of which contain toxic cationic 
proteins.
Cells tightly bound together into sheets.
An alternative term for antigenic determinant.
44/42 kDa Extracellular signal-Regulated protein Kinase. ERK1 (p44mapk) and ERK2 (p42mapk) are 
proline-directed protein kinases that are activated by dual phosphorylation (pT x pY motif) and catalyzed by 
MEKs. They regulate transcription, cell cycle, differentiation, and learning and memory. ERK3 (p62mapk) 
is believed to be an unique ERK with distinct functional roles. ERK4 plays a role in intracellular signaling 
via phosphorylation by Ras. ERK5 is stimulated by oxidative stress and helps control c-jun expression. 
Erythrocyte production.
The region of a gene that contains the code for producing the gene's protein. Each exon codes for a specific 
portion of the complete protein.
Pathogenic protein secreted by bacteria.
Extrinsic asthma is asthma that is triggered by an allergic reaction, usually something that is inhaled.
The extravascular fluid (containing proteins and cellular debris) which accumulates during inflammation. 
Ezrin, radixin and moesin (ERM) proteins function as linkers between the plasma membrane and the actin 
cytoskeleton, and are involved in cell adhesion, membrane ruffling and microvilli formation.
A Bivalent antigen-binding fragment of an antibody containing two antigen-binding sites generated by 
cleavage of the antibody molecule with the enzyme pepsin which cuts at the hinge region C-terminally to 
the inter-H-chain disulphide bond. Thus, consists o f both light chains and the N-terminal part of both heavy 
chains linked by disulfide bonds.
The first generation of mice generated from 2 different inbred strains. These mice are genetically identical 
to one another but different from either inbred parent.
The progeny produced from matings between FI mice. These mice are different from one another and will 
contain different mixtures of the genetic variations that were present in the original inbred progenitors.
A monovalent antigen-binding fragment of antibody containing the antigen-binding site, generated by 
cleavage of the antibody with the enzyme papain, which cuts at the hinge region N-terminally to the inter- 
H-chain disulphide bond and generates two Fab fragments from one antibody molecule. Consists of an 
intact light chain and the N-terminal VH and CH1 domains o f the heavy chain.
42 kDa focal adhesion protein that links to integrins.
23 kDa Fas-associated Death Domain; an adaptor protein that mediates apoptosis from receptor to protease.
125 kDa Focal Adhesion Kinase (ppl25FAK) is a non-receptor tyrosine kinase that functions in integrin- 
and growth factor-mediated signaling and is involved in regulating cell adhesion, migration, and cell cycle 
events.
A member of the TNF receptor gene family. Engagement o f Fas (CD95) on the surface o f the cell by the 
Fas ligand (CD178) present on cytotoxic cells, can trigger apoptosis in the Fas-bearing target cell.
Crystallizable, non-antigen binding fragment o f an immunoglobulin molecule obtained following papain 
digestion. Consists of the C-terminal portion of both heavy immunoglobulin chains, which is responsible for 
binding to Fc receptors and Clq.
A receptor on a cell surface with specific binding affinity for the Fc portion of particular immunoglobulin 
classes. Fc receptors are found on many types of cells.






































A member of the Forkhead family o f transcription factors involved in cell survival and cell cycle regulation. 
The DNA sequences extending on either side of a specific locus or gene.
Green flu-orescent dye used to ‘tag’ antibodies for use in immunofluorescence.
An antibody coupled with a fluorescent dye (e.g. FITC), used with a fluorescence microscope to detect 
antigen on cells, tissues, or microorganisms.
MHC class II-negative Fc receptor-positive dendritic cells which bear immune complexes on their surface 
and are probably involved in the generation of antibody-secreting cells and maintenance of B-cell memory 
in germinal centres. (N.B. a different cell type to interdigitating dendritic cells).
46 kDa FBJ osteosarcoma virus, an AP-1 family member, associated with tumors expressing Rb.
Family of G protein subunits that can inhibit adenylyl cyclase.
Family of G protein subunits that controls the activity o f Pi-specific phospholipases.
Family of G protein subunits that can stimulate adenylyl cyclases.
110 kDa Grb2-associated binder 1; an IRS-related adaptor protein that forms a complex with SHP2 and 
PI3kinase. Promotes both ERK and Elk-1 activation.
100 kDa Grb2-associated binder 2; an IRS-related adaptor protein that associates with SHP2 and Grb2. It 
can activate ERK but negatively regulates Elk-1.
The serum proteins, mostly immunoglobulins, which have the greatest mobility towards the cathode during 
electrophoresis.
Guanine nucleotide Exchange Factor.
The fundamental physical and functional unit of heredity. A gene is an ordered sequence of nucleotides 
located in a particular position on a particular chromosome that encodes a specific functional product (i.e., a 
protein or RNA molecule). See gene expression.
The process by which a gene's coded information is converted into the structures present and operating in 
the cell. Expressed genes include those that are transcribed into mRNA and then translated into protein and 
those that are transcribed into RNA but not translated into protein (e.g., transfer and ribosomal RNAs). 
Determination of the relative positions o f genes on a DNA molecule (chromosome or plasmid) and of the 
distance, in linkage units or physical units, between them.
The creation of a null or mutant allele by homologous recombination or gene replacement.
The process of introducing genes into a person's cells to correct a disease or genetic flaw. This technique 
has been useful in developing animal models for a variety of genetic disorders (i.e. growth, immunological, 
neurological, reproductive, and hematological disorders).
Vectors that carry the reporter gene (with or without the start codon ATG) 3' to a splice acceptor site (a 
splice acceptor site is used instead of a promoter). Used primarily in ES cells to screen for genes expressed 
during mouse embryogenesis.
All the genetic material in the chromosomes of a particular organism; its size is generally given as its total 
number of base pairs.
All of the genes possessed by an individual; in practice it refers to the particular alleles present at the loci in 
question.
Discrete areas within lymph node and spleen where B-cell maturation and memory development occur.
Large multinucleate cell derived from fused macrophages and often present in granulomas.
Supporting cells of the nervous system, including oligodendrocytes and astrocytes in the vertebrate central 
nervous system and Schwann cells in the peripheralnervous system.
Inflammation of renal glomerular capillary loops, often resulting from immune complex deposition.
Polysaccharide composed exclusively o f glucose units used to store energy in animal cells. Large granules 
of glycogen are especially abundant in the liver and muscle cells.
Membrane lipid molecule with a short carbohydrate chain attached to a hydrophobic tail.
The degradation of carbohydrates in a sequence o f enzymatically catalyzed steps.
Any protein with one or more covalently linked oligosaccharide chains. Included most secreted proteins and 
most proteins exposed on the outer surface of the plasma membrane.
The carbon that carries the aldehyde or the ketone can react with any hydroxyl group on a second sugar 
molecule to form a glycosidic bond.
Membrane-bounded organelle in eucaryotic cells where the proteins and lipids made in the endoplasmic 
reticulum are modified and stored.
When immunologically competent graft is transported into an immunologically compromised host, the graft 
tissue (containing T cells) can mount an immunologic attack on the recipient.
Myeloid cells containing cytoplasmic granules (i.e. neutrophils, eosinophils and basophils).
A tissue nodule containing proliferating lymphocytes, fibroblasts, and giant cells and epithelioid cells (both 
derived from activated macrophages), which forms due to inflammation in response to chronic infection or 

















Heavy chain (H chain)
Helix
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Serine esterases present in the granules of cytotoxic T lymphocytes and NK cells. They induce apoptosis in 
the target cell which they enter through perforin channels inserted into the target cell membrane by the 
cytotoxic lymphocyte.
25 kDa Growth factor Receptor Binding protein-2.
80 kDa G protein-coupled Receptor Kinase; serves to uncouple G protein- coupled receptors, which can 
lead to ERK activation.
46 & 54 kDa Glycogen Synthase Kinase; a serine/threonine kinase with two unique isoforms, Gsk-3ot and 
Gsk-3p. GSK functions to phosphorylate glycogen synthase thereby inactivating it. Many other roles. 
Includes Peyer’s patches, appendix, and solitary lymphoid nodules in the submucosa.
The mouse major histocompatibility complex (MHC).
The major histocompatibility complex situated on chromosome 17 of the mouse; contains subregions K, I 
and D.
Any molecule that agglutinates erythrocytes.
The production of erythrocytes and leukocytes.
The number of chromosomes in a sperm or egg cell, half the diploid number.
A particular combination of closely linked genes on a chromosome inherited from one patient; the set of 
allelic variants present at a given genetic region.
A compound, usually o f low molecular weight, that is not itself immunogenic (but recognized by pre­
formed antibody) that, after conjugation to a carrier protein or cells (which provides epitopes), becomes 
immunogenic and induces antibody, which can bind the hapten alone in the absence of carrier.
See Rhinitis.
The larger of the two types of chains that comprise a normal immunoglobulin or antibody molecule.
A secondary structural motif of proteins in which a linear sequence of amino acids folds into a right-handed 
helix stabilized by internal hydrogen bonding between backbone atoms.
A subclass o f T cells which help trigger B cells (in the form of cytokines and/or cognate interactions) to 
make antibody against thymus-dependent antigens. Helper T cells also help generate cytotoxic T cells.
RNA transcripts freshly synthesized by RNA polymerase II in the nucleus; also known as primary RNA 
transcript
A cross-reacting antigen that appears in widely ranging species such as humans and bacteria.
The presence o f different alleles at one or more loci on homologous chromosomes.
Containing two different alleles of the same gene.
Capillary venule composed of specialized endothelial cells allowing migration of lymphocytes into 
lymphoid organs.
Amino acids between the Fab and Fc regions of immunoglobulin which permit flexibility of the molecule. 
This area is susceptible to enzymatic cleavage.
Literally, the ability o f tissues to get along; in immunology, it means identity in all transplantation antigens. 
These antigens, in turn, are collectively referred to as histocompatibility antigens.
Modified insertion vectors which have a mutation in the homologous sequences. These vectors will form a 
variety o f different integration products upon targeting.
Human leukocyte antigen: The human major histocompatibility complex (MHC).
A short stretch of nucleotides whose base sequence is virtually identical in all the genes that contain it. It 
has been found in many organisms from fruit flies to human beings.
A pair o f chromosomes containing the same linear gene sequences, each derived from one parent.
The exchange of DNA fragments between two DNA molecules or chromatids of paired chromosomes 
(during crossing over) at the site of identical nucleotide sequences.
An organism whose genotype is characterized by two identical alleles of a gene.
Containing 2 copies o f the same allele.
A genetically engineered monoclonal antibody of non-human origin in which all but the antigen-binding 
CDR sequences have been replaced with sequences derived from human antibodies. This procedure is 
carried out to minimize the immunogenicity o f therapeutic monoclonal antibodies.
Pertaining to extracellular fluid such as plasma and lymph. The term humoral immunity is used to denote 
antibody-mediated immune responses.
Any immune reaction that can be transferred with immune serum is termed humoral immunity (as opposed 
to cell-mediated immunity). In general, this term refers to resistance that results from the presence of 
specific antibody.
The production of antibodies by plasma (B) cells; the defense by fluids ("humors") the antibody response.
An offspring o f parents from different species or sub-species. Hybrid mice are generated by mating mice 
from two different inbred strains.
Process whereby two complementary nucleic acid strands form a double helix during an annealing period; a 


































Hybrid cell line obtained by fusing a lymphoid tumor cell with a lymphocyte which then has both the 
immortality of the tumor cell and the effector function (e.g. monoclonal antibody secretion) o f the 
lymphocyte. B cell hybridomas are usually used to make monoclonal antibodies.
Bonds formed by polarized molecules (+ -), i.e. water.
Reaction in which water breaks the covalently linked compound A-B.
Water "loving," hydrophilic molecule are soluble in water.
Water "fearing,” hydrophobic molecules are quite insoluble in water.
State of reactivity to antigen that is greater than normal for the antigenic challenge, leading to undesirable 
consequences e.g. tissue or organ damage; hypersensitivity is the same as allergy and denotes a deleterious 
outcome rather than a protective one.
Portions of the light and heavy immunoglobulin chains that are highly variable in amino acid sequence from 
one immunoglobulin molecule to another, and that, together, constitute the antigen-binding site of an 
antibody molecule. Also, portions of the T-cell receptor that constitute the antigen-binding site.
"Immune response-associated" proteins, found on B cells and antigen-presenting cells of mice; an old term 
now replaced with MHC (major histocompatibility complex) class II molecules.
An epitope made up of amino acids within the variable region of an antibody or T-cell receptor which reacts 
with an anti-idiotope.
The combined antigenic determinants (idiotopes) found on antibodies or T cell receptor (in the variable 
region) of an individual that are directed at a particular antigen (and react with an anti-idiotypic serum); 
such antigenic determinants are found only in the variable region.
A regulatory network based on interactions of idiotypes and anti-idiotypes present on antibodies and T-cell 
receptors.
38 kDa cytoplasmic inhibitory protein that exerts its affects on NFkB. Upon phosphorylation by IkB 
kinases, Ixfia  is degraded, allowing NFkB translocation to the nucleus where it regulates transcription. 
IkBoc appears to be controlled by Bcl-2.
~38 kDa cytoplasmic inhibitory protein that exerts its effects on NFkB. Upon phosphorylation by IkB 
kinases, IkB is degraded allowing NFkB translocation to the nucleus where it regulates transcription. 
Phosphorylated by MEKK1.
IkB kinases that phosphorylate IkB. Kinase is present in two isoforms, IKKa and IKKf).
48 kDa noncatalytic component of the IkB kinase complex.
Interleukin-2; a lymphokine required by activated T cells for growth.
Interleukin-2 receptor expressed on activated T and B lymphocytes.
Interleukin-4; a cytokine produced by T cells to help antibody responses.
Hypersensitivity tissue reaction occurring within minutes after the interaction of antigen and antibody.
The adherence of particulate antigen coated with C3b to tissue having cells with C3b receptors.
Complex of antibody bound to antigen which may also contain complement components.
Substances that control the expression of the immune response.
A gene controlling an immune response to a particular antigen; most genes o f this type are in the MHC 
(major histocompatibility complex), and the term is rarely used to describe other types of Ir genes outside 
the MHC.
The immune system is a collection of cells and proteins that works to protect the body from potentially 
harmful, infectious microorganisms (microscopic life-forms), such as bacteria, viruses and fungi. The 
immune system plays a role in the control of cancer and other diseases, but also is the culprit in the 
phenomena of allergies, hypersensitivity and the rejection of transplanted organs, tissues and medical 
implants.
Natural or acquired (specific) resistance to infection or disease.
Technique for detection of cell or tissue-associated antigens by the use of a fluorescently-tagged ligand (e.g. 
an anti-immunoglobulin conjugated to fluorescein isothiocyanate).
A substance capable of inducing an immune response (as well as reacting with the products of an immune 
response). Whilst all immunogens are antigens, not all antigens are immunogens (see hapten).
Large family of proteins characterized by possession of ‘immunoglobulin-type’ domains o f approximately 
110 amino acids folded into two P-pleated sheets. Members include immunoglobulins, T-cell receptors and 
MHC molecules.
Immunoglobulins, also known as antibodies, are proteins found in blood and in tissue fluids. 
Immunoglobulins are produced by cells o f the immune system called B-lymphocytes. Their function is to 
bind to substances in the body that are recognized as foreign antigens (often proteins on the surface of 
bacteria and viruses). 5 classes: IgG & IgM (humoral response), IgA (found in tears, saliva and milk), IgD 
(plays a role in B cell triggering) and IgE (histamine/inflammatory response). Each Ig unit is made up of 
two heavy chains and two light chains and has two antigen- binding sites.
A contact point between the T-cell and antigen-presenting cell which is generated by reorganization and 
clustering of cell surface molecules in lipid rafts. The synapse facilitates interactions between TCR and 

































Refers to performing experiments or tests with intact tissues.
Use of a DNA or RNA probe to detect the presence of the complementary DNA sequence in cloned 
bacterial or cultured eukaryotic cells; is an effective method for analyzing transgene expression at the 
cellular level.
A biologic or biochemical process occurring outside a living organism.
A biologic or biochemical process occurring within a living organism.
Strain of mice that has been maintained by successive brother to sister matings over more than 20 
generations (i.e. BALB/c, C57BL/6, etc.).
Expression of the targeted gene is not by itself harmful to the cell but is capable of rendering cells 
selectively sensitive to the killing action of certain drugs that cannot be metabolized by normal cells. 
Example; expression of the herpes gene tk is not deleterious, however the addition of drugs to the cell 
extract (such as gancyclovir) kills dividing cells expressing the herpes tk gene. Hence expression of the 
herpes tk gene under the control of a cell type-specific promoter, followed by drug administration, 
constitutes an inducible system for achieving cell ablation.
A self perpetuating state o f tolerance that can be transferred by T lymphocytes.
The tissue response to trauma, characterized by increased blood flow and entry of leukocytes into the 
tissues, resulting in swelling, redness, elevated temperature and pain.
Immunity which is not intrinsically affected by prior contact with antigen, i.e. all aspects o f immunity not 
directly mediated by lymphocytes.
A 66 kDa receptor for integrins that are a group of alpha/beta heterodimeric proteins responsible for 
transducing intracellularsignals on binding to the extracellular matrix.
A 35-50 kDa multiple membrane spanning member of the immunoglobulin superfamily that regulates some 
adhesion-dependent cell functions through formation of a complex with alphaVbeta3 integrin and trimeric 
G proteins.
MHC class II-positive, Fc receptor-negative, antigen-presenting dendritic cell found in T-cell areas of 
lymph nodes and spleen. (N.B. a different cell type to follicular dendritic cells).
A substance produced by the body that inhibits viral DNA-RNA transcripts, i.e. group of cytokines that 
activate protection against viruses.
IFNa is derived from various leukocytes, IFN(3 from fibroblasts and IFNy from T lymphocytes. All three 
types induce an anti-viral state in cells and IFNy acts as a cytokine in the regulation of immune responses. 
Intrinsic asthma is asthma that has no apparent external cause.
A non-coding sequence of DNA that is initially copied into RNA but is cut out o f the final RNA transcript; 
the intervening sequence of nucleotides between coding sequences or exons.
A polypeptide which binds MHC class II molecules in the endoplasmic reticulum, directs them to the late 
endosomal compartment and prevents premature association with self peptides.
Non-covalent bond; ionic interactions occur either between fully charged groups (ionic bond) or between 
partially charged groups.
The genes, including those within the MHC, that together determine the overall level of immune response to 
a given antigen.
A tissue transplanted between two genetically identical individuals.
Antibodies to major red blood cell antigens present normally as a result of inapparent immunization by 
cross-reactive antigens in bacteria, food, etc.
The shift of a B cell or its progeny from the secretion of antibody of one isotype or class o f antibody with 
the same V regions but a different heavy- chain constant region and, hence, a different isotype (class 
switch).
Classes of antibody that differ in the constant region of their heavy chain (Fc portion); distinguishable also 
on the basis of reaction with antisera raised in another species. These differences also result in different 
biological activities of the antibodies.
/mmunoreceptor Tyrosine-based Activation A/otifs are consensus sequences for src-family tyrosine kinases. 
These motifs are found in the cytoplasmic domains of several signaling molecules including the signal 
transduction units o f lymphocyte antigen receptors and of Fc receptors.
/mmunoreceptor Tyrosine-based /nhibitory A/otifs present in the cytoplasmic domains of certain cell surface 
molecules, e.g. FcD RUB, inhibitory NK cell receptors, and which mediate inhibitory signals.
A polypeptide involved in the polymerization of immunoglobulin molecules IgM (pentameric) and IgA 
(dimeric).
A gene segment coding for the J or joining segment in immunoglobulin DNA; V genes translocate to J 
segments in L chains, and to D and J segments in H chains. Also, codes for a portion of the T-cell receptor, 
and upon gene rearrangement, encode part o f the third hypervariable region of the antigen receptors.
Janus Activating Kinases; tyrosine kinases that are activated via tyrosine phosphorylation in response to 
cytokines and growth factors. Induction of JAK’s (3 isotypes) lead to phosphorylation of ST AT’s. 
c-Jun amino-terminal kinases (JNKs -  3 isoforms); a superfamily of Map kinase. Activated in response to 
stress stimuli, growth factors, and cytokines. JNK has been studied for its role in regulating cell fate, 
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Large granular lymphocyte (express CD8), which mediates antibody-dependent cellular cytotoxicity 
(ADCC), and is Fc receptor positive, but does not rearrange or express either immunoglobulin or T-cell 
receptor genes. Also called cytotoxic T cells, and posses a particular immune specificty.
A family of polypeptides released during inflammatory responses and which increase vascular permeability 
and smooth muscle contraction.
Killer cell /mmunoglobulin-like Receptors found on NK cells, some aP and some 78 T-cells. KIRs 
recognize MHC class I molecules and, like the C-type lectin receptors also found on these cells, can either 
inhibit or activate the killer cells. If ITIM sequences are present in their cytoplasmic domain they are 
inhibitory. KIRs lacking ITIMs can associate with ITAM-containing adaptor molecules, in which case they 
can activate the killer cell.
The use of homologous genetic recombination in embryonal stem cells to replace a functional gene with a 
defective copy of the gene. The animals that are produced by this technique can be bred to homozygosity, 
thus allowing the generation of a null phenotype for that gene product.
Fixed tissue macrophages lining the blood sinuses in the liver.
One of the two newly made strands o f DNA found at the replication fork. The lagging strand is made in 
discontinuous lengths that are later joined covalently.
Fc receptor and MHC class II-positive antigen-presenting dendritic cell found in the skin.
Large lymphocytes that contain cytoplasmic granules and function as natural killer (NK) and killer (K) 
cells. Activated CD8 cytotoxic T lymphocytes (Tc) also assume an LGL morphology.
40 kDa Linker for Activation of T cells; a palmitoylated integral membrane protein that is localized in the 
plasma membrane and promotes T cell activation by recruiting kinases to specific domains o f the TCR 
complex.
A 56 kDa member of the Src non-receptor protein tyrosine kinase family that has an important role.
One of the two newly made strands of DNA found at the replication fork. The leading strand is made by 
continuous synthesis in the 5'-3' direction
A family of proteins, mostly of plant origin, which bind specific sugars on glycoproteins and glycolipids. 
Some lectins are mitogenic (e.g. PH A, Con A).
Metabolic products of arachidonic acid, which promote inflammatory processes (e.g. chemotaxis, increased 
vascular permeability) and are produced by a variety of cell types including mast cells, basophils and 
macrophages.
Lymphocyte associated antigen-1; a molecule involved in lymphocyte adhesion to antigen presenting cells. 
General term for a molecule recognized by a binding structure such as a receptor.
The light chain of immunoglobulin is a structural feature that occurs in two forms: kappa and lambda.
The limiting separation at which two objects can still be seen as distinct.
LIM kinases are serine/threonine kinases that have 2 zinc finger motifs, known as LIM motifs, in their 
amino-terminal regulatory domain. LIMK are involved in the regulation of the actin cytoskeleton through 
Rho-family GTPases and their downstream kinases PAK and ROCK. ROCK/PAK phosphorylate LIMK in 
the activation loop, activating it. LIMK then inhibit the actin depolymerisation activity of cofilin.
The proximity of two or more markers (e.g., genes, RFLP markers) on a chromosome; the closer together 
the markers are, the the probability that they will be separated during DNA repair or replication processes 
(binary fission in prokaryotes, mitosis or meiosis in eukaryotes), and hence the greater the probability that 
they will be inherited together.
The occurrence at a greater frequency, in a population of linked genes, of two alleles being inherited 
together than that expected from the product o f their individual frequencies, which is governed by factors 
other than change.
A map of the relative positions of genetic loci on a chromosome, determined on the basis o f how often the 
loci are inherited together. Distance is measured in centimorgans (cM).
Cholesterol- and glycosphingolipid-rich membrane subdomain in which molecules involved in cellular 
activation become concentrated.
The introduction of transgenes across cell membranes by using liposome vesicles formed by phagocytosis. 
This method is advantagous in that it is tissue-specific.
Endotoxin derived from Gram-negative bacterial cell walls, which has inflammatory and mitogenic actions. 
Synthetic bilayer in the form of a spherical vesicle.
The position on a chromosome of a gene or other chromosome marker; also, the DNA at that position. The 
use of locus is sometimes restricted to mean regions of DNA that are expressed. See gene expression.
The tissue fluid that drains into and through the lymphatic system.
Secondary lymphoid organs found throughout the body that contain mature lymphocytes capable of 
responding to foreign antigens.
Enlarged lymph nodes.
A lymphocyte is a group of white blood cells (with virtually no cytoplasm) of crucial importance to the 
adaptive part of the body's immune system, and includes the B and T cells. The adaptive portion of the 
immune system mounts a tailor-made defence when dangerous invading organisms penetrate the body's 
general defences. Found in blood, in all tissue, and in lymphoid organs, such as lymph nodes, spleen, and 




























Messenger RNA (mRNA) 
MHC class I molecule
MHC class II molecule
MHC restriction 
Microvillus
Migration inhibition factor 
(MIF)
Cytokine produced by lymphocytes.
Killer (K) and natural killer (NK) cells activated in vitro by IL-2 to give enhanced killing of target cells.
A T-cell derived cytokine which is cytotoxic for certain tumor cells and also has immunoregulatory 
functions.
A 59 kDa member of the Src family proto-oncogene non-receptor protein tyrosine kinase family 
predominantly expressed in hematopoietic tissues.
Molecule such as a protein, nucleic acid, or polysaccharide with a molecular mass greater that a few 
thousand Daltons.
A large phagocytic (“cell eating”) white blood cell of the mononuclear series found within tissues. 
Properties include phagocytosis, and antigen presentation to T cells, and can mediate ADCC. Located in 
the tissues
A cluster of genes on chromosome 6 in humans, that are polymorphic cell surface proteins that characterize 
the tissue or cell as self or non-self (code for antigens which lead to rapid graft rejection between members 
of a single species which differ at these loci). These proteins also help to regulate the immune response of 
the T-cells. Several classes of protein such as MHC class I and II proteins are encoded in this region. These 
in humans, are known as 'Human leukocyte antigens' (HLA). See also ‘MHC’.
The outer area of the splenic periarteriolar lymphoid sheath (PALS) that is rich in B cells, particularly those 
responding to thymus-independent antigens.
Leukocyte adhesion to the endothelium of blood vessels in the early phase of an acute inflammatory 
reaction.
An identifiable physical location on a chromosome (e.g., restriction enzyme cutting site, gene) whose 
inheritance can be monitored. Markers can be expressed regions of DNA (genes) or some segment of DNA  
with no known coding function but whose pattern of inheritance can be determined. See RFLP, restriction 
fragment length polymorphism.
A tissue (particularly numerous in connective tissue, such as the dermis (innermost layer) of skin) cell with 
abundant granules which resembles the blood basophil. Both these cell types bear Fc receptors for IgE, 
which when crosslinked by IgE and antigen cause degranulation and the release of a number of mediators 
including histamine and leukotrienes. Participates in 'Immediate hypersensitivity' reactions.
Inner (central) region of an organ.
51 kDa Transcription factor; regulates muscle-specific gene expression by binding to MAPK proteins.
A bone marrow precursor o f platelets.
40-42 kDa Mitogen-activated ERK-activating Kinase, phosphorylates and activates MAPK/ERK family 
kinases; thereby regulating cell development and proliferation. Also known as MAPKK.
A 71 kDa MEK protein that regulates JNK and p38.
A1 1 0  kDa MEK protein that regulates MAPK and JNK1.
A 161 kDa MEK kinase that regulates MEK activity by phosphorylation.
Voltage difference across a membrane due to a slight excess of positive ions on one side and of negative 
ions on the other.
Movement of molecules across a membrane mediated by amembrane transport protein.
A characteristic of the acquired (adaptive) immune response o f lymphocytes whereby a second encounter 
with a given antigen produces a secondary immune response; faster, greater and longer lasting than the 
primary immune response.
Clonally expanded T- and B-cells produced during a primary immune response and which are ‘primed’ to 
mediate a secondary immune response to the original antigen. After exposure to an antigen the first time 
the cells acquire a "molecular memory", so that on a second exposure to the same antigen they respond 
more quickly.
RNA that serves as a template for protein synthesis.
A molecule encoded to genes of the MHC, which participates in antigen presentation to cytotoxic T (CD8+) 
cells. Class I MHC molecules are present on virtually all nucleated cells and are encoded mainly by the H- 
2K, D, and L loci in mice and by HLA-A, B, and C in man.
A molecule encoded by genes of the MHC which participates in antigen presentation to helper T (CD4+) 
cells. Class II MHC molecules are expressed on antigen-presenting cells (primarily macrophages, B-cells 
and interdigitating dendritic cells) and are encoded by H-2A and E in mice and HLA-DR, DQ, and DP in 
man.
The ability o f T lymphocytes to respond only when they 'see' the appropriate antigen in association with 
"self' MHC class I or class II proteins (of the original haplotype associated with T-cell priming) on the 
antigen presenting cells.
Thin cylindrical membrane-covered projection on the surface of an animal cell containing a core bundled of 
actin filaments. They are present especially large numbers on the absorptive surface of intestinal epithelial 
cells.






































NK (natural killer) cell
NK-T cell
Nonspecific response
These antigens (cell surface processed peptides), encoded outside the MHC (i.e. non-MHC encoded), are 
numerous, but do not generate rapid graft rejection or primary responses of T cells in vitro. They do not 
serve as restricting elements in cell interactions.
Membrane-bounded organelle, about the size of bacterium, that carriesout oxidative phosphorylation and 
produces most of the ATP in eucaryotic cells.
A substance that stimulates (non-specifically) the proliferation of many different clones o f lymphocytes.
When lymphocytes from two individuals are cultured together, a proliferative response is generally 
observed, as the result of reactions of T cells o f one individual to MHC antigens (allogenic) on the other 
individual's cells.
43 kDa MAP Kinase PPase; dephosphorylates MAPK.
Myosin is composed of six polypeptide chains: 2 identical heavy chains and 2 pairs of light chains. 
‘Myosin light chain 2’ (MRLC/RLC/LC20) has many isoforms with different tissue distributions. MLC2 
can be phosphorylated by MLCK and ROCK, and regulate actin:myosin contraction.
129 kDa Myosin light chain kinase; phosphorylates myosin light chain protein.
115 kDa Myosin Light Chain Kinase PPase; dephosphorylates myosin light chain protein.
Homogeneous antibody derived from a single immortal B-cell clone (the progeny of a single cell) and 
therefore all bearing identical antigen-binding sites and isotype (single specificity).
Large circulating phagocytic white blood cell, 2-10% of total white cells, with indented nucleus. Migrates 
to tissues, where it is known as a macrophage.
Soluble substances secreted by monocytes, which have a variety of effects on other cells.
A system comprising blood monocytes and tissue macrophages.
RNA molecule that specifies the amino acid sequence of a protein. See ‘messenger RNA’.
A mitogen- and stress-activated kinase regulated by ERK and p38. Resembles p90RSK.
‘Mammalian target o f rapamycin’ is a serine/threonine kinase regulated by PKB and activates p70S6K and 
inhibits the elF4E inhibitor 4E-BP1.
Lymphoid tissue present in the surface mucosa of the respiratory, gastrointestinal and genitourinary tracts.
Plasma cell malignancy resulting in high levels of monoclonal immunoglobulin in serum and of free light 
chains (Bence-Jones protein) in urine.
Pertaining to mice.
Change in DNA sequence resulting from mutagens. Various types of mutations include frame-shift 
mutations, missense mutations, and nonsense mutations.
The lineages of bone-marrow-derived phagocytes (including neutrophils, eosinophils and monocytes), and 
other cells (mast cell, basophil, megakaryocyte).
A tumour of plasma cells, generally secreting a single species o f immunoglobulin.
Monoclonal antibody secreted by myeloma cells.
Made of light and heavy chains; regulates muscle contraction and action (530 kDa in size).
The state of lymphocytes before first exposure to their specific antigen.
An adaptor protein.
Deletion by apoptosis in the thymus of T-cells which recognize self peptides presented by self MHC 
molecules, thus preventing the development of autoimmune T-cells. Negative selection of developing B- 
cells is also thought to occur if  they encounter high levels of self antigen in the bone marrow.
A synonym for cancerous tissue.
The major circulating phagocytic polymorphonuclear granulocyte. Enters tissues early in an inflammatory 
response and is also able to mediate antibody-dependent cellular cytotoxicity (ADCC).
120 kDa Nuclear Factor o f Activated T-cells; regulates expression of DL-2 in activated T-cells.
65 + 105 kDa Nuclear Factor Kappa B, a transcription factor used as a primary regulator of a wide variety 
of proinflammatory mediators.
104 kDa NFkappaB Inducing Kinase.
Large granular lymphocyte which does not rearrange nor express either immunoglobulin or T-cell receptor 
genes but is able to recognize and destroy certain tumor and virally-infected cells in an MHC and antibody- 
independent manner. Also, they participate in ADCC. They do not exhibit antigenic specificity, and their 
number does not increase by immunization.
NK1.1+ lymphoid cells with a morphology and granule content intermediate between T-cells and NK cells. 
They are potent producers o f IL-4, may be CD4~8" or CD4+8", and express low levels of □ □ TCR with an 
invariant a  chain and very restricted p chain specificity. Many of these TCR recognize antigens presented 
by the non-classical MHC-like molecule CD1. Their lectin-like NK1.1 receptor may recognize microbial 
carbohydrates.
A nonspecific response is immediate and general in nature; physical barriers such as the skin, chemicals 













































Structure in the nucleus where ribosomal RNA is transcribed and ribosomal subunits are assembled. 
Compound composed of a purine or pydimidine base linked to either a ribose or deoxyribose sugar. DNA 
and RNA are not polymers of nucleosides.
Serve as building blocks for the construction of nucleic acids. Nucleoside with one or more phosphate 
group joined in ester linkages to the sugar moiety. DNA and RNA are polymers of nucleotides.
Prominent membrane-bound organelle in a eucaryotic cell, containing DNA organized into chromosomes. 
An early population of lymphocytes bearing neither T-cell nor B-cell differentiation antigens.
Swelling caused by accumulation of fluid in the tissues.
Short lengths o f DNA produced on the lagging strand during DNA replication.
A gene, one or more forms of which is associated with cancer. Many oncogenes are involved, directly or 
indirectly, in controlling the rate of cell growth.
A substance (e.g. antibody or C3b) that coats a particle, such as a bacterium, and enhances phagocytosis by 
phagocytic cells (by promoting adhesion of the antigen to the phagocyte).
Literally means "preparation for eating". The coating of a bacterium (antigen) with antibody and/or 
complement (opsonin) that leads to enhanced phagocytosis of the bacterium by phagocytic cells.
Movement of solvent from low concentration of solute molecules to high concentration of solute molecules. 
The solvent moves from a hypotonic to a hypertonic solution. The two solutions that have identical solute 
concentrations are said to be isotonic.
Strains of mice propagated by nonstandardized matings. These mice retain substantial genetic variability. 
Removal o f electrons.
The last step in catabolism and the point at which the major portion of metabolic energy is released.
130 kDa Focal adhesion docking protein.
190 kDa Rho GTPase activating protein; a multi-domain protein regulator o f actin cytoskeleton.
38 kDa MAPK family member required for growth in hyper- osmolar states.
42 kDa MAPK family member that phosphorylates ATF-2 and MBP, but not MAPK APK-2 and -3.
53 kDa Tumor suppressor gene.
62 kDa Cytoplasmic protein which binds to SH2 domain of lck.
62 kDa GAP-associated protein which is tyrosine phosphorylated upon activation of the c-Kit receptor.
A serine/threonine kinase activated by ERK 1/2, PDK1 and PKC.
An alkyl phospholipid released by a variety of cell types including mast cells and basophils, which has 
immuno- regulatory effects on lymphocytes and monocytes/macrophages as well as causing platelet 
aggregation and degranulation.
‘p21 -activated kinase’ family is involved in multiple cellular processes, including cytoskeletal 
reorganization, MAPK signalling and apoptotic signalling. Rac/cdc42 binding to PBD domain causes 
autophosphorylation of PAK and a conformational change. PDK-1 phosphorylates and activates PAK. Has 
been implicated in cell motility, cell survival, cell growth, and actin reorganization.
The part o f an organ (e.g. lymph node) that lies between the cortex and the medulla.
An antibody-combining site that is complementary to an epitope.
Immunization by the administration of preformed antibody into a nonimmune individual.
Movement of a molecule across a membrane down its concentration gradient.
Molecules such as lipopolysaccharide, peptidoglycan, lipoteichoic acids and mannans, which are widely 
expressed by microbial pathogens as repetitive motifs but are not present on host tissues. They are therefore 
utilized by the pattern recognition receptors (PRRs) of the immune system to distinguish pathogens from 
self-antigens.
Receptors on professional antigen-presenting cells and phagocytes which enable them to recognize 
pathogen-associated molecular patterns (PAMPs). Amongst the large number of different PRRs are the 
mannose receptor (CD206) and the macrophage scavenger receptor (CD204).
68 kDa Cytoskeletal protein found at the end of actin stress fiber focal adhesions. It is a multidomain 
protein that is a key component of integrin signalling and required for cytoskeletal reorganization. Paxillin 
can be phosphorylated by FAK, and Crk can bind to Paxillin via its SH2 domain.
60-66 kDa Phosphoinositide-Dependent Kinase-1; A serine/threonine kinase that activates PKB, p70S6K, 
PKC and p90RSK.
82.5 kDa Platelet-Endothelial Cell Adhesion Molecule-1.
A linear sequence o f amino acids (often derived from proteins by degradation, but they can be artificially 
synthesised).
Molecule produced by cytotoxic T-cells and NK cells which, like complement component C9, polymerizes 
to form a pore in the membrane of the target cell leading to cell death.
The lymphoid tissue that forms the white pulp of the spleen.































Pluripotent stem cells 





Polymerase chain reaction 
(PCR)
Part of the gut associated lymphoid tissue (GALT) and found as distinct lymphoid nodules mainly in the 
small intestine.
A plant lectin that acts as a T-cell mitogen.
Any virus that infects bacteria; widely used as cloning vectors.
A collection of cloned antibody variable region gene sequences which can be expressed as Fab or scFv 
fusion proteins with bacteriophage coat proteins. These can be displayed on the surface o f the phages. The 
gene encoding a monoclonal recombinant antibody is enclosed in the phage particle and can be selected 
from the library by binding of the phage to specific antigen.
Cells, including monocytes/macrophages and neutrophils, which are specialized for the engulfment of 
cellular and particulate matter.
The engulfment of a particle or a microorganism by leukocytes.
Intracellular vacuole where killing and digestion of phagocytosed material occurs following the fusion of a 
phagosome with a lysosome.
Intracellular vacuole produced following invagination of the cell membrane around phagocytosed material. 
The physical expression (observable characteristics) of an individual's genotype.
A mitogenic phorbol ester which directly stimulates protein kinase C and acts as a tumor promoter.
Covalent bond that joins the 5’ and 3' carbon atoms to form nucleic acids.
The major category of lipid molecules used to construct biological membranes. Generally composed of two 
fatty acids linked through glycerol phosphate to one of a variety o f polar groups.
A map of the locations of identifiable landmarks on DNA (e.g., restriction enzyme cutting sites, genes), 
regardless of inheritance. Distance is measured in base pairs.
Phosphatidylinositol-3-Kinase. Phosphorylates the D3 position of the inositol ring.
Ingestion of liquid or very small particles by vesicle formation in a cell.
40 kDa Protein Kinase A alpha isoform; a serine/threonine protein kinase activated by the second
messenger cAMP.
See ‘A k f.
81 kDa Protein Kinase C alpha isoform; a serine/threonine protein kinase involved in many cellular 
responses.
110/115 kDa Protein Kinase D; a serine/threonine kinase that can be activated in parallel or downstream of 
PKC. Also known as PKCp.
65-68 kDa Protein Kinase R; a double-stranded RNA-activated serine/threonine protein kinase.
Terminally differentiated B lymphocyte which actively secretes large amounts o f antibody.
Encloses the cell, defines its boundaries, and maintains the essential differences between the cytosol and the
extracellular environment
Autonomously replicating, extrachromosomal circular DNA molecules, distinct from the normal bacterial 
genome and nonessential for cell survival under nonselective conditions. Some plasmids are capable of 
integrating into the host genome. A number of artificially constructed plasmids are used as cloning vectors.
An enzyme that catalyses the hydrolysis of glycerolipids to produce lysophospholipids and the release of 
arachidonic acid. Implicated in mitogenesis, differentiation, inflammation and cytotoxicity.
150 kDa Phospholipase C-gammal. Breaks down PI(4,5)P2 lipids to form IP3 and DAG which serve as 
potent second messengers that activate multiple signaling cascades.
Phospholipase D hydrolyses phosphatidylcholine to produce choline and phosphatidic acid, which is the 
precursor of the second messenger DAG. Two isoforms identified and both regulated by protein kinases, 
small GTPases and calcium.
Cells capable of giving rise to all classes of cells.
A plant lectin which is a T-cell dependent B-cell mitogen.
Addition made to RNA polymerase II's transcript; aids in the export o f mature mRNA from the nucleus, 
affects the stability of at least some mRNAs in the cytoplasm, and seems to serve as a recognition signal for 
the ribosome that is require for efficient translation of Mma.
Many different clones, or the product of many different clones, e.g. polyclonal antiserum.
A substance that induces activation of many individual clones of either T or B cells. See Mitogen.
A receptor molecule which specifically binds J-chain containing polymeric Ig, i.e. dimeric secretory IgA 
and pentameric IgM, and transports it across mucosal epithelium.
A method for amplifying a DNA base sequence using a heat- stable polymerase and two 20-base primers, 
one complementary to the (+)-strand at one end of the sequence to be amplified and the other 
complementary to the (-)-strand at the other end. Because the newly synthesized DNA strand can 
subsequently serve as additional templates for the same primer sequences, successive rounds of primer 
annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired 
sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample; technique 
for amplifying specific regions of DNA by multiple cycles of DNA polymerization, each followed by a 











































Literally, "having many shapes"; in genetics polymorphism means occurring in more than one form within a 
species; the existence o f multiple alleles at a particular genetic locus.
White blood cell with granular cytoplasm, e.g. neutrophil
mRNA molecule to which are attached a number of ribosomes engaged in protein synthesis.
The selection of those developing T-cells in the thymus which are able to recognize self MHC molecules. 
This occurs by preventing apoptosis in these cells.
The relatively weak immune response which occurs upon the first encounter of naive lymphocytes with a 
given antigen. The primary response is generally small, has a long induction phase or lag period, consists 
primarily of IgM antibodies, and generates immunologic memory.
Organs in which the maturation of immunocompetent T and B lymphocytes take place and antigen-specific 
receptors are first acquired, i.e. bone marrow and thymus in mammals.
The process of giving an initial sensitization to andgen.
Single-stranded DNA or RNA molecules o f specific base sequence, labeled either radioactively or 
immunologically, that are used to detect the complementary base sequence by hybridization.
A site (nucleotide sequence) on DNA to which RNA polymerase will bind and initiate transcription. 
Protection.
Acidic lipids derived from arachidonic acid which are able to increase vascular permeability, mediate fever, 
and can both stimulate and inhibit immunological responses.
Enzymes, such as trypsin, that degrades proteins by hydrolyzing some of their peptide bonds.
Cytoplasmic proteolytic enzyme complex involved in antigen processing for association with MHC. 
Staphylococcus aureus cell wall protein which binds to the Fc region of IgG.
Enzymes that transfers the terminal phosphate group of ATP to a specific amino acid of a target protein.
Enzymes that are able to phosphorylate proteins on tyrosines, and often act in a cascade-like fashion in the 
signal transduction systems of cells.
Long linear polymers of amino acids joined head to tail by peptide bond between carboxylic acid group of 
one amino acid to the amino group of the next.
Molecules consisting of one or more glucosaminoglycan (GAG) chains attached to a core protein.
225 kDa MMAC1, a tumor suppressor gene; dephosphorylates D3-PI lipids and to some extent proteins. 
99-125 kDa Protein tyrosine Kinase, see CAKbeta.
‘Non-classical’ MHC class I molecules of mice.
21 kDa Members o f the small molecular weight GTPase superfamily.
A solid-phase radioimmunoassay for detecting IgE antibody specific for a particular allergen (see ‘RAST’).
A widely used technique for measurement o f primary antigen-antibody interactions, and for the 
determination of the level o f important biological substances in mixed samples. It takes advantage o f the 
specificity of the antigen-antibody interaction and the sensitivity that derives from measurement of 
radioactively labelled materials.
A small GTPase
74 kDa Cytoplasmic Raf proto-oncogene serine/threonine protein kinase that is activated by Ras-GTP; a 
MAPKKK
116 kDa Related Adhesion Focal Tyrosine Kinase. See CAKbeta, Pyk2.
73 kDa Inactivator o f Rap-1.
21 kDa Member of Ras family of low molecular weight GTP/GDP binding proteins; a small GTPase.
21 kDa GDP/GTP binding protein. Activates Raf-MEK-MAPK pathway; a small GTPase.
RAST is an abbreviation for RadioAllergoSorbent Test, a trademark of Pharmacia Diagnostics, which 
originated the test. RAST is a laboratory test used to detect IgE antibodies to specific allergens.
Protein that binds to specific extracellular signaling molecule (ligand) and initiates a response in the cell. 
Cell-surface receptors such as the acetylcholine receptor and the insulin receptor, are located in the plasma 
membrane, with their ligand-binding site exposed to the external medium. Intracellular receptors, such as 
steroid hormonereceptors, bind ligands that diffuse into the cell across the plasma membrane.
A genetic disorder that appears only in patients who have received two copies of a mutant gene, one from 
each parent.
A combination of DNA molecules of different origin that are joined using recombinant DNA technologies.
The process by which offspring derive a combination of genes different from that o f either parent. In higher 
organisms, this can occur by crossing over.
Addition of electrons.
A T lymphocyte that turns off specific immune responses.
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Encodes for an easily detectable protein. For example, lacZ, CAT (chloramphenicol acetyltransferase), and 
the luciferase genes all encode for bacterial enzymes. The presence of bacterial enzymes can be easily 
monitored by simple and sensitive assays of enzyme activity, without any interference from host cell 
enzymes. The regulatory sequence for the gene o f interest can be identified by attaching the reporter 
sequence to various fragments of DNA sequence taken from upstream or downstream of the gene.
Oxygen dependent increase in metabolic activity (increased oxidative metabolism) within phagocytic cells 
stimulated by bacteria or parasites, to be microbicidal.
The name given to the electron-transport chain in the mitochondria
Diagrammatic representation of a DNA molecule indicating the sites of cleavage by various restriction 
enzymes.
One of a large number of nucleases that can cleave a DNA molecule at any site where a specific short 
sequence of nucleotides occurs.
An old term for the network of phagocytes and endothelial cells throughout the body.
Retroviral vectors with recombinant DNA incorporate their genome into the chromosomes of cells it 
infects.
An autoantibody (usually IgM, but also IgG and IgA) that reacts with the individual's own IgG, particularly 
the Fc region. Present in rheumatoid arthritis.
Rhinitis is an inflammation of the mucous membrane that lines the nose, often due to an allergy to pollen, 
dust or other airborne substances. Seasonal allergic rhinitis also is known as "hay fever," a disorder that 
causes sneezing, itching, a runny nose and nasal congestion.
21.6 kDa Small molecular weight GTPase.
A complex composed of ribosomal RNAs and ribosomal proteins that associates with messenger RNA and 
catalyzes the synthesis o f protein.
75-76 kDa Receptor Interacting Protein.
Enzyme that catalyzes the synthesis of an RNA molecule on a DNA template from nucleoside triphosphate 
precursors.
Makes the large ribosomal RNAs.
Transcribes genes whose RNA's will be translated into proteins.
Makes a variety of very small, stable RNAs including 5s ribosomal RNAs and transfer RNAs.
Primers used to synthesize DNA strands by acting as a template.
RNA-processing step in which all of the intron sequences are excised from RNA molecules in the nucleus, 
with exon sequences kept, therebv producing messenger RNA.
160 kDa Rho-activated kinase.
Any one of a number of specific RNA molecules that form part of the structure of a ribosome and 
participate in the synthesis of proteins.
70 kDa S6 Kinase is a mitogen-activated serine/threonine kinase that plays a key role in the regulation of 
cell growth by controlling the biosynthesis of translational components, which make up the protein 
synthetic apparatus, most notably ribosomal proteins.
The degree of disorder in the universe can only increase.
The qualitatively and quantitatively improved immune response which occurs upon the second encounter of 
primed lymphocytes with a given antigen.
Organs in which antigen-driven proliferation and differentiation of B and T lymphocytes takes place.
Proteolytic cleavage product of the poly-Ig receptor which remains associated with dimeric IgA in sero- 
mucus secretions.
One of the two chromosomes that specify an organism's genetic sex. Humans have two kinds of sex 
chromosomes, one called X and the other Y. Normal females possess two X chromosomes and normal 
males one X and one Y.
Located on the X chromosome. Sex-linked (or X-linked) diseases are generally observed only in males.
Early signaling intermediates between the RTK and GPCR via Ras pathway; a scaffolding protein for a 
variety of RTKs. Exists in 3 forms: p46, p52 and p66 isoforms. Grb2/Sos binds to phosphorylated She, 
activating the Ras-Raf-MAPK pathway.
145 kDa SH2 domain containing Inositol Phosphatase; dephosphorylates PIP3.
68 kDa Protein Tyrosine Phosphatase which has 2 N-terminal SH2 domains.
72 kDa Protein Tyrosine Phosphatase which has 2 N-terminal SH2domains.
Group attached to -carbon of amino acid and gives the amino acid its chemical properties.
Molecules involved in transmitting signals from the cell surface to the nucleus to switch genes on or off. 
Bind to exposed DNA strands without covering the bases; they aid helicase by stabilizing the unwound, 
single-stranded conformation.
The sinuses (paranasal sinuses) are air cavities within the facial bones. They are lined by mucous 
membranes similar to those in other parts of the airways.
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Sinusitis is inflammation of the membrane lining the facial sinuses, often caused by bacterial or viral 
infection.
A group of leukotrienes released by mast cells during anaphylaxis which induces a prolonged constriction 
of smooth muscle. This prolonged constriction is not reversible by treatment with antihistamines.
Complexes of proteins with small RNAs contained in the nucleus; individually, they recognize specific 
nucleic acid sequences through RNA- RNA base-pairing.
All body cells, except the reproductive cells.
The enhanced rate of point mutation in the immunoglobulin variable region genes which occurs following 
antigenic stimulation and acts as a mechanism for increasing antibody diversity and affinity.
153 kDa Son of Seven less.
Technique in which DNA fragments, separated by electrophoresis, are immobilized on a paper sheet; 
specific molecules are then detected with a labeled nucleic acid probe.
Relating to, occupying, or having the character of space.
An immune response to a specific antigen. This response can have a cell-mediated component and a
humoral component (the production of antibodies).
60 kDa pp60v-src, Rous Sarcoma Virus, a non-receptor tyrosine kinase that plays a role in ligand-induced 
cellular responses such as proliferation, survival, adhesion, and cell migration, as well as ion 
channel/receptor phosphorylation.
52 kDa Serum Response Factor.
Polysaccharide composed exclusively of glucose units, used as an energy store in plant cells.
‘Signal transducers and activators o f transcription’ are regulated by JAKs, where upon phosphorylation they 
dimerise and translocate to the nucleus where they participate in transcriptional activation.
Multipotential cell from which differ-entiated cells derive.
Hydrophobic molecules related to cholesterol. Many important hormones are steroids.
An antigen which reacts with all the T-cells belonging to a particular T-cell receptor V region family, and 
which therefore stimulates (or deletes) a much larger number of cells than does conventional antigen.
A mechanism for producing a specific state of immunologic unresponsiveness by the induction of 
suppressor T cells. This type of unresponsiveness is passively transferable by suppressor T cells or their 
soluble products.
Diminishes/controls specific immune response. Carries the CD8 antigen on their surface.
72 kDa Spleen tyrosine kinase (non-receptor). Plays critical role in signaling through immune receptors. 
Communicating cell-cell junction that allows signals to pass from a nerve cell to another cell.
22-46 kDa Family of four transmembrane proteoglycans; act as putative integrators of extracellular signals. 
Members of the same species that are genetically identical, e.g. a fully inbred strain of mice.
Same as isograft.
Refers to genes on the same chromosome. Synteny conservation is defined as the occurrence of two or more 
pairs of homologous markers on the same chromosome in two or more species. Linkage conservation is 
conservation not only of synteny, but also o f gene order.
A lymphocyte which undergoes a developmental stage in the thymus.
T cell antigen receptor that specifically recognizes processed antigens bound to MHC class I and II 
molecules. The TCR exists in two alternative forms, consisting of a  and P chains, or y and 8 chains. The 
ap  TCR recognizes peptide fragments of protein antigens presented by MHC molecules on cell surfaces. 
The function of the y8 TCR is less clearly defined but it can recognize native proteins on the cell surface. 
The Transporters associated with Antigen Processing (TAP-1 and TAP-2) are molecules which carry 
antigenic peptides from the cytoplasm into the lumen of the endoplasmic reticulum for incorporation into 
MHC class I molecules.
Technique for inactivating a gene by deleting it from the genome. May be accomplished by homologous 
recombination or inducible gene targeting.
Alteration of the germline by the introduction of a site-directed mutation.
The frequency with which a vector transfected into cells recombines with the desired chromosomal target.
The degree of homology in length and polymorphic variation between the vector and the host targeted
sequence effect targeting frequency.
A 43 kDa Microtubule-associated protein involved in cytoskeleton regulation; when phosphorylated leads 
to formation of paired helical filaments observed in Alzheimer's disease and various tauopathies.
30-34 kDa T-cell Factor. Also known as Lymphoid Enhancer Factor.
An antigen (immunogen) that requires helper T-cells in order to elicit an antibody response.
O f or relating to time as distinguished from space; o f or relating to the sequence of time or to a particular 
tim e: CHRONOLOGICAL.
187 kDa Actin filament capping protein.
T lymphocytes making cytokines to help inflammation and anti-viral responses.
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T lymphocytes making predominantly TGF (and helping IgA antibody responses).
Developing T-cell in the thymus.
Primary lymphoid organ located above the heart from which T cells are derived.
A guanine nucleotide-releasing factor for Rac.
An antigen (immunogen) that is able to elicit an antibody response in the absence of T-cells (lymphokines
released by T cells). The antibodies are generally only of the IgM isotype.
Molecules on the surface of tissue cells recognised by the immune system.
A nucleated white blood cell made in the thymus.
A non-aggressive state specific immunological tolerance) of the immune system normally associated with 
self-recognition.
An antigen used to induce tolerance. Often depends more on the circumstances of administration (e.g. route 
and concentration) than on any inherent property o f the molecule.
T lymphocytes that regulate Thl responses (may be related to Th3).
The synthesis of an RNA copy from a sequence of DNA (a gene); the first step in gene expression.
The uptake, incorporation, and expression of recombinant DNA by eukaryotic cells.
Morphological changes in a lymphocyte associated with the onset of division. Also used to denote the
change to the autonomously dividing state of a cancer cell.
A cytokine that down-regulates antigen presentation.
The foreign gene.
This term describes an organism that has had genes from another organism put into its genome through 
recombinant DNA techniques. These animals are usually made by microinjection of DNA into the 
pronucleus of fertilized eggs, with the DNA integrating at random.
A transgenic mouse strain in which the transgene is stably integrated into the germline and therefore 
inherited in Mendelian fashion by succeeding generations.
Structure that forms transiently in the course of a chemical reaction and has the highest free energy of any 
reaction intermediate; a rate-limiting step in the reaction.
The process in which the genetic code carried by mRNA directs the synthesis of proteins from amino acids.
Amphipathic proteins that extend through the bilayer with part of their mass on both sides of the bilayer.
Glycerol ester o f fatty acids. The main constituent of fat droplets in animal tissues (where fatty acids are 
saturated) and of vegetable oil (where fatty acids are mainly unsaturated).
Set of small RNA molecules used in protein synthesis as an interface (adapter) between mRNA and amino 
acids.
At very short distances, any two atoms show a weak bonding interaction due to their fluctuating electrical 
charges. However, two atoms will very strongly repel each other if they are brought too close together. This 
latter phenomenon is known as van der Waals repulsions.
Genes that rearrange together with D  (diversity) and J (joining) gene segments in order to encode the 
variable region amino acid sequences of immunoglobulins and T-cell receptors.
Substances including histamine and 5-hydroxytryptamine which increase vascular permeability and smooth 
muscle contraction.
The one F proto-oncogene.
A DNA molecule that replicates on its own in a host cell and can be used as a vehicle in the laboratory for 
replicating other types of DNA.
117-130 kDa cytoskeletal protein which is found at the end of actin stress fiber focal adhesions.
Obligate intracellular parasites that require the host cell's biochemical machinery to drive protein synthesis 
and metabolize sugars. Some produce acute infection and are eliminated from the host, whereas others 
persist indefinitely producing late disease.
Contained in the membrane of all electrically excitable cells; responsible for generating the action 
potentials.
68 kDa Viral serine/threonine protein kinase that is activated by Ras- GTP.
53 kDa Wiskott-Aldrich Syndrome Protein.
A technique similar to Southern blotting, though it is used for proteins.
Genetic differences between species.
A tissue or organ graft between individuals of different species.
A non-receptor tyrosine kinase.
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